#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Apparent Effects of Opioid Use on Neural Responses to Reward in Chronic Pain
#Text=Neural responses to incentives are altered in chronic pain and by opioid use.
1-1	0-8	Apparent	_	
1-2	9-16	Effects	_	
1-3	17-19	of	_	
1-4	20-26	Opioid	_	
1-5	27-30	Use	_	
1-6	31-33	on	_	
1-7	34-40	Neural	_	
1-8	41-50	Responses	_	
1-9	51-53	to	_	
1-10	54-60	Reward	_	
1-11	61-63	in	_	
1-12	64-71	Chronic	_	
1-13	72-76	Pain	_	
1-14	77-83	Neural	_	
1-15	84-93	responses	_	
1-16	94-96	to	_	
1-17	97-107	incentives	_	
1-18	108-111	are	_	
1-19	112-119	altered	_	
1-20	120-122	in	_	
1-21	123-130	chronic	_	
1-22	131-135	pain	_	
1-23	136-139	and	_	
1-24	140-142	by	_	
1-25	143-149	opioid	_	
1-26	150-153	use	_	
1-27	153-154	.	_	

#Text=To understand how opioid use modulates the neural response to reward/value in chronic pain, we compared brain functional magnetic resonance imaging (fMRI) responses to a monetary incentive delay (MID) task in patients with fibromyalgia taking opioids (N = 17), patients with fibromyalgia not taking opioids (N = 17), and healthy controls (N = 15).
2-1	155-157	To	_	
2-2	158-168	understand	_	
2-3	169-172	how	_	
2-4	173-179	opioid	_	
2-5	180-183	use	_	
2-6	184-193	modulates	_	
2-7	194-197	the	_	
2-8	198-204	neural	_	
2-9	205-213	response	_	
2-10	214-216	to	_	
2-11	217-223	reward	_	
2-12	223-224	/	_	
2-13	224-229	value	_	
2-14	230-232	in	_	
2-15	233-240	chronic	_	
2-16	241-245	pain	_	
2-17	245-246	,	_	
2-18	247-249	we	_	
2-19	250-258	compared	_	
2-20	259-264	brain	_	
2-21	265-275	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-22	276-284	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-23	285-294	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-24	295-302	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-25	303-304	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-26	304-308	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-27	308-309	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
2-28	310-319	responses	_	
2-29	320-322	to	_	
2-30	323-324	a	_	
2-31	325-333	monetary	_	
2-32	334-343	incentive	_	
2-33	344-349	delay	_	
2-34	350-351	(	_	
2-35	351-354	MID	_	
2-36	354-355	)	_	
2-37	356-360	task	_	
2-38	361-363	in	_	
2-39	364-372	patients	_	
2-40	373-377	with	_	
2-41	378-390	fibromyalgia	_	
2-42	391-397	taking	_	
2-43	398-405	opioids	_	
2-44	406-407	(	_	
2-45	407-408	N	_	
2-46	409-410	=	_	
2-47	411-413	17	_	
2-48	413-414	)	_	
2-49	414-415	,	_	
2-50	416-424	patients	_	
2-51	425-429	with	_	
2-52	430-442	fibromyalgia	_	
2-53	443-446	not	_	
2-54	447-453	taking	_	
2-55	454-461	opioids	_	
2-56	462-463	(	_	
2-57	463-464	N	_	
2-58	465-466	=	_	
2-59	467-469	17	_	
2-60	469-470	)	_	
2-61	470-471	,	_	
2-62	472-475	and	_	
2-63	476-483	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
2-64	484-492	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
2-65	493-494	(	_	
2-66	494-495	N	_	
2-67	496-497	=	_	
2-68	498-500	15	_	
2-69	500-501	)	_	
2-70	501-502	.	_	

#Text=Both groups of patients with fibromyalgia taking and not taking opioids had similar levels of pain, psychological measures, and clinical symptoms.
3-1	503-507	Both	_	
3-2	508-514	groups	_	
3-3	515-517	of	_	
3-4	518-526	patients	_	
3-5	527-531	with	_	
3-6	532-544	fibromyalgia	_	
3-7	545-551	taking	_	
3-8	552-555	and	_	
3-9	556-559	not	_	
3-10	560-566	taking	_	
3-11	567-574	opioids	_	
3-12	575-578	had	_	
3-13	579-586	similar	_	
3-14	587-593	levels	_	
3-15	594-596	of	_	
3-16	597-601	pain	_	
3-17	601-602	,	_	
3-18	603-616	psychological	_	
3-19	617-625	measures	_	
3-20	625-626	,	_	
3-21	627-630	and	_	
3-22	631-639	clinical	_	
3-23	640-648	symptoms	_	
3-24	648-649	.	_	

#Text=Neural responses in the nucleus accumbens to anticipated reward and non-loss outcomes did not differ from healthy controls in either fibromyalgia group.
4-1	650-656	Neural	_	
4-2	657-666	responses	_	
4-3	667-669	in	_	
4-4	670-673	the	_	
4-5	674-681	nucleus	_	
4-6	682-691	accumbens	_	
4-7	692-694	to	_	
4-8	695-706	anticipated	_	
4-9	707-713	reward	_	
4-10	714-717	and	_	
4-11	718-726	non-loss	_	
4-12	727-735	outcomes	_	
4-13	736-739	did	_	
4-14	740-743	not	_	
4-15	744-750	differ	_	
4-16	751-755	from	_	
4-17	756-763	healthy	_	
4-18	764-772	controls	_	
4-19	773-775	in	_	
4-20	776-782	either	_	
4-21	783-795	fibromyalgia	_	
4-22	796-801	group	_	
4-23	801-802	.	_	

#Text=However, neural responses in the medial prefrontal cortex differed, such that patients with fibromyalgia not taking opioids demonstrated significantly altered responses to anticipated rewards and non-loss outcomes compared to healthy controls, but patients with fibromyalgia taking opioids did not.
5-1	803-810	However	_	
5-2	810-811	,	_	
5-3	812-818	neural	_	
5-4	819-828	responses	_	
5-5	829-831	in	_	
5-6	832-835	the	_	
5-7	836-842	medial	_	
5-8	843-853	prefrontal	_	
5-9	854-860	cortex	_	
5-10	861-869	differed	_	
5-11	869-870	,	_	
5-12	871-875	such	_	
5-13	876-880	that	_	
5-14	881-889	patients	_	
5-15	890-894	with	_	
5-16	895-907	fibromyalgia	_	
5-17	908-911	not	_	
5-18	912-918	taking	_	
5-19	919-926	opioids	_	
5-20	927-939	demonstrated	_	
5-21	940-953	significantly	_	
5-22	954-961	altered	_	
5-23	962-971	responses	_	
5-24	972-974	to	_	
5-25	975-986	anticipated	_	
5-26	987-994	rewards	_	
5-27	995-998	and	_	
5-28	999-1007	non-loss	_	
5-29	1008-1016	outcomes	_	
5-30	1017-1025	compared	_	
5-31	1026-1028	to	_	
5-32	1029-1036	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
5-33	1037-1045	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
5-34	1045-1046	,	_	
5-35	1047-1050	but	_	
5-36	1051-1059	patients	_	
5-37	1060-1064	with	_	
5-38	1065-1077	fibromyalgia	_	
5-39	1078-1084	taking	_	
5-40	1085-1092	opioids	_	
5-41	1093-1096	did	_	
5-42	1097-1100	not	_	
5-43	1100-1101	.	_	

#Text=Despite limitations including the use of additional non-opioid medications by fibromyalgia patients taking opioids, these preliminary findings suggest relatively “normalized” neural responses to monetary incentives in chronic pain patients who take opioids versus those who do not.
6-1	1102-1109	Despite	_	
6-2	1110-1121	limitations	_	
6-3	1122-1131	including	_	
6-4	1132-1135	the	_	
6-5	1136-1139	use	_	
6-6	1140-1142	of	_	
6-7	1143-1153	additional	_	
6-8	1154-1164	non-opioid	_	
6-9	1165-1176	medications	_	
6-10	1177-1179	by	_	
6-11	1180-1192	fibromyalgia	_	
6-12	1193-1201	patients	_	
6-13	1202-1208	taking	_	
6-14	1209-1216	opioids	_	
6-15	1216-1217	,	_	
6-16	1218-1223	these	_	
6-17	1224-1235	preliminary	_	
6-18	1236-1244	findings	_	
6-19	1245-1252	suggest	_	
6-20	1253-1263	relatively	_	
6-21	1264-1265	“	_	
6-22	1265-1275	normalized	_	
6-23	1275-1276	”	_	
6-24	1277-1283	neural	_	
6-25	1284-1293	responses	_	
6-26	1294-1296	to	_	
6-27	1297-1305	monetary	_	
6-28	1306-1316	incentives	_	
6-29	1317-1319	in	_	
6-30	1320-1327	chronic	_	
6-31	1328-1332	pain	_	
6-32	1333-1341	patients	_	
6-33	1342-1345	who	_	
6-34	1346-1350	take	_	
6-35	1351-1358	opioids	_	
6-36	1359-1365	versus	_	
6-37	1366-1371	those	_	
6-38	1372-1375	who	_	
6-39	1376-1378	do	_	
6-40	1379-1382	not	_	
6-41	1382-1383	.	_	

#Text=Introduction
#Text=Exogenous opioids are potent analgesics that exert their effects at the level of the spinal cord and by involving supraspinal sites via descending circuits (for review).
7-1	1384-1396	Introduction	_	
7-2	1397-1406	Exogenous	_	
7-3	1407-1414	opioids	_	
7-4	1415-1418	are	_	
7-5	1419-1425	potent	_	
7-6	1426-1436	analgesics	_	
7-7	1437-1441	that	_	
7-8	1442-1447	exert	_	
7-9	1448-1453	their	_	
7-10	1454-1461	effects	_	
7-11	1462-1464	at	_	
7-12	1465-1468	the	_	
7-13	1469-1474	level	_	
7-14	1475-1477	of	_	
7-15	1478-1481	the	_	
7-16	1482-1488	spinal	_	
7-17	1489-1493	cord	_	
7-18	1494-1497	and	_	
7-19	1498-1500	by	_	
7-20	1501-1510	involving	_	
7-21	1511-1522	supraspinal	_	
7-22	1523-1528	sites	_	
7-23	1529-1532	via	_	
7-24	1533-1543	descending	_	
7-25	1544-1552	circuits	_	
7-26	1553-1554	(	_	
7-27	1554-1557	for	_	
7-28	1558-1564	review	_	
7-29	1564-1565	)	_	
7-30	1565-1566	.	_	

#Text=However, evidence suggests that long-term opioid use may not clinically improve the condition of individuals with chronic pain.
8-1	1567-1574	However	_	
8-2	1574-1575	,	_	
8-3	1576-1584	evidence	_	
8-4	1585-1593	suggests	_	
8-5	1594-1598	that	_	
8-6	1599-1608	long-term	_	
8-7	1609-1615	opioid	_	
8-8	1616-1619	use	_	
8-9	1620-1623	may	_	
8-10	1624-1627	not	_	
8-11	1628-1638	clinically	_	
8-12	1639-1646	improve	_	
8-13	1647-1650	the	_	
8-14	1651-1660	condition	_	
8-15	1661-1663	of	_	
8-16	1664-1675	individuals	_	
8-17	1676-1680	with	_	
8-18	1681-1688	chronic	_	
8-19	1689-1693	pain	_	
8-20	1693-1694	.	_	

#Text=Current guidelines do not recommend opioids for the treatment of fibromyalgia, a condition of widespread chronic pain, due to the overlap between side effects of opioids (e.g., negative impacts on mood, sleep, cognition) and many co-occurring symptoms of fibromyalgia (e.g., impaired cognition, anxiety, depression, fatigue, poor sleep quality) as well as the potential for addictive behaviors when taking opioids.
9-1	1695-1702	Current	_	
9-2	1703-1713	guidelines	_	
9-3	1714-1716	do	_	
9-4	1717-1720	not	_	
9-5	1721-1730	recommend	_	
9-6	1731-1738	opioids	_	
9-7	1739-1742	for	_	
9-8	1743-1746	the	_	
9-9	1747-1756	treatment	_	
9-10	1757-1759	of	_	
9-11	1760-1772	fibromyalgia	_	
9-12	1772-1773	,	_	
9-13	1774-1775	a	_	
9-14	1776-1785	condition	_	
9-15	1786-1788	of	_	
9-16	1789-1799	widespread	_	
9-17	1800-1807	chronic	_	
9-18	1808-1812	pain	_	
9-19	1812-1813	,	_	
9-20	1814-1817	due	_	
9-21	1818-1820	to	_	
9-22	1821-1824	the	_	
9-23	1825-1832	overlap	_	
9-24	1833-1840	between	_	
9-25	1841-1845	side	_	
9-26	1846-1853	effects	_	
9-27	1854-1856	of	_	
9-28	1857-1864	opioids	_	
9-29	1865-1866	(	_	
9-30	1866-1869	e.g	_	
9-31	1869-1870	.	_	
9-32	1870-1871	,	_	
9-33	1872-1880	negative	_	
9-34	1881-1888	impacts	_	
9-35	1889-1891	on	_	
9-36	1892-1896	mood	_	
9-37	1896-1897	,	_	
9-38	1898-1903	sleep	_	
9-39	1903-1904	,	_	
9-40	1905-1914	cognition	_	
9-41	1914-1915	)	_	
9-42	1916-1919	and	_	
9-43	1920-1924	many	_	
9-44	1925-1937	co-occurring	_	
9-45	1938-1946	symptoms	_	
9-46	1947-1949	of	_	
9-47	1950-1962	fibromyalgia	_	
9-48	1963-1964	(	_	
9-49	1964-1967	e.g	_	
9-50	1967-1968	.	_	
9-51	1968-1969	,	_	
9-52	1970-1978	impaired	_	
9-53	1979-1988	cognition	_	
9-54	1988-1989	,	_	
9-55	1990-1997	anxiety	_	
9-56	1997-1998	,	_	
9-57	1999-2009	depression	_	
9-58	2009-2010	,	_	
9-59	2011-2018	fatigue	_	
9-60	2018-2019	,	_	
9-61	2020-2024	poor	_	
9-62	2025-2030	sleep	_	
9-63	2031-2038	quality	_	
9-64	2038-2039	)	_	
9-65	2040-2042	as	_	
9-66	2043-2047	well	_	
9-67	2048-2050	as	_	
9-68	2051-2054	the	_	
9-69	2055-2064	potential	_	
9-70	2065-2068	for	_	
9-71	2069-2078	addictive	_	
9-72	2079-2088	behaviors	_	
9-73	2089-2093	when	_	
9-74	2094-2100	taking	_	
9-75	2101-2108	opioids	_	
9-76	2108-2109	.	_	

#Text=Other than a small number of studies investigating efficacy of tramadol, there are no randomized controlled trials of pure mu-opioid agonists on fibromyalgia.
10-1	2110-2115	Other	_	
10-2	2116-2120	than	_	
10-3	2121-2122	a	_	
10-4	2123-2128	small	_	
10-5	2129-2135	number	_	
10-6	2136-2138	of	_	
10-7	2139-2146	studies	_	
10-8	2147-2160	investigating	_	
10-9	2161-2169	efficacy	_	
10-10	2170-2172	of	_	
10-11	2173-2181	tramadol	_	
10-12	2181-2182	,	_	
10-13	2183-2188	there	_	
10-14	2189-2192	are	_	
10-15	2193-2195	no	_	
10-16	2196-2206	randomized	_	
10-17	2207-2217	controlled	_	
10-18	2218-2224	trials	_	
10-19	2225-2227	of	_	
10-20	2228-2232	pure	_	
10-21	2233-2242	mu-opioid	_	
10-22	2243-2251	agonists	_	
10-23	2252-2254	on	_	
10-24	2255-2267	fibromyalgia	_	
10-25	2267-2268	.	_	

#Text=However, despite opioid treatment not proving superior to non-opioid treatment for chronic pain, some individuals with chronic pain report benefitting over 12 months when taking opioids, similar to their non-opioid taking counterparts.
11-1	2269-2276	However	_	
11-2	2276-2277	,	_	
11-3	2278-2285	despite	_	
11-4	2286-2292	opioid	_	
11-5	2293-2302	treatment	_	
11-6	2303-2306	not	_	
11-7	2307-2314	proving	_	
11-8	2315-2323	superior	_	
11-9	2324-2326	to	_	
11-10	2327-2337	non-opioid	_	
11-11	2338-2347	treatment	_	
11-12	2348-2351	for	_	
11-13	2352-2359	chronic	_	
11-14	2360-2364	pain	_	
11-15	2364-2365	,	_	
11-16	2366-2370	some	_	
11-17	2371-2382	individuals	_	
11-18	2383-2387	with	_	
11-19	2388-2395	chronic	_	
11-20	2396-2400	pain	_	
11-21	2401-2407	report	_	
11-22	2408-2419	benefitting	_	
11-23	2420-2424	over	_	
11-24	2425-2427	12	_	
11-25	2428-2434	months	_	
11-26	2435-2439	when	_	
11-27	2440-2446	taking	_	
11-28	2447-2454	opioids	_	
11-29	2454-2455	,	_	
11-30	2456-2463	similar	_	
11-31	2464-2466	to	_	
11-32	2467-2472	their	_	
11-33	2473-2483	non-opioid	_	
11-34	2484-2490	taking	_	
11-35	2491-2503	counterparts	_	
11-36	2503-2504	.	_	

#Text=Further, recent data from opioid taper clinical trials indicate that approximately 25% of patients with chronic pain taking opioids choose not to participate in opioid tapering (and almost another 25% withdraw), suggesting that these individuals may believe they are benefiting from opioids despite myriad known side-effects.
12-1	2505-2512	Further	_	
12-2	2512-2513	,	_	
12-3	2514-2520	recent	_	
12-4	2521-2525	data	_	
12-5	2526-2530	from	_	
12-6	2531-2537	opioid	_	
12-7	2538-2543	taper	_	
12-8	2544-2552	clinical	_	
12-9	2553-2559	trials	_	
12-10	2560-2568	indicate	_	
12-11	2569-2573	that	_	
12-12	2574-2587	approximately	_	
12-13	2588-2591	25%	_	
12-14	2592-2594	of	_	
12-15	2595-2603	patients	_	
12-16	2604-2608	with	_	
12-17	2609-2616	chronic	_	
12-18	2617-2621	pain	_	
12-19	2622-2628	taking	_	
12-20	2629-2636	opioids	_	
12-21	2637-2643	choose	_	
12-22	2644-2647	not	_	
12-23	2648-2650	to	_	
12-24	2651-2662	participate	_	
12-25	2663-2665	in	_	
12-26	2666-2672	opioid	_	
12-27	2673-2681	tapering	_	
12-28	2682-2683	(	_	
12-29	2683-2686	and	_	
12-30	2687-2693	almost	_	
12-31	2694-2701	another	_	
12-32	2702-2705	25%	_	
12-33	2706-2714	withdraw	_	
12-34	2714-2715	)	_	
12-35	2715-2716	,	_	
12-36	2717-2727	suggesting	_	
12-37	2728-2732	that	_	
12-38	2733-2738	these	_	
12-39	2739-2750	individuals	_	
12-40	2751-2754	may	_	
12-41	2755-2762	believe	_	
12-42	2763-2767	they	_	
12-43	2768-2771	are	_	
12-44	2772-2782	benefiting	_	
12-45	2783-2787	from	_	
12-46	2788-2795	opioids	_	
12-47	2796-2803	despite	_	
12-48	2804-2810	myriad	_	
12-49	2811-2816	known	_	
12-50	2817-2829	side-effects	_	
12-51	2829-2830	.	_	

#Text=This discrepancy between clinical observations and patients’ beliefs is not trivial given significant and increasing concerns regarding the risks of opioid use, including overdose and addiction.
13-1	2831-2835	This	_	
13-2	2836-2847	discrepancy	_	
13-3	2848-2855	between	_	
13-4	2856-2864	clinical	_	
13-5	2865-2877	observations	_	
13-6	2878-2881	and	_	
13-7	2882-2890	patients	_	
13-8	2890-2891	’	_	
13-9	2892-2899	beliefs	_	
13-10	2900-2902	is	_	
13-11	2903-2906	not	_	
13-12	2907-2914	trivial	_	
13-13	2915-2920	given	_	
13-14	2921-2932	significant	_	
13-15	2933-2936	and	_	
13-16	2937-2947	increasing	_	
13-17	2948-2956	concerns	_	
13-18	2957-2966	regarding	_	
13-19	2967-2970	the	_	
13-20	2971-2976	risks	_	
13-21	2977-2979	of	_	
13-22	2980-2986	opioid	_	
13-23	2987-2990	use	_	
13-24	2990-2991	,	_	
13-25	2992-3001	including	_	
13-26	3002-3010	overdose	_	
13-27	3011-3014	and	_	
13-28	3015-3024	addiction	_	
13-29	3024-3025	.	_	

#Text=Prescription of opioids for the treatment of fibromyalgia, in particular, remains controversial and poorly informed.
14-1	3026-3038	Prescription	_	
14-2	3039-3041	of	_	
14-3	3042-3049	opioids	_	
14-4	3050-3053	for	_	
14-5	3054-3057	the	_	
14-6	3058-3067	treatment	_	
14-7	3068-3070	of	_	
14-8	3071-3083	fibromyalgia	_	
14-9	3083-3084	,	_	
14-10	3085-3087	in	_	
14-11	3088-3098	particular	_	
14-12	3098-3099	,	_	
14-13	3100-3107	remains	_	
14-14	3108-3121	controversial	_	
14-15	3122-3125	and	_	
14-16	3126-3132	poorly	_	
14-17	3133-3141	informed	_	
14-18	3141-3142	.	_	

#Text=While the use of long-term opioid medications might not be beneficial for chronic pain per se (i.e., in terms of not improving physical function and not reducing pain interference for example), it is possible that opioid medications could be benefiting brain reward processing and associated reward behavior in patients with chronic pain.
15-1	3143-3148	While	_	
15-2	3149-3152	the	_	
15-3	3153-3156	use	_	
15-4	3157-3159	of	_	
15-5	3160-3169	long-term	_	
15-6	3170-3176	opioid	_	
15-7	3177-3188	medications	_	
15-8	3189-3194	might	_	
15-9	3195-3198	not	_	
15-10	3199-3201	be	_	
15-11	3202-3212	beneficial	_	
15-12	3213-3216	for	_	
15-13	3217-3224	chronic	_	
15-14	3225-3229	pain	_	
15-15	3230-3233	per	_	
15-16	3234-3236	se	_	
15-17	3237-3238	(	_	
15-18	3238-3241	i.e	_	
15-19	3241-3242	.	_	
15-20	3242-3243	,	_	
15-21	3244-3246	in	_	
15-22	3247-3252	terms	_	
15-23	3253-3255	of	_	
15-24	3256-3259	not	_	
15-25	3260-3269	improving	_	
15-26	3270-3278	physical	_	
15-27	3279-3287	function	_	
15-28	3288-3291	and	_	
15-29	3292-3295	not	_	
15-30	3296-3304	reducing	_	
15-31	3305-3309	pain	_	
15-32	3310-3322	interference	_	
15-33	3323-3326	for	_	
15-34	3327-3334	example	_	
15-35	3334-3335	)	_	
15-36	3335-3336	,	_	
15-37	3337-3339	it	_	
15-38	3340-3342	is	_	
15-39	3343-3351	possible	_	
15-40	3352-3356	that	_	
15-41	3357-3363	opioid	_	
15-42	3364-3375	medications	_	
15-43	3376-3381	could	_	
15-44	3382-3384	be	_	
15-45	3385-3395	benefiting	_	
15-46	3396-3401	brain	_	
15-47	3402-3408	reward	_	
15-48	3409-3419	processing	_	
15-49	3420-3423	and	_	
15-50	3424-3434	associated	_	
15-51	3435-3441	reward	_	
15-52	3442-3450	behavior	_	
15-53	3451-3453	in	_	
15-54	3454-3462	patients	_	
15-55	3463-3467	with	_	
15-56	3468-3475	chronic	_	
15-57	3476-3480	pain	_	
15-58	3480-3481	.	_	

#Text=Endogenous opioids are heavily involved in neural circuits implicated in reward processing.
16-1	3482-3492	Endogenous	_	
16-2	3493-3500	opioids	_	
16-3	3501-3504	are	_	
16-4	3505-3512	heavily	_	
16-5	3513-3521	involved	_	
16-6	3522-3524	in	_	
16-7	3525-3531	neural	_	
16-8	3532-3540	circuits	_	
16-9	3541-3551	implicated	_	
16-10	3552-3554	in	_	
16-11	3555-3561	reward	_	
16-12	3562-3572	processing	_	
16-13	3572-3573	.	_	

#Text=Neural circuits implicated in reward processing include a network of cortical and subcortical regions including the nucleus accumbens (NAcc) within the ventral striatum, medial prefrontal cortex (MPFC), ventral tegmental area (VTA), amygdala, insular cortex, thalamus, and anterior cingulate cortex (ACC).
17-1	3574-3580	Neural	_	
17-2	3581-3589	circuits	_	
17-3	3590-3600	implicated	_	
17-4	3601-3603	in	_	
17-5	3604-3610	reward	_	
17-6	3611-3621	processing	_	
17-7	3622-3629	include	_	
17-8	3630-3631	a	_	
17-9	3632-3639	network	_	
17-10	3640-3642	of	_	
17-11	3643-3651	cortical	_	
17-12	3652-3655	and	_	
17-13	3656-3667	subcortical	_	
17-14	3668-3675	regions	_	
17-15	3676-3685	including	_	
17-16	3686-3689	the	_	
17-17	3690-3697	nucleus	_	
17-18	3698-3707	accumbens	_	
17-19	3708-3709	(	_	
17-20	3709-3713	NAcc	_	
17-21	3713-3714	)	_	
17-22	3715-3721	within	_	
17-23	3722-3725	the	_	
17-24	3726-3733	ventral	_	
17-25	3734-3742	striatum	_	
17-26	3742-3743	,	_	
17-27	3744-3750	medial	_	
17-28	3751-3761	prefrontal	_	
17-29	3762-3768	cortex	_	
17-30	3769-3770	(	_	
17-31	3770-3774	MPFC	_	
17-32	3774-3775	)	_	
17-33	3775-3776	,	_	
17-34	3777-3784	ventral	_	
17-35	3785-3794	tegmental	_	
17-36	3795-3799	area	_	
17-37	3800-3801	(	_	
17-38	3801-3804	VTA	_	
17-39	3804-3805	)	_	
17-40	3805-3806	,	_	
17-41	3807-3815	amygdala	_	
17-42	3815-3816	,	_	
17-43	3817-3824	insular	_	
17-44	3825-3831	cortex	_	
17-45	3831-3832	,	_	
17-46	3833-3841	thalamus	_	
17-47	3841-3842	,	_	
17-48	3843-3846	and	_	
17-49	3847-3855	anterior	_	
17-50	3856-3865	cingulate	_	
17-51	3866-3872	cortex	_	
17-52	3873-3874	(	_	
17-53	3874-3877	ACC	_	
17-54	3877-3878	)	_	
17-55	3878-3879	.	_	

#Text=Exogenous opioids can modulate reward-related behavior in animals (i.e., enhance drug reinforcement/place preference), and endogenous opioids partially mediate stress-induced analgesia in humans.
18-1	3880-3889	Exogenous	_	
18-2	3890-3897	opioids	_	
18-3	3898-3901	can	_	
18-4	3902-3910	modulate	_	
18-5	3911-3925	reward-related	_	
18-6	3926-3934	behavior	_	
18-7	3935-3937	in	_	
18-8	3938-3945	animals	_	
18-9	3946-3947	(	_	
18-10	3947-3950	i.e	_	
18-11	3950-3951	.	_	
18-12	3951-3952	,	_	
18-13	3953-3960	enhance	_	
18-14	3961-3965	drug	_	
18-15	3966-3979	reinforcement	_	
18-16	3979-3980	/	_	
18-17	3980-3985	place	_	
18-18	3986-3996	preference	_	
18-19	3996-3997	)	_	
18-20	3997-3998	,	_	
18-21	3999-4002	and	_	
18-22	4003-4013	endogenous	_	
18-23	4014-4021	opioids	_	
18-24	4022-4031	partially	_	
18-25	4032-4039	mediate	_	
18-26	4040-4054	stress-induced	_	
18-27	4055-4064	analgesia	_	
18-28	4065-4067	in	_	
18-29	4068-4074	humans	_	
18-30	4074-4075	.	_	

#Text=To date, a fair amount of published data exists on reward processing and effects of opioids on brain reward circuits in animal models of chronic pain.
19-1	4076-4078	To	_	
19-2	4079-4083	date	_	
19-3	4083-4084	,	_	
19-4	4085-4086	a	_	
19-5	4087-4091	fair	_	
19-6	4092-4098	amount	_	
19-7	4099-4101	of	_	
19-8	4102-4111	published	_	
19-9	4112-4116	data	_	
19-10	4117-4123	exists	_	
19-11	4124-4126	on	_	
19-12	4127-4133	reward	_	
19-13	4134-4144	processing	_	
19-14	4145-4148	and	_	
19-15	4149-4156	effects	_	
19-16	4157-4159	of	_	
19-17	4160-4167	opioids	_	
19-18	4168-4170	on	_	
19-19	4171-4176	brain	_	
19-20	4177-4183	reward	_	
19-21	4184-4192	circuits	_	
19-22	4193-4195	in	_	
19-23	4196-4202	animal	_	
19-24	4203-4209	models	_	
19-25	4210-4212	of	_	
19-26	4213-4220	chronic	_	
19-27	4221-4225	pain	_	
19-28	4225-4226	.	_	

#Text=In sharp contrast, limited data currently exist on how use of exogenous opioids influence reward processing in humans with chronic pain.
20-1	4227-4229	In	_	
20-2	4230-4235	sharp	_	
20-3	4236-4244	contrast	_	
20-4	4244-4245	,	_	
20-5	4246-4253	limited	_	
20-6	4254-4258	data	_	
20-7	4259-4268	currently	_	
20-8	4269-4274	exist	_	
20-9	4275-4277	on	_	
20-10	4278-4281	how	_	
20-11	4282-4285	use	_	
20-12	4286-4288	of	_	
20-13	4289-4298	exogenous	_	
20-14	4299-4306	opioids	_	
20-15	4307-4316	influence	_	
20-16	4317-4323	reward	_	
20-17	4324-4334	processing	_	
20-18	4335-4337	in	_	
20-19	4338-4344	humans	_	
20-20	4345-4349	with	_	
20-21	4350-4357	chronic	_	
20-22	4358-4362	pain	_	
20-23	4362-4363	.	_	

#Text=It has been shown that individuals taking opioids (without chronic pain) have reduced functional connectivity (correlated activity) between the NAcc and other reward-related regions including the medial inferior orbitofrontal cortex.
21-1	4364-4366	It	_	
21-2	4367-4370	has	_	
21-3	4371-4375	been	_	
21-4	4376-4381	shown	_	
21-5	4382-4386	that	_	
21-6	4387-4398	individuals	_	
21-7	4399-4405	taking	_	
21-8	4406-4413	opioids	_	
21-9	4414-4415	(	_	
21-10	4415-4422	without	_	
21-11	4423-4430	chronic	_	
21-12	4431-4435	pain	_	
21-13	4435-4436	)	_	
21-14	4437-4441	have	_	
21-15	4442-4449	reduced	_	
21-16	4450-4460	functional	_	
21-17	4461-4473	connectivity	_	
21-18	4474-4475	(	_	
21-19	4475-4485	correlated	_	
21-20	4486-4494	activity	_	
21-21	4494-4495	)	_	
21-22	4496-4503	between	_	
21-23	4504-4507	the	_	
21-24	4508-4512	NAcc	_	
21-25	4513-4516	and	_	
21-26	4517-4522	other	_	
21-27	4523-4537	reward-related	_	
21-28	4538-4545	regions	_	
21-29	4546-4555	including	_	
21-30	4556-4559	the	_	
21-31	4560-4566	medial	_	
21-32	4567-4575	inferior	_	
21-33	4576-4589	orbitofrontal	_	
21-34	4590-4596	cortex	_	
21-35	4596-4597	.	_	

#Text=Additionally, in individuals with chronic low back pain, rapid structural changes occur in brain regions involved in pain and reward processing (including the amygdala and orbitofrontal cortex) after only one month of opioid therapy.
22-1	4598-4610	Additionally	_	
22-2	4610-4611	,	_	
22-3	4612-4614	in	_	
22-4	4615-4626	individuals	_	
22-5	4627-4631	with	_	
22-6	4632-4639	chronic	_	
22-7	4640-4643	low	_	
22-8	4644-4648	back	_	
22-9	4649-4653	pain	_	
22-10	4653-4654	,	_	
22-11	4655-4660	rapid	_	
22-12	4661-4671	structural	_	
22-13	4672-4679	changes	_	
22-14	4680-4685	occur	_	
22-15	4686-4688	in	_	
22-16	4689-4694	brain	_	
22-17	4695-4702	regions	_	
22-18	4703-4711	involved	_	
22-19	4712-4714	in	_	
22-20	4715-4719	pain	_	
22-21	4720-4723	and	_	
22-22	4724-4730	reward	_	
22-23	4731-4741	processing	_	
22-24	4742-4743	(	_	
22-25	4743-4752	including	_	
22-26	4753-4756	the	_	
22-27	4757-4765	amygdala	_	
22-28	4766-4769	and	_	
22-29	4770-4783	orbitofrontal	_	
22-30	4784-4790	cortex	_	
22-31	4790-4791	)	_	
22-32	4792-4797	after	_	
22-33	4798-4802	only	_	
22-34	4803-4806	one	_	
22-35	4807-4812	month	_	
22-36	4813-4815	of	_	
22-37	4816-4822	opioid	_	
22-38	4823-4830	therapy	_	
22-39	4830-4831	.	_	

#Text=The study of reward and punishment is highly relevant for chronic pain.
23-1	4832-4835	The	_	
23-2	4836-4841	study	_	
23-3	4842-4844	of	_	
23-4	4845-4851	reward	_	
23-5	4852-4855	and	_	
23-6	4856-4866	punishment	_	
23-7	4867-4869	is	_	
23-8	4870-4876	highly	_	
23-9	4877-4885	relevant	_	
23-10	4886-4889	for	_	
23-11	4890-4897	chronic	_	
23-12	4898-4902	pain	_	
23-13	4902-4903	.	_	

#Text=One of the most common features of someone in chronic pain, including fibromyalgia, is the development of fear-avoidance to movement, or kinesophobia.
24-1	4904-4907	One	_	
24-2	4908-4910	of	_	
24-3	4911-4914	the	_	
24-4	4915-4919	most	_	
24-5	4920-4926	common	_	
24-6	4927-4935	features	_	
24-7	4936-4938	of	_	
24-8	4939-4946	someone	_	
24-9	4947-4949	in	_	
24-10	4950-4957	chronic	_	
24-11	4958-4962	pain	_	
24-12	4962-4963	,	_	
24-13	4964-4973	including	_	
24-14	4974-4986	fibromyalgia	_	
24-15	4986-4987	,	_	
24-16	4988-4990	is	_	
24-17	4991-4994	the	_	
24-18	4995-5006	development	_	
24-19	5007-5009	of	_	
24-20	5010-5024	fear-avoidance	_	
24-21	5025-5027	to	_	
24-22	5028-5036	movement	_	
24-23	5036-5037	,	_	
24-24	5038-5040	or	_	
24-25	5041-5053	kinesophobia	_	
24-26	5053-5054	.	_	

#Text=This phenomenon is a great barrier to treating patients and helping improve their physical function and quality of life.
25-1	5055-5059	This	_	
25-2	5060-5070	phenomenon	_	
25-3	5071-5073	is	_	
25-4	5074-5075	a	_	
25-5	5076-5081	great	_	
25-6	5082-5089	barrier	_	
25-7	5090-5092	to	_	
25-8	5093-5101	treating	_	
25-9	5102-5110	patients	_	
25-10	5111-5114	and	_	
25-11	5115-5122	helping	_	
25-12	5123-5130	improve	_	
25-13	5131-5136	their	_	
25-14	5137-5145	physical	_	
25-15	5146-5154	function	_	
25-16	5155-5158	and	_	
25-17	5159-5166	quality	_	
25-18	5167-5169	of	_	
25-19	5170-5174	life	_	
25-20	5174-5175	.	_	

#Text=Physical activity leads to pain (a punishment), which in turn progressively diminishes physical activity frequency, while avoidance of movement (and pain) is rewarding in the short-term which reinforces this maladaptive cycle.
26-1	5176-5184	Physical	_	
26-2	5185-5193	activity	_	
26-3	5194-5199	leads	_	
26-4	5200-5202	to	_	
26-5	5203-5207	pain	_	
26-6	5208-5209	(	_	
26-7	5209-5210	a	_	
26-8	5211-5221	punishment	_	
26-9	5221-5222	)	_	
26-10	5222-5223	,	_	
26-11	5224-5229	which	_	
26-12	5230-5232	in	_	
26-13	5233-5237	turn	_	
26-14	5238-5251	progressively	_	
26-15	5252-5262	diminishes	_	
26-16	5263-5271	physical	_	
26-17	5272-5280	activity	_	
26-18	5281-5290	frequency	_	
26-19	5290-5291	,	_	
26-20	5292-5297	while	_	
26-21	5298-5307	avoidance	_	
26-22	5308-5310	of	_	
26-23	5311-5319	movement	_	
26-24	5320-5321	(	_	
26-25	5321-5324	and	_	
26-26	5325-5329	pain	_	
26-27	5329-5330	)	_	
26-28	5331-5333	is	_	
26-29	5334-5343	rewarding	_	
26-30	5344-5346	in	_	
26-31	5347-5350	the	_	
26-32	5351-5361	short-term	_	
26-33	5362-5367	which	_	
26-34	5368-5378	reinforces	_	
26-35	5379-5383	this	_	
26-36	5384-5395	maladaptive	_	
26-37	5396-5401	cycle	_	
26-38	5401-5402	.	_	

#Text=Thus, it is important to understand the mediators, moderators, and mechanisms of reward and punishment to develop and optimize safe and effective treatments to reduce or break this cycle.
27-1	5403-5407	Thus	_	
27-2	5407-5408	,	_	
27-3	5409-5411	it	_	
27-4	5412-5414	is	_	
27-5	5415-5424	important	_	
27-6	5425-5427	to	_	
27-7	5428-5438	understand	_	
27-8	5439-5442	the	_	
27-9	5443-5452	mediators	_	
27-10	5452-5453	,	_	
27-11	5454-5464	moderators	_	
27-12	5464-5465	,	_	
27-13	5466-5469	and	_	
27-14	5470-5480	mechanisms	_	
27-15	5481-5483	of	_	
27-16	5484-5490	reward	_	
27-17	5491-5494	and	_	
27-18	5495-5505	punishment	_	
27-19	5506-5508	to	_	
27-20	5509-5516	develop	_	
27-21	5517-5520	and	_	
27-22	5521-5529	optimize	_	
27-23	5530-5534	safe	_	
27-24	5535-5538	and	_	
27-25	5539-5548	effective	_	
27-26	5549-5559	treatments	_	
27-27	5560-5562	to	_	
27-28	5563-5569	reduce	_	
27-29	5570-5572	or	_	
27-30	5573-5578	break	_	
27-31	5579-5583	this	_	
27-32	5584-5589	cycle	_	
27-33	5589-5590	.	_	

#Text=Chronic pain can alter neural function implicated in incentive processing, for example via reduced neurotransmission in motivational circuits in rodent models of chronic pain and as evidenced by reduced NAcc response to painful stimulus offset in chronic pain patients.
28-1	5591-5598	Chronic	_	
28-2	5599-5603	pain	_	
28-3	5604-5607	can	_	
28-4	5608-5613	alter	_	
28-5	5614-5620	neural	_	
28-6	5621-5629	function	_	
28-7	5630-5640	implicated	_	
28-8	5641-5643	in	_	
28-9	5644-5653	incentive	_	
28-10	5654-5664	processing	_	
28-11	5664-5665	,	_	
28-12	5666-5669	for	_	
28-13	5670-5677	example	_	
28-14	5678-5681	via	_	
28-15	5682-5689	reduced	_	
28-16	5690-5707	neurotransmission	_	
28-17	5708-5710	in	_	
28-18	5711-5723	motivational	_	
28-19	5724-5732	circuits	_	
28-20	5733-5735	in	_	
28-21	5736-5742	rodent	_	
28-22	5743-5749	models	_	
28-23	5750-5752	of	_	
28-24	5753-5760	chronic	_	
28-25	5761-5765	pain	_	
28-26	5766-5769	and	_	
28-27	5770-5772	as	_	
28-28	5773-5782	evidenced	_	
28-29	5783-5785	by	_	
28-30	5786-5793	reduced	_	
28-31	5794-5798	NAcc	_	
28-32	5799-5807	response	_	
28-33	5808-5810	to	_	
28-34	5811-5818	painful	_	
28-35	5819-5827	stimulus	_	
28-36	5828-5834	offset	_	
28-37	5835-5837	in	_	
28-38	5838-5845	chronic	_	
28-39	5846-5850	pain	_	
28-40	5851-5859	patients	_	
28-41	5859-5860	.	_	

#Text=Further, individuals with chronic pain may have reduced brain opioid and dopamine function.
29-1	5861-5868	Further	_	
29-2	5868-5869	,	_	
29-3	5870-5881	individuals	_	
29-4	5882-5886	with	_	
29-5	5887-5894	chronic	_	
29-6	5895-5899	pain	_	
29-7	5900-5903	may	_	
29-8	5904-5908	have	_	
29-9	5909-5916	reduced	_	
29-10	5917-5922	brain	_	
29-11	5923-5929	opioid	_	
29-12	5930-5933	and	_	
29-13	5934-5942	dopamine	_	
29-14	5943-5951	function	_	
29-15	5951-5952	.	_	

#Text=Moreover, we have shown in a previous publication that individuals with fibromyalgia have reduced arousal to monetary incentive cues, reduced responses in the MPFC during reward anticipation, and increased MPFC response to non-loss outcomes (or avoidance of punishment).
30-1	5953-5961	Moreover	_	
30-2	5961-5962	,	_	
30-3	5963-5965	we	_	
30-4	5966-5970	have	_	
30-5	5971-5976	shown	_	
30-6	5977-5979	in	_	
30-7	5980-5981	a	_	
30-8	5982-5990	previous	_	
30-9	5991-6002	publication	_	
30-10	6003-6007	that	_	
30-11	6008-6019	individuals	_	
30-12	6020-6024	with	_	
30-13	6025-6037	fibromyalgia	_	
30-14	6038-6042	have	_	
30-15	6043-6050	reduced	_	
30-16	6051-6058	arousal	_	
30-17	6059-6061	to	_	
30-18	6062-6070	monetary	_	
30-19	6071-6080	incentive	_	
30-20	6081-6085	cues	_	
30-21	6085-6086	,	_	
30-22	6087-6094	reduced	_	
30-23	6095-6104	responses	_	
30-24	6105-6107	in	_	
30-25	6108-6111	the	_	
30-26	6112-6116	MPFC	_	
30-27	6117-6123	during	_	
30-28	6124-6130	reward	_	
30-29	6131-6143	anticipation	_	
30-30	6143-6144	,	_	
30-31	6145-6148	and	_	
30-32	6149-6158	increased	_	
30-33	6159-6163	MPFC	_	
30-34	6164-6172	response	_	
30-35	6173-6175	to	_	
30-36	6176-6184	non-loss	_	
30-37	6185-6193	outcomes	_	
30-38	6194-6195	(	_	
30-39	6195-6197	or	_	
30-40	6198-6207	avoidance	_	
30-41	6208-6210	of	_	
30-42	6211-6221	punishment	_	
30-43	6221-6222	)	_	
30-44	6222-6223	.	_	

#Text=Neural responses to rewards can be influenced by the experience of chronic pain, use of exogenous opioids, and potential for addictive behavior associated with opioid use - and all of these factors likely interact in complex ways.
31-1	6224-6230	Neural	_	
31-2	6231-6240	responses	_	
31-3	6241-6243	to	_	
31-4	6244-6251	rewards	_	
31-5	6252-6255	can	_	
31-6	6256-6258	be	_	
31-7	6259-6269	influenced	_	
31-8	6270-6272	by	_	
31-9	6273-6276	the	_	
31-10	6277-6287	experience	_	
31-11	6288-6290	of	_	
31-12	6291-6298	chronic	_	
31-13	6299-6303	pain	_	
31-14	6303-6304	,	_	
31-15	6305-6308	use	_	
31-16	6309-6311	of	_	
31-17	6312-6321	exogenous	_	
31-18	6322-6329	opioids	_	
31-19	6329-6330	,	_	
31-20	6331-6334	and	_	
31-21	6335-6344	potential	_	
31-22	6345-6348	for	_	
31-23	6349-6358	addictive	_	
31-24	6359-6367	behavior	_	
31-25	6368-6378	associated	_	
31-26	6379-6383	with	_	
31-27	6384-6390	opioid	_	
31-28	6391-6394	use	_	
31-29	6395-6396	-	_	
31-30	6397-6400	and	_	
31-31	6401-6404	all	_	
31-32	6405-6407	of	_	
31-33	6408-6413	these	_	
31-34	6414-6421	factors	_	
31-35	6422-6428	likely	_	
31-36	6429-6437	interact	_	
31-37	6438-6440	in	_	
31-38	6441-6448	complex	_	
31-39	6449-6453	ways	_	
31-40	6453-6454	.	_	

#Text=However, very limited data currently exist on how the use of exogenous opioids influences reward processing in humans with chronic pain.
32-1	6455-6462	However	_	
32-2	6462-6463	,	_	
32-3	6464-6468	very	_	
32-4	6469-6476	limited	_	
32-5	6477-6481	data	_	
32-6	6482-6491	currently	_	
32-7	6492-6497	exist	_	
32-8	6498-6500	on	_	
32-9	6501-6504	how	_	
32-10	6505-6508	the	_	
32-11	6509-6512	use	_	
32-12	6513-6515	of	_	
32-13	6516-6525	exogenous	_	
32-14	6526-6533	opioids	_	
32-15	6534-6544	influences	_	
32-16	6545-6551	reward	_	
32-17	6552-6562	processing	_	
32-18	6563-6565	in	_	
32-19	6566-6572	humans	_	
32-20	6573-6577	with	_	
32-21	6578-6585	chronic	_	
32-22	6586-6590	pain	_	
32-23	6590-6591	.	_	

#Text=To begin characterizing effects of opioid use on reward behavior and brain reward processing in patients with chronic pain, we studied a cohort of individuals with fibromyalgia taking opioids using a well-validated monetary incentive delay (MID) task.
33-1	6592-6594	To	_	
33-2	6595-6600	begin	_	
33-3	6601-6615	characterizing	_	
33-4	6616-6623	effects	_	
33-5	6624-6626	of	_	
33-6	6627-6633	opioid	_	
33-7	6634-6637	use	_	
33-8	6638-6640	on	_	
33-9	6641-6647	reward	_	
33-10	6648-6656	behavior	_	
33-11	6657-6660	and	_	
33-12	6661-6666	brain	_	
33-13	6667-6673	reward	_	
33-14	6674-6684	processing	_	
33-15	6685-6687	in	_	
33-16	6688-6696	patients	_	
33-17	6697-6701	with	_	
33-18	6702-6709	chronic	_	
33-19	6710-6714	pain	_	
33-20	6714-6715	,	_	
33-21	6716-6718	we	_	
33-22	6719-6726	studied	_	
33-23	6727-6728	a	_	
33-24	6729-6735	cohort	_	
33-25	6736-6738	of	_	
33-26	6739-6750	individuals	_	
33-27	6751-6755	with	_	
33-28	6756-6768	fibromyalgia	_	
33-29	6769-6775	taking	_	
33-30	6776-6783	opioids	_	
33-31	6784-6789	using	_	
33-32	6790-6791	a	_	
33-33	6792-6806	well-validated	_	
33-34	6807-6815	monetary	_	
33-35	6816-6825	incentive	_	
33-36	6826-6831	delay	_	
33-37	6832-6833	(	_	
33-38	6833-6836	MID	_	
33-39	6836-6837	)	_	
33-40	6838-6842	task	_	
33-41	6842-6843	.	_	

#Text=The MID task manipulates potential monetary incentives involving gains (e.g., +$5 versus $0) and losses (e.g., −$5 versus $0) and yields measures of brain activity in response to both anticipation and outcome phases of these experiences across repeated trials.
34-1	6844-6847	The	_	
34-2	6848-6851	MID	_	
34-3	6852-6856	task	_	
34-4	6857-6868	manipulates	_	
34-5	6869-6878	potential	_	
34-6	6879-6887	monetary	_	
34-7	6888-6898	incentives	_	
34-8	6899-6908	involving	_	
34-9	6909-6914	gains	_	
34-10	6915-6916	(	_	
34-11	6916-6919	e.g	_	
34-12	6919-6920	.	_	
34-13	6920-6921	,	_	
34-14	6922-6923	+	_	
34-15	6923-6925	$5	_	
34-16	6926-6932	versus	_	
34-17	6933-6935	$0	_	
34-18	6935-6936	)	_	
34-19	6937-6940	and	_	
34-20	6941-6947	losses	_	
34-21	6948-6949	(	_	
34-22	6949-6952	e.g	_	
34-23	6952-6953	.	_	
34-24	6953-6954	,	_	
34-25	6955-6956	−	_	
34-26	6956-6958	$5	_	
34-27	6959-6965	versus	_	
34-28	6966-6968	$0	_	
34-29	6968-6969	)	_	
34-30	6970-6973	and	_	
34-31	6974-6980	yields	_	
34-32	6981-6989	measures	_	
34-33	6990-6992	of	_	
34-34	6993-6998	brain	_	
34-35	6999-7007	activity	_	
34-36	7008-7010	in	_	
34-37	7011-7019	response	_	
34-38	7020-7022	to	_	
34-39	7023-7027	both	_	
34-40	7028-7040	anticipation	_	
34-41	7041-7044	and	_	
34-42	7045-7052	outcome	_	
34-43	7053-7059	phases	_	
34-44	7060-7062	of	_	
34-45	7063-7068	these	_	
34-46	7069-7080	experiences	_	
34-47	7081-7087	across	_	
34-48	7088-7096	repeated	_	
34-49	7097-7103	trials	_	
34-50	7103-7104	.	_	

#Text=In healthy individuals participating in the MID task, reward anticipation typically elicits robust increases in bilateral NAcc activity, which correlates with ratings of positive aroused affect.
35-1	7105-7107	In	_	
35-2	7108-7115	healthy	_	
35-3	7116-7127	individuals	_	
35-4	7128-7141	participating	_	
35-5	7142-7144	in	_	
35-6	7145-7148	the	_	
35-7	7149-7152	MID	_	
35-8	7153-7157	task	_	
35-9	7157-7158	,	_	
35-10	7159-7165	reward	_	
35-11	7166-7178	anticipation	_	
35-12	7179-7188	typically	_	
35-13	7189-7196	elicits	_	
35-14	7197-7203	robust	_	
35-15	7204-7213	increases	_	
35-16	7214-7216	in	_	
35-17	7217-7226	bilateral	_	
35-18	7227-7231	NAcc	_	
35-19	7232-7240	activity	_	
35-20	7240-7241	,	_	
35-21	7242-7247	which	_	
35-22	7248-7258	correlates	_	
35-23	7259-7263	with	_	
35-24	7264-7271	ratings	_	
35-25	7272-7274	of	_	
35-26	7275-7283	positive	_	
35-27	7284-7291	aroused	_	
35-28	7292-7298	affect	_	
35-29	7298-7299	.	_	

#Text=This response is often accompanied by increased activity in the insular cortex (associated with risk), as well as other regions including the caudate and thalamus.
36-1	7300-7304	This	_	
36-2	7305-7313	response	_	
36-3	7314-7316	is	_	
36-4	7317-7322	often	_	
36-5	7323-7334	accompanied	_	
36-6	7335-7337	by	_	
36-7	7338-7347	increased	_	
36-8	7348-7356	activity	_	
36-9	7357-7359	in	_	
36-10	7360-7363	the	_	
36-11	7364-7371	insular	_	
36-12	7372-7378	cortex	_	
36-13	7379-7380	(	_	
36-14	7380-7390	associated	_	
36-15	7391-7395	with	_	
36-16	7396-7400	risk	_	
36-17	7400-7401	)	_	
36-18	7401-7402	,	_	
36-19	7403-7405	as	_	
36-20	7406-7410	well	_	
36-21	7411-7413	as	_	
36-22	7414-7419	other	_	
36-23	7420-7427	regions	_	
36-24	7428-7437	including	_	
36-25	7438-7441	the	_	
36-26	7442-7449	caudate	_	
36-27	7450-7453	and	_	
36-28	7454-7462	thalamus	_	
36-29	7462-7463	.	_	

#Text=Conversely, reward outcomes typically elicit increased activity within regions of the MPFC, along with the caudate, amygdala and putamen, indicating that anticipation and outcome represent distinct components of reward processing.
37-1	7464-7474	Conversely	_	
37-2	7474-7475	,	_	
37-3	7476-7482	reward	_	
37-4	7483-7491	outcomes	_	
37-5	7492-7501	typically	_	
37-6	7502-7508	elicit	_	
37-7	7509-7518	increased	_	
37-8	7519-7527	activity	_	
37-9	7528-7534	within	_	
37-10	7535-7542	regions	_	
37-11	7543-7545	of	_	
37-12	7546-7549	the	_	
37-13	7550-7554	MPFC	_	
37-14	7554-7555	,	_	
37-15	7556-7561	along	_	
37-16	7562-7566	with	_	
37-17	7567-7570	the	_	
37-18	7571-7578	caudate	_	
37-19	7578-7579	,	_	
37-20	7580-7588	amygdala	_	
37-21	7589-7592	and	_	
37-22	7593-7600	putamen	_	
37-23	7600-7601	,	_	
37-24	7602-7612	indicating	_	
37-25	7613-7617	that	_	
37-26	7618-7630	anticipation	_	
37-27	7631-7634	and	_	
37-28	7635-7642	outcome	_	
37-29	7643-7652	represent	_	
37-30	7653-7661	distinct	_	
37-31	7662-7672	components	_	
37-32	7673-7675	of	_	
37-33	7676-7682	reward	_	
37-34	7683-7693	processing	_	
37-35	7693-7694	.	_	

#Text=In our previous publication, fibromyalgia patients not taking opioids show normal NAcc reward anticipatory activity, but reduced MPFC reward anticipatory activity, and increased MPFC response to non-loss outcomes (non-punishment), as compared with healthy controls.
38-1	7695-7697	In	_	
38-2	7698-7701	our	_	
38-3	7702-7710	previous	_	
38-4	7711-7722	publication	_	
38-5	7722-7723	,	_	
38-6	7724-7736	fibromyalgia	_	
38-7	7737-7745	patients	_	
38-8	7746-7749	not	_	
38-9	7750-7756	taking	_	
38-10	7757-7764	opioids	_	
38-11	7765-7769	show	_	
38-12	7770-7776	normal	_	
38-13	7777-7781	NAcc	_	
38-14	7782-7788	reward	_	
38-15	7789-7801	anticipatory	_	
38-16	7802-7810	activity	_	
38-17	7810-7811	,	_	
38-18	7812-7815	but	_	
38-19	7816-7823	reduced	_	
38-20	7824-7828	MPFC	_	
38-21	7829-7835	reward	_	
38-22	7836-7848	anticipatory	_	
38-23	7849-7857	activity	_	
38-24	7857-7858	,	_	
38-25	7859-7862	and	_	
38-26	7863-7872	increased	_	
38-27	7873-7877	MPFC	_	
38-28	7878-7886	response	_	
38-29	7887-7889	to	_	
38-30	7890-7898	non-loss	_	
38-31	7899-7907	outcomes	_	
38-32	7908-7909	(	_	
38-33	7909-7923	non-punishment	_	
38-34	7923-7924	)	_	
38-35	7924-7925	,	_	
38-36	7926-7928	as	_	
38-37	7929-7937	compared	_	
38-38	7938-7942	with	_	
38-39	7943-7950	healthy	_	
38-40	7951-7959	controls	_	
38-41	7959-7960	.	_	

#Text=In the present study, we compared a new cohort of fibromyalgia patients taking opioids to the previously published data set.
39-1	7961-7963	In	_	
39-2	7964-7967	the	_	
39-3	7968-7975	present	_	
39-4	7976-7981	study	_	
39-5	7981-7982	,	_	
39-6	7983-7985	we	_	
39-7	7986-7994	compared	_	
39-8	7995-7996	a	_	
39-9	7997-8000	new	_	
39-10	8001-8007	cohort	_	
39-11	8008-8010	of	_	
39-12	8011-8023	fibromyalgia	_	
39-13	8024-8032	patients	_	
39-14	8033-8039	taking	_	
39-15	8040-8047	opioids	_	
39-16	8048-8050	to	_	
39-17	8051-8054	the	_	
39-18	8055-8065	previously	_	
39-19	8066-8075	published	_	
39-20	8076-8080	data	_	
39-21	8081-8084	set	_	
39-22	8084-8085	.	_	

#Text=While the effects of long-term opioid use on reward processing in chronic pain patients are generally unknown, we developed our current predictions based on these prior results.
40-1	8086-8091	While	_	
40-2	8092-8095	the	_	
40-3	8096-8103	effects	_	
40-4	8104-8106	of	_	
40-5	8107-8116	long-term	_	
40-6	8117-8123	opioid	_	
40-7	8124-8127	use	_	
40-8	8128-8130	on	_	
40-9	8131-8137	reward	_	
40-10	8138-8148	processing	_	
40-11	8149-8151	in	_	
40-12	8152-8159	chronic	_	
40-13	8160-8164	pain	_	
40-14	8165-8173	patients	_	
40-15	8174-8177	are	_	
40-16	8178-8187	generally	_	
40-17	8188-8195	unknown	_	
40-18	8195-8196	,	_	
40-19	8197-8199	we	_	
40-20	8200-8209	developed	_	
40-21	8210-8213	our	_	
40-22	8214-8221	current	_	
40-23	8222-8233	predictions	_	
40-24	8234-8239	based	_	
40-25	8240-8242	on	_	
40-26	8243-8248	these	_	
40-27	8249-8254	prior	_	
40-28	8255-8262	results	_	
40-29	8262-8263	.	_	

#Text=We specifically predicted that NAcc and MPFC responses to anticipated rewards and non-loss outcomes might be similarly altered in individuals with fibromyalgia taking opioids, as compared with healthy controls, and that this pattern would occur to a greater extent than in patients with fibromyalgia not taking opioids.
41-1	8264-8266	We	_	
41-2	8267-8279	specifically	_	
41-3	8280-8289	predicted	_	
41-4	8290-8294	that	_	
41-5	8295-8299	NAcc	_	
41-6	8300-8303	and	_	
41-7	8304-8308	MPFC	_	
41-8	8309-8318	responses	_	
41-9	8319-8321	to	_	
41-10	8322-8333	anticipated	_	
41-11	8334-8341	rewards	_	
41-12	8342-8345	and	_	
41-13	8346-8354	non-loss	_	
41-14	8355-8363	outcomes	_	
41-15	8364-8369	might	_	
41-16	8370-8372	be	_	
41-17	8373-8382	similarly	_	
41-18	8383-8390	altered	_	
41-19	8391-8393	in	_	
41-20	8394-8405	individuals	_	
41-21	8406-8410	with	_	
41-22	8411-8423	fibromyalgia	_	
41-23	8424-8430	taking	_	
41-24	8431-8438	opioids	_	
41-25	8438-8439	,	_	
41-26	8440-8442	as	_	
41-27	8443-8451	compared	_	
41-28	8452-8456	with	_	
41-29	8457-8464	healthy	_	
41-30	8465-8473	controls	_	
41-31	8473-8474	,	_	
41-32	8475-8478	and	_	
41-33	8479-8483	that	_	
41-34	8484-8488	this	_	
41-35	8489-8496	pattern	_	
41-36	8497-8502	would	_	
41-37	8503-8508	occur	_	
41-38	8509-8511	to	_	
41-39	8512-8513	a	_	
41-40	8514-8521	greater	_	
41-41	8522-8528	extent	_	
41-42	8529-8533	than	_	
41-43	8534-8536	in	_	
41-44	8537-8545	patients	_	
41-45	8546-8550	with	_	
41-46	8551-8563	fibromyalgia	_	
41-47	8564-8567	not	_	
41-48	8568-8574	taking	_	
41-49	8575-8582	opioids	_	
41-50	8582-8583	.	_	

#Text=Results
#Text=Participants
#Text=Participant Demographics.
42-1	8584-8591	Results	_	
42-2	8592-8604	Participants	_	
42-3	8605-8616	Participant	_	
42-4	8617-8629	Demographics	_	
42-5	8629-8630	.	_	

#Text=Controls\tNon-Opioid\tOpioid\t \tTotal Participants (all female)\t15\t17\t17\t \tRighthanded\t14\t16\t17\t \tSelf-Identified Race\t \tAsian\t6\t2\t0\t \tAfrican American\t0\t0\t1\t \tCaucasian\t8\t13\t14\t \tOther\t1\t2\t2\t \tHispanic or Latina Ethnicity\t1\t3\t2\t \tEmployment Status\t \tPart-time employed\t2\t3\t2\t \tFull-time employed\t10\t6\t2\t \tUnemployed\t3\t8\t13\t \tIncome Level\t \t$0-$29,999\t0\t5\t7\t \t$30,000-$59,999\t2\t3\t5\t \t$60,000 or more\t11\t8\t4\t \tEducation Level\t \tHigh School\t0\t3\t0\t \tCollege/University\t7\t11\t11\t \tAdvanced Degree\t8\t3\t6\t \t
#Text=“Non-opioid” and “Opioid” refer to the non-opioid fibromyalgia group and opioid fibromyalgia group respectively.
43-1	8632-8640	Controls	_	
43-2	8641-8651	Non-Opioid	_	
43-3	8652-8658	Opioid	_	
43-4	8661-8666	Total	_	
43-5	8667-8679	Participants	_	
43-6	8680-8681	(	_	
43-7	8681-8684	all	_	
43-8	8685-8691	female	_	
43-9	8691-8692	)	_	
43-10	8693-8695	15	_	
43-11	8696-8698	17	_	
43-12	8699-8701	17	_	
43-13	8704-8715	Righthanded	_	
43-14	8716-8718	14	_	
43-15	8719-8721	16	_	
43-16	8722-8724	17	_	
43-17	8727-8742	Self-Identified	_	
43-18	8743-8747	Race	_	
43-19	8750-8755	Asian	_	
43-20	8756-8757	6	_	
43-21	8758-8759	2	_	
43-22	8760-8761	0	_	
43-23	8764-8771	African	_	
43-24	8772-8780	American	_	
43-25	8781-8782	0	_	
43-26	8783-8784	0	_	
43-27	8785-8786	1	_	
43-28	8789-8798	Caucasian	_	
43-29	8799-8800	8	_	
43-30	8801-8803	13	_	
43-31	8804-8806	14	_	
43-32	8809-8814	Other	_	
43-33	8815-8816	1	_	
43-34	8817-8818	2	_	
43-35	8819-8820	2	_	
43-36	8823-8831	Hispanic	_	
43-37	8832-8834	or	_	
43-38	8835-8841	Latina	_	
43-39	8842-8851	Ethnicity	_	
43-40	8852-8853	1	_	
43-41	8854-8855	3	_	
43-42	8856-8857	2	_	
43-43	8860-8870	Employment	_	
43-44	8871-8877	Status	_	
43-45	8880-8889	Part-time	_	
43-46	8890-8898	employed	_	
43-47	8899-8900	2	_	
43-48	8901-8902	3	_	
43-49	8903-8904	2	_	
43-50	8907-8916	Full-time	_	
43-51	8917-8925	employed	_	
43-52	8926-8928	10	_	
43-53	8929-8930	6	_	
43-54	8931-8932	2	_	
43-55	8935-8945	Unemployed	_	
43-56	8946-8947	3	_	
43-57	8948-8949	8	_	
43-58	8950-8952	13	_	
43-59	8955-8961	Income	_	
43-60	8962-8967	Level	_	
43-61	8970-8972	$0	_	
43-62	8972-8973	-	_	
43-63	8973-8980	$29,999	_	
43-64	8981-8982	0	_	
43-65	8983-8984	5	_	
43-66	8985-8986	7	_	
43-67	8989-8996	$30,000	_	
43-68	8996-8997	-	_	
43-69	8997-9004	$59,999	_	
43-70	9005-9006	2	_	
43-71	9007-9008	3	_	
43-72	9009-9010	5	_	
43-73	9013-9020	$60,000	_	
43-74	9021-9023	or	_	
43-75	9024-9028	more	_	
43-76	9029-9031	11	_	
43-77	9032-9033	8	_	
43-78	9034-9035	4	_	
43-79	9038-9047	Education	_	
43-80	9048-9053	Level	_	
43-81	9056-9060	High	_	
43-82	9061-9067	School	_	
43-83	9068-9069	0	_	
43-84	9070-9071	3	_	
43-85	9072-9073	0	_	
43-86	9076-9083	College	_	
43-87	9083-9084	/	_	
43-88	9084-9094	University	_	
43-89	9095-9096	7	_	
43-90	9097-9099	11	_	
43-91	9100-9102	11	_	
43-92	9105-9113	Advanced	_	
43-93	9114-9120	Degree	_	
43-94	9121-9122	8	_	
43-95	9123-9124	3	_	
43-96	9125-9126	6	_	
43-97	9130-9131	“	_	
43-98	9131-9141	Non-opioid	_	
43-99	9141-9142	”	_	
43-100	9143-9146	and	_	
43-101	9147-9148	“	_	
43-102	9148-9154	Opioid	_	
43-103	9154-9155	”	_	
43-104	9156-9161	refer	_	
43-105	9162-9164	to	_	
43-106	9165-9168	the	_	
43-107	9169-9179	non-opioid	_	
43-108	9180-9192	fibromyalgia	_	
43-109	9193-9198	group	_	
43-110	9199-9202	and	_	
43-111	9203-9209	opioid	_	
43-112	9210-9222	fibromyalgia	_	
43-113	9223-9228	group	_	
43-114	9229-9241	respectively	_	
43-115	9241-9242	.	_	

#Text=One control participant did not indicate handedness, one non-opioid fibromyalgia subject was left handed.
44-1	9243-9246	One	_	
44-2	9247-9254	control	_	
44-3	9255-9266	participant	_	
44-4	9267-9270	did	_	
44-5	9271-9274	not	_	
44-6	9275-9283	indicate	_	
44-7	9284-9294	handedness	_	
44-8	9294-9295	,	_	
44-9	9296-9299	one	_	
44-10	9300-9310	non-opioid	_	
44-11	9311-9323	fibromyalgia	_	
44-12	9324-9331	subject	_	
44-13	9332-9335	was	_	
44-14	9336-9340	left	_	
44-15	9341-9347	handed	_	
44-16	9347-9348	.	_	

#Text=No participants were of race categories for Pacific Islander or Alaskan, or Native American (i.e., “other” refers to race other than all of these categories).
45-1	9349-9351	No	_	
45-2	9352-9364	participants	_	
45-3	9365-9369	were	_	
45-4	9370-9372	of	_	
45-5	9373-9377	race	_	
45-6	9378-9388	categories	_	
45-7	9389-9392	for	_	
45-8	9393-9400	Pacific	_	
45-9	9401-9409	Islander	_	
45-10	9410-9412	or	_	
45-11	9413-9420	Alaskan	_	
45-12	9420-9421	,	_	
45-13	9422-9424	or	_	
45-14	9425-9431	Native	_	
45-15	9432-9440	American	_	
45-16	9441-9442	(	_	
45-17	9442-9445	i.e	_	
45-18	9445-9446	.	_	
45-19	9446-9447	,	_	
45-20	9448-9449	“	_	
45-21	9449-9454	other	_	
45-22	9454-9455	”	_	
45-23	9456-9462	refers	_	
45-24	9463-9465	to	_	
45-25	9466-9470	race	_	
45-26	9471-9476	other	_	
45-27	9477-9481	than	_	
45-28	9482-9485	all	_	
45-29	9486-9488	of	_	
45-30	9489-9494	these	_	
45-31	9495-9505	categories	_	
45-32	9505-9506	)	_	
45-33	9506-9507	.	_	

#Text=High school refers to “up to or through high school”, college/university refers to “up to or through college/university”, and advanced degrees refer to “any amount of education post college/university”.
46-1	9508-9512	High	_	
46-2	9513-9519	school	_	
46-3	9520-9526	refers	_	
46-4	9527-9529	to	_	
46-5	9530-9531	“	_	
46-6	9531-9533	up	_	
46-7	9534-9536	to	_	
46-8	9537-9539	or	_	
46-9	9540-9547	through	_	
46-10	9548-9552	high	_	
46-11	9553-9559	school	_	
46-12	9559-9560	”	_	
46-13	9560-9561	,	_	
46-14	9562-9569	college	_	
46-15	9569-9570	/	_	
46-16	9570-9580	university	_	
46-17	9581-9587	refers	_	
46-18	9588-9590	to	_	
46-19	9591-9592	“	_	
46-20	9592-9594	up	_	
46-21	9595-9597	to	_	
46-22	9598-9600	or	_	
46-23	9601-9608	through	_	
46-24	9609-9616	college	_	
46-25	9616-9617	/	_	
46-26	9617-9627	university	_	
46-27	9627-9628	”	_	
46-28	9628-9629	,	_	
46-29	9630-9633	and	_	
46-30	9634-9642	advanced	_	
46-31	9643-9650	degrees	_	
46-32	9651-9656	refer	_	
46-33	9657-9659	to	_	
46-34	9660-9661	“	_	
46-35	9661-9664	any	_	
46-36	9665-9671	amount	_	
46-37	9672-9674	of	_	
46-38	9675-9684	education	_	
46-39	9685-9689	post	_	
46-40	9690-9697	college	_	
46-41	9697-9698	/	_	
46-42	9698-9708	university	_	
46-43	9708-9709	”	_	
46-44	9709-9710	.	_	

#Text=Participants in the study underwent two sequential fMRI scans involving the monetary incentive delay (MID) task (MID-1 and MID-2, which used the same MID task but differently ordered trials) which together took approximately 20 minutes total.
47-1	9711-9723	Participants	_	
47-2	9724-9726	in	_	
47-3	9727-9730	the	_	
47-4	9731-9736	study	_	
47-5	9737-9746	underwent	_	
47-6	9747-9750	two	_	
47-7	9751-9761	sequential	_	
47-8	9762-9766	fMRI	_	
47-9	9767-9772	scans	_	
47-10	9773-9782	involving	_	
47-11	9783-9786	the	_	
47-12	9787-9795	monetary	_	
47-13	9796-9805	incentive	_	
47-14	9806-9811	delay	_	
47-15	9812-9813	(	_	
47-16	9813-9816	MID	_	
47-17	9816-9817	)	_	
47-18	9818-9822	task	_	
47-19	9823-9824	(	_	
47-20	9824-9827	MID	_	
47-21	9827-9828	-	_	
47-22	9828-9829	1	_	
47-23	9830-9833	and	_	
47-24	9834-9837	MID	_	
47-25	9837-9838	-	_	
47-26	9838-9839	2	_	
47-27	9839-9840	,	_	
47-28	9841-9846	which	_	
47-29	9847-9851	used	_	
47-30	9852-9855	the	_	
47-31	9856-9860	same	_	
47-32	9861-9864	MID	_	
47-33	9865-9869	task	_	
47-34	9870-9873	but	_	
47-35	9874-9885	differently	_	
47-36	9886-9893	ordered	_	
47-37	9894-9900	trials	_	
47-38	9900-9901	)	_	
47-39	9902-9907	which	_	
47-40	9908-9916	together	_	
47-41	9917-9921	took	_	
47-42	9922-9935	approximately	_	
47-43	9936-9938	20	_	
47-44	9939-9946	minutes	_	
47-45	9947-9952	total	_	
47-46	9952-9953	.	_	

#Text=Post-scan cue-associated ratings of arousal and valence, and clinical and psychological questionnaires were collected to assess potential correlations between brain (fMRI) and behavioral data (see Methods for details).
48-1	9954-9963	Post-scan	_	
48-2	9964-9978	cue-associated	_	
48-3	9979-9986	ratings	_	
48-4	9987-9989	of	_	
48-5	9990-9997	arousal	_	
48-6	9998-10001	and	_	
48-7	10002-10009	valence	_	
48-8	10009-10010	,	_	
48-9	10011-10014	and	_	
48-10	10015-10023	clinical	_	
48-11	10024-10027	and	_	
48-12	10028-10041	psychological	_	
48-13	10042-10056	questionnaires	_	
48-14	10057-10061	were	_	
48-15	10062-10071	collected	_	
48-16	10072-10074	to	_	
48-17	10075-10081	assess	_	
48-18	10082-10091	potential	_	
48-19	10092-10104	correlations	_	
48-20	10105-10112	between	_	
48-21	10113-10118	brain	_	
48-22	10119-10120	(	_	
48-23	10120-10124	fMRI	_	
48-24	10124-10125	)	_	
48-25	10126-10129	and	_	
48-26	10130-10140	behavioral	_	
48-27	10141-10145	data	_	
48-28	10146-10147	(	_	
48-29	10147-10150	see	_	
48-30	10151-10158	Methods	_	
48-31	10159-10162	for	_	
48-32	10163-10170	details	_	
48-33	10170-10171	)	_	
48-34	10171-10172	.	_	

#Text=Seventeen healthy control participants, 18 individuals with fibromyalgia not taking opioids, and 19 individuals with fibromyalgia taking opioids signed informed consent for the study.
49-1	10173-10182	Seventeen	_	
49-2	10183-10190	healthy	_	
49-3	10191-10198	control	_	
49-4	10199-10211	participants	_	
49-5	10211-10212	,	_	
49-6	10213-10215	18	_	
49-7	10216-10227	individuals	_	
49-8	10228-10232	with	_	
49-9	10233-10245	fibromyalgia	_	
49-10	10246-10249	not	_	
49-11	10250-10256	taking	_	
49-12	10257-10264	opioids	_	
49-13	10264-10265	,	_	
49-14	10266-10269	and	_	
49-15	10270-10272	19	_	
49-16	10273-10284	individuals	_	
49-17	10285-10289	with	_	
49-18	10290-10302	fibromyalgia	_	
49-19	10303-10309	taking	_	
49-20	10310-10317	opioids	_	
49-21	10318-10324	signed	_	
49-22	10325-10333	informed	_	
49-23	10334-10341	consent	_	
49-24	10342-10345	for	_	
49-25	10346-10349	the	_	
49-26	10350-10355	study	_	
49-27	10355-10356	.	_	

#Text=Data from 5 participants were excluded because of an incomplete scanning session due to artifacts (N = 1 non-opioid fibromyalgia), excessive head motion (N = 2 controls, N = 1 opioid fibromyalgia), presentation of two MID-1 scans during the scans (different number of trials, and different trial order; N = 1 opioid fibromyalgia).
50-1	10357-10361	Data	_	
50-2	10362-10366	from	_	
50-3	10367-10368	5	_	
50-4	10369-10381	participants	_	
50-5	10382-10386	were	_	
50-6	10387-10395	excluded	_	
50-7	10396-10403	because	_	
50-8	10404-10406	of	_	
50-9	10407-10409	an	_	
50-10	10410-10420	incomplete	_	
50-11	10421-10429	scanning	_	
50-12	10430-10437	session	_	
50-13	10438-10441	due	_	
50-14	10442-10444	to	_	
50-15	10445-10454	artifacts	_	
50-16	10455-10456	(	_	
50-17	10456-10457	N	_	
50-18	10458-10459	=	_	
50-19	10460-10461	1	_	
50-20	10462-10472	non-opioid	_	
50-21	10473-10485	fibromyalgia	_	
50-22	10485-10486	)	_	
50-23	10486-10487	,	_	
50-24	10488-10497	excessive	_	
50-25	10498-10502	head	_	
50-26	10503-10509	motion	_	
50-27	10510-10511	(	_	
50-28	10511-10512	N	_	
50-29	10513-10514	=	_	
50-30	10515-10516	2	_	
50-31	10517-10525	controls	_	
50-32	10525-10526	,	_	
50-33	10527-10528	N	_	
50-34	10529-10530	=	_	
50-35	10531-10532	1	_	
50-36	10533-10539	opioid	_	
50-37	10540-10552	fibromyalgia	_	
50-38	10552-10553	)	_	
50-39	10553-10554	,	_	
50-40	10555-10567	presentation	_	
50-41	10568-10570	of	_	
50-42	10571-10574	two	_	
50-43	10575-10578	MID	_	
50-44	10578-10579	-	_	
50-45	10579-10580	1	_	
50-46	10581-10586	scans	_	
50-47	10587-10593	during	_	
50-48	10594-10597	the	_	
50-49	10598-10603	scans	_	
50-50	10604-10605	(	_	
50-51	10605-10614	different	_	
50-52	10615-10621	number	_	
50-53	10622-10624	of	_	
50-54	10625-10631	trials	_	
50-55	10631-10632	,	_	
50-56	10633-10636	and	_	
50-57	10637-10646	different	_	
50-58	10647-10652	trial	_	
50-59	10653-10658	order	_	
50-60	10658-10659	;	_	
50-61	10660-10661	N	_	
50-62	10662-10663	=	_	
50-63	10664-10665	1	_	
50-64	10666-10672	opioid	_	
50-65	10673-10685	fibromyalgia	_	
50-66	10685-10686	)	_	
50-67	10686-10687	.	_	

#Text=Thus, data from 15 healthy controls and 34 females with fibromyalgia (17 taking opioids, 17 not taking opioids) were included in the analysis (Table 1).
51-1	10688-10692	Thus	_	
51-2	10692-10693	,	_	
51-3	10694-10698	data	_	
51-4	10699-10703	from	_	
51-5	10704-10706	15	_	
51-6	10707-10714	healthy	_	
51-7	10715-10723	controls	_	
51-8	10724-10727	and	_	
51-9	10728-10730	34	_	
51-10	10731-10738	females	_	
51-11	10739-10743	with	_	
51-12	10744-10756	fibromyalgia	_	
51-13	10757-10758	(	_	
51-14	10758-10760	17	_	
51-15	10761-10767	taking	_	
51-16	10768-10775	opioids	_	
51-17	10775-10776	,	_	
51-18	10777-10779	17	_	
51-19	10780-10783	not	_	
51-20	10784-10790	taking	_	
51-21	10791-10798	opioids	_	
51-22	10798-10799	)	_	
51-23	10800-10804	were	_	
51-24	10805-10813	included	_	
51-25	10814-10816	in	_	
51-26	10817-10820	the	_	
51-27	10821-10829	analysis	_	
51-28	10830-10831	(	_	
51-29	10831-10836	Table	_	
51-30	10836-10837	 	_	
51-31	10837-10838	1	_	
51-32	10838-10839	)	_	
51-33	10839-10840	.	_	

#Text=Clinical, and psychological patient profiles
#Text=Clinical, Behavioral, and Psychological Measures.
52-1	10841-10849	Clinical	_	
52-2	10849-10850	,	_	
52-3	10851-10854	and	_	
52-4	10855-10868	psychological	_	
52-5	10869-10876	patient	_	
52-6	10877-10885	profiles	_	
52-7	10886-10894	Clinical	_	
52-8	10894-10895	,	_	
52-9	10896-10906	Behavioral	_	
52-10	10906-10907	,	_	
52-11	10908-10911	and	_	
52-12	10912-10925	Psychological	_	
52-13	10926-10934	Measures	_	
52-14	10934-10935	.	_	

#Text=Controls\tNon-opioid FM\tOpioid FM\tANOVA\tFM t-test\t \tN\tMean ± sd\tN\tMean ± sd\tN\tMean ± sd\tP-Value\tP-Value\t \tAge\t15\t48.1 ± 10.2\t17\t48.1 ± 9.6\t17\t52.8 ± 6.9\t0.237\t0.295\t \tPositive Affect (PANAS)\t15\t36.4 ± 5.4\t17\t26.4 ± 8.5\t17\t24.2 ± 7.2\tp < 0.001\t0.655\t \tNegative Affect (PANAS)\t15\t13.1 ± 4.1\t17\t21.2 ± 8.0\t17\t21.6 ± 7.1\t0.001\t0.982\t \tBehavioral Reward (BAS)\t14\t20.4 ± 2.9\t16\t20.4 ± 2.6\t17\t16.4 ± 8.1\t0.412\t0.453\t \tBehavioral Drive (BAS)\t14\t13.7 ± 3.9\t16\t13.8 ± 3.6\t17\t9.3 ± 5.0\t0.064\t0.088\t \tBehavioral Fun (BAS)\t14\t14.6 ± 2.3\t16\t13.3 ± 2.8\t17\t9.5 ± 5.0\t0.034\t0.147\t \tBehavioral Inhibition (BIS)\t14\t21.1 ± 6.0\t16\t28.2 ± 3.5\t17\t23.1 ± 11.6\t0.125\t0.515\t \tMood Disturbance (POMS)\t15\t−4.5 ± 8.6\t17\t21.6 ± 15.8\t17\t24.2 ± 17.2\tp < 0.001\t0.862\t \tFatigue (PROMIS)\t15\t48 ± 6.5\t17\t65.5 ± 8.0\t16\t70.7 ± 5.0\tp < 0.001\t0.075\t \tTrait Anxiety (STAI)\t15\t34.9 ± 8.3\t17\t49.7 ± 8.5\t17\t51.9 ± 12.4\tp < 0.001\t0.793\t \tState Anxiety (STAI)\t15\t27.1 ± 7.5\t17\t41.4 ± 7.0\t17\t41.9 ± 12.8\tp < 0.001\t0.989\t \tDepression (BDI)\t15\t2.3 ± 3.1\t17\t15.8 ± 8.9\t17\t15.2 ± 9.3\tp < 0.001\t0.973\t \tNumber of Pain Areas (FAF)\t15\t1.5 ± 2.0\t17\t13.9 ± 3.9\t17\t12.6 ± 3.7\tp < 0.001\t0.508\t \tPain Severity (BPI)\t15\t0.4 ± 1.0\t17\t5.7 ± 2.1\t17\t6.0 ± 1.5\tp < 0.001\t0.848\t \tPain Interference (BPI)\t15\t3.5 ± 6.4\t17\t36.9 ± 19.5\t17\t42.8 ± 17\tp < 0.001\t0.515\t \t
#Text=Participant counts for each measure differ from the total number of participants (controls N = 15, non-opioid fibromyalgia (FM) N = 17, opioid FM N = 17) because some participants did not complete all questionnaires.
53-1	10937-10945	Controls	_	
53-2	10946-10956	Non-opioid	_	
53-3	10957-10959	FM	_	
53-4	10960-10966	Opioid	_	
53-5	10967-10969	FM	_	
53-6	10970-10975	ANOVA	_	
53-7	10976-10978	FM	_	
53-8	10979-10985	t-test	_	
53-9	10988-10989	N	_	
53-10	10990-10994	Mean	_	
53-11	10995-10996	±	_	
53-12	10997-10999	sd	_	
53-13	11000-11001	N	_	
53-14	11002-11006	Mean	_	
53-15	11007-11008	±	_	
53-16	11009-11011	sd	_	
53-17	11012-11013	N	_	
53-18	11014-11018	Mean	_	
53-19	11019-11020	±	_	
53-20	11021-11023	sd	_	
53-21	11024-11031	P-Value	_	
53-22	11032-11039	P-Value	_	
53-23	11042-11045	Age	_	
53-24	11046-11048	15	_	
53-25	11049-11053	48.1	_	
53-26	11054-11055	±	_	
53-27	11056-11060	10.2	_	
53-28	11061-11063	17	_	
53-29	11064-11068	48.1	_	
53-30	11069-11070	±	_	
53-31	11071-11074	9.6	_	
53-32	11075-11077	17	_	
53-33	11078-11082	52.8	_	
53-34	11083-11084	±	_	
53-35	11085-11088	6.9	_	
53-36	11089-11094	0.237	_	
53-37	11095-11100	0.295	_	
53-38	11103-11111	Positive	_	
53-39	11112-11118	Affect	_	
53-40	11119-11120	(	_	
53-41	11120-11125	PANAS	_	
53-42	11125-11126	)	_	
53-43	11127-11129	15	_	
53-44	11130-11134	36.4	_	
53-45	11135-11136	±	_	
53-46	11137-11140	5.4	_	
53-47	11141-11143	17	_	
53-48	11144-11148	26.4	_	
53-49	11149-11150	±	_	
53-50	11151-11154	8.5	_	
53-51	11155-11157	17	_	
53-52	11158-11162	24.2	_	
53-53	11163-11164	±	_	
53-54	11165-11168	7.2	_	
53-55	11169-11170	p	_	
53-56	11171-11172	<	_	
53-57	11173-11178	0.001	_	
53-58	11179-11184	0.655	_	
53-59	11187-11195	Negative	_	
53-60	11196-11202	Affect	_	
53-61	11203-11204	(	_	
53-62	11204-11209	PANAS	_	
53-63	11209-11210	)	_	
53-64	11211-11213	15	_	
53-65	11214-11218	13.1	_	
53-66	11219-11220	±	_	
53-67	11221-11224	4.1	_	
53-68	11225-11227	17	_	
53-69	11228-11232	21.2	_	
53-70	11233-11234	±	_	
53-71	11235-11238	8.0	_	
53-72	11239-11241	17	_	
53-73	11242-11246	21.6	_	
53-74	11247-11248	±	_	
53-75	11249-11252	7.1	_	
53-76	11253-11258	0.001	_	
53-77	11259-11264	0.982	_	
53-78	11267-11277	Behavioral	_	
53-79	11278-11284	Reward	_	
53-80	11285-11286	(	_	
53-81	11286-11289	BAS	_	
53-82	11289-11290	)	_	
53-83	11291-11293	14	_	
53-84	11294-11298	20.4	_	
53-85	11299-11300	±	_	
53-86	11301-11304	2.9	_	
53-87	11305-11307	16	_	
53-88	11308-11312	20.4	_	
53-89	11313-11314	±	_	
53-90	11315-11318	2.6	_	
53-91	11319-11321	17	_	
53-92	11322-11326	16.4	_	
53-93	11327-11328	±	_	
53-94	11329-11332	8.1	_	
53-95	11333-11338	0.412	_	
53-96	11339-11344	0.453	_	
53-97	11347-11357	Behavioral	_	
53-98	11358-11363	Drive	_	
53-99	11364-11365	(	_	
53-100	11365-11368	BAS	_	
53-101	11368-11369	)	_	
53-102	11370-11372	14	_	
53-103	11373-11377	13.7	_	
53-104	11378-11379	±	_	
53-105	11380-11383	3.9	_	
53-106	11384-11386	16	_	
53-107	11387-11391	13.8	_	
53-108	11392-11393	±	_	
53-109	11394-11397	3.6	_	
53-110	11398-11400	17	_	
53-111	11401-11404	9.3	_	
53-112	11405-11406	±	_	
53-113	11407-11410	5.0	_	
53-114	11411-11416	0.064	_	
53-115	11417-11422	0.088	_	
53-116	11425-11435	Behavioral	_	
53-117	11436-11439	Fun	_	
53-118	11440-11441	(	_	
53-119	11441-11444	BAS	_	
53-120	11444-11445	)	_	
53-121	11446-11448	14	_	
53-122	11449-11453	14.6	_	
53-123	11454-11455	±	_	
53-124	11456-11459	2.3	_	
53-125	11460-11462	16	_	
53-126	11463-11467	13.3	_	
53-127	11468-11469	±	_	
53-128	11470-11473	2.8	_	
53-129	11474-11476	17	_	
53-130	11477-11480	9.5	_	
53-131	11481-11482	±	_	
53-132	11483-11486	5.0	_	
53-133	11487-11492	0.034	_	
53-134	11493-11498	0.147	_	
53-135	11501-11511	Behavioral	_	
53-136	11512-11522	Inhibition	_	
53-137	11523-11524	(	_	
53-138	11524-11527	BIS	_	
53-139	11527-11528	)	_	
53-140	11529-11531	14	_	
53-141	11532-11536	21.1	_	
53-142	11537-11538	±	_	
53-143	11539-11542	6.0	_	
53-144	11543-11545	16	_	
53-145	11546-11550	28.2	_	
53-146	11551-11552	±	_	
53-147	11553-11556	3.5	_	
53-148	11557-11559	17	_	
53-149	11560-11564	23.1	_	
53-150	11565-11566	±	_	
53-151	11567-11571	11.6	_	
53-152	11572-11577	0.125	_	
53-153	11578-11583	0.515	_	
53-154	11586-11590	Mood	_	
53-155	11591-11602	Disturbance	_	
53-156	11603-11604	(	_	
53-157	11604-11608	POMS	_	
53-158	11608-11609	)	_	
53-159	11610-11612	15	_	
53-160	11613-11614	−	_	
53-161	11614-11617	4.5	_	
53-162	11618-11619	±	_	
53-163	11620-11623	8.6	_	
53-164	11624-11626	17	_	
53-165	11627-11631	21.6	_	
53-166	11632-11633	±	_	
53-167	11634-11638	15.8	_	
53-168	11639-11641	17	_	
53-169	11642-11646	24.2	_	
53-170	11647-11648	±	_	
53-171	11649-11653	17.2	_	
53-172	11654-11655	p	_	
53-173	11656-11657	<	_	
53-174	11658-11663	0.001	_	
53-175	11664-11669	0.862	_	
53-176	11672-11679	Fatigue	_	
53-177	11680-11681	(	_	
53-178	11681-11687	PROMIS	_	
53-179	11687-11688	)	_	
53-180	11689-11691	15	_	
53-181	11692-11694	48	_	
53-182	11695-11696	±	_	
53-183	11697-11700	6.5	_	
53-184	11701-11703	17	_	
53-185	11704-11708	65.5	_	
53-186	11709-11710	±	_	
53-187	11711-11714	8.0	_	
53-188	11715-11717	16	_	
53-189	11718-11722	70.7	_	
53-190	11723-11724	±	_	
53-191	11725-11728	5.0	_	
53-192	11729-11730	p	_	
53-193	11731-11732	<	_	
53-194	11733-11738	0.001	_	
53-195	11739-11744	0.075	_	
53-196	11747-11752	Trait	_	
53-197	11753-11760	Anxiety	_	
53-198	11761-11762	(	_	
53-199	11762-11766	STAI	_	
53-200	11766-11767	)	_	
53-201	11768-11770	15	_	
53-202	11771-11775	34.9	_	
53-203	11776-11777	±	_	
53-204	11778-11781	8.3	_	
53-205	11782-11784	17	_	
53-206	11785-11789	49.7	_	
53-207	11790-11791	±	_	
53-208	11792-11795	8.5	_	
53-209	11796-11798	17	_	
53-210	11799-11803	51.9	_	
53-211	11804-11805	±	_	
53-212	11806-11810	12.4	_	
53-213	11811-11812	p	_	
53-214	11813-11814	<	_	
53-215	11815-11820	0.001	_	
53-216	11821-11826	0.793	_	
53-217	11829-11834	State	_	
53-218	11835-11842	Anxiety	_	
53-219	11843-11844	(	_	
53-220	11844-11848	STAI	_	
53-221	11848-11849	)	_	
53-222	11850-11852	15	_	
53-223	11853-11857	27.1	_	
53-224	11858-11859	±	_	
53-225	11860-11863	7.5	_	
53-226	11864-11866	17	_	
53-227	11867-11871	41.4	_	
53-228	11872-11873	±	_	
53-229	11874-11877	7.0	_	
53-230	11878-11880	17	_	
53-231	11881-11885	41.9	_	
53-232	11886-11887	±	_	
53-233	11888-11892	12.8	_	
53-234	11893-11894	p	_	
53-235	11895-11896	<	_	
53-236	11897-11902	0.001	_	
53-237	11903-11908	0.989	_	
53-238	11911-11921	Depression	_	
53-239	11922-11923	(	_	
53-240	11923-11926	BDI	_	
53-241	11926-11927	)	_	
53-242	11928-11930	15	_	
53-243	11931-11934	2.3	_	
53-244	11935-11936	±	_	
53-245	11937-11940	3.1	_	
53-246	11941-11943	17	_	
53-247	11944-11948	15.8	_	
53-248	11949-11950	±	_	
53-249	11951-11954	8.9	_	
53-250	11955-11957	17	_	
53-251	11958-11962	15.2	_	
53-252	11963-11964	±	_	
53-253	11965-11968	9.3	_	
53-254	11969-11970	p	_	
53-255	11971-11972	<	_	
53-256	11973-11978	0.001	_	
53-257	11979-11984	0.973	_	
53-258	11987-11993	Number	_	
53-259	11994-11996	of	_	
53-260	11997-12001	Pain	_	
53-261	12002-12007	Areas	_	
53-262	12008-12009	(	_	
53-263	12009-12012	FAF	_	
53-264	12012-12013	)	_	
53-265	12014-12016	15	_	
53-266	12017-12020	1.5	_	
53-267	12021-12022	±	_	
53-268	12023-12026	2.0	_	
53-269	12027-12029	17	_	
53-270	12030-12034	13.9	_	
53-271	12035-12036	±	_	
53-272	12037-12040	3.9	_	
53-273	12041-12043	17	_	
53-274	12044-12048	12.6	_	
53-275	12049-12050	±	_	
53-276	12051-12054	3.7	_	
53-277	12055-12056	p	_	
53-278	12057-12058	<	_	
53-279	12059-12064	0.001	_	
53-280	12065-12070	0.508	_	
53-281	12073-12077	Pain	_	
53-282	12078-12086	Severity	_	
53-283	12087-12088	(	_	
53-284	12088-12091	BPI	_	
53-285	12091-12092	)	_	
53-286	12093-12095	15	_	
53-287	12096-12099	0.4	_	
53-288	12100-12101	±	_	
53-289	12102-12105	1.0	_	
53-290	12106-12108	17	_	
53-291	12109-12112	5.7	_	
53-292	12113-12114	±	_	
53-293	12115-12118	2.1	_	
53-294	12119-12121	17	_	
53-295	12122-12125	6.0	_	
53-296	12126-12127	±	_	
53-297	12128-12131	1.5	_	
53-298	12132-12133	p	_	
53-299	12134-12135	<	_	
53-300	12136-12141	0.001	_	
53-301	12142-12147	0.848	_	
53-302	12150-12154	Pain	_	
53-303	12155-12167	Interference	_	
53-304	12168-12169	(	_	
53-305	12169-12172	BPI	_	
53-306	12172-12173	)	_	
53-307	12174-12176	15	_	
53-308	12177-12180	3.5	_	
53-309	12181-12182	±	_	
53-310	12183-12186	6.4	_	
53-311	12187-12189	17	_	
53-312	12190-12194	36.9	_	
53-313	12195-12196	±	_	
53-314	12197-12201	19.5	_	
53-315	12202-12204	17	_	
53-316	12205-12209	42.8	_	
53-317	12210-12211	±	_	
53-318	12212-12214	17	_	
53-319	12215-12216	p	_	
53-320	12217-12218	<	_	
53-321	12219-12224	0.001	_	
53-322	12225-12230	0.515	_	
53-323	12234-12245	Participant	_	
53-324	12246-12252	counts	_	
53-325	12253-12256	for	_	
53-326	12257-12261	each	_	
53-327	12262-12269	measure	_	
53-328	12270-12276	differ	_	
53-329	12277-12281	from	_	
53-330	12282-12285	the	_	
53-331	12286-12291	total	_	
53-332	12292-12298	number	_	
53-333	12299-12301	of	_	
53-334	12302-12314	participants	_	
53-335	12315-12316	(	_	
53-336	12316-12324	controls	_	
53-337	12325-12326	N	_	
53-338	12327-12328	=	_	
53-339	12329-12331	15	_	
53-340	12331-12332	,	_	
53-341	12333-12343	non-opioid	_	
53-342	12344-12356	fibromyalgia	_	
53-343	12357-12358	(	_	
53-344	12358-12360	FM	_	
53-345	12360-12361	)	_	
53-346	12362-12363	N	_	
53-347	12364-12365	=	_	
53-348	12366-12368	17	_	
53-349	12368-12369	,	_	
53-350	12370-12376	opioid	_	
53-351	12377-12379	FM	_	
53-352	12380-12381	N	_	
53-353	12382-12383	=	_	
53-354	12384-12386	17	_	
53-355	12386-12387	)	_	
53-356	12388-12395	because	_	
53-357	12396-12400	some	_	
53-358	12401-12413	participants	_	
53-359	12414-12417	did	_	
53-360	12418-12421	not	_	
53-361	12422-12430	complete	_	
53-362	12431-12434	all	_	
53-363	12435-12449	questionnaires	_	
53-364	12449-12450	.	_	

#Text=Abbreviations: PANAS, Positive and Negative Affect Schedule; BIS/BAS, Behavioral Inhibition System/Behavioral Activation System; PROMIS, Patient-Reported Outcomes Measurement Information System; STAI, State-Trait Anxiety Inventory; FAF, Fibromyalgia Assessment Form; BDI, Beck Depression Inventory; POMS, Profile of Mood States; BPI, Brief Pain Inventory; sd, standard deviation.
54-1	12451-12464	Abbreviations	_	
54-2	12464-12465	:	_	
54-3	12466-12471	PANAS	_	
54-4	12471-12472	,	_	
54-5	12473-12481	Positive	_	
54-6	12482-12485	and	_	
54-7	12486-12494	Negative	_	
54-8	12495-12501	Affect	_	
54-9	12502-12510	Schedule	_	
54-10	12510-12511	;	_	
54-11	12512-12515	BIS	_	
54-12	12515-12516	/	_	
54-13	12516-12519	BAS	_	
54-14	12519-12520	,	_	
54-15	12521-12531	Behavioral	_	
54-16	12532-12542	Inhibition	_	
54-17	12543-12549	System	_	
54-18	12549-12550	/	_	
54-19	12550-12560	Behavioral	_	
54-20	12561-12571	Activation	_	
54-21	12572-12578	System	_	
54-22	12578-12579	;	_	
54-23	12580-12586	PROMIS	_	
54-24	12586-12587	,	_	
54-25	12588-12604	Patient-Reported	_	
54-26	12605-12613	Outcomes	_	
54-27	12614-12625	Measurement	_	
54-28	12626-12637	Information	_	
54-29	12638-12644	System	_	
54-30	12644-12645	;	_	
54-31	12646-12650	STAI	_	
54-32	12650-12651	,	_	
54-33	12652-12663	State-Trait	_	
54-34	12664-12671	Anxiety	_	
54-35	12672-12681	Inventory	_	
54-36	12681-12682	;	_	
54-37	12683-12686	FAF	_	
54-38	12686-12687	,	_	
54-39	12688-12700	Fibromyalgia	_	
54-40	12701-12711	Assessment	_	
54-41	12712-12716	Form	_	
54-42	12716-12717	;	_	
54-43	12718-12721	BDI	_	
54-44	12721-12722	,	_	
54-45	12723-12727	Beck	_	
54-46	12728-12738	Depression	_	
54-47	12739-12748	Inventory	_	
54-48	12748-12749	;	_	
54-49	12750-12754	POMS	_	
54-50	12754-12755	,	_	
54-51	12756-12763	Profile	_	
54-52	12764-12766	of	_	
54-53	12767-12771	Mood	_	
54-54	12772-12778	States	_	
54-55	12778-12779	;	_	
54-56	12780-12783	BPI	_	
54-57	12783-12784	,	_	
54-58	12785-12790	Brief	_	
54-59	12791-12795	Pain	_	
54-60	12796-12805	Inventory	_	
54-61	12805-12806	;	_	
54-62	12807-12809	sd	_	
54-63	12809-12810	,	_	
54-64	12811-12819	standard	_	
54-65	12820-12829	deviation	_	
54-66	12829-12830	.	_	

#Text=Repeated measures analysis of variance (ANOVA) across the 3 groups (group effect) P-values are reported.
55-1	12831-12839	Repeated	_	
55-2	12840-12848	measures	_	
55-3	12849-12857	analysis	_	
55-4	12858-12860	of	_	
55-5	12861-12869	variance	_	
55-6	12870-12871	(	_	
55-7	12871-12876	ANOVA	_	
55-8	12876-12877	)	_	
55-9	12878-12884	across	_	
55-10	12885-12888	the	_	
55-11	12889-12890	3	_	
55-12	12891-12897	groups	_	
55-13	12898-12899	(	_	
55-14	12899-12904	group	_	
55-15	12905-12911	effect	_	
55-16	12911-12912	)	_	
55-17	12913-12921	P-values	_	
55-18	12922-12925	are	_	
55-19	12926-12934	reported	_	
55-20	12934-12935	.	_	

#Text=Tukey post-hoc t-test values are reported for comparison between the two patient groups.
56-1	12936-12941	Tukey	_	
56-2	12942-12950	post-hoc	_	
56-3	12951-12957	t-test	_	
56-4	12958-12964	values	_	
56-5	12965-12968	are	_	
56-6	12969-12977	reported	_	
56-7	12978-12981	for	_	
56-8	12982-12992	comparison	_	
56-9	12993-13000	between	_	
56-10	13001-13004	the	_	
56-11	13005-13008	two	_	
56-12	13009-13016	patient	_	
56-13	13017-13023	groups	_	
56-14	13023-13024	.	_	

#Text=Data are presented for descriptive purposes only, therefore significance values (P-Value) shown are not corrected for multiple comparisons.
57-1	13025-13029	Data	_	
57-2	13030-13033	are	_	
57-3	13034-13043	presented	_	
57-4	13044-13047	for	_	
57-5	13048-13059	descriptive	_	
57-6	13060-13068	purposes	_	
57-7	13069-13073	only	_	
57-8	13073-13074	,	_	
57-9	13075-13084	therefore	_	
57-10	13085-13097	significance	_	
57-11	13098-13104	values	_	
57-12	13105-13106	(	_	
57-13	13106-13113	P-Value	_	
57-14	13113-13114	)	_	
57-15	13115-13120	shown	_	
57-16	13121-13124	are	_	
57-17	13125-13128	not	_	
57-18	13129-13138	corrected	_	
57-19	13139-13142	for	_	
57-20	13143-13151	multiple	_	
57-21	13152-13163	comparisons	_	
57-22	13163-13164	.	_	

#Text=Responses to clinical and psychological questionnaires were collected from study participants (Table 2).
58-1	13165-13174	Responses	_	
58-2	13175-13177	to	_	
58-3	13178-13186	clinical	_	
58-4	13187-13190	and	_	
58-5	13191-13204	psychological	_	
58-6	13205-13219	questionnaires	_	
58-7	13220-13224	were	_	
58-8	13225-13234	collected	_	
58-9	13235-13239	from	_	
58-10	13240-13245	study	_	
58-11	13246-13258	participants	_	
58-12	13259-13260	(	_	
58-13	13260-13265	Table	_	
58-14	13265-13266	 	_	
58-15	13266-13267	2	_	
58-16	13267-13268	)	_	
58-17	13268-13269	.	_	

#Text=The majority of these measures showed significant differences across the three groups due to differences between control and fibromyalgia groups.
59-1	13270-13273	The	_	
59-2	13274-13282	majority	_	
59-3	13283-13285	of	_	
59-4	13286-13291	these	_	
59-5	13292-13300	measures	_	
59-6	13301-13307	showed	_	
59-7	13308-13319	significant	_	
59-8	13320-13331	differences	_	
59-9	13332-13338	across	_	
59-10	13339-13342	the	_	
59-11	13343-13348	three	_	
59-12	13349-13355	groups	_	
59-13	13356-13359	due	_	
59-14	13360-13362	to	_	
59-15	13363-13374	differences	_	
59-16	13375-13382	between	_	
59-17	13383-13390	control	_	
59-18	13391-13394	and	_	
59-19	13395-13407	fibromyalgia	_	
59-20	13408-13414	groups	_	
59-21	13414-13415	.	_	

#Text=Post-hoc t-tests between the opioid and non-opioid fibromyalgia groups revealed similar levels of pain, psychological, and clinical measures.
60-1	13416-13424	Post-hoc	_	
60-2	13425-13432	t-tests	_	
60-3	13433-13440	between	_	
60-4	13441-13444	the	_	
60-5	13445-13451	opioid	_	
60-6	13452-13455	and	_	
60-7	13456-13466	non-opioid	_	
60-8	13467-13479	fibromyalgia	_	
60-9	13480-13486	groups	_	
60-10	13487-13495	revealed	_	
60-11	13496-13503	similar	_	
60-12	13504-13510	levels	_	
60-13	13511-13513	of	_	
60-14	13514-13518	pain	_	
60-15	13518-13519	,	_	
60-16	13520-13533	psychological	_	
60-17	13533-13534	,	_	
60-18	13535-13538	and	_	
60-19	13539-13547	clinical	_	
60-20	13548-13556	measures	_	
60-21	13556-13557	.	_	

#Text=Additionally, no severe depression (i.e., no BDI scores greater than 30) was observed in the fibromyalgia groups.
61-1	13558-13570	Additionally	_	
61-2	13570-13571	,	_	
61-3	13572-13574	no	_	
61-4	13575-13581	severe	_	
61-5	13582-13592	depression	_	
61-6	13593-13594	(	_	
61-7	13594-13597	i.e	_	
61-8	13597-13598	.	_	
61-9	13598-13599	,	_	
61-10	13600-13602	no	_	
61-11	13603-13606	BDI	_	
61-12	13607-13613	scores	_	
61-13	13614-13621	greater	_	
61-14	13622-13626	than	_	
61-15	13627-13629	30	_	
61-16	13629-13630	)	_	
61-17	13631-13634	was	_	
61-18	13635-13643	observed	_	
61-19	13644-13646	in	_	
61-20	13647-13650	the	_	
61-21	13651-13663	fibromyalgia	_	
61-22	13664-13670	groups	_	
61-23	13670-13671	.	_	

#Text=Clinically significant anxiety (i.e., STAI-State scores greater than 40) was observed in the non-opioid fibromyalgia group (N = 10) and opioid fibromyalgia group (N = 9).
62-1	13672-13682	Clinically	_	
62-2	13683-13694	significant	_	
62-3	13695-13702	anxiety	_	
62-4	13703-13704	(	_	
62-5	13704-13707	i.e	_	
62-6	13707-13708	.	_	
62-7	13708-13709	,	_	
62-8	13710-13720	STAI-State	_	
62-9	13721-13727	scores	_	
62-10	13728-13735	greater	_	
62-11	13736-13740	than	_	
62-12	13741-13743	40	_	
62-13	13743-13744	)	_	
62-14	13745-13748	was	_	
62-15	13749-13757	observed	_	
62-16	13758-13760	in	_	
62-17	13761-13764	the	_	
62-18	13765-13775	non-opioid	_	
62-19	13776-13788	fibromyalgia	_	
62-20	13789-13794	group	_	
62-21	13795-13796	(	_	
62-22	13796-13797	N	_	
62-23	13798-13799	=	_	
62-24	13800-13802	10	_	
62-25	13802-13803	)	_	
62-26	13804-13807	and	_	
62-27	13808-13814	opioid	_	
62-28	13815-13827	fibromyalgia	_	
62-29	13828-13833	group	_	
62-30	13834-13835	(	_	
62-31	13835-13836	N	_	
62-32	13837-13838	=	_	
62-33	13839-13840	9	_	
62-34	13840-13841	)	_	
62-35	13841-13842	.	_	

#Text=Using a brief measure of fibromyalgia associated symptoms and severity (Fibromyalgia Assessment Form, based on the ACR Fibromyalgia Diagnostic Criteria), both patient groups demonstrated similar number of painful regions across the body (Table 2).
63-1	13843-13848	Using	_	
63-2	13849-13850	a	_	
63-3	13851-13856	brief	_	
63-4	13857-13864	measure	_	
63-5	13865-13867	of	_	
63-6	13868-13880	fibromyalgia	_	
63-7	13881-13891	associated	_	
63-8	13892-13900	symptoms	_	
63-9	13901-13904	and	_	
63-10	13905-13913	severity	_	
63-11	13914-13915	(	_	
63-12	13915-13927	Fibromyalgia	_	
63-13	13928-13938	Assessment	_	
63-14	13939-13943	Form	_	
63-15	13943-13944	,	_	
63-16	13945-13950	based	_	
63-17	13951-13953	on	_	
63-18	13954-13957	the	_	
63-19	13958-13961	ACR	_	
63-20	13962-13974	Fibromyalgia	_	
63-21	13975-13985	Diagnostic	_	
63-22	13986-13994	Criteria	_	
63-23	13994-13995	)	_	
63-24	13995-13996	,	_	
63-25	13997-14001	both	_	
63-26	14002-14009	patient	_	
63-27	14010-14016	groups	_	
63-28	14017-14029	demonstrated	_	
63-29	14030-14037	similar	_	
63-30	14038-14044	number	_	
63-31	14045-14047	of	_	
63-32	14048-14055	painful	_	
63-33	14056-14063	regions	_	
63-34	14064-14070	across	_	
63-35	14071-14074	the	_	
63-36	14075-14079	body	_	
63-37	14080-14081	(	_	
63-38	14081-14086	Table	_	
63-39	14086-14087	 	_	
63-40	14087-14088	2	_	
63-41	14088-14089	)	_	
63-42	14089-14090	.	_	

#Text=The number of painful areas ranged from 9–19 for non-opioid fibromyalgia participants and 6–19 for the opioid fibromyalgia participants out of a total 19 regions.
64-1	14091-14094	The	_	
64-2	14095-14101	number	_	
64-3	14102-14104	of	_	
64-4	14105-14112	painful	_	
64-5	14113-14118	areas	_	
64-6	14119-14125	ranged	_	
64-7	14126-14130	from	_	
64-8	14131-14132	9	_	
64-9	14132-14133	–	_	
64-10	14133-14135	19	_	
64-11	14136-14139	for	_	
64-12	14140-14150	non-opioid	_	
64-13	14151-14163	fibromyalgia	_	
64-14	14164-14176	participants	_	
64-15	14177-14180	and	_	
64-16	14181-14182	6	_	
64-17	14182-14183	–	_	
64-18	14183-14185	19	_	
64-19	14186-14189	for	_	
64-20	14190-14193	the	_	
64-21	14194-14200	opioid	_	
64-22	14201-14213	fibromyalgia	_	
64-23	14214-14226	participants	_	
64-24	14227-14230	out	_	
64-25	14231-14233	of	_	
64-26	14234-14235	a	_	
64-27	14236-14241	total	_	
64-28	14242-14244	19	_	
64-29	14245-14252	regions	_	
64-30	14252-14253	.	_	

#Text=The duration of pain symptoms reported ranged from 2–28 years with an average duration of 11.5 years (standard deviation of 7.7 years) in the non-opioid fibromyalgia group and 2–25 years with an average duration of 10.0 years (standard deviation of 7.0 years) in the opioid fibromyalgia group.
65-1	14254-14257	The	_	
65-2	14258-14266	duration	_	
65-3	14267-14269	of	_	
65-4	14270-14274	pain	_	
65-5	14275-14283	symptoms	_	
65-6	14284-14292	reported	_	
65-7	14293-14299	ranged	_	
65-8	14300-14304	from	_	
65-9	14305-14306	2	_	
65-10	14306-14307	–	_	
65-11	14307-14309	28	_	
65-12	14310-14315	years	_	
65-13	14316-14320	with	_	
65-14	14321-14323	an	_	
65-15	14324-14331	average	_	
65-16	14332-14340	duration	_	
65-17	14341-14343	of	_	
65-18	14344-14348	11.5	_	
65-19	14349-14354	years	_	
65-20	14355-14356	(	_	
65-21	14356-14364	standard	_	
65-22	14365-14374	deviation	_	
65-23	14375-14377	of	_	
65-24	14378-14381	7.7	_	
65-25	14382-14387	years	_	
65-26	14387-14388	)	_	
65-27	14389-14391	in	_	
65-28	14392-14395	the	_	
65-29	14396-14406	non-opioid	_	
65-30	14407-14419	fibromyalgia	_	
65-31	14420-14425	group	_	
65-32	14426-14429	and	_	
65-33	14430-14431	2	_	
65-34	14431-14432	–	_	
65-35	14432-14434	25	_	
65-36	14435-14440	years	_	
65-37	14441-14445	with	_	
65-38	14446-14448	an	_	
65-39	14449-14456	average	_	
65-40	14457-14465	duration	_	
65-41	14466-14468	of	_	
65-42	14469-14473	10.0	_	
65-43	14474-14479	years	_	
65-44	14480-14481	(	_	
65-45	14481-14489	standard	_	
65-46	14490-14499	deviation	_	
65-47	14500-14502	of	_	
65-48	14503-14506	7.0	_	
65-49	14507-14512	years	_	
65-50	14512-14513	)	_	
65-51	14514-14516	in	_	
65-52	14517-14520	the	_	
65-53	14521-14527	opioid	_	
65-54	14528-14540	fibromyalgia	_	
65-55	14541-14546	group	_	
65-56	14546-14547	.	_	

#Text=Medication and opioid use
#Text=Medications.
66-1	14548-14558	Medication	_	
66-2	14559-14562	and	_	
66-3	14563-14569	opioid	_	
66-4	14570-14573	use	_	
66-5	14574-14585	Medications	_	
66-6	14585-14586	.	_	

#Text=Controls\tFMN\tFMO\t \tOpioids\t0\t0\t17\t \t   Tramadol\t\t\t5\t \t   Hydrocodone/acetominophen (Norco)\t\t\t9\t \t   Morphine ER (MS-Contin)\t\t\t1\t \t   Oxycodone/acetominophen (Percocet)\t\t\t2\t \t   Codeine\t\t\t1\t \tNSAID\t0*\t7\t12\t \tAcetaminophen\t0\t0\t12\t \tTopical Lidocaine Patch\t0\t1\t0\t \tSNRI (e.g., duloxetine)\t0\t4\t7\t \tSSRI (e.g., fluoxetine)\t0*\t2\t4\t \tTricyclic Antidepressant (e.g., amitryptyline)\t0\t3\t1\t \tOther Anxiolytic (e.g., buspirone)\t0\t2\t2\t \tAntiepileptic (e.g., topiramate)\t0\t2\t5\t \tTriptans (e.g., sumatriptan)\t0\t0\t6\t \tBenzodiazepine\t0\t0\t3\t \tBenzodiazepine-like (e.g., eszopiclone)\t0\t0\t2\t \tMuscle Relaxant (e.g., cyclobenzaprine)\t0\t2\t6\t \tGABA Analogue (e.g., gabapentin)\t0*\t6\t7\t \tLow Dose Naltrexone\t0\t2\t0\t \tMedical Cannabis\t0\t1\t0\t \tSARI (e.g., trazodone)\t0\t0\t4\t \tNDRI (e.g., methylphenidate, buproprion)\t0\t0\t3\t \tOndansetron\t0\t0\t1\t \tTaking No Medications\t13\t4\t0\t \t
#Text=The number of individuals in each group taking the class of medications is shown for the control group, non-opioid taking fibromyalgia group (FMN) and opioid taking fibromyalgia group (FMO).
67-1	14588-14596	Controls	_	
67-2	14597-14600	FMN	_	
67-3	14601-14604	FMO	_	
67-4	14607-14614	Opioids	_	
67-5	14615-14616	0	_	
67-6	14617-14618	0	_	
67-7	14619-14621	17	_	
67-8	14624-14627	   	_	
67-9	14627-14635	Tramadol	_	
67-10	14638-14639	5	_	
67-11	14642-14645	   	_	
67-12	14645-14656	Hydrocodone	_	
67-13	14656-14657	/	_	
67-14	14657-14670	acetominophen	_	
67-15	14671-14672	(	_	
67-16	14672-14677	Norco	_	
67-17	14677-14678	)	_	
67-18	14681-14682	9	_	
67-19	14685-14688	   	_	
67-20	14688-14696	Morphine	_	
67-21	14697-14699	ER	_	
67-22	14700-14701	(	_	
67-23	14701-14710	MS-Contin	_	
67-24	14710-14711	)	_	
67-25	14714-14715	1	_	
67-26	14718-14721	   	_	
67-27	14721-14730	Oxycodone	_	
67-28	14730-14731	/	_	
67-29	14731-14744	acetominophen	_	
67-30	14745-14746	(	_	
67-31	14746-14754	Percocet	_	
67-32	14754-14755	)	_	
67-33	14758-14759	2	_	
67-34	14762-14765	   	_	
67-35	14765-14772	Codeine	_	
67-36	14775-14776	1	_	
67-37	14779-14784	NSAID	_	
67-38	14785-14786	0	_	
67-39	14786-14787	*	_	
67-40	14788-14789	7	_	
67-41	14790-14792	12	_	
67-42	14795-14808	Acetaminophen	_	
67-43	14809-14810	0	_	
67-44	14811-14812	0	_	
67-45	14813-14815	12	_	
67-46	14818-14825	Topical	_	
67-47	14826-14835	Lidocaine	_	
67-48	14836-14841	Patch	_	
67-49	14842-14843	0	_	
67-50	14844-14845	1	_	
67-51	14846-14847	0	_	
67-52	14850-14854	SNRI	_	
67-53	14855-14856	(	_	
67-54	14856-14859	e.g	_	
67-55	14859-14860	.	_	
67-56	14860-14861	,	_	
67-57	14862-14872	duloxetine	_	
67-58	14872-14873	)	_	
67-59	14874-14875	0	_	
67-60	14876-14877	4	_	
67-61	14878-14879	7	_	
67-62	14882-14886	SSRI	_	
67-63	14887-14888	(	_	
67-64	14888-14891	e.g	_	
67-65	14891-14892	.	_	
67-66	14892-14893	,	_	
67-67	14894-14904	fluoxetine	_	
67-68	14904-14905	)	_	
67-69	14906-14907	0	_	
67-70	14907-14908	*	_	
67-71	14909-14910	2	_	
67-72	14911-14912	4	_	
67-73	14915-14924	Tricyclic	_	
67-74	14925-14939	Antidepressant	_	
67-75	14940-14941	(	_	
67-76	14941-14944	e.g	_	
67-77	14944-14945	.	_	
67-78	14945-14946	,	_	
67-79	14947-14960	amitryptyline	_	
67-80	14960-14961	)	_	
67-81	14962-14963	0	_	
67-82	14964-14965	3	_	
67-83	14966-14967	1	_	
67-84	14970-14975	Other	_	
67-85	14976-14986	Anxiolytic	_	
67-86	14987-14988	(	_	
67-87	14988-14991	e.g	_	
67-88	14991-14992	.	_	
67-89	14992-14993	,	_	
67-90	14994-15003	buspirone	_	
67-91	15003-15004	)	_	
67-92	15005-15006	0	_	
67-93	15007-15008	2	_	
67-94	15009-15010	2	_	
67-95	15013-15026	Antiepileptic	_	
67-96	15027-15028	(	_	
67-97	15028-15031	e.g	_	
67-98	15031-15032	.	_	
67-99	15032-15033	,	_	
67-100	15034-15044	topiramate	_	
67-101	15044-15045	)	_	
67-102	15046-15047	0	_	
67-103	15048-15049	2	_	
67-104	15050-15051	5	_	
67-105	15054-15062	Triptans	_	
67-106	15063-15064	(	_	
67-107	15064-15067	e.g	_	
67-108	15067-15068	.	_	
67-109	15068-15069	,	_	
67-110	15070-15081	sumatriptan	_	
67-111	15081-15082	)	_	
67-112	15083-15084	0	_	
67-113	15085-15086	0	_	
67-114	15087-15088	6	_	
67-115	15091-15105	Benzodiazepine	_	
67-116	15106-15107	0	_	
67-117	15108-15109	0	_	
67-118	15110-15111	3	_	
67-119	15114-15133	Benzodiazepine-like	_	
67-120	15134-15135	(	_	
67-121	15135-15138	e.g	_	
67-122	15138-15139	.	_	
67-123	15139-15140	,	_	
67-124	15141-15152	eszopiclone	_	
67-125	15152-15153	)	_	
67-126	15154-15155	0	_	
67-127	15156-15157	0	_	
67-128	15158-15159	2	_	
67-129	15162-15168	Muscle	_	
67-130	15169-15177	Relaxant	_	
67-131	15178-15179	(	_	
67-132	15179-15182	e.g	_	
67-133	15182-15183	.	_	
67-134	15183-15184	,	_	
67-135	15185-15200	cyclobenzaprine	_	
67-136	15200-15201	)	_	
67-137	15202-15203	0	_	
67-138	15204-15205	2	_	
67-139	15206-15207	6	_	
67-140	15210-15214	GABA	_	
67-141	15215-15223	Analogue	_	
67-142	15224-15225	(	_	
67-143	15225-15228	e.g	_	
67-144	15228-15229	.	_	
67-145	15229-15230	,	_	
67-146	15231-15241	gabapentin	_	
67-147	15241-15242	)	_	
67-148	15243-15244	0	_	
67-149	15244-15245	*	_	
67-150	15246-15247	6	_	
67-151	15248-15249	7	_	
67-152	15252-15255	Low	_	
67-153	15256-15260	Dose	_	
67-154	15261-15271	Naltrexone	_	
67-155	15272-15273	0	_	
67-156	15274-15275	2	_	
67-157	15276-15277	0	_	
67-158	15280-15287	Medical	_	
67-159	15288-15296	Cannabis	_	
67-160	15297-15298	0	_	
67-161	15299-15300	1	_	
67-162	15301-15302	0	_	
67-163	15305-15309	SARI	_	
67-164	15310-15311	(	_	
67-165	15311-15314	e.g	_	
67-166	15314-15315	.	_	
67-167	15315-15316	,	_	
67-168	15317-15326	trazodone	_	
67-169	15326-15327	)	_	
67-170	15328-15329	0	_	
67-171	15330-15331	0	_	
67-172	15332-15333	4	_	
67-173	15336-15340	NDRI	_	
67-174	15341-15342	(	_	
67-175	15342-15345	e.g	_	
67-176	15345-15346	.	_	
67-177	15346-15347	,	_	
67-178	15348-15363	methylphenidate	_	
67-179	15363-15364	,	_	
67-180	15365-15375	buproprion	_	
67-181	15375-15376	)	_	
67-182	15377-15378	0	_	
67-183	15379-15380	0	_	
67-184	15381-15382	3	_	
67-185	15385-15396	Ondansetron	_	
67-186	15397-15398	0	_	
67-187	15399-15400	0	_	
67-188	15401-15402	1	_	
67-189	15405-15411	Taking	_	
67-190	15412-15414	No	_	
67-191	15415-15426	Medications	_	
67-192	15427-15429	13	_	
67-193	15430-15431	4	_	
67-194	15432-15433	0	_	
67-195	15437-15440	The	_	
67-196	15441-15447	number	_	
67-197	15448-15450	of	_	
67-198	15451-15462	individuals	_	
67-199	15463-15465	in	_	
67-200	15466-15470	each	_	
67-201	15471-15476	group	_	
67-202	15477-15483	taking	_	
67-203	15484-15487	the	_	
67-204	15488-15493	class	_	
67-205	15494-15496	of	_	
67-206	15497-15508	medications	_	
67-207	15509-15511	is	_	
67-208	15512-15517	shown	_	
67-209	15518-15521	for	_	
67-210	15522-15525	the	_	
67-211	15526-15533	control	_	
67-212	15534-15539	group	_	
67-213	15539-15540	,	_	
67-214	15541-15551	non-opioid	_	
67-215	15552-15558	taking	_	
67-216	15559-15571	fibromyalgia	_	
67-217	15572-15577	group	_	
67-218	15578-15579	(	_	
67-219	15579-15582	FMN	_	
67-220	15582-15583	)	_	
67-221	15584-15587	and	_	
67-222	15588-15594	opioid	_	
67-223	15595-15601	taking	_	
67-224	15602-15614	fibromyalgia	_	
67-225	15615-15620	group	_	
67-226	15621-15622	(	_	
67-227	15622-15625	FMO	_	
67-228	15625-15626	)	_	
67-229	15626-15627	.	_	

#Text=*One control participant with premenstrual symptoms (2 days per month) reported taking gabapentin (100 mg/day, 2 days per month) and fluoxetine (40 mg/day), and another control participant reported taking celecoxib (200 mg) 3 weeks prior to the study visit due to a sports-related ankle injury.
68-1	15628-15629	*	_	
68-2	15629-15632	One	_	
68-3	15633-15640	control	_	
68-4	15641-15652	participant	_	
68-5	15653-15657	with	_	
68-6	15658-15670	premenstrual	_	
68-7	15671-15679	symptoms	_	
68-8	15680-15681	(	_	
68-9	15681-15682	2	_	
68-10	15683-15687	days	_	
68-11	15688-15691	per	_	
68-12	15692-15697	month	_	
68-13	15697-15698	)	_	
68-14	15699-15707	reported	_	
68-15	15708-15714	taking	_	
68-16	15715-15725	gabapentin	_	
68-17	15726-15727	(	_	
68-18	15727-15730	100	_	
68-19	15731-15733	mg	_	
68-20	15733-15734	/	_	
68-21	15734-15737	day	_	
68-22	15737-15738	,	_	
68-23	15739-15740	2	_	
68-24	15741-15745	days	_	
68-25	15746-15749	per	_	
68-26	15750-15755	month	_	
68-27	15755-15756	)	_	
68-28	15757-15760	and	_	
68-29	15761-15771	fluoxetine	_	
68-30	15772-15773	(	_	
68-31	15773-15775	40	_	
68-32	15776-15778	mg	_	
68-33	15778-15779	/	_	
68-34	15779-15782	day	_	
68-35	15782-15783	)	_	
68-36	15783-15784	,	_	
68-37	15785-15788	and	_	
68-38	15789-15796	another	_	
68-39	15797-15804	control	_	
68-40	15805-15816	participant	_	
68-41	15817-15825	reported	_	
68-42	15826-15832	taking	_	
68-43	15833-15842	celecoxib	_	
68-44	15843-15844	(	_	
68-45	15844-15847	200	_	
68-46	15848-15850	mg	_	
68-47	15850-15851	)	_	
68-48	15852-15853	3	_	
68-49	15854-15859	weeks	_	
68-50	15860-15865	prior	_	
68-51	15866-15868	to	_	
68-52	15869-15872	the	_	
68-53	15873-15878	study	_	
68-54	15879-15884	visit	_	
68-55	15885-15888	due	_	
68-56	15889-15891	to	_	
68-57	15892-15893	a	_	
68-58	15894-15908	sports-related	_	
68-59	15909-15914	ankle	_	
68-60	15915-15921	injury	_	
68-61	15921-15922	.	_	

#Text=A post-hoc analysis excluding the 2 patients taking low-dose naltrexone did not change the results, therefore data from these patients were included in the presented analysis.
69-1	15923-15924	A	_	
69-2	15925-15933	post-hoc	_	
69-3	15934-15942	analysis	_	
69-4	15943-15952	excluding	_	
69-5	15953-15956	the	_	
69-6	15957-15958	2	_	
69-7	15959-15967	patients	_	
69-8	15968-15974	taking	_	
69-9	15975-15983	low-dose	_	
69-10	15984-15994	naltrexone	_	
69-11	15995-15998	did	_	
69-12	15999-16002	not	_	
69-13	16003-16009	change	_	
69-14	16010-16013	the	_	
69-15	16014-16021	results	_	
69-16	16021-16022	,	_	
69-17	16023-16032	therefore	_	
69-18	16033-16037	data	_	
69-19	16038-16042	from	_	
69-20	16043-16048	these	_	
69-21	16049-16057	patients	_	
69-22	16058-16062	were	_	
69-23	16063-16071	included	_	
69-24	16072-16074	in	_	
69-25	16075-16078	the	_	
69-26	16079-16088	presented	_	
69-27	16089-16097	analysis	_	
69-28	16097-16098	.	_	

#Text=Abbreviations: Nonsteroidal anti-inflammatory drug, NSAID; serotonin and noradrenergic reuptake inhibitor, SNRI; selective serotonin reuptake inhibitor, SSRI; gamma-aminobutyric acid, GABA; serotonin antagonist and reuptake inhibitor, SARI; norepinephrine-dopamine reuptake inhibitor, NDRI.
70-1	16099-16112	Abbreviations	_	
70-2	16112-16113	:	_	
70-3	16114-16126	Nonsteroidal	_	
70-4	16127-16144	anti-inflammatory	_	
70-5	16145-16149	drug	_	
70-6	16149-16150	,	_	
70-7	16151-16156	NSAID	_	
70-8	16156-16157	;	_	
70-9	16158-16167	serotonin	_	
70-10	16168-16171	and	_	
70-11	16172-16185	noradrenergic	_	
70-12	16186-16194	reuptake	_	
70-13	16195-16204	inhibitor	_	
70-14	16204-16205	,	_	
70-15	16206-16210	SNRI	_	
70-16	16210-16211	;	_	
70-17	16212-16221	selective	_	
70-18	16222-16231	serotonin	_	
70-19	16232-16240	reuptake	_	
70-20	16241-16250	inhibitor	_	
70-21	16250-16251	,	_	
70-22	16252-16256	SSRI	_	
70-23	16256-16257	;	_	
70-24	16258-16276	gamma-aminobutyric	_	
70-25	16277-16281	acid	_	
70-26	16281-16282	,	_	
70-27	16283-16287	GABA	_	
70-28	16287-16288	;	_	
70-29	16289-16298	serotonin	_	
70-30	16299-16309	antagonist	_	
70-31	16310-16313	and	_	
70-32	16314-16322	reuptake	_	
70-33	16323-16332	inhibitor	_	
70-34	16332-16333	,	_	
70-35	16334-16338	SARI	_	
70-36	16338-16339	;	_	
70-37	16340-16363	norepinephrine-dopamine	_	
70-38	16364-16372	reuptake	_	
70-39	16373-16382	inhibitor	_	
70-40	16382-16383	,	_	
70-41	16384-16388	NDRI	_	
70-42	16388-16389	.	_	

#Text=All patients were allowed to continue their usual medication use during the study.
71-1	16390-16393	All	_	
71-2	16394-16402	patients	_	
71-3	16403-16407	were	_	
71-4	16408-16415	allowed	_	
71-5	16416-16418	to	_	
71-6	16419-16427	continue	_	
71-7	16428-16433	their	_	
71-8	16434-16439	usual	_	
71-9	16440-16450	medication	_	
71-10	16451-16454	use	_	
71-11	16455-16461	during	_	
71-12	16462-16465	the	_	
71-13	16466-16471	study	_	
71-14	16471-16472	.	_	

#Text=Medication, particularly opioid use, was recorded (by verbal report) from all study participants.
72-1	16473-16483	Medication	_	
72-2	16483-16484	,	_	
72-3	16485-16497	particularly	_	
72-4	16498-16504	opioid	_	
72-5	16505-16508	use	_	
72-6	16508-16509	,	_	
72-7	16510-16513	was	_	
72-8	16514-16522	recorded	_	
72-9	16523-16524	(	_	
72-10	16524-16526	by	_	
72-11	16527-16533	verbal	_	
72-12	16534-16540	report	_	
72-13	16540-16541	)	_	
72-14	16542-16546	from	_	
72-15	16547-16550	all	_	
72-16	16551-16556	study	_	
72-17	16557-16569	participants	_	
72-18	16569-16570	.	_	

#Text=In the opioid fibromyalgia group, the distributions of duration of opioid use and morphine equivalent daily dose were right-skewed with all individuals taking 1–75 mg except for one taking 355 mg, and all individuals taking opioids for 3 months −16 years except for one taking opioids for 40 years.
73-1	16571-16573	In	_	
73-2	16574-16577	the	_	
73-3	16578-16584	opioid	_	
73-4	16585-16597	fibromyalgia	_	
73-5	16598-16603	group	_	
73-6	16603-16604	,	_	
73-7	16605-16608	the	_	
73-8	16609-16622	distributions	_	
73-9	16623-16625	of	_	
73-10	16626-16634	duration	_	
73-11	16635-16637	of	_	
73-12	16638-16644	opioid	_	
73-13	16645-16648	use	_	
73-14	16649-16652	and	_	
73-15	16653-16661	morphine	_	
73-16	16662-16672	equivalent	_	
73-17	16673-16678	daily	_	
73-18	16679-16683	dose	_	
73-19	16684-16688	were	_	
73-20	16689-16701	right-skewed	_	
73-21	16702-16706	with	_	
73-22	16707-16710	all	_	
73-23	16711-16722	individuals	_	
73-24	16723-16729	taking	_	
73-25	16730-16731	1	_	
73-26	16731-16732	–	_	
73-27	16732-16734	75	_	
73-28	16735-16737	mg	_	
73-29	16738-16744	except	_	
73-30	16745-16748	for	_	
73-31	16749-16752	one	_	
73-32	16753-16759	taking	_	
73-33	16760-16763	355	_	
73-34	16764-16766	mg	_	
73-35	16766-16767	,	_	
73-36	16768-16771	and	_	
73-37	16772-16775	all	_	
73-38	16776-16787	individuals	_	
73-39	16788-16794	taking	_	
73-40	16795-16802	opioids	_	
73-41	16803-16806	for	_	
73-42	16807-16808	3	_	
73-43	16809-16815	months	_	
73-44	16816-16817	−	_	
73-45	16817-16819	16	_	
73-46	16820-16825	years	_	
73-47	16826-16832	except	_	
73-48	16833-16836	for	_	
73-49	16837-16840	one	_	
73-50	16841-16847	taking	_	
73-51	16848-16855	opioids	_	
73-52	16856-16859	for	_	
73-53	16860-16862	40	_	
73-54	16863-16868	years	_	
73-55	16868-16869	.	_	

#Text=Across all individuals with fibromyalgia taking opioids, the median duration of opioid use was 6.17 years and median morphine equivalent daily dose was 20 mg (N = 17).
74-1	16870-16876	Across	_	
74-2	16877-16880	all	_	
74-3	16881-16892	individuals	_	
74-4	16893-16897	with	_	
74-5	16898-16910	fibromyalgia	_	
74-6	16911-16917	taking	_	
74-7	16918-16925	opioids	_	
74-8	16925-16926	,	_	
74-9	16927-16930	the	_	
74-10	16931-16937	median	_	
74-11	16938-16946	duration	_	
74-12	16947-16949	of	_	
74-13	16950-16956	opioid	_	
74-14	16957-16960	use	_	
74-15	16961-16964	was	_	
74-16	16965-16969	6.17	_	
74-17	16970-16975	years	_	
74-18	16976-16979	and	_	
74-19	16980-16986	median	_	
74-20	16987-16995	morphine	_	
74-21	16996-17006	equivalent	_	
74-22	17007-17012	daily	_	
74-23	17013-17017	dose	_	
74-24	17018-17021	was	_	
74-25	17022-17024	20	_	
74-26	17025-17027	mg	_	
74-27	17028-17029	(	_	
74-28	17029-17030	N	_	
74-29	17031-17032	=	_	
74-30	17033-17035	17	_	
74-31	17035-17036	)	_	
74-32	17036-17037	.	_	

#Text=Excluding the one high opioid dose, the median morphine equivalent daily dose was 17.5 mg (N = 16).
75-1	17038-17047	Excluding	_	
75-2	17048-17051	the	_	
75-3	17052-17055	one	_	
75-4	17056-17060	high	_	
75-5	17061-17067	opioid	_	
75-6	17068-17072	dose	_	
75-7	17072-17073	,	_	
75-8	17074-17077	the	_	
75-9	17078-17084	median	_	
75-10	17085-17093	morphine	_	
75-11	17094-17104	equivalent	_	
75-12	17105-17110	daily	_	
75-13	17111-17115	dose	_	
75-14	17116-17119	was	_	
75-15	17120-17124	17.5	_	
75-16	17125-17127	mg	_	
75-17	17128-17129	(	_	
75-18	17129-17130	N	_	
75-19	17131-17132	=	_	
75-20	17133-17135	16	_	
75-21	17135-17136	)	_	
75-22	17136-17137	.	_	

#Text=Excluding the one long duration opioid use, the median opioid use duration was 5.58 years (N = 16).
76-1	17138-17147	Excluding	_	
76-2	17148-17151	the	_	
76-3	17152-17155	one	_	
76-4	17156-17160	long	_	
76-5	17161-17169	duration	_	
76-6	17170-17176	opioid	_	
76-7	17177-17180	use	_	
76-8	17180-17181	,	_	
76-9	17182-17185	the	_	
76-10	17186-17192	median	_	
76-11	17193-17199	opioid	_	
76-12	17200-17203	use	_	
76-13	17204-17212	duration	_	
76-14	17213-17216	was	_	
76-15	17217-17221	5.58	_	
76-16	17222-17227	years	_	
76-17	17228-17229	(	_	
76-18	17229-17230	N	_	
76-19	17231-17232	=	_	
76-20	17233-17235	16	_	
76-21	17235-17236	)	_	
76-22	17236-17237	.	_	

#Text=Additional information on medications taken by all participants is provided in Table 3.
77-1	17238-17248	Additional	_	
77-2	17249-17260	information	_	
77-3	17261-17263	on	_	
77-4	17264-17275	medications	_	
77-5	17276-17281	taken	_	
77-6	17282-17284	by	_	
77-7	17285-17288	all	_	
77-8	17289-17301	participants	_	
77-9	17302-17304	is	_	
77-10	17305-17313	provided	_	
77-11	17314-17316	in	_	
77-12	17317-17322	Table	_	
77-13	17322-17323	 	_	
77-14	17323-17324	3	_	
77-15	17324-17325	.	_	

#Text=Arousal and valence ratings
#Text=Behavioral Ratings.
78-1	17326-17333	Arousal	_	
78-2	17334-17337	and	_	
78-3	17338-17345	valence	_	
78-4	17346-17353	ratings	_	
78-5	17354-17364	Behavioral	_	
78-6	17365-17372	Ratings	_	
78-7	17372-17373	.	_	

#Text=After the MID task fMRI experiment, study participants provided ratings of retrospective arousal and valence (7-point scale) to each of the 6 cues that had been presented during the MID task (e.g., +/− $0, $1, $5).
79-1	17374-17379	After	_	
79-2	17380-17383	the	_	
79-3	17384-17387	MID	_	
79-4	17388-17392	task	_	
79-5	17393-17397	fMRI	_	
79-6	17398-17408	experiment	_	
79-7	17408-17409	,	_	
79-8	17410-17415	study	_	
79-9	17416-17428	participants	_	
79-10	17429-17437	provided	_	
79-11	17438-17445	ratings	_	
79-12	17446-17448	of	_	
79-13	17449-17462	retrospective	_	
79-14	17463-17470	arousal	_	
79-15	17471-17474	and	_	
79-16	17475-17482	valence	_	
79-17	17483-17484	(	_	
79-18	17484-17485	7	_	
79-19	17485-17486	-	_	
79-20	17486-17491	point	_	
79-21	17492-17497	scale	_	
79-22	17497-17498	)	_	
79-23	17499-17501	to	_	
79-24	17502-17506	each	_	
79-25	17507-17509	of	_	
79-26	17510-17513	the	_	
79-27	17514-17515	6	_	
79-28	17516-17520	cues	_	
79-29	17521-17525	that	_	
79-30	17526-17529	had	_	
79-31	17530-17534	been	_	
79-32	17535-17544	presented	_	
79-33	17545-17551	during	_	
79-34	17552-17555	the	_	
79-35	17556-17559	MID	_	
79-36	17560-17564	task	_	
79-37	17565-17566	(	_	
79-38	17566-17569	e.g	_	
79-39	17569-17570	.	_	
79-40	17570-17571	,	_	
79-41	17572-17573	+	_	
79-42	17573-17574	/	_	
79-43	17574-17575	−	_	
79-44	17576-17578	$0	_	
79-45	17578-17579	,	_	
79-46	17580-17582	$1	_	
79-47	17582-17583	,	_	
79-48	17584-17586	$5	_	
79-49	17586-17587	)	_	
79-50	17587-17588	.	_	

#Text=Positive arousal and negative arousal ratings were calculated from ratings of arousal and valence.
80-1	17589-17597	Positive	_	
80-2	17598-17605	arousal	_	
80-3	17606-17609	and	_	
80-4	17610-17618	negative	_	
80-5	17619-17626	arousal	_	
80-6	17627-17634	ratings	_	
80-7	17635-17639	were	_	
80-8	17640-17650	calculated	_	
80-9	17651-17655	from	_	
80-10	17656-17663	ratings	_	
80-11	17664-17666	of	_	
80-12	17667-17674	arousal	_	
80-13	17675-17678	and	_	
80-14	17679-17686	valence	_	
80-15	17686-17687	.	_	

#Text=Two-way ANOVA was used for analysis of all behavioral values (effect of cue, effect of group, and cue by group interaction).
81-1	17688-17695	Two-way	_	
81-2	17696-17701	ANOVA	_	
81-3	17702-17705	was	_	
81-4	17706-17710	used	_	
81-5	17711-17714	for	_	
81-6	17715-17723	analysis	_	
81-7	17724-17726	of	_	
81-8	17727-17730	all	_	
81-9	17731-17741	behavioral	_	
81-10	17742-17748	values	_	
81-11	17749-17750	(	_	
81-12	17750-17756	effect	_	
81-13	17757-17759	of	_	
81-14	17760-17763	cue	_	
81-15	17763-17764	,	_	
81-16	17765-17771	effect	_	
81-17	17772-17774	of	_	
81-18	17775-17780	group	_	
81-19	17780-17781	,	_	
81-20	17782-17785	and	_	
81-21	17786-17789	cue	_	
81-22	17790-17792	by	_	
81-23	17793-17798	group	_	
81-24	17799-17810	interaction	_	
81-25	17810-17811	)	_	
81-26	17811-17812	.	_	

#Text=(a) Arousal ratings showed a main effect of group [F(2,215) = 4.5; p = 0.017], main effect of cue [F(5,215) = 32.3; p < 0.001], and no group by cue interaction [F(10,215) = 0.3; p = 0.971].
82-1	17813-17814	(	_	
82-2	17814-17815	a	_	
82-3	17815-17816	)	_	
82-4	17817-17824	Arousal	_	
82-5	17825-17832	ratings	_	
82-6	17833-17839	showed	_	
82-7	17840-17841	a	_	
82-8	17842-17846	main	_	
82-9	17847-17853	effect	_	
82-10	17854-17856	of	_	
82-11	17857-17862	group	_	
82-12	17863-17864	[	_	
82-13	17864-17865	F	_	
82-14	17865-17866	(	_	
82-15	17866-17871	2,215	_	
82-16	17871-17872	)	_	
82-17	17873-17874	=	_	
82-18	17875-17878	4.5	_	
82-19	17878-17879	;	_	
82-20	17880-17881	p	_	
82-21	17882-17883	=	_	
82-22	17884-17889	0.017	_	
82-23	17889-17890	]	_	
82-24	17890-17891	,	_	
82-25	17892-17896	main	_	
82-26	17897-17903	effect	_	
82-27	17904-17906	of	_	
82-28	17907-17910	cue	_	
82-29	17911-17912	[	_	
82-30	17912-17913	F	_	
82-31	17913-17914	(	_	
82-32	17914-17919	5,215	_	
82-33	17919-17920	)	_	
82-34	17921-17922	=	_	
82-35	17923-17927	32.3	_	
82-36	17927-17928	;	_	
82-37	17929-17930	p	_	
82-38	17931-17932	<	_	
82-39	17933-17938	0.001	_	
82-40	17938-17939	]	_	
82-41	17939-17940	,	_	
82-42	17941-17944	and	_	
82-43	17945-17947	no	_	
82-44	17948-17953	group	_	
82-45	17954-17956	by	_	
82-46	17957-17960	cue	_	
82-47	17961-17972	interaction	_	
82-48	17973-17974	[	_	
82-49	17974-17975	F	_	
82-50	17975-17976	(	_	
82-51	17976-17982	10,215	_	
82-52	17982-17983	)	_	
82-53	17984-17985	=	_	
82-54	17986-17989	0.3	_	
82-55	17989-17990	;	_	
82-56	17991-17992	p	_	
82-57	17993-17994	=	_	
82-58	17995-18000	0.971	_	
82-59	18000-18001	]	_	
82-60	18001-18002	.	_	

#Text=(b) Valence ratings showed no effect of group [F(2,215) = 0.2; p = 0.840], a main effect of cue [F(5,215) = 61.3; p < 0.001], and no group by cue interaction [F(10,215) = 1.7; p = 0.088].
83-1	18003-18004	(	_	
83-2	18004-18005	b	_	
83-3	18005-18006	)	_	
83-4	18007-18014	Valence	_	
83-5	18015-18022	ratings	_	
83-6	18023-18029	showed	_	
83-7	18030-18032	no	_	
83-8	18033-18039	effect	_	
83-9	18040-18042	of	_	
83-10	18043-18048	group	_	
83-11	18049-18050	[	_	
83-12	18050-18051	F	_	
83-13	18051-18052	(	_	
83-14	18052-18057	2,215	_	
83-15	18057-18058	)	_	
83-16	18059-18060	=	_	
83-17	18061-18064	0.2	_	
83-18	18064-18065	;	_	
83-19	18066-18067	p	_	
83-20	18068-18069	=	_	
83-21	18070-18075	0.840	_	
83-22	18075-18076	]	_	
83-23	18076-18077	,	_	
83-24	18078-18079	a	_	
83-25	18080-18084	main	_	
83-26	18085-18091	effect	_	
83-27	18092-18094	of	_	
83-28	18095-18098	cue	_	
83-29	18099-18100	[	_	
83-30	18100-18101	F	_	
83-31	18101-18102	(	_	
83-32	18102-18107	5,215	_	
83-33	18107-18108	)	_	
83-34	18109-18110	=	_	
83-35	18111-18115	61.3	_	
83-36	18115-18116	;	_	
83-37	18117-18118	p	_	
83-38	18119-18120	<	_	
83-39	18121-18126	0.001	_	
83-40	18126-18127	]	_	
83-41	18127-18128	,	_	
83-42	18129-18132	and	_	
83-43	18133-18135	no	_	
83-44	18136-18141	group	_	
83-45	18142-18144	by	_	
83-46	18145-18148	cue	_	
83-47	18149-18160	interaction	_	
83-48	18161-18162	[	_	
83-49	18162-18163	F	_	
83-50	18163-18164	(	_	
83-51	18164-18170	10,215	_	
83-52	18170-18171	)	_	
83-53	18172-18173	=	_	
83-54	18174-18177	1.7	_	
83-55	18177-18178	;	_	
83-56	18179-18180	p	_	
83-57	18181-18182	=	_	
83-58	18183-18188	0.088	_	
83-59	18188-18189	]	_	
83-60	18189-18190	.	_	

#Text=(c) Positive arousal showed a main effect of group [F(2,210) = 4.5; p = 0.017], main effect of cue [F(5,210) = 60; p < 0.001], and no group by cue interaction [F(10,210) = 1.3; p = 0.232].
84-1	18191-18192	(	_	
84-2	18192-18193	c	_	
84-3	18193-18194	)	_	
84-4	18195-18203	Positive	_	
84-5	18204-18211	arousal	_	
84-6	18212-18218	showed	_	
84-7	18219-18220	a	_	
84-8	18221-18225	main	_	
84-9	18226-18232	effect	_	
84-10	18233-18235	of	_	
84-11	18236-18241	group	_	
84-12	18242-18243	[	_	
84-13	18243-18244	F	_	
84-14	18244-18245	(	_	
84-15	18245-18250	2,210	_	
84-16	18250-18251	)	_	
84-17	18252-18253	=	_	
84-18	18254-18257	4.5	_	
84-19	18257-18258	;	_	
84-20	18259-18260	p	_	
84-21	18261-18262	=	_	
84-22	18263-18268	0.017	_	
84-23	18268-18269	]	_	
84-24	18269-18270	,	_	
84-25	18271-18275	main	_	
84-26	18276-18282	effect	_	
84-27	18283-18285	of	_	
84-28	18286-18289	cue	_	
84-29	18290-18291	[	_	
84-30	18291-18292	F	_	
84-31	18292-18293	(	_	
84-32	18293-18298	5,210	_	
84-33	18298-18299	)	_	
84-34	18300-18301	=	_	
84-35	18302-18304	60	_	
84-36	18304-18305	;	_	
84-37	18306-18307	p	_	
84-38	18308-18309	<	_	
84-39	18310-18315	0.001	_	
84-40	18315-18316	]	_	
84-41	18316-18317	,	_	
84-42	18318-18321	and	_	
84-43	18322-18324	no	_	
84-44	18325-18330	group	_	
84-45	18331-18333	by	_	
84-46	18334-18337	cue	_	
84-47	18338-18349	interaction	_	
84-48	18350-18351	[	_	
84-49	18351-18352	F	_	
84-50	18352-18353	(	_	
84-51	18353-18359	10,210	_	
84-52	18359-18360	)	_	
84-53	18361-18362	=	_	
84-54	18363-18366	1.3	_	
84-55	18366-18367	;	_	
84-56	18368-18369	p	_	
84-57	18370-18371	=	_	
84-58	18372-18377	0.232	_	
84-59	18377-18378	]	_	
84-60	18378-18379	.	_	

#Text=(d) Negative arousal showed no effect of group [F(2,210) = 0.3; p = 0.739], a main effect of cue [F(5,210) = 20.8; p < 0.001], and no group by cue interaction [F(10,210) = 0.5; p = 0.918].
85-1	18380-18381	(	_	
85-2	18381-18382	d	_	
85-3	18382-18383	)	_	
85-4	18384-18392	Negative	_	
85-5	18393-18400	arousal	_	
85-6	18401-18407	showed	_	
85-7	18408-18410	no	_	
85-8	18411-18417	effect	_	
85-9	18418-18420	of	_	
85-10	18421-18426	group	_	
85-11	18427-18428	[	_	
85-12	18428-18429	F	_	
85-13	18429-18430	(	_	
85-14	18430-18435	2,210	_	
85-15	18435-18436	)	_	
85-16	18437-18438	=	_	
85-17	18439-18442	0.3	_	
85-18	18442-18443	;	_	
85-19	18444-18445	p	_	
85-20	18446-18447	=	_	
85-21	18448-18453	0.739	_	
85-22	18453-18454	]	_	
85-23	18454-18455	,	_	
85-24	18456-18457	a	_	
85-25	18458-18462	main	_	
85-26	18463-18469	effect	_	
85-27	18470-18472	of	_	
85-28	18473-18476	cue	_	
85-29	18477-18478	[	_	
85-30	18478-18479	F	_	
85-31	18479-18480	(	_	
85-32	18480-18485	5,210	_	
85-33	18485-18486	)	_	
85-34	18487-18488	=	_	
85-35	18489-18493	20.8	_	
85-36	18493-18494	;	_	
85-37	18495-18496	p	_	
85-38	18497-18498	<	_	
85-39	18499-18504	0.001	_	
85-40	18504-18505	]	_	
85-41	18505-18506	,	_	
85-42	18507-18510	and	_	
85-43	18511-18513	no	_	
85-44	18514-18519	group	_	
85-45	18520-18522	by	_	
85-46	18523-18526	cue	_	
85-47	18527-18538	interaction	_	
85-48	18539-18540	[	_	
85-49	18540-18541	F	_	
85-50	18541-18542	(	_	
85-51	18542-18548	10,210	_	
85-52	18548-18549	)	_	
85-53	18550-18551	=	_	
85-54	18552-18555	0.5	_	
85-55	18555-18556	;	_	
85-56	18557-18558	p	_	
85-57	18559-18560	=	_	
85-58	18561-18566	0.918	_	
85-59	18566-18567	]	_	
85-60	18567-18568	.	_	

#Text=Asterisks indicate significant group differences for individual cues (*p < 0.05; **p < 0.01).
86-1	18569-18578	Asterisks	_	
86-2	18579-18587	indicate	_	
86-3	18588-18599	significant	_	
86-4	18600-18605	group	_	
86-5	18606-18617	differences	_	
86-6	18618-18621	for	_	
86-7	18622-18632	individual	_	
86-8	18633-18637	cues	_	
86-9	18638-18639	(	_	
86-10	18639-18640	*	_	
86-11	18640-18641	p	_	
86-12	18642-18643	<	_	
86-13	18644-18648	0.05	_	
86-14	18648-18649	;	_	
86-15	18650-18651	*	_	
86-16	18651-18652	*	_	
86-17	18652-18653	p	_	
86-18	18654-18655	<	_	
86-19	18656-18660	0.01	_	
86-20	18660-18661	)	_	
86-21	18661-18662	.	_	

#Text=One control and two fibromyalgia participants did not complete arousal and valence ratings after the scan.
87-1	18663-18666	One	_	
87-2	18667-18674	control	_	
87-3	18675-18678	and	_	
87-4	18679-18682	two	_	
87-5	18683-18695	fibromyalgia	_	
87-6	18696-18708	participants	_	
87-7	18709-18712	did	_	
87-8	18713-18716	not	_	
87-9	18717-18725	complete	_	
87-10	18726-18733	arousal	_	
87-11	18734-18737	and	_	
87-12	18738-18745	valence	_	
87-13	18746-18753	ratings	_	
87-14	18754-18759	after	_	
87-15	18760-18763	the	_	
87-16	18764-18768	scan	_	
87-17	18768-18769	.	_	

#Text=After the MID task fMRI scans, separate ratings of arousal and valence were collected in response to each of the 6 MID task monetary cues presented (i.e., +$0, +$1, +$5, −$0, −$1, −$5).
88-1	18770-18775	After	_	
88-2	18776-18779	the	_	
88-3	18780-18783	MID	_	
88-4	18784-18788	task	_	
88-5	18789-18793	fMRI	_	
88-6	18794-18799	scans	_	
88-7	18799-18800	,	_	
88-8	18801-18809	separate	_	
88-9	18810-18817	ratings	_	
88-10	18818-18820	of	_	
88-11	18821-18828	arousal	_	
88-12	18829-18832	and	_	
88-13	18833-18840	valence	_	
88-14	18841-18845	were	_	
88-15	18846-18855	collected	_	
88-16	18856-18858	in	_	
88-17	18859-18867	response	_	
88-18	18868-18870	to	_	
88-19	18871-18875	each	_	
88-20	18876-18878	of	_	
88-21	18879-18882	the	_	
88-22	18883-18884	6	_	
88-23	18885-18888	MID	_	
88-24	18889-18893	task	_	
88-25	18894-18902	monetary	_	
88-26	18903-18907	cues	_	
88-27	18908-18917	presented	_	
88-28	18918-18919	(	_	
88-29	18919-18922	i.e	_	
88-30	18922-18923	.	_	
88-31	18923-18924	,	_	
88-32	18925-18926	+	_	
88-33	18926-18928	$0	_	
88-34	18928-18929	,	_	
88-35	18930-18931	+	_	
88-36	18931-18933	$1	_	
88-37	18933-18934	,	_	
88-38	18935-18936	+	_	
88-39	18936-18938	$5	_	
88-40	18938-18939	,	_	
88-41	18940-18941	−	_	
88-42	18941-18943	$0	_	
88-43	18943-18944	,	_	
88-44	18945-18946	−	_	
88-45	18946-18948	$1	_	
88-46	18948-18949	,	_	
88-47	18950-18951	−	_	
88-48	18951-18953	$5	_	
88-49	18953-18954	)	_	
88-50	18954-18955	.	_	

#Text=Both fibromyalgia groups had lower arousal ratings to all cues as compared with controls (group effect) [F(2,215) = 4.5; p = 0.017].
89-1	18956-18960	Both	_	
89-2	18961-18973	fibromyalgia	_	
89-3	18974-18980	groups	_	
89-4	18981-18984	had	_	
89-5	18985-18990	lower	_	
89-6	18991-18998	arousal	_	
89-7	18999-19006	ratings	_	
89-8	19007-19009	to	_	
89-9	19010-19013	all	_	
89-10	19014-19018	cues	_	
89-11	19019-19021	as	_	
89-12	19022-19030	compared	_	
89-13	19031-19035	with	_	
89-14	19036-19044	controls	_	
89-15	19045-19046	(	_	
89-16	19046-19051	group	_	
89-17	19052-19058	effect	_	
89-18	19058-19059	)	_	
89-19	19060-19061	[	_	
89-20	19061-19062	F	_	
89-21	19062-19063	(	_	
89-22	19063-19068	2,215	_	
89-23	19068-19069	)	_	
89-24	19070-19071	=	_	
89-25	19072-19075	4.5	_	
89-26	19075-19076	;	_	
89-27	19077-19078	p	_	
89-28	19079-19080	=	_	
89-29	19081-19086	0.017	_	
89-30	19086-19087	]	_	
89-31	19087-19088	.	_	

#Text=Additionally, arousal ratings varied based on cue type for all groups [F(5,215) = 32.3; p < 0.001]; however, there was no group by cue interaction [F(10,215) = 0.3; p = 0.971] (Fig. 1).
90-1	19089-19101	Additionally	_	
90-2	19101-19102	,	_	
90-3	19103-19110	arousal	_	
90-4	19111-19118	ratings	_	
90-5	19119-19125	varied	_	
90-6	19126-19131	based	_	
90-7	19132-19134	on	_	
90-8	19135-19138	cue	_	
90-9	19139-19143	type	_	
90-10	19144-19147	for	_	
90-11	19148-19151	all	_	
90-12	19152-19158	groups	_	
90-13	19159-19160	[	_	
90-14	19160-19161	F	_	
90-15	19161-19162	(	_	
90-16	19162-19167	5,215	_	
90-17	19167-19168	)	_	
90-18	19169-19170	=	_	
90-19	19171-19175	32.3	_	
90-20	19175-19176	;	_	
90-21	19177-19178	p	_	
90-22	19179-19180	<	_	
90-23	19181-19186	0.001	_	
90-24	19186-19187	]	_	
90-25	19187-19188	;	_	
90-26	19189-19196	however	_	
90-27	19196-19197	,	_	
90-28	19198-19203	there	_	
90-29	19204-19207	was	_	
90-30	19208-19210	no	_	
90-31	19211-19216	group	_	
90-32	19217-19219	by	_	
90-33	19220-19223	cue	_	
90-34	19224-19235	interaction	_	
90-35	19236-19237	[	_	
90-36	19237-19238	F	_	
90-37	19238-19239	(	_	
90-38	19239-19245	10,215	_	
90-39	19245-19246	)	_	
90-40	19247-19248	=	_	
90-41	19249-19252	0.3	_	
90-42	19252-19253	;	_	
90-43	19254-19255	p	_	
90-44	19256-19257	=	_	
90-45	19258-19263	0.971	_	
90-46	19263-19264	]	_	
90-47	19265-19266	(	_	
90-48	19266-19269	Fig	_	
90-49	19269-19270	.	_	
90-50	19270-19271	 	_	
90-51	19271-19272	1	_	
90-52	19272-19273	)	_	
90-53	19273-19274	.	_	

#Text=Arousal ratings were not correlated with pain severity, duration of symptoms, anxiety, depression, or mood in the fibromyalgia groups, and none of these measures were significantly different between the opioid and non-opioid fibromyalgia groups.
91-1	19275-19282	Arousal	_	
91-2	19283-19290	ratings	_	
91-3	19291-19295	were	_	
91-4	19296-19299	not	_	
91-5	19300-19310	correlated	_	
91-6	19311-19315	with	_	
91-7	19316-19320	pain	_	
91-8	19321-19329	severity	_	
91-9	19329-19330	,	_	
91-10	19331-19339	duration	_	
91-11	19340-19342	of	_	
91-12	19343-19351	symptoms	_	
91-13	19351-19352	,	_	
91-14	19353-19360	anxiety	_	
91-15	19360-19361	,	_	
91-16	19362-19372	depression	_	
91-17	19372-19373	,	_	
91-18	19374-19376	or	_	
91-19	19377-19381	mood	_	
91-20	19382-19384	in	_	
91-21	19385-19388	the	_	
91-22	19389-19401	fibromyalgia	_	
91-23	19402-19408	groups	_	
91-24	19408-19409	,	_	
91-25	19410-19413	and	_	
91-26	19414-19418	none	_	
91-27	19419-19421	of	_	
91-28	19422-19427	these	_	
91-29	19428-19436	measures	_	
91-30	19437-19441	were	_	
91-31	19442-19455	significantly	_	
91-32	19456-19465	different	_	
91-33	19466-19473	between	_	
91-34	19474-19477	the	_	
91-35	19478-19484	opioid	_	
91-36	19485-19488	and	_	
91-37	19489-19499	non-opioid	_	
91-38	19500-19512	fibromyalgia	_	
91-39	19513-19519	groups	_	
91-40	19519-19520	.	_	

#Text=Valence ratings varied based on cue type for all groups [F(5,215) = 61.3; p < 0.001]; however, there was no group effect [F(2,215) = 0.2; p = 0.840] and no group by cue interaction [F(10,215) = 1.7; p = 0.088] (Fig. 1).
92-1	19521-19528	Valence	_	
92-2	19529-19536	ratings	_	
92-3	19537-19543	varied	_	
92-4	19544-19549	based	_	
92-5	19550-19552	on	_	
92-6	19553-19556	cue	_	
92-7	19557-19561	type	_	
92-8	19562-19565	for	_	
92-9	19566-19569	all	_	
92-10	19570-19576	groups	_	
92-11	19577-19578	[	_	
92-12	19578-19579	F	_	
92-13	19579-19580	(	_	
92-14	19580-19585	5,215	_	
92-15	19585-19586	)	_	
92-16	19587-19588	=	_	
92-17	19589-19593	61.3	_	
92-18	19593-19594	;	_	
92-19	19595-19596	p	_	
92-20	19597-19598	<	_	
92-21	19599-19604	0.001	_	
92-22	19604-19605	]	_	
92-23	19605-19606	;	_	
92-24	19607-19614	however	_	
92-25	19614-19615	,	_	
92-26	19616-19621	there	_	
92-27	19622-19625	was	_	
92-28	19626-19628	no	_	
92-29	19629-19634	group	_	
92-30	19635-19641	effect	_	
92-31	19642-19643	[	_	
92-32	19643-19644	F	_	
92-33	19644-19645	(	_	
92-34	19645-19650	2,215	_	
92-35	19650-19651	)	_	
92-36	19652-19653	=	_	
92-37	19654-19657	0.2	_	
92-38	19657-19658	;	_	
92-39	19659-19660	p	_	
92-40	19661-19662	=	_	
92-41	19663-19668	0.840	_	
92-42	19668-19669	]	_	
92-43	19670-19673	and	_	
92-44	19674-19676	no	_	
92-45	19677-19682	group	_	
92-46	19683-19685	by	_	
92-47	19686-19689	cue	_	
92-48	19690-19701	interaction	_	
92-49	19702-19703	[	_	
92-50	19703-19704	F	_	
92-51	19704-19705	(	_	
92-52	19705-19711	10,215	_	
92-53	19711-19712	)	_	
92-54	19713-19714	=	_	
92-55	19715-19718	1.7	_	
92-56	19718-19719	;	_	
92-57	19720-19721	p	_	
92-58	19722-19723	=	_	
92-59	19724-19729	0.088	_	
92-60	19729-19730	]	_	
92-61	19731-19732	(	_	
92-62	19732-19735	Fig	_	
92-63	19735-19736	.	_	
92-64	19736-19737	 	_	
92-65	19737-19738	1	_	
92-66	19738-19739	)	_	
92-67	19739-19740	.	_	

#Text=Positive arousal and negative arousal followed similar patterns as arousal and valence (see Fig. 1 for details).
93-1	19741-19749	Positive	_	
93-2	19750-19757	arousal	_	
93-3	19758-19761	and	_	
93-4	19762-19770	negative	_	
93-5	19771-19778	arousal	_	
93-6	19779-19787	followed	_	
93-7	19788-19795	similar	_	
93-8	19796-19804	patterns	_	
93-9	19805-19807	as	_	
93-10	19808-19815	arousal	_	
93-11	19816-19819	and	_	
93-12	19820-19827	valence	_	
93-13	19828-19829	(	_	
93-14	19829-19832	see	_	
93-15	19833-19836	Fig	_	
93-16	19836-19837	.	_	
93-17	19837-19838	 	_	
93-18	19838-19839	1	_	
93-19	19840-19843	for	_	
93-20	19844-19851	details	_	
93-21	19851-19852	)	_	
93-22	19852-19853	.	_	

#Text=MID task reaction times and accuracy
#Text=Briefly, each trial of the MID task consisted sequentially of a cue presentation (potential gain cues: +$0, +$1, +$5; potential loss cues: −$0, −$1, −$5), short delay, target presentation, and outcome presentation.
94-1	19854-19857	MID	_	
94-2	19858-19862	task	_	
94-3	19863-19871	reaction	_	
94-4	19872-19877	times	_	
94-5	19878-19881	and	_	
94-6	19882-19890	accuracy	_	
94-7	19891-19898	Briefly	_	
94-8	19898-19899	,	_	
94-9	19900-19904	each	_	
94-10	19905-19910	trial	_	
94-11	19911-19913	of	_	
94-12	19914-19917	the	_	
94-13	19918-19921	MID	_	
94-14	19922-19926	task	_	
94-15	19927-19936	consisted	_	
94-16	19937-19949	sequentially	_	
94-17	19950-19952	of	_	
94-18	19953-19954	a	_	
94-19	19955-19958	cue	_	
94-20	19959-19971	presentation	_	
94-21	19972-19973	(	_	
94-22	19973-19982	potential	_	
94-23	19983-19987	gain	_	
94-24	19988-19992	cues	_	
94-25	19992-19993	:	_	
94-26	19994-19995	+	_	
94-27	19995-19997	$0	_	
94-28	19997-19998	,	_	
94-29	19999-20000	+	_	
94-30	20000-20002	$1	_	
94-31	20002-20003	,	_	
94-32	20004-20005	+	_	
94-33	20005-20007	$5	_	
94-34	20007-20008	;	_	
94-35	20009-20018	potential	_	
94-36	20019-20023	loss	_	
94-37	20024-20028	cues	_	
94-38	20028-20029	:	_	
94-39	20030-20031	−	_	
94-40	20031-20033	$0	_	
94-41	20033-20034	,	_	
94-42	20035-20036	−	_	
94-43	20036-20038	$1	_	
94-44	20038-20039	,	_	
94-45	20040-20041	−	_	
94-46	20041-20043	$5	_	
94-47	20043-20044	)	_	
94-48	20044-20045	,	_	
94-49	20046-20051	short	_	
94-50	20052-20057	delay	_	
94-51	20057-20058	,	_	
94-52	20059-20065	target	_	
94-53	20066-20078	presentation	_	
94-54	20078-20079	,	_	
94-55	20080-20083	and	_	
94-56	20084-20091	outcome	_	
94-57	20092-20104	presentation	_	
94-58	20104-20105	.	_	

#Text=Participants needed to respond to the target (button press) as fast as possible to either gain money (for trials associated with gain cues) or avoid losing money (for trials associated with loss cues) in the previously shown cue amount (see Methods for details).
95-1	20106-20118	Participants	_	
95-2	20119-20125	needed	_	
95-3	20126-20128	to	_	
95-4	20129-20136	respond	_	
95-5	20137-20139	to	_	
95-6	20140-20143	the	_	
95-7	20144-20150	target	_	
95-8	20151-20152	(	_	
95-9	20152-20158	button	_	
95-10	20159-20164	press	_	
95-11	20164-20165	)	_	
95-12	20166-20168	as	_	
95-13	20169-20173	fast	_	
95-14	20174-20176	as	_	
95-15	20177-20185	possible	_	
95-16	20186-20188	to	_	
95-17	20189-20195	either	_	
95-18	20196-20200	gain	_	
95-19	20201-20206	money	_	
95-20	20207-20208	(	_	
95-21	20208-20211	for	_	
95-22	20212-20218	trials	_	
95-23	20219-20229	associated	_	
95-24	20230-20234	with	_	
95-25	20235-20239	gain	_	
95-26	20240-20244	cues	_	
95-27	20244-20245	)	_	
95-28	20246-20248	or	_	
95-29	20249-20254	avoid	_	
95-30	20255-20261	losing	_	
95-31	20262-20267	money	_	
95-32	20268-20269	(	_	
95-33	20269-20272	for	_	
95-34	20273-20279	trials	_	
95-35	20280-20290	associated	_	
95-36	20291-20295	with	_	
95-37	20296-20300	loss	_	
95-38	20301-20305	cues	_	
95-39	20305-20306	)	_	
95-40	20307-20309	in	_	
95-41	20310-20313	the	_	
95-42	20314-20324	previously	_	
95-43	20325-20330	shown	_	
95-44	20331-20334	cue	_	
95-45	20335-20341	amount	_	
95-46	20342-20343	(	_	
95-47	20343-20346	see	_	
95-48	20347-20354	Methods	_	
95-49	20355-20358	for	_	
95-50	20359-20366	details	_	
95-51	20366-20367	)	_	
95-52	20367-20368	.	_	

#Text=To evaluate performance on the MID task among all groups, we analyzed reaction time and accuracy.
96-1	20369-20371	To	_	
96-2	20372-20380	evaluate	_	
96-3	20381-20392	performance	_	
96-4	20393-20395	on	_	
96-5	20396-20399	the	_	
96-6	20400-20403	MID	_	
96-7	20404-20408	task	_	
96-8	20409-20414	among	_	
96-9	20415-20418	all	_	
96-10	20419-20425	groups	_	
96-11	20425-20426	,	_	
96-12	20427-20429	we	_	
96-13	20430-20438	analyzed	_	
96-14	20439-20447	reaction	_	
96-15	20448-20452	time	_	
96-16	20453-20456	and	_	
96-17	20457-20465	accuracy	_	
96-18	20465-20466	.	_	

#Text=Trials with more salient (i.e., higher) gain (+$5) and loss (−$5) cues produced faster reaction times as compared to trials with less salient cues (i.e., +$1, +$0, −$1, −$0) [F(5,225) = 9.2; p < 0.001] across all groups as expected.
97-1	20467-20473	Trials	_	
97-2	20474-20478	with	_	
97-3	20479-20483	more	_	
97-4	20484-20491	salient	_	
97-5	20492-20493	(	_	
97-6	20493-20496	i.e	_	
97-7	20496-20497	.	_	
97-8	20497-20498	,	_	
97-9	20499-20505	higher	_	
97-10	20505-20506	)	_	
97-11	20507-20511	gain	_	
97-12	20512-20513	(	_	
97-13	20513-20514	+	_	
97-14	20514-20516	$5	_	
97-15	20516-20517	)	_	
97-16	20518-20521	and	_	
97-17	20522-20526	loss	_	
97-18	20527-20528	(	_	
97-19	20528-20529	−	_	
97-20	20529-20531	$5	_	
97-21	20531-20532	)	_	
97-22	20533-20537	cues	_	
97-23	20538-20546	produced	_	
97-24	20547-20553	faster	_	
97-25	20554-20562	reaction	_	
97-26	20563-20568	times	_	
97-27	20569-20571	as	_	
97-28	20572-20580	compared	_	
97-29	20581-20583	to	_	
97-30	20584-20590	trials	_	
97-31	20591-20595	with	_	
97-32	20596-20600	less	_	
97-33	20601-20608	salient	_	
97-34	20609-20613	cues	_	
97-35	20614-20615	(	_	
97-36	20615-20618	i.e	_	
97-37	20618-20619	.	_	
97-38	20619-20620	,	_	
97-39	20621-20622	+	_	
97-40	20622-20624	$1	_	
97-41	20624-20625	,	_	
97-42	20626-20627	+	_	
97-43	20627-20629	$0	_	
97-44	20629-20630	,	_	
97-45	20631-20632	−	_	
97-46	20632-20634	$1	_	
97-47	20634-20635	,	_	
97-48	20636-20637	−	_	
97-49	20637-20639	$0	_	
97-50	20639-20640	)	_	
97-51	20641-20642	[	_	
97-52	20642-20643	F	_	
97-53	20643-20644	(	_	
97-54	20644-20649	5,225	_	
97-55	20649-20650	)	_	
97-56	20651-20652	=	_	
97-57	20653-20656	9.2	_	
97-58	20656-20657	;	_	
97-59	20658-20659	p	_	
97-60	20660-20661	<	_	
97-61	20662-20667	0.001	_	
97-62	20667-20668	]	_	
97-63	20669-20675	across	_	
97-64	20676-20679	all	_	
97-65	20680-20686	groups	_	
97-66	20687-20689	as	_	
97-67	20690-20698	expected	_	
97-68	20698-20699	.	_	

#Text=No group effect [F(2,225) = 0.5; p = 0.638] or group by trial (here, trial varies based on the different cues presented) interaction effect [F(10,225) = 1.2; p = 0.307] was observed for reaction time, indicating similar task performance (i.e., effort and speed) across all three groups.
98-1	20700-20702	No	_	
98-2	20703-20708	group	_	
98-3	20709-20715	effect	_	
98-4	20716-20717	[	_	
98-5	20717-20718	F	_	
98-6	20718-20719	(	_	
98-7	20719-20724	2,225	_	
98-8	20724-20725	)	_	
98-9	20726-20727	=	_	
98-10	20728-20731	0.5	_	
98-11	20731-20732	;	_	
98-12	20733-20734	p	_	
98-13	20735-20736	=	_	
98-14	20737-20742	0.638	_	
98-15	20742-20743	]	_	
98-16	20744-20746	or	_	
98-17	20747-20752	group	_	
98-18	20753-20755	by	_	
98-19	20756-20761	trial	_	
98-20	20762-20763	(	_	
98-21	20763-20767	here	_	
98-22	20767-20768	,	_	
98-23	20769-20774	trial	_	
98-24	20775-20781	varies	_	
98-25	20782-20787	based	_	
98-26	20788-20790	on	_	
98-27	20791-20794	the	_	
98-28	20795-20804	different	_	
98-29	20805-20809	cues	_	
98-30	20810-20819	presented	_	
98-31	20819-20820	)	_	
98-32	20821-20832	interaction	_	
98-33	20833-20839	effect	_	
98-34	20840-20841	[	_	
98-35	20841-20842	F	_	
98-36	20842-20843	(	_	
98-37	20843-20849	10,225	_	
98-38	20849-20850	)	_	
98-39	20851-20852	=	_	
98-40	20853-20856	1.2	_	
98-41	20856-20857	;	_	
98-42	20858-20859	p	_	
98-43	20860-20861	=	_	
98-44	20862-20867	0.307	_	
98-45	20867-20868	]	_	
98-46	20869-20872	was	_	
98-47	20873-20881	observed	_	
98-48	20882-20885	for	_	
98-49	20886-20894	reaction	_	
98-50	20895-20899	time	_	
98-51	20899-20900	,	_	
98-52	20901-20911	indicating	_	
98-53	20912-20919	similar	_	
98-54	20920-20924	task	_	
98-55	20925-20936	performance	_	
98-56	20937-20938	(	_	
98-57	20938-20941	i.e	_	
98-58	20941-20942	.	_	
98-59	20942-20943	,	_	
98-60	20944-20950	effort	_	
98-61	20951-20954	and	_	
98-62	20955-20960	speed	_	
98-63	20960-20961	)	_	
98-64	20962-20968	across	_	
98-65	20969-20972	all	_	
98-66	20973-20978	three	_	
98-67	20979-20985	groups	_	
98-68	20985-20986	.	_	

#Text=This version of the MID task used an algorithm to target overall 66% accuracy rates across all trials; however, despite this automatic adjustment of task difficulty, trials with larger gain (+$5) and loss (−$5) cues resulted in higher accuracy as compared to trials with less salient cues (i.e., +$1, +$0, −$1, −$0) across all groups [F(5,230) = 4.8; p < 0.001].
99-1	20987-20991	This	_	
99-2	20992-20999	version	_	
99-3	21000-21002	of	_	
99-4	21003-21006	the	_	
99-5	21007-21010	MID	_	
99-6	21011-21015	task	_	
99-7	21016-21020	used	_	
99-8	21021-21023	an	_	
99-9	21024-21033	algorithm	_	
99-10	21034-21036	to	_	
99-11	21037-21043	target	_	
99-12	21044-21051	overall	_	
99-13	21052-21055	66%	_	
99-14	21056-21064	accuracy	_	
99-15	21065-21070	rates	_	
99-16	21071-21077	across	_	
99-17	21078-21081	all	_	
99-18	21082-21088	trials	_	
99-19	21088-21089	;	_	
99-20	21090-21097	however	_	
99-21	21097-21098	,	_	
99-22	21099-21106	despite	_	
99-23	21107-21111	this	_	
99-24	21112-21121	automatic	_	
99-25	21122-21132	adjustment	_	
99-26	21133-21135	of	_	
99-27	21136-21140	task	_	
99-28	21141-21151	difficulty	_	
99-29	21151-21152	,	_	
99-30	21153-21159	trials	_	
99-31	21160-21164	with	_	
99-32	21165-21171	larger	_	
99-33	21172-21176	gain	_	
99-34	21177-21178	(	_	
99-35	21178-21179	+	_	
99-36	21179-21181	$5	_	
99-37	21181-21182	)	_	
99-38	21183-21186	and	_	
99-39	21187-21191	loss	_	
99-40	21192-21193	(	_	
99-41	21193-21194	−	_	
99-42	21194-21196	$5	_	
99-43	21196-21197	)	_	
99-44	21198-21202	cues	_	
99-45	21203-21211	resulted	_	
99-46	21212-21214	in	_	
99-47	21215-21221	higher	_	
99-48	21222-21230	accuracy	_	
99-49	21231-21233	as	_	
99-50	21234-21242	compared	_	
99-51	21243-21245	to	_	
99-52	21246-21252	trials	_	
99-53	21253-21257	with	_	
99-54	21258-21262	less	_	
99-55	21263-21270	salient	_	
99-56	21271-21275	cues	_	
99-57	21276-21277	(	_	
99-58	21277-21280	i.e	_	
99-59	21280-21281	.	_	
99-60	21281-21282	,	_	
99-61	21283-21284	+	_	
99-62	21284-21286	$1	_	
99-63	21286-21287	,	_	
99-64	21288-21289	+	_	
99-65	21289-21291	$0	_	
99-66	21291-21292	,	_	
99-67	21293-21294	−	_	
99-68	21294-21296	$1	_	
99-69	21296-21297	,	_	
99-70	21298-21299	−	_	
99-71	21299-21301	$0	_	
99-72	21301-21302	)	_	
99-73	21303-21309	across	_	
99-74	21310-21313	all	_	
99-75	21314-21320	groups	_	
99-76	21321-21322	[	_	
99-77	21322-21323	F	_	
99-78	21323-21324	(	_	
99-79	21324-21329	5,230	_	
99-80	21329-21330	)	_	
99-81	21331-21332	=	_	
99-82	21333-21336	4.8	_	
99-83	21336-21337	;	_	
99-84	21338-21339	p	_	
99-85	21340-21341	<	_	
99-86	21342-21347	0.001	_	
99-87	21347-21348	]	_	
99-88	21348-21349	.	_	

#Text=No group effect for accuracy was observed [F(2,230) = 0.0; p = 0.981].
100-1	21350-21352	No	_	
100-2	21353-21358	group	_	
100-3	21359-21365	effect	_	
100-4	21366-21369	for	_	
100-5	21370-21378	accuracy	_	
100-6	21379-21382	was	_	
100-7	21383-21391	observed	_	
100-8	21392-21393	[	_	
100-9	21393-21394	F	_	
100-10	21394-21395	(	_	
100-11	21395-21400	2,230	_	
100-12	21400-21401	)	_	
100-13	21402-21403	=	_	
100-14	21404-21407	0.0	_	
100-15	21407-21408	;	_	
100-16	21409-21410	p	_	
100-17	21411-21412	=	_	
100-18	21413-21418	0.981	_	
100-19	21418-21419	]	_	
100-20	21419-21420	.	_	

#Text=However, a group by trial (i.e., here, trials differ by cue type) interaction effect was observed for accuracy [F(10,230) = 2.1; p = 0.022].
101-1	21421-21428	However	_	
101-2	21428-21429	,	_	
101-3	21430-21431	a	_	
101-4	21432-21437	group	_	
101-5	21438-21440	by	_	
101-6	21441-21446	trial	_	
101-7	21447-21448	(	_	
101-8	21448-21451	i.e	_	
101-9	21451-21452	.	_	
101-10	21452-21453	,	_	
101-11	21454-21458	here	_	
101-12	21458-21459	,	_	
101-13	21460-21466	trials	_	
101-14	21467-21473	differ	_	
101-15	21474-21476	by	_	
101-16	21477-21480	cue	_	
101-17	21481-21485	type	_	
101-18	21485-21486	)	_	
101-19	21487-21498	interaction	_	
101-20	21499-21505	effect	_	
101-21	21506-21509	was	_	
101-22	21510-21518	observed	_	
101-23	21519-21522	for	_	
101-24	21523-21531	accuracy	_	
101-25	21532-21533	[	_	
101-26	21533-21534	F	_	
101-27	21534-21535	(	_	
101-28	21535-21541	10,230	_	
101-29	21541-21542	)	_	
101-30	21543-21544	=	_	
101-31	21545-21548	2.1	_	
101-32	21548-21549	;	_	
101-33	21550-21551	p	_	
101-34	21552-21553	=	_	
101-35	21554-21559	0.022	_	
101-36	21559-21560	]	_	
101-37	21560-21561	.	_	

#Text=Post-hoc within-group analyses revealed this interaction was due to significant effects of trial (i.e., here, trials differ by cue type) in the control group [F(5,70) = 3.3; p = 0.010] and in the non-opioid fibromyalgia group [F(5,80) = 3.5; p = 0.007], but not in the opioid fibromyalgia group [F(5,80) = 1.8; p = 0.114], which suggests that the opioid fibromyalgia group’s performance was less sensitive to trial (i.e., cue) type relative to the other groups.
102-1	21562-21570	Post-hoc	_	
102-2	21571-21583	within-group	_	
102-3	21584-21592	analyses	_	
102-4	21593-21601	revealed	_	
102-5	21602-21606	this	_	
102-6	21607-21618	interaction	_	
102-7	21619-21622	was	_	
102-8	21623-21626	due	_	
102-9	21627-21629	to	_	
102-10	21630-21641	significant	_	
102-11	21642-21649	effects	_	
102-12	21650-21652	of	_	
102-13	21653-21658	trial	_	
102-14	21659-21660	(	_	
102-15	21660-21663	i.e	_	
102-16	21663-21664	.	_	
102-17	21664-21665	,	_	
102-18	21666-21670	here	_	
102-19	21670-21671	,	_	
102-20	21672-21678	trials	_	
102-21	21679-21685	differ	_	
102-22	21686-21688	by	_	
102-23	21689-21692	cue	_	
102-24	21693-21697	type	_	
102-25	21697-21698	)	_	
102-26	21699-21701	in	_	
102-27	21702-21705	the	_	
102-28	21706-21713	control	_	
102-29	21714-21719	group	_	
102-30	21720-21721	[	_	
102-31	21721-21722	F	_	
102-32	21722-21723	(	_	
102-33	21723-21727	5,70	_	
102-34	21727-21728	)	_	
102-35	21729-21730	=	_	
102-36	21731-21734	3.3	_	
102-37	21734-21735	;	_	
102-38	21736-21737	p	_	
102-39	21738-21739	=	_	
102-40	21740-21745	0.010	_	
102-41	21745-21746	]	_	
102-42	21747-21750	and	_	
102-43	21751-21753	in	_	
102-44	21754-21757	the	_	
102-45	21758-21768	non-opioid	_	
102-46	21769-21781	fibromyalgia	_	
102-47	21782-21787	group	_	
102-48	21788-21789	[	_	
102-49	21789-21790	F	_	
102-50	21790-21791	(	_	
102-51	21791-21795	5,80	_	
102-52	21795-21796	)	_	
102-53	21797-21798	=	_	
102-54	21799-21802	3.5	_	
102-55	21802-21803	;	_	
102-56	21804-21805	p	_	
102-57	21806-21807	=	_	
102-58	21808-21813	0.007	_	
102-59	21813-21814	]	_	
102-60	21814-21815	,	_	
102-61	21816-21819	but	_	
102-62	21820-21823	not	_	
102-63	21824-21826	in	_	
102-64	21827-21830	the	_	
102-65	21831-21837	opioid	_	
102-66	21838-21850	fibromyalgia	_	
102-67	21851-21856	group	_	
102-68	21857-21858	[	_	
102-69	21858-21859	F	_	
102-70	21859-21860	(	_	
102-71	21860-21864	5,80	_	
102-72	21864-21865	)	_	
102-73	21866-21867	=	_	
102-74	21868-21871	1.8	_	
102-75	21871-21872	;	_	
102-76	21873-21874	p	_	
102-77	21875-21876	=	_	
102-78	21877-21882	0.114	_	
102-79	21882-21883	]	_	
102-80	21883-21884	,	_	
102-81	21885-21890	which	_	
102-82	21891-21899	suggests	_	
102-83	21900-21904	that	_	
102-84	21905-21908	the	_	
102-85	21909-21915	opioid	_	
102-86	21916-21928	fibromyalgia	_	
102-87	21929-21934	group	_	
102-88	21934-21935	’	_	
102-89	21935-21936	s	_	
102-90	21937-21948	performance	_	
102-91	21949-21952	was	_	
102-92	21953-21957	less	_	
102-93	21958-21967	sensitive	_	
102-94	21968-21970	to	_	
102-95	21971-21976	trial	_	
102-96	21977-21978	(	_	
102-97	21978-21981	i.e	_	
102-98	21981-21982	.	_	
102-99	21982-21983	,	_	
102-100	21984-21987	cue	_	
102-101	21987-21988	)	_	
102-102	21989-21993	type	_	
102-103	21994-22002	relative	_	
102-104	22003-22005	to	_	
102-105	22006-22009	the	_	
102-106	22010-22015	other	_	
102-107	22016-22022	groups	_	
102-108	22022-22023	.	_	

#Text=Region of interest: nucleus accumbens response
#Text=Brain reward anticipatory response was analyzed by comparing the blood oxygenation level dependent (BOLD) signal from preprocessed fMRI data during trials with +$5 cues versus trials with $0 cues for each participant.
103-1	22024-22030	Region	_	
103-2	22031-22033	of	_	
103-3	22034-22042	interest	_	
103-4	22042-22043	:	_	
103-5	22044-22051	nucleus	_	
103-6	22052-22061	accumbens	_	
103-7	22062-22070	response	_	
103-8	22071-22076	Brain	_	
103-9	22077-22083	reward	_	
103-10	22084-22096	anticipatory	_	
103-11	22097-22105	response	_	
103-12	22106-22109	was	_	
103-13	22110-22118	analyzed	_	
103-14	22119-22121	by	_	
103-15	22122-22131	comparing	_	
103-16	22132-22135	the	_	
103-17	22136-22141	blood	_	
103-18	22142-22153	oxygenation	_	
103-19	22154-22159	level	_	
103-20	22160-22169	dependent	_	
103-21	22170-22171	(	_	
103-22	22171-22175	BOLD	_	
103-23	22175-22176	)	_	
103-24	22177-22183	signal	_	
103-25	22184-22188	from	_	
103-26	22189-22201	preprocessed	_	
103-27	22202-22206	fMRI	_	
103-28	22207-22211	data	_	
103-29	22212-22218	during	_	
103-30	22219-22225	trials	_	
103-31	22226-22230	with	_	
103-32	22231-22232	+	_	
103-33	22232-22234	$5	_	
103-34	22235-22239	cues	_	
103-35	22240-22246	versus	_	
103-36	22247-22253	trials	_	
103-37	22254-22258	with	_	
103-38	22259-22261	$0	_	
103-39	22262-22266	cues	_	
103-40	22267-22270	for	_	
103-41	22271-22275	each	_	
103-42	22276-22287	participant	_	
103-43	22287-22288	.	_	

#Text=Thus, a gain versus no-gain anticipation (GVNant) task-based regressor was used to extract the BOLD signal at the relevant associated timepoints and average across multiple trials.
104-1	22289-22293	Thus	_	
104-2	22293-22294	,	_	
104-3	22295-22296	a	_	
104-4	22297-22301	gain	_	
104-5	22302-22308	versus	_	
104-6	22309-22316	no-gain	_	
104-7	22317-22329	anticipation	_	
104-8	22330-22331	(	_	
104-9	22331-22337	GVNant	_	
104-10	22337-22338	)	_	
104-11	22339-22349	task-based	_	
104-12	22350-22359	regressor	_	
104-13	22360-22363	was	_	
104-14	22364-22368	used	_	
104-15	22369-22371	to	_	
104-16	22372-22379	extract	_	
104-17	22380-22383	the	_	
104-18	22384-22388	BOLD	_	
104-19	22389-22395	signal	_	
104-20	22396-22398	at	_	
104-21	22399-22402	the	_	
104-22	22403-22411	relevant	_	
104-23	22412-22422	associated	_	
104-24	22423-22433	timepoints	_	
104-25	22434-22437	and	_	
104-26	22438-22445	average	_	
104-27	22446-22452	across	_	
104-28	22453-22461	multiple	_	
104-29	22462-22468	trials	_	
104-30	22468-22469	.	_	

#Text=The GVNant contrast was used to evaluate both NAcc and MPFC regions of interest (extracted beta values) for group differences in reward anticipatory response.
105-1	22470-22473	The	_	
105-2	22474-22480	GVNant	_	
105-3	22481-22489	contrast	_	
105-4	22490-22493	was	_	
105-5	22494-22498	used	_	
105-6	22499-22501	to	_	
105-7	22502-22510	evaluate	_	
105-8	22511-22515	both	_	
105-9	22516-22520	NAcc	_	
105-10	22521-22524	and	_	
105-11	22525-22529	MPFC	_	
105-12	22530-22537	regions	_	
105-13	22538-22540	of	_	
105-14	22541-22549	interest	_	
105-15	22550-22551	(	_	
105-16	22551-22560	extracted	_	
105-17	22561-22565	beta	_	
105-18	22566-22572	values	_	
105-19	22572-22573	)	_	
105-20	22574-22577	for	_	
105-21	22578-22583	group	_	
105-22	22584-22595	differences	_	
105-23	22596-22598	in	_	
105-24	22599-22605	reward	_	
105-25	22606-22618	anticipatory	_	
105-26	22619-22627	response	_	
105-27	22627-22628	.	_	

#Text=Brain reward outcome response was analyzed by comparing the BOLD signal from preprocessed fMRI data during successful (hit) trials with −$5 cues versus unsuccessful (miss) trials with −$5 cues for each participant.
106-1	22629-22634	Brain	_	
106-2	22635-22641	reward	_	
106-3	22642-22649	outcome	_	
106-4	22650-22658	response	_	
106-5	22659-22662	was	_	
106-6	22663-22671	analyzed	_	
106-7	22672-22674	by	_	
106-8	22675-22684	comparing	_	
106-9	22685-22688	the	_	
106-10	22689-22693	BOLD	_	
106-11	22694-22700	signal	_	
106-12	22701-22705	from	_	
106-13	22706-22718	preprocessed	_	
106-14	22719-22723	fMRI	_	
106-15	22724-22728	data	_	
106-16	22729-22735	during	_	
106-17	22736-22746	successful	_	
106-18	22747-22748	(	_	
106-19	22748-22751	hit	_	
106-20	22751-22752	)	_	
106-21	22753-22759	trials	_	
106-22	22760-22764	with	_	
106-23	22765-22766	−	_	
106-24	22766-22768	$5	_	
106-25	22769-22773	cues	_	
106-26	22774-22780	versus	_	
106-27	22781-22793	unsuccessful	_	
106-28	22794-22795	(	_	
106-29	22795-22799	miss	_	
106-30	22799-22800	)	_	
106-31	22801-22807	trials	_	
106-32	22808-22812	with	_	
106-33	22813-22814	−	_	
106-34	22814-22816	$5	_	
106-35	22817-22821	cues	_	
106-36	22822-22825	for	_	
106-37	22826-22830	each	_	
106-38	22831-22842	participant	_	
106-39	22842-22843	.	_	

#Text=Thus, a non-loss versus loss outcome (NVLout) task-based regressor was used to extract the BOLD signal at the relevant associated timepoints and average across multiple trials.
107-1	22844-22848	Thus	_	
107-2	22848-22849	,	_	
107-3	22850-22851	a	_	
107-4	22852-22860	non-loss	_	
107-5	22861-22867	versus	_	
107-6	22868-22872	loss	_	
107-7	22873-22880	outcome	_	
107-8	22881-22882	(	_	
107-9	22882-22888	NVLout	_	
107-10	22888-22889	)	_	
107-11	22890-22900	task-based	_	
107-12	22901-22910	regressor	_	
107-13	22911-22914	was	_	
107-14	22915-22919	used	_	
107-15	22920-22922	to	_	
107-16	22923-22930	extract	_	
107-17	22931-22934	the	_	
107-18	22935-22939	BOLD	_	
107-19	22940-22946	signal	_	
107-20	22947-22949	at	_	
107-21	22950-22953	the	_	
107-22	22954-22962	relevant	_	
107-23	22963-22973	associated	_	
107-24	22974-22984	timepoints	_	
107-25	22985-22988	and	_	
107-26	22989-22996	average	_	
107-27	22997-23003	across	_	
107-28	23004-23012	multiple	_	
107-29	23013-23019	trials	_	
107-30	23019-23020	.	_	

#Text=The NVLout contrast was used to evaluate both NAcc and MPFC regions of interest (extracted beta values) for group differences in non-loss outcome response.
108-1	23021-23024	The	_	
108-2	23025-23031	NVLout	_	
108-3	23032-23040	contrast	_	
108-4	23041-23044	was	_	
108-5	23045-23049	used	_	
108-6	23050-23052	to	_	
108-7	23053-23061	evaluate	_	
108-8	23062-23066	both	_	
108-9	23067-23071	NAcc	_	
108-10	23072-23075	and	_	
108-11	23076-23080	MPFC	_	
108-12	23081-23088	regions	_	
108-13	23089-23091	of	_	
108-14	23092-23100	interest	_	
108-15	23101-23102	(	_	
108-16	23102-23111	extracted	_	
108-17	23112-23116	beta	_	
108-18	23117-23123	values	_	
108-19	23123-23124	)	_	
108-20	23125-23128	for	_	
108-21	23129-23134	group	_	
108-22	23135-23146	differences	_	
108-23	23147-23149	in	_	
108-24	23150-23158	non-loss	_	
108-25	23159-23166	outcome	_	
108-26	23167-23175	response	_	
108-27	23175-23176	.	_	

#Text=(See Methods and Supplementary Methods for details.)
109-1	23177-23178	(	_	
109-2	23178-23181	See	_	
109-3	23182-23189	Methods	_	
109-4	23190-23193	and	_	
109-5	23194-23207	Supplementary	_	
109-6	23208-23215	Methods	_	
109-7	23216-23219	for	_	
109-8	23220-23227	details	_	
109-9	23227-23228	.	_	
109-10	23228-23229	)	_	

#Text=Nucleus Accumbens Activation during Gain Anticipation and No-loss Outcome.
110-1	23230-23237	Nucleus	_	
110-2	23238-23247	Accumbens	_	
110-3	23248-23258	Activation	_	
110-4	23259-23265	during	_	
110-5	23266-23270	Gain	_	
110-6	23271-23283	Anticipation	_	
110-7	23284-23287	and	_	
110-8	23288-23295	No-loss	_	
110-9	23296-23303	Outcome	_	
110-10	23303-23304	.	_	

#Text=(a) Bilateral nucleus accumbens (NAcc) region of interest (ROI) is shown in red.
111-1	23305-23306	(	_	
111-2	23306-23307	a	_	
111-3	23307-23308	)	_	
111-4	23309-23318	Bilateral	_	
111-5	23319-23326	nucleus	_	
111-6	23327-23336	accumbens	_	
111-7	23337-23338	(	_	
111-8	23338-23342	NAcc	_	
111-9	23342-23343	)	_	
111-10	23344-23350	region	_	
111-11	23351-23353	of	_	
111-12	23354-23362	interest	_	
111-13	23363-23364	(	_	
111-14	23364-23367	ROI	_	
111-15	23367-23368	)	_	
111-16	23369-23371	is	_	
111-17	23372-23377	shown	_	
111-18	23378-23380	in	_	
111-19	23381-23384	red	_	
111-20	23384-23385	.	_	

#Text=(b) Extracted fMRI beta values from the NAcc ROI (“NAcc activity”) during gain anticipation (gain versus no-gain anticipation, GVNant contrast) were not significantly different among the three groups.
112-1	23386-23387	(	_	
112-2	23387-23388	b	_	
112-3	23388-23389	)	_	
112-4	23390-23399	Extracted	_	
112-5	23400-23404	fMRI	_	
112-6	23405-23409	beta	_	
112-7	23410-23416	values	_	
112-8	23417-23421	from	_	
112-9	23422-23425	the	_	
112-10	23426-23430	NAcc	_	
112-11	23431-23434	ROI	_	
112-12	23435-23436	(	_	
112-13	23436-23437	“	_	
112-14	23437-23441	NAcc	_	
112-15	23442-23450	activity	_	
112-16	23450-23451	”	_	
112-17	23451-23452	)	_	
112-18	23453-23459	during	_	
112-19	23460-23464	gain	_	
112-20	23465-23477	anticipation	_	
112-21	23478-23479	(	_	
112-22	23479-23483	gain	_	
112-23	23484-23490	versus	_	
112-24	23491-23498	no-gain	_	
112-25	23499-23511	anticipation	_	
112-26	23511-23512	,	_	
112-27	23513-23519	GVNant	_	
112-28	23520-23528	contrast	_	
112-29	23528-23529	)	_	
112-30	23530-23534	were	_	
112-31	23535-23538	not	_	
112-32	23539-23552	significantly	_	
112-33	23553-23562	different	_	
112-34	23563-23568	among	_	
112-35	23569-23572	the	_	
112-36	23573-23578	three	_	
112-37	23579-23585	groups	_	
112-38	23585-23586	.	_	

#Text=(c) Raw time courses of NAcc activity [percent fMRI blood oxygenation level dependent (BOLD) signal change] for potential “no-gain” trials with $0 cues (left panel) and potential “gain” trials with +$5 cues (right panel).
113-1	23587-23588	(	_	
113-2	23588-23589	c	_	
113-3	23589-23590	)	_	
113-4	23591-23594	Raw	_	
113-5	23595-23599	time	_	
113-6	23600-23607	courses	_	
113-7	23608-23610	of	_	
113-8	23611-23615	NAcc	_	
113-9	23616-23624	activity	_	
113-10	23625-23626	[	_	
113-11	23626-23633	percent	_	
113-12	23634-23638	fMRI	_	
113-13	23639-23644	blood	_	
113-14	23645-23656	oxygenation	_	
113-15	23657-23662	level	_	
113-16	23663-23672	dependent	_	
113-17	23673-23674	(	_	
113-18	23674-23678	BOLD	_	
113-19	23678-23679	)	_	
113-20	23680-23686	signal	_	
113-21	23687-23693	change	_	
113-22	23693-23694	]	_	
113-23	23695-23698	for	_	
113-24	23699-23708	potential	_	
113-25	23709-23710	“	_	
113-26	23710-23717	no-gain	_	
113-27	23717-23718	”	_	
113-28	23719-23725	trials	_	
113-29	23726-23730	with	_	
113-30	23731-23733	$0	_	
113-31	23734-23738	cues	_	
113-32	23739-23740	(	_	
113-33	23740-23744	left	_	
113-34	23745-23750	panel	_	
113-35	23750-23751	)	_	
113-36	23752-23755	and	_	
113-37	23756-23765	potential	_	
113-38	23766-23767	“	_	
113-39	23767-23771	gain	_	
113-40	23771-23772	”	_	
113-41	23773-23779	trials	_	
113-42	23780-23784	with	_	
113-43	23785-23786	+	_	
113-44	23786-23788	$5	_	
113-45	23789-23793	cues	_	
113-46	23794-23795	(	_	
113-47	23795-23800	right	_	
113-48	23801-23806	panel	_	
113-49	23806-23807	)	_	
113-50	23807-23808	.	_	

#Text=Gray shading indicates periods included (from which beta values were extracted for each condition) in each contrast.
114-1	23809-23813	Gray	_	
114-2	23814-23821	shading	_	
114-3	23822-23831	indicates	_	
114-4	23832-23839	periods	_	
114-5	23840-23848	included	_	
114-6	23849-23850	(	_	
114-7	23850-23854	from	_	
114-8	23855-23860	which	_	
114-9	23861-23865	beta	_	
114-10	23866-23872	values	_	
114-11	23873-23877	were	_	
114-12	23878-23887	extracted	_	
114-13	23888-23891	for	_	
114-14	23892-23896	each	_	
114-15	23897-23906	condition	_	
114-16	23906-23907	)	_	
114-17	23908-23910	in	_	
114-18	23911-23915	each	_	
114-19	23916-23924	contrast	_	
114-20	23924-23925	.	_	

#Text=The anticipation fMRI BOLD response was estimated to correspond to 4–8 seconds [cue and fixation during TR 1 and TR 2 (0–4 seconds) plus a 4 second delay accounting for hemodynamic response function (HRF)].
115-1	23926-23929	The	_	
115-2	23930-23942	anticipation	_	
115-3	23943-23947	fMRI	_	
115-4	23948-23952	BOLD	_	
115-5	23953-23961	response	_	
115-6	23962-23965	was	_	
115-7	23966-23975	estimated	_	
115-8	23976-23978	to	_	
115-9	23979-23989	correspond	_	
115-10	23990-23992	to	_	
115-11	23993-23994	4	_	
115-12	23994-23995	–	_	
115-13	23995-23996	8	_	
115-14	23997-24004	seconds	_	
115-15	24005-24006	[	_	
115-16	24006-24009	cue	_	
115-17	24010-24013	and	_	
115-18	24014-24022	fixation	_	
115-19	24023-24029	during	_	
115-20	24030-24032	TR	_	
115-21	24033-24034	1	_	
115-22	24035-24038	and	_	
115-23	24039-24041	TR	_	
115-24	24042-24043	2	_	
115-25	24044-24045	(	_	
115-26	24045-24046	0	_	
115-27	24046-24047	–	_	
115-28	24047-24048	4	_	
115-29	24049-24056	seconds	_	
115-30	24056-24057	)	_	
115-31	24058-24062	plus	_	
115-32	24063-24064	a	_	
115-33	24065-24066	4	_	
115-34	24067-24073	second	_	
115-35	24074-24079	delay	_	
115-36	24080-24090	accounting	_	
115-37	24091-24094	for	_	
115-38	24095-24106	hemodynamic	_	
115-39	24107-24115	response	_	
115-40	24116-24124	function	_	
115-41	24125-24126	(	_	
115-42	24126-24129	HRF	_	
115-43	24129-24130	)	_	
115-44	24130-24131	]	_	
115-45	24131-24132	.	_	

#Text=(d) Extracted fMRI beta values from the NAcc ROI (“NAcc activity”) during no-loss outcome (no-loss versus loss outcome, NVLout contrast) were not significantly different among the three groups.
116-1	24133-24134	(	_	
116-2	24134-24135	d	_	
116-3	24135-24136	)	_	
116-4	24137-24146	Extracted	_	
116-5	24147-24151	fMRI	_	
116-6	24152-24156	beta	_	
116-7	24157-24163	values	_	
116-8	24164-24168	from	_	
116-9	24169-24172	the	_	
116-10	24173-24177	NAcc	_	
116-11	24178-24181	ROI	_	
116-12	24182-24183	(	_	
116-13	24183-24184	“	_	
116-14	24184-24188	NAcc	_	
116-15	24189-24197	activity	_	
116-16	24197-24198	”	_	
116-17	24198-24199	)	_	
116-18	24200-24206	during	_	
116-19	24207-24214	no-loss	_	
116-20	24215-24222	outcome	_	
116-21	24223-24224	(	_	
116-22	24224-24231	no-loss	_	
116-23	24232-24238	versus	_	
116-24	24239-24243	loss	_	
116-25	24244-24251	outcome	_	
116-26	24251-24252	,	_	
116-27	24253-24259	NVLout	_	
116-28	24260-24268	contrast	_	
116-29	24268-24269	)	_	
116-30	24270-24274	were	_	
116-31	24275-24278	not	_	
116-32	24279-24292	significantly	_	
116-33	24293-24302	different	_	
116-34	24303-24308	among	_	
116-35	24309-24312	the	_	
116-36	24313-24318	three	_	
116-37	24319-24325	groups	_	
116-38	24325-24326	.	_	

#Text=(e) Raw time courses of NAcc activity [percent fMRI BOLD signal change] for “no-loss” [trials with −$5 cues and “hit” outcomes (i.e., net loss outcome equal to −$0; left panel)] and “loss” [trials with −$5 cues and “miss” outcomes (i.e., net loss outcome equal to −$5; right panel)].
117-1	24327-24328	(	_	
117-2	24328-24329	e	_	
117-3	24329-24330	)	_	
117-4	24331-24334	Raw	_	
117-5	24335-24339	time	_	
117-6	24340-24347	courses	_	
117-7	24348-24350	of	_	
117-8	24351-24355	NAcc	_	
117-9	24356-24364	activity	_	
117-10	24365-24366	[	_	
117-11	24366-24373	percent	_	
117-12	24374-24378	fMRI	_	
117-13	24379-24383	BOLD	_	
117-14	24384-24390	signal	_	
117-15	24391-24397	change	_	
117-16	24397-24398	]	_	
117-17	24399-24402	for	_	
117-18	24403-24404	“	_	
117-19	24404-24411	no-loss	_	
117-20	24411-24412	”	_	
117-21	24413-24414	[	_	
117-22	24414-24420	trials	_	
117-23	24421-24425	with	_	
117-24	24426-24427	−	_	
117-25	24427-24429	$5	_	
117-26	24430-24434	cues	_	
117-27	24435-24438	and	_	
117-28	24439-24440	“	_	
117-29	24440-24443	hit	_	
117-30	24443-24444	”	_	
117-31	24445-24453	outcomes	_	
117-32	24454-24455	(	_	
117-33	24455-24458	i.e	_	
117-34	24458-24459	.	_	
117-35	24459-24460	,	_	
117-36	24461-24464	net	_	
117-37	24465-24469	loss	_	
117-38	24470-24477	outcome	_	
117-39	24478-24483	equal	_	
117-40	24484-24486	to	_	
117-41	24487-24488	−	_	
117-42	24488-24490	$0	_	
117-43	24490-24491	;	_	
117-44	24492-24496	left	_	
117-45	24497-24502	panel	_	
117-46	24502-24503	)	_	
117-47	24503-24504	]	_	
117-48	24505-24508	and	_	
117-49	24509-24510	“	_	
117-50	24510-24514	loss	_	
117-51	24514-24515	”	_	
117-52	24516-24517	[	_	
117-53	24517-24523	trials	_	
117-54	24524-24528	with	_	
117-55	24529-24530	−	_	
117-56	24530-24532	$5	_	
117-57	24533-24537	cues	_	
117-58	24538-24541	and	_	
117-59	24542-24543	“	_	
117-60	24543-24547	miss	_	
117-61	24547-24548	”	_	
117-62	24549-24557	outcomes	_	
117-63	24558-24559	(	_	
117-64	24559-24562	i.e	_	
117-65	24562-24563	.	_	
117-66	24563-24564	,	_	
117-67	24565-24568	net	_	
117-68	24569-24573	loss	_	
117-69	24574-24581	outcome	_	
117-70	24582-24587	equal	_	
117-71	24588-24590	to	_	
117-72	24591-24592	−	_	
117-73	24592-24594	$5	_	
117-74	24594-24595	;	_	
117-75	24596-24601	right	_	
117-76	24602-24607	panel	_	
117-77	24607-24608	)	_	
117-78	24608-24609	]	_	
117-79	24609-24610	.	_	

#Text=Gray shading indicates periods included (from which beta values were extracted for each condition) in each contrast (“hit” minus “miss”).
118-1	24611-24615	Gray	_	
118-2	24616-24623	shading	_	
118-3	24624-24633	indicates	_	
118-4	24634-24641	periods	_	
118-5	24642-24650	included	_	
118-6	24651-24652	(	_	
118-7	24652-24656	from	_	
118-8	24657-24662	which	_	
118-9	24663-24667	beta	_	
118-10	24668-24674	values	_	
118-11	24675-24679	were	_	
118-12	24680-24689	extracted	_	
118-13	24690-24693	for	_	
118-14	24694-24698	each	_	
118-15	24699-24708	condition	_	
118-16	24708-24709	)	_	
118-17	24710-24712	in	_	
118-18	24713-24717	each	_	
118-19	24718-24726	contrast	_	
118-20	24727-24728	(	_	
118-21	24728-24729	“	_	
118-22	24729-24732	hit	_	
118-23	24732-24733	”	_	
118-24	24734-24739	minus	_	
118-25	24740-24741	“	_	
118-26	24741-24745	miss	_	
118-27	24745-24746	”	_	
118-28	24746-24747	)	_	
118-29	24747-24748	.	_	

#Text=Outcome fMRI BOLD response was estimated to correspond to 10–14 seconds [cue and fixation during TR 4 and TR 5 (6–10 seconds) plus a 4 second delay accounting for HRF].
119-1	24749-24756	Outcome	_	
119-2	24757-24761	fMRI	_	
119-3	24762-24766	BOLD	_	
119-4	24767-24775	response	_	
119-5	24776-24779	was	_	
119-6	24780-24789	estimated	_	
119-7	24790-24792	to	_	
119-8	24793-24803	correspond	_	
119-9	24804-24806	to	_	
119-10	24807-24809	10	_	
119-11	24809-24810	–	_	
119-12	24810-24812	14	_	
119-13	24813-24820	seconds	_	
119-14	24821-24822	[	_	
119-15	24822-24825	cue	_	
119-16	24826-24829	and	_	
119-17	24830-24838	fixation	_	
119-18	24839-24845	during	_	
119-19	24846-24848	TR	_	
119-20	24849-24850	4	_	
119-21	24851-24854	and	_	
119-22	24855-24857	TR	_	
119-23	24858-24859	5	_	
119-24	24860-24861	(	_	
119-25	24861-24862	6	_	
119-26	24862-24863	–	_	
119-27	24863-24865	10	_	
119-28	24866-24873	seconds	_	
119-29	24873-24874	)	_	
119-30	24875-24879	plus	_	
119-31	24880-24881	a	_	
119-32	24882-24883	4	_	
119-33	24884-24890	second	_	
119-34	24891-24896	delay	_	
119-35	24897-24907	accounting	_	
119-36	24908-24911	for	_	
119-37	24912-24915	HRF	_	
119-38	24915-24916	]	_	
119-39	24916-24917	.	_	

#Text=Due to its involvement as a key region implicated in reward processing, the bilateral NAcc was selected as a region of interest and beta values were calculated and extracted from each participants’ fMRI data using the GVNant and NVLout regressors.
120-1	24918-24921	Due	_	
120-2	24922-24924	to	_	
120-3	24925-24928	its	_	
120-4	24929-24940	involvement	_	
120-5	24941-24943	as	_	
120-6	24944-24945	a	_	
120-7	24946-24949	key	_	
120-8	24950-24956	region	_	
120-9	24957-24967	implicated	_	
120-10	24968-24970	in	_	
120-11	24971-24977	reward	_	
120-12	24978-24988	processing	_	
120-13	24988-24989	,	_	
120-14	24990-24993	the	_	
120-15	24994-25003	bilateral	_	
120-16	25004-25008	NAcc	_	
120-17	25009-25012	was	_	
120-18	25013-25021	selected	_	
120-19	25022-25024	as	_	
120-20	25025-25026	a	_	
120-21	25027-25033	region	_	
120-22	25034-25036	of	_	
120-23	25037-25045	interest	_	
120-24	25046-25049	and	_	
120-25	25050-25054	beta	_	
120-26	25055-25061	values	_	
120-27	25062-25066	were	_	
120-28	25067-25077	calculated	_	
120-29	25078-25081	and	_	
120-30	25082-25091	extracted	_	
120-31	25092-25096	from	_	
120-32	25097-25101	each	_	
120-33	25102-25114	participants	_	
120-34	25114-25115	’	_	
120-35	25116-25120	fMRI	_	
120-36	25121-25125	data	_	
120-37	25126-25131	using	_	
120-38	25132-25135	the	_	
120-39	25136-25142	GVNant	_	
120-40	25143-25146	and	_	
120-41	25147-25153	NVLout	_	
120-42	25154-25164	regressors	_	
120-43	25164-25165	.	_	

#Text=For reward anticipation (GVNant contrast), NAcc response was not significantly different across the three groups (one-way ANOVA) despite slight reductions in anticipatory response to monetary rewards in both patient groups compared to healthy controls [F(2,46) = 1.3, p = 0.286] (Fig. 2).
121-1	25166-25169	For	_	
121-2	25170-25176	reward	_	
121-3	25177-25189	anticipation	_	
121-4	25190-25191	(	_	
121-5	25191-25197	GVNant	_	
121-6	25198-25206	contrast	_	
121-7	25206-25207	)	_	
121-8	25207-25208	,	_	
121-9	25209-25213	NAcc	_	
121-10	25214-25222	response	_	
121-11	25223-25226	was	_	
121-12	25227-25230	not	_	
121-13	25231-25244	significantly	_	
121-14	25245-25254	different	_	
121-15	25255-25261	across	_	
121-16	25262-25265	the	_	
121-17	25266-25271	three	_	
121-18	25272-25278	groups	_	
121-19	25279-25280	(	_	
121-20	25280-25287	one-way	_	
121-21	25288-25293	ANOVA	_	
121-22	25293-25294	)	_	
121-23	25295-25302	despite	_	
121-24	25303-25309	slight	_	
121-25	25310-25320	reductions	_	
121-26	25321-25323	in	_	
121-27	25324-25336	anticipatory	_	
121-28	25337-25345	response	_	
121-29	25346-25348	to	_	
121-30	25349-25357	monetary	_	
121-31	25358-25365	rewards	_	
121-32	25366-25368	in	_	
121-33	25369-25373	both	_	
121-34	25374-25381	patient	_	
121-35	25382-25388	groups	_	
121-36	25389-25397	compared	_	
121-37	25398-25400	to	_	
121-38	25401-25408	healthy	_	
121-39	25409-25417	controls	_	
121-40	25418-25419	[	_	
121-41	25419-25420	F	_	
121-42	25420-25421	(	_	
121-43	25421-25425	2,46	_	
121-44	25425-25426	)	_	
121-45	25427-25428	=	_	
121-46	25429-25432	1.3	_	
121-47	25432-25433	,	_	
121-48	25434-25435	p	_	
121-49	25436-25437	=	_	
121-50	25438-25443	0.286	_	
121-51	25443-25444	]	_	
121-52	25445-25446	(	_	
121-53	25446-25449	Fig	_	
121-54	25449-25450	.	_	
121-55	25450-25451	 	_	
121-56	25451-25452	2	_	
121-57	25452-25453	)	_	
121-58	25453-25454	.	_	

#Text=Tukey post-hoc tests indicated no significant group differences between control and non-opioid fibromyalgia groups (p = 0.338), between control and opioid fibromyalgia groups (p = 0.357), nor between non-opioid fibromyalgia and opioid fibromyalgia groups (p = 0.999) for NAcc reward anticipatory response.
122-1	25455-25460	Tukey	_	
122-2	25461-25469	post-hoc	_	
122-3	25470-25475	tests	_	
122-4	25476-25485	indicated	_	
122-5	25486-25488	no	_	
122-6	25489-25500	significant	_	
122-7	25501-25506	group	_	
122-8	25507-25518	differences	_	
122-9	25519-25526	between	_	
122-10	25527-25534	control	_	
122-11	25535-25538	and	_	
122-12	25539-25549	non-opioid	_	
122-13	25550-25562	fibromyalgia	_	
122-14	25563-25569	groups	_	
122-15	25570-25571	(	_	
122-16	25571-25572	p	_	
122-17	25573-25574	=	_	
122-18	25575-25580	0.338	_	
122-19	25580-25581	)	_	
122-20	25581-25582	,	_	
122-21	25583-25590	between	_	
122-22	25591-25598	control	_	
122-23	25599-25602	and	_	
122-24	25603-25609	opioid	_	
122-25	25610-25622	fibromyalgia	_	
122-26	25623-25629	groups	_	
122-27	25630-25631	(	_	
122-28	25631-25632	p	_	
122-29	25633-25634	=	_	
122-30	25635-25640	0.357	_	
122-31	25640-25641	)	_	
122-32	25641-25642	,	_	
122-33	25643-25646	nor	_	
122-34	25647-25654	between	_	
122-35	25655-25665	non-opioid	_	
122-36	25666-25678	fibromyalgia	_	
122-37	25679-25682	and	_	
122-38	25683-25689	opioid	_	
122-39	25690-25702	fibromyalgia	_	
122-40	25703-25709	groups	_	
122-41	25710-25711	(	_	
122-42	25711-25712	p	_	
122-43	25713-25714	=	_	
122-44	25715-25720	0.999	_	
122-45	25720-25721	)	_	
122-46	25722-25725	for	_	
122-47	25726-25730	NAcc	_	
122-48	25731-25737	reward	_	
122-49	25738-25750	anticipatory	_	
122-50	25751-25759	response	_	
122-51	25759-25760	.	_	

#Text=Similarly, for non-loss outcome (NVLout contrast), NAcc response was not significantly different across the three groups (one-way ANOVA) [F(2,46) = 1.6, p = 0.211].
123-1	25761-25770	Similarly	_	
123-2	25770-25771	,	_	
123-3	25772-25775	for	_	
123-4	25776-25784	non-loss	_	
123-5	25785-25792	outcome	_	
123-6	25793-25794	(	_	
123-7	25794-25800	NVLout	_	
123-8	25801-25809	contrast	_	
123-9	25809-25810	)	_	
123-10	25810-25811	,	_	
123-11	25812-25816	NAcc	_	
123-12	25817-25825	response	_	
123-13	25826-25829	was	_	
123-14	25830-25833	not	_	
123-15	25834-25847	significantly	_	
123-16	25848-25857	different	_	
123-17	25858-25864	across	_	
123-18	25865-25868	the	_	
123-19	25869-25874	three	_	
123-20	25875-25881	groups	_	
123-21	25882-25883	(	_	
123-22	25883-25890	one-way	_	
123-23	25891-25896	ANOVA	_	
123-24	25896-25897	)	_	
123-25	25898-25899	[	_	
123-26	25899-25900	F	_	
123-27	25900-25901	(	_	
123-28	25901-25905	2,46	_	
123-29	25905-25906	)	_	
123-30	25907-25908	=	_	
123-31	25909-25912	1.6	_	
123-32	25912-25913	,	_	
123-33	25914-25915	p	_	
123-34	25916-25917	=	_	
123-35	25918-25923	0.211	_	
123-36	25923-25924	]	_	
123-37	25924-25925	.	_	

#Text=Tukey post-hoc tests indicated no significant group differences between control and non-opioid fibromyalgia groups (p = 0.993), between control and opioid fibromyalgia groups (p = 0.392), nor between non-opioid fibromyalgia and opioid fibromyalgia groups (p = 0.432) for NAcc non-loss outcome response.
124-1	25926-25931	Tukey	_	
124-2	25932-25940	post-hoc	_	
124-3	25941-25946	tests	_	
124-4	25947-25956	indicated	_	
124-5	25957-25959	no	_	
124-6	25960-25971	significant	_	
124-7	25972-25977	group	_	
124-8	25978-25989	differences	_	
124-9	25990-25997	between	_	
124-10	25998-26005	control	_	
124-11	26006-26009	and	_	
124-12	26010-26020	non-opioid	_	
124-13	26021-26033	fibromyalgia	_	
124-14	26034-26040	groups	_	
124-15	26041-26042	(	_	
124-16	26042-26043	p	_	
124-17	26044-26045	=	_	
124-18	26046-26051	0.993	_	
124-19	26051-26052	)	_	
124-20	26052-26053	,	_	
124-21	26054-26061	between	_	
124-22	26062-26069	control	_	
124-23	26070-26073	and	_	
124-24	26074-26080	opioid	_	
124-25	26081-26093	fibromyalgia	_	
124-26	26094-26100	groups	_	
124-27	26101-26102	(	_	
124-28	26102-26103	p	_	
124-29	26104-26105	=	_	
124-30	26106-26111	0.392	_	
124-31	26111-26112	)	_	
124-32	26112-26113	,	_	
124-33	26114-26117	nor	_	
124-34	26118-26125	between	_	
124-35	26126-26136	non-opioid	_	
124-36	26137-26149	fibromyalgia	_	
124-37	26150-26153	and	_	
124-38	26154-26160	opioid	_	
124-39	26161-26173	fibromyalgia	_	
124-40	26174-26180	groups	_	
124-41	26181-26182	(	_	
124-42	26182-26183	p	_	
124-43	26184-26185	=	_	
124-44	26186-26191	0.432	_	
124-45	26191-26192	)	_	
124-46	26193-26196	for	_	
124-47	26197-26201	NAcc	_	
124-48	26202-26210	non-loss	_	
124-49	26211-26218	outcome	_	
124-50	26219-26227	response	_	
124-51	26227-26228	.	_	

#Text=Region of interest: medial prefrontal cortex response
#Text=Medial Prefrontal Cortex Activation during Gain Anticipation and No-loss Outcome.
125-1	26229-26235	Region	_	
125-2	26236-26238	of	_	
125-3	26239-26247	interest	_	
125-4	26247-26248	:	_	
125-5	26249-26255	medial	_	
125-6	26256-26266	prefrontal	_	
125-7	26267-26273	cortex	_	
125-8	26274-26282	response	_	
125-9	26283-26289	Medial	_	
125-10	26290-26300	Prefrontal	_	
125-11	26301-26307	Cortex	_	
125-12	26308-26318	Activation	_	
125-13	26319-26325	during	_	
125-14	26326-26330	Gain	_	
125-15	26331-26343	Anticipation	_	
125-16	26344-26347	and	_	
125-17	26348-26355	No-loss	_	
125-18	26356-26363	Outcome	_	
125-19	26363-26364	.	_	

#Text=(a) Bilateral medial prefrontal cortex (MPFC) region of interest (ROI) is shown in red (mirrored across cerebral hemispheres; but only one cerebral hemisphere is shown in this sagittal image).
126-1	26365-26366	(	_	
126-2	26366-26367	a	_	
126-3	26367-26368	)	_	
126-4	26369-26378	Bilateral	_	
126-5	26379-26385	medial	_	
126-6	26386-26396	prefrontal	_	
126-7	26397-26403	cortex	_	
126-8	26404-26405	(	_	
126-9	26405-26409	MPFC	_	
126-10	26409-26410	)	_	
126-11	26411-26417	region	_	
126-12	26418-26420	of	_	
126-13	26421-26429	interest	_	
126-14	26430-26431	(	_	
126-15	26431-26434	ROI	_	
126-16	26434-26435	)	_	
126-17	26436-26438	is	_	
126-18	26439-26444	shown	_	
126-19	26445-26447	in	_	
126-20	26448-26451	red	_	
126-21	26452-26453	(	_	
126-22	26453-26461	mirrored	_	
126-23	26462-26468	across	_	
126-24	26469-26477	cerebral	_	
126-25	26478-26489	hemispheres	_	
126-26	26489-26490	;	_	
126-27	26491-26494	but	_	
126-28	26495-26499	only	_	
126-29	26500-26503	one	_	
126-30	26504-26512	cerebral	_	
126-31	26513-26523	hemisphere	_	
126-32	26524-26526	is	_	
126-33	26527-26532	shown	_	
126-34	26533-26535	in	_	
126-35	26536-26540	this	_	
126-36	26541-26549	sagittal	_	
126-37	26550-26555	image	_	
126-38	26555-26556	)	_	
126-39	26556-26557	.	_	

#Text=(b) Extracted fMRI beta values from the MPFC ROI (“MPFC activity”) during gain anticipation (gain versus no-gain anticipation, GVNant contrast) were significantly different among the groups, with post-hoc testing indicating this was driven by the difference between healthy control and non-opioid fibromyalgia (FM) groups.
127-1	26558-26559	(	_	
127-2	26559-26560	b	_	
127-3	26560-26561	)	_	
127-4	26562-26571	Extracted	_	
127-5	26572-26576	fMRI	_	
127-6	26577-26581	beta	_	
127-7	26582-26588	values	_	
127-8	26589-26593	from	_	
127-9	26594-26597	the	_	
127-10	26598-26602	MPFC	_	
127-11	26603-26606	ROI	_	
127-12	26607-26608	(	_	
127-13	26608-26609	“	_	
127-14	26609-26613	MPFC	_	
127-15	26614-26622	activity	_	
127-16	26622-26623	”	_	
127-17	26623-26624	)	_	
127-18	26625-26631	during	_	
127-19	26632-26636	gain	_	
127-20	26637-26649	anticipation	_	
127-21	26650-26651	(	_	
127-22	26651-26655	gain	_	
127-23	26656-26662	versus	_	
127-24	26663-26670	no-gain	_	
127-25	26671-26683	anticipation	_	
127-26	26683-26684	,	_	
127-27	26685-26691	GVNant	_	
127-28	26692-26700	contrast	_	
127-29	26700-26701	)	_	
127-30	26702-26706	were	_	
127-31	26707-26720	significantly	_	
127-32	26721-26730	different	_	
127-33	26731-26736	among	_	
127-34	26737-26740	the	_	
127-35	26741-26747	groups	_	
127-36	26747-26748	,	_	
127-37	26749-26753	with	_	
127-38	26754-26762	post-hoc	_	
127-39	26763-26770	testing	_	
127-40	26771-26781	indicating	_	
127-41	26782-26786	this	_	
127-42	26787-26790	was	_	
127-43	26791-26797	driven	_	
127-44	26798-26800	by	_	
127-45	26801-26804	the	_	
127-46	26805-26815	difference	_	
127-47	26816-26823	between	_	
127-48	26824-26831	healthy	_	
127-49	26832-26839	control	_	
127-50	26840-26843	and	_	
127-51	26844-26854	non-opioid	_	
127-52	26855-26867	fibromyalgia	_	
127-53	26868-26869	(	_	
127-54	26869-26871	FM	_	
127-55	26871-26872	)	_	
127-56	26873-26879	groups	_	
127-57	26879-26880	.	_	

#Text=(c) Raw time courses of MPFC activity [percent fMRI blood oxygenation level dependent (BOLD) signal change] for potential “no-gain” trials with $0 cues (left panel) and potential “gain” trials with +$5 cues (right panel).
128-1	26881-26882	(	_	
128-2	26882-26883	c	_	
128-3	26883-26884	)	_	
128-4	26885-26888	Raw	_	
128-5	26889-26893	time	_	
128-6	26894-26901	courses	_	
128-7	26902-26904	of	_	
128-8	26905-26909	MPFC	_	
128-9	26910-26918	activity	_	
128-10	26919-26920	[	_	
128-11	26920-26927	percent	_	
128-12	26928-26932	fMRI	_	
128-13	26933-26938	blood	_	
128-14	26939-26950	oxygenation	_	
128-15	26951-26956	level	_	
128-16	26957-26966	dependent	_	
128-17	26967-26968	(	_	
128-18	26968-26972	BOLD	_	
128-19	26972-26973	)	_	
128-20	26974-26980	signal	_	
128-21	26981-26987	change	_	
128-22	26987-26988	]	_	
128-23	26989-26992	for	_	
128-24	26993-27002	potential	_	
128-25	27003-27004	“	_	
128-26	27004-27011	no-gain	_	
128-27	27011-27012	”	_	
128-28	27013-27019	trials	_	
128-29	27020-27024	with	_	
128-30	27025-27027	$0	_	
128-31	27028-27032	cues	_	
128-32	27033-27034	(	_	
128-33	27034-27038	left	_	
128-34	27039-27044	panel	_	
128-35	27044-27045	)	_	
128-36	27046-27049	and	_	
128-37	27050-27059	potential	_	
128-38	27060-27061	“	_	
128-39	27061-27065	gain	_	
128-40	27065-27066	”	_	
128-41	27067-27073	trials	_	
128-42	27074-27078	with	_	
128-43	27079-27080	+	_	
128-44	27080-27082	$5	_	
128-45	27083-27087	cues	_	
128-46	27088-27089	(	_	
128-47	27089-27094	right	_	
128-48	27095-27100	panel	_	
128-49	27100-27101	)	_	
128-50	27101-27102	.	_	

#Text=Gray shading indicates periods included (from which beta values were extracted for each condition) in each contrast.
129-1	27103-27107	Gray	_	
129-2	27108-27115	shading	_	
129-3	27116-27125	indicates	_	
129-4	27126-27133	periods	_	
129-5	27134-27142	included	_	
129-6	27143-27144	(	_	
129-7	27144-27148	from	_	
129-8	27149-27154	which	_	
129-9	27155-27159	beta	_	
129-10	27160-27166	values	_	
129-11	27167-27171	were	_	
129-12	27172-27181	extracted	_	
129-13	27182-27185	for	_	
129-14	27186-27190	each	_	
129-15	27191-27200	condition	_	
129-16	27200-27201	)	_	
129-17	27202-27204	in	_	
129-18	27205-27209	each	_	
129-19	27210-27218	contrast	_	
129-20	27218-27219	.	_	

#Text=The anticipation fMRI BOLD response was estimated to correspond to 4–8 seconds [cue and fixation during TR 1 and TR 2 (0–4 seconds) plus a 4 second delay accounting for hemodynamic response function (HRF)].
130-1	27220-27223	The	_	
130-2	27224-27236	anticipation	_	
130-3	27237-27241	fMRI	_	
130-4	27242-27246	BOLD	_	
130-5	27247-27255	response	_	
130-6	27256-27259	was	_	
130-7	27260-27269	estimated	_	
130-8	27270-27272	to	_	
130-9	27273-27283	correspond	_	
130-10	27284-27286	to	_	
130-11	27287-27288	4	_	
130-12	27288-27289	–	_	
130-13	27289-27290	8	_	
130-14	27291-27298	seconds	_	
130-15	27299-27300	[	_	
130-16	27300-27303	cue	_	
130-17	27304-27307	and	_	
130-18	27308-27316	fixation	_	
130-19	27317-27323	during	_	
130-20	27324-27326	TR	_	
130-21	27327-27328	1	_	
130-22	27329-27332	and	_	
130-23	27333-27335	TR	_	
130-24	27336-27337	2	_	
130-25	27338-27339	(	_	
130-26	27339-27340	0	_	
130-27	27340-27341	–	_	
130-28	27341-27342	4	_	
130-29	27343-27350	seconds	_	
130-30	27350-27351	)	_	
130-31	27352-27356	plus	_	
130-32	27357-27358	a	_	
130-33	27359-27360	4	_	
130-34	27361-27367	second	_	
130-35	27368-27373	delay	_	
130-36	27374-27384	accounting	_	
130-37	27385-27388	for	_	
130-38	27389-27400	hemodynamic	_	
130-39	27401-27409	response	_	
130-40	27410-27418	function	_	
130-41	27419-27420	(	_	
130-42	27420-27423	HRF	_	
130-43	27423-27424	)	_	
130-44	27424-27425	]	_	
130-45	27425-27426	.	_	

#Text=(d) Extracted fMRI beta values from the MPFC ROI (“MPFC activity”) during no-loss outcome (no-loss versus loss outcome, NVLout contrast) was significantly different among the three groups.
131-1	27427-27428	(	_	
131-2	27428-27429	d	_	
131-3	27429-27430	)	_	
131-4	27431-27440	Extracted	_	
131-5	27441-27445	fMRI	_	
131-6	27446-27450	beta	_	
131-7	27451-27457	values	_	
131-8	27458-27462	from	_	
131-9	27463-27466	the	_	
131-10	27467-27471	MPFC	_	
131-11	27472-27475	ROI	_	
131-12	27476-27477	(	_	
131-13	27477-27478	“	_	
131-14	27478-27482	MPFC	_	
131-15	27483-27491	activity	_	
131-16	27491-27492	”	_	
131-17	27492-27493	)	_	
131-18	27494-27500	during	_	
131-19	27501-27508	no-loss	_	
131-20	27509-27516	outcome	_	
131-21	27517-27518	(	_	
131-22	27518-27525	no-loss	_	
131-23	27526-27532	versus	_	
131-24	27533-27537	loss	_	
131-25	27538-27545	outcome	_	
131-26	27545-27546	,	_	
131-27	27547-27553	NVLout	_	
131-28	27554-27562	contrast	_	
131-29	27562-27563	)	_	
131-30	27564-27567	was	_	
131-31	27568-27581	significantly	_	
131-32	27582-27591	different	_	
131-33	27592-27597	among	_	
131-34	27598-27601	the	_	
131-35	27602-27607	three	_	
131-36	27608-27614	groups	_	
131-37	27614-27615	.	_	

#Text=(e) Raw time courses of MPFC activity [percent fMRI BOLD signal change] for “no-loss” [trials with −$5 cues and “hit” outcomes (i.e., net loss outcome equal to −$0; left panel)] and “loss” [trials with −$5 cues and “miss” outcomes (i.e., net loss outcome equal to −$5; right panel)].
132-1	27616-27617	(	_	
132-2	27617-27618	e	_	
132-3	27618-27619	)	_	
132-4	27620-27623	Raw	_	
132-5	27624-27628	time	_	
132-6	27629-27636	courses	_	
132-7	27637-27639	of	_	
132-8	27640-27644	MPFC	_	
132-9	27645-27653	activity	_	
132-10	27654-27655	[	_	
132-11	27655-27662	percent	_	
132-12	27663-27667	fMRI	_	
132-13	27668-27672	BOLD	_	
132-14	27673-27679	signal	_	
132-15	27680-27686	change	_	
132-16	27686-27687	]	_	
132-17	27688-27691	for	_	
132-18	27692-27693	“	_	
132-19	27693-27700	no-loss	_	
132-20	27700-27701	”	_	
132-21	27702-27703	[	_	
132-22	27703-27709	trials	_	
132-23	27710-27714	with	_	
132-24	27715-27716	−	_	
132-25	27716-27718	$5	_	
132-26	27719-27723	cues	_	
132-27	27724-27727	and	_	
132-28	27728-27729	“	_	
132-29	27729-27732	hit	_	
132-30	27732-27733	”	_	
132-31	27734-27742	outcomes	_	
132-32	27743-27744	(	_	
132-33	27744-27747	i.e	_	
132-34	27747-27748	.	_	
132-35	27748-27749	,	_	
132-36	27750-27753	net	_	
132-37	27754-27758	loss	_	
132-38	27759-27766	outcome	_	
132-39	27767-27772	equal	_	
132-40	27773-27775	to	_	
132-41	27776-27777	−	_	
132-42	27777-27779	$0	_	
132-43	27779-27780	;	_	
132-44	27781-27785	left	_	
132-45	27786-27791	panel	_	
132-46	27791-27792	)	_	
132-47	27792-27793	]	_	
132-48	27794-27797	and	_	
132-49	27798-27799	“	_	
132-50	27799-27803	loss	_	
132-51	27803-27804	”	_	
132-52	27805-27806	[	_	
132-53	27806-27812	trials	_	
132-54	27813-27817	with	_	
132-55	27818-27819	−	_	
132-56	27819-27821	$5	_	
132-57	27822-27826	cues	_	
132-58	27827-27830	and	_	
132-59	27831-27832	“	_	
132-60	27832-27836	miss	_	
132-61	27836-27837	”	_	
132-62	27838-27846	outcomes	_	
132-63	27847-27848	(	_	
132-64	27848-27851	i.e	_	
132-65	27851-27852	.	_	
132-66	27852-27853	,	_	
132-67	27854-27857	net	_	
132-68	27858-27862	loss	_	
132-69	27863-27870	outcome	_	
132-70	27871-27876	equal	_	
132-71	27877-27879	to	_	
132-72	27880-27881	−	_	
132-73	27881-27883	$5	_	
132-74	27883-27884	;	_	
132-75	27885-27890	right	_	
132-76	27891-27896	panel	_	
132-77	27896-27897	)	_	
132-78	27897-27898	]	_	
132-79	27898-27899	.	_	

#Text=Gray shading indicates periods included (from which beta values were extracted for each condition) in each contrast (“hit” minus “miss”).
133-1	27900-27904	Gray	_	
133-2	27905-27912	shading	_	
133-3	27913-27922	indicates	_	
133-4	27923-27930	periods	_	
133-5	27931-27939	included	_	
133-6	27940-27941	(	_	
133-7	27941-27945	from	_	
133-8	27946-27951	which	_	
133-9	27952-27956	beta	_	
133-10	27957-27963	values	_	
133-11	27964-27968	were	_	
133-12	27969-27978	extracted	_	
133-13	27979-27982	for	_	
133-14	27983-27987	each	_	
133-15	27988-27997	condition	_	
133-16	27997-27998	)	_	
133-17	27999-28001	in	_	
133-18	28002-28006	each	_	
133-19	28007-28015	contrast	_	
133-20	28016-28017	(	_	
133-21	28017-28018	“	_	
133-22	28018-28021	hit	_	
133-23	28021-28022	”	_	
133-24	28023-28028	minus	_	
133-25	28029-28030	“	_	
133-26	28030-28034	miss	_	
133-27	28034-28035	”	_	
133-28	28035-28036	)	_	
133-29	28036-28037	.	_	

#Text=Outcome fMRI BOLD response was estimated to correspond to 10–14 seconds [cue and fixation during TR 4 and TR 5 (6–10 seconds) plus a 4 second delay accounting for HRF].
134-1	28038-28045	Outcome	_	
134-2	28046-28050	fMRI	_	
134-3	28051-28055	BOLD	_	
134-4	28056-28064	response	_	
134-5	28065-28068	was	_	
134-6	28069-28078	estimated	_	
134-7	28079-28081	to	_	
134-8	28082-28092	correspond	_	
134-9	28093-28095	to	_	
134-10	28096-28098	10	_	
134-11	28098-28099	–	_	
134-12	28099-28101	14	_	
134-13	28102-28109	seconds	_	
134-14	28110-28111	[	_	
134-15	28111-28114	cue	_	
134-16	28115-28118	and	_	
134-17	28119-28127	fixation	_	
134-18	28128-28134	during	_	
134-19	28135-28137	TR	_	
134-20	28138-28139	4	_	
134-21	28140-28143	and	_	
134-22	28144-28146	TR	_	
134-23	28147-28148	5	_	
134-24	28149-28150	(	_	
134-25	28150-28151	6	_	
134-26	28151-28152	–	_	
134-27	28152-28154	10	_	
134-28	28155-28162	seconds	_	
134-29	28162-28163	)	_	
134-30	28164-28168	plus	_	
134-31	28169-28170	a	_	
134-32	28171-28172	4	_	
134-33	28173-28179	second	_	
134-34	28180-28185	delay	_	
134-35	28186-28196	accounting	_	
134-36	28197-28200	for	_	
134-37	28201-28204	HRF	_	
134-38	28204-28205	]	_	
134-39	28205-28206	.	_	

#Text=(f) Correlation between MPFC no-loss outcome fMRI beta values (NVLout contrast) and behavioral drive (BAS subscale) (r = 0.507, p = 0.004, N = 30).
135-1	28207-28208	(	_	
135-2	28208-28209	f	_	
135-3	28209-28210	)	_	
135-4	28211-28222	Correlation	_	
135-5	28223-28230	between	_	
135-6	28231-28235	MPFC	_	
135-7	28236-28243	no-loss	_	
135-8	28244-28251	outcome	_	
135-9	28252-28256	fMRI	_	
135-10	28257-28261	beta	_	
135-11	28262-28268	values	_	
135-12	28269-28270	(	_	
135-13	28270-28276	NVLout	_	
135-14	28277-28285	contrast	_	
135-15	28285-28286	)	_	
135-16	28287-28290	and	_	
135-17	28291-28301	behavioral	_	
135-18	28302-28307	drive	_	
135-19	28308-28309	(	_	
135-20	28309-28312	BAS	_	
135-21	28313-28321	subscale	_	
135-22	28321-28322	)	_	
135-23	28323-28324	(	_	
135-24	28324-28325	r	_	
135-25	28326-28327	=	_	
135-26	28328-28333	0.507	_	
135-27	28333-28334	,	_	
135-28	28335-28336	p	_	
135-29	28337-28338	=	_	
135-30	28339-28344	0.004	_	
135-31	28344-28345	,	_	
135-32	28346-28347	N	_	
135-33	28348-28349	=	_	
135-34	28350-28352	30	_	
135-35	28352-28353	)	_	
135-36	28353-28354	.	_	

#Text=Four participants were missing BAS questionnaire data.
136-1	28355-28359	Four	_	
136-2	28360-28372	participants	_	
136-3	28373-28377	were	_	
136-4	28378-28385	missing	_	
136-5	28386-28389	BAS	_	
136-6	28390-28403	questionnaire	_	
136-7	28404-28408	data	_	
136-8	28408-28409	.	_	

#Text=Behavioral Activation Systems, BAS; medial prefrontal cortex, MPFC.
137-1	28410-28420	Behavioral	_	
137-2	28421-28431	Activation	_	
137-3	28432-28439	Systems	_	
137-4	28439-28440	,	_	
137-5	28441-28444	BAS	_	
137-6	28444-28445	;	_	
137-7	28446-28452	medial	_	
137-8	28453-28463	prefrontal	_	
137-9	28464-28470	cortex	_	
137-10	28470-28471	,	_	
137-11	28472-28476	MPFC	_	
137-12	28476-28477	.	_	

#Text=***p < 0.001, **p < 0.01, *p < 0.05.
138-1	28478-28479	*	_	
138-2	28479-28480	*	_	
138-3	28480-28481	*	_	
138-4	28481-28482	p	_	
138-5	28483-28484	<	_	
138-6	28485-28490	0.001	_	
138-7	28490-28491	,	_	
138-8	28492-28493	*	_	
138-9	28493-28494	*	_	
138-10	28494-28495	p	_	
138-11	28496-28497	<	_	
138-12	28498-28502	0.01	_	
138-13	28502-28503	,	_	
138-14	28504-28505	*	_	
138-15	28505-28506	p	_	
138-16	28507-28508	<	_	
138-17	28509-28513	0.05	_	
138-18	28513-28514	.	_	

#Text=Due to its involvement in reward processing, a bilateral MPFC region was selected as a volume of interest and beta values were calculated and extracted from each participants’ fMRI data using the GVNant and NVLout regressors.
139-1	28515-28518	Due	_	
139-2	28519-28521	to	_	
139-3	28522-28525	its	_	
139-4	28526-28537	involvement	_	
139-5	28538-28540	in	_	
139-6	28541-28547	reward	_	
139-7	28548-28558	processing	_	
139-8	28558-28559	,	_	
139-9	28560-28561	a	_	
139-10	28562-28571	bilateral	_	
139-11	28572-28576	MPFC	_	
139-12	28577-28583	region	_	
139-13	28584-28587	was	_	
139-14	28588-28596	selected	_	
139-15	28597-28599	as	_	
139-16	28600-28601	a	_	
139-17	28602-28608	volume	_	
139-18	28609-28611	of	_	
139-19	28612-28620	interest	_	
139-20	28621-28624	and	_	
139-21	28625-28629	beta	_	
139-22	28630-28636	values	_	
139-23	28637-28641	were	_	
139-24	28642-28652	calculated	_	
139-25	28653-28656	and	_	
139-26	28657-28666	extracted	_	
139-27	28667-28671	from	_	
139-28	28672-28676	each	_	
139-29	28677-28689	participants	_	
139-30	28689-28690	’	_	
139-31	28691-28695	fMRI	_	
139-32	28696-28700	data	_	
139-33	28701-28706	using	_	
139-34	28707-28710	the	_	
139-35	28711-28717	GVNant	_	
139-36	28718-28721	and	_	
139-37	28722-28728	NVLout	_	
139-38	28729-28739	regressors	_	
139-39	28739-28740	.	_	

#Text=For reward anticipation (GVNant contrast), MPFC reward anticipatory response (one-way ANOVA across the 3 groups) revealed a significant effect of group in individuals with fibromyalgia compared to controls [F(2,46) = 6.1, p = 0.005].
140-1	28741-28744	For	_	
140-2	28745-28751	reward	_	
140-3	28752-28764	anticipation	_	
140-4	28765-28766	(	_	
140-5	28766-28772	GVNant	_	
140-6	28773-28781	contrast	_	
140-7	28781-28782	)	_	
140-8	28782-28783	,	_	
140-9	28784-28788	MPFC	_	
140-10	28789-28795	reward	_	
140-11	28796-28808	anticipatory	_	
140-12	28809-28817	response	_	
140-13	28818-28819	(	_	
140-14	28819-28826	one-way	_	
140-15	28827-28832	ANOVA	_	
140-16	28833-28839	across	_	
140-17	28840-28843	the	_	
140-18	28844-28845	3	_	
140-19	28846-28852	groups	_	
140-20	28852-28853	)	_	
140-21	28854-28862	revealed	_	
140-22	28863-28864	a	_	
140-23	28865-28876	significant	_	
140-24	28877-28883	effect	_	
140-25	28884-28886	of	_	
140-26	28887-28892	group	_	
140-27	28893-28895	in	_	
140-28	28896-28907	individuals	_	
140-29	28908-28912	with	_	
140-30	28913-28925	fibromyalgia	_	
140-31	28926-28934	compared	_	
140-32	28935-28937	to	_	
140-33	28938-28946	controls	_	
140-34	28947-28948	[	_	
140-35	28948-28949	F	_	
140-36	28949-28950	(	_	
140-37	28950-28954	2,46	_	
140-38	28954-28955	)	_	
140-39	28956-28957	=	_	
140-40	28958-28961	6.1	_	
140-41	28961-28962	,	_	
140-42	28963-28964	p	_	
140-43	28965-28966	=	_	
140-44	28967-28972	0.005	_	
140-45	28972-28973	]	_	
140-46	28973-28974	.	_	

#Text=Tukey post-hoc tests indicated significant group differences between control and non-opioid fibromyalgia groups (p = 0.003), but not between control and opioid fibromyalgia groups (p = 0.102), nor between non-opioid fibromyalgia and opioid fibromyalgia groups (p = 0.336).
141-1	28975-28980	Tukey	_	
141-2	28981-28989	post-hoc	_	
141-3	28990-28995	tests	_	
141-4	28996-29005	indicated	_	
141-5	29006-29017	significant	_	
141-6	29018-29023	group	_	
141-7	29024-29035	differences	_	
141-8	29036-29043	between	_	
141-9	29044-29051	control	_	
141-10	29052-29055	and	_	
141-11	29056-29066	non-opioid	_	
141-12	29067-29079	fibromyalgia	_	
141-13	29080-29086	groups	_	
141-14	29087-29088	(	_	
141-15	29088-29089	p	_	
141-16	29090-29091	=	_	
141-17	29092-29097	0.003	_	
141-18	29097-29098	)	_	
141-19	29098-29099	,	_	
141-20	29100-29103	but	_	
141-21	29104-29107	not	_	
141-22	29108-29115	between	_	
141-23	29116-29123	control	_	
141-24	29124-29127	and	_	
141-25	29128-29134	opioid	_	
141-26	29135-29147	fibromyalgia	_	
141-27	29148-29154	groups	_	
141-28	29155-29156	(	_	
141-29	29156-29157	p	_	
141-30	29158-29159	=	_	
141-31	29160-29165	0.102	_	
141-32	29165-29166	)	_	
141-33	29166-29167	,	_	
141-34	29168-29171	nor	_	
141-35	29172-29179	between	_	
141-36	29180-29190	non-opioid	_	
141-37	29191-29203	fibromyalgia	_	
141-38	29204-29207	and	_	
141-39	29208-29214	opioid	_	
141-40	29215-29227	fibromyalgia	_	
141-41	29228-29234	groups	_	
141-42	29235-29236	(	_	
141-43	29236-29237	p	_	
141-44	29238-29239	=	_	
141-45	29240-29245	0.336	_	
141-46	29245-29246	)	_	
141-47	29246-29247	.	_	

#Text=Thus, the overall group difference was driven by a significant reduction in MPFC reward anticipatory response in the non-opioid fibromyalgia group (Fig. 3B).
142-1	29248-29252	Thus	_	
142-2	29252-29253	,	_	
142-3	29254-29257	the	_	
142-4	29258-29265	overall	_	
142-5	29266-29271	group	_	
142-6	29272-29282	difference	_	
142-7	29283-29286	was	_	
142-8	29287-29293	driven	_	
142-9	29294-29296	by	_	
142-10	29297-29298	a	_	
142-11	29299-29310	significant	_	
142-12	29311-29320	reduction	_	
142-13	29321-29323	in	_	
142-14	29324-29328	MPFC	_	
142-15	29329-29335	reward	_	
142-16	29336-29348	anticipatory	_	
142-17	29349-29357	response	_	
142-18	29358-29360	in	_	
142-19	29361-29364	the	_	
142-20	29365-29375	non-opioid	_	
142-21	29376-29388	fibromyalgia	_	
142-22	29389-29394	group	_	
142-23	29395-29396	(	_	
142-24	29396-29399	Fig	_	
142-25	29399-29400	.	_	
142-26	29400-29401	 	_	
142-27	29401-29403	3B	_	
142-28	29403-29404	)	_	
142-29	29404-29405	.	_	

#Text=For reward outcome response (NVLout contrast), MPFC non-loss outcome response (one-way ANOVA across the 3 groups) revealed a significant effect of the fibromyalgia groups compared to controls [F(2,46) = 9.8, p < 0.001].
143-1	29406-29409	For	_	
143-2	29410-29416	reward	_	
143-3	29417-29424	outcome	_	
143-4	29425-29433	response	_	
143-5	29434-29435	(	_	
143-6	29435-29441	NVLout	_	
143-7	29442-29450	contrast	_	
143-8	29450-29451	)	_	
143-9	29451-29452	,	_	
143-10	29453-29457	MPFC	_	
143-11	29458-29466	non-loss	_	
143-12	29467-29474	outcome	_	
143-13	29475-29483	response	_	
143-14	29484-29485	(	_	
143-15	29485-29492	one-way	_	
143-16	29493-29498	ANOVA	_	
143-17	29499-29505	across	_	
143-18	29506-29509	the	_	
143-19	29510-29511	3	_	
143-20	29512-29518	groups	_	
143-21	29518-29519	)	_	
143-22	29520-29528	revealed	_	
143-23	29529-29530	a	_	
143-24	29531-29542	significant	_	
143-25	29543-29549	effect	_	
143-26	29550-29552	of	_	
143-27	29553-29556	the	_	
143-28	29557-29569	fibromyalgia	_	
143-29	29570-29576	groups	_	
143-30	29577-29585	compared	_	
143-31	29586-29588	to	_	
143-32	29589-29597	controls	_	
143-33	29598-29599	[	_	
143-34	29599-29600	F	_	
143-35	29600-29601	(	_	
143-36	29601-29605	2,46	_	
143-37	29605-29606	)	_	
143-38	29607-29608	=	_	
143-39	29609-29612	9.8	_	
143-40	29612-29613	,	_	
143-41	29614-29615	p	_	
143-42	29616-29617	<	_	
143-43	29618-29623	0.001	_	
143-44	29623-29624	]	_	
143-45	29624-29625	.	_	

#Text=Tukey post-hoc tests indicated significant group differences between control and non-opioid fibromyalgia groups (p = 0.013) and between non-opioid fibromyalgia and opioid fibromyalgia groups (p < 0.001), but not between control and opioid fibromyalgia groups (p = 0.467) (Fig. 3D).
144-1	29626-29631	Tukey	_	
144-2	29632-29640	post-hoc	_	
144-3	29641-29646	tests	_	
144-4	29647-29656	indicated	_	
144-5	29657-29668	significant	_	
144-6	29669-29674	group	_	
144-7	29675-29686	differences	_	
144-8	29687-29694	between	_	
144-9	29695-29702	control	_	
144-10	29703-29706	and	_	
144-11	29707-29717	non-opioid	_	
144-12	29718-29730	fibromyalgia	_	
144-13	29731-29737	groups	_	
144-14	29738-29739	(	_	
144-15	29739-29740	p	_	
144-16	29741-29742	=	_	
144-17	29743-29748	0.013	_	
144-18	29748-29749	)	_	
144-19	29750-29753	and	_	
144-20	29754-29761	between	_	
144-21	29762-29772	non-opioid	_	
144-22	29773-29785	fibromyalgia	_	
144-23	29786-29789	and	_	
144-24	29790-29796	opioid	_	
144-25	29797-29809	fibromyalgia	_	
144-26	29810-29816	groups	_	
144-27	29817-29818	(	_	
144-28	29818-29819	p	_	
144-29	29820-29821	<	_	
144-30	29822-29827	0.001	_	
144-31	29827-29828	)	_	
144-32	29828-29829	,	_	
144-33	29830-29833	but	_	
144-34	29834-29837	not	_	
144-35	29838-29845	between	_	
144-36	29846-29853	control	_	
144-37	29854-29857	and	_	
144-38	29858-29864	opioid	_	
144-39	29865-29877	fibromyalgia	_	
144-40	29878-29884	groups	_	
144-41	29885-29886	(	_	
144-42	29886-29887	p	_	
144-43	29888-29889	=	_	
144-44	29890-29895	0.467	_	
144-45	29895-29896	)	_	
144-46	29897-29898	(	_	
144-47	29898-29901	Fig	_	
144-48	29901-29902	.	_	
144-49	29902-29903	 	_	
144-50	29903-29905	3D	_	
144-51	29905-29906	)	_	
144-52	29906-29907	.	_	

#Text=Clinical, behavioral, and psychological correlations with region of interest fMRI results
#Text=To determine relationships between the fMRI results and clinical, behavioral and psychological measures, correlational analyses were conducted using extracted betas from the main contrasts [NAcc and MPFC reward anticipatory responses (GVNant betas) and non-loss outcome responses (NVLout betas)] and questionnaire scores for each participant.
145-1	29908-29916	Clinical	_	
145-2	29916-29917	,	_	
145-3	29918-29928	behavioral	_	
145-4	29928-29929	,	_	
145-5	29930-29933	and	_	
145-6	29934-29947	psychological	_	
145-7	29948-29960	correlations	_	
145-8	29961-29965	with	_	
145-9	29966-29972	region	_	
145-10	29973-29975	of	_	
145-11	29976-29984	interest	_	
145-12	29985-29989	fMRI	_	
145-13	29990-29997	results	_	
145-14	29998-30000	To	_	
145-15	30001-30010	determine	_	
145-16	30011-30024	relationships	_	
145-17	30025-30032	between	_	
145-18	30033-30036	the	_	
145-19	30037-30041	fMRI	_	
145-20	30042-30049	results	_	
145-21	30050-30053	and	_	
145-22	30054-30062	clinical	_	
145-23	30062-30063	,	_	
145-24	30064-30074	behavioral	_	
145-25	30075-30078	and	_	
145-26	30079-30092	psychological	_	
145-27	30093-30101	measures	_	
145-28	30101-30102	,	_	
145-29	30103-30116	correlational	_	
145-30	30117-30125	analyses	_	
145-31	30126-30130	were	_	
145-32	30131-30140	conducted	_	
145-33	30141-30146	using	_	
145-34	30147-30156	extracted	_	
145-35	30157-30162	betas	_	
145-36	30163-30167	from	_	
145-37	30168-30171	the	_	
145-38	30172-30176	main	_	
145-39	30177-30186	contrasts	_	
145-40	30187-30188	[	_	
145-41	30188-30192	NAcc	_	
145-42	30193-30196	and	_	
145-43	30197-30201	MPFC	_	
145-44	30202-30208	reward	_	
145-45	30209-30221	anticipatory	_	
145-46	30222-30231	responses	_	
145-47	30232-30233	(	_	
145-48	30233-30239	GVNant	_	
145-49	30240-30245	betas	_	
145-50	30245-30246	)	_	
145-51	30247-30250	and	_	
145-52	30251-30259	non-loss	_	
145-53	30260-30267	outcome	_	
145-54	30268-30277	responses	_	
145-55	30278-30279	(	_	
145-56	30279-30285	NVLout	_	
145-57	30286-30291	betas	_	
145-58	30291-30292	)	_	
145-59	30292-30293	]	_	
145-60	30294-30297	and	_	
145-61	30298-30311	questionnaire	_	
145-62	30312-30318	scores	_	
145-63	30319-30322	for	_	
145-64	30323-30327	each	_	
145-65	30328-30339	participant	_	
145-66	30339-30340	.	_	

#Text=Across the patient groups, MPFC non-loss outcome responses (non-punishment, NVLout betas) were correlated with behavioral drive (BAS, behavioral activation system – drive subscale) (r = 0.507, p = 0.004, N = 30) (Fig. 3F).
146-1	30341-30347	Across	_	
146-2	30348-30351	the	_	
146-3	30352-30359	patient	_	
146-4	30360-30366	groups	_	
146-5	30366-30367	,	_	
146-6	30368-30372	MPFC	_	
146-7	30373-30381	non-loss	_	
146-8	30382-30389	outcome	_	
146-9	30390-30399	responses	_	
146-10	30400-30401	(	_	
146-11	30401-30415	non-punishment	_	
146-12	30415-30416	,	_	
146-13	30417-30423	NVLout	_	
146-14	30424-30429	betas	_	
146-15	30429-30430	)	_	
146-16	30431-30435	were	_	
146-17	30436-30446	correlated	_	
146-18	30447-30451	with	_	
146-19	30452-30462	behavioral	_	
146-20	30463-30468	drive	_	
146-21	30469-30470	(	_	
146-22	30470-30473	BAS	_	
146-23	30473-30474	,	_	
146-24	30475-30485	behavioral	_	
146-25	30486-30496	activation	_	
146-26	30497-30503	system	_	
146-27	30504-30505	–	_	
146-28	30506-30511	drive	_	
146-29	30512-30520	subscale	_	
146-30	30520-30521	)	_	
146-31	30522-30523	(	_	
146-32	30523-30524	r	_	
146-33	30525-30526	=	_	
146-34	30527-30532	0.507	_	
146-35	30532-30533	,	_	
146-36	30534-30535	p	_	
146-37	30536-30537	=	_	
146-38	30538-30543	0.004	_	
146-39	30543-30544	,	_	
146-40	30545-30546	N	_	
146-41	30547-30548	=	_	
146-42	30549-30551	30	_	
146-43	30551-30552	)	_	
146-44	30553-30554	(	_	
146-45	30554-30557	Fig	_	
146-46	30557-30558	.	_	
146-47	30558-30559	 	_	
146-48	30559-30561	3F	_	
146-49	30561-30562	)	_	
146-50	30562-30563	.	_	

#Text=Additional trend-level correlations (that did not survive adjusted Bonferroni correction corrected threshold p < 0.007) included MPFC non-loss outcome response with BAS fun seeking subscale (p = 0.365, r = 0.047, N = 30) and MPFC reward anticipatory response (GVNant betas) with BAS reward responsiveness subscale (r = 0.397, p = 0.030, N = 30).
147-1	30564-30574	Additional	_	
147-2	30575-30586	trend-level	_	
147-3	30587-30599	correlations	_	
147-4	30600-30601	(	_	
147-5	30601-30605	that	_	
147-6	30606-30609	did	_	
147-7	30610-30613	not	_	
147-8	30614-30621	survive	_	
147-9	30622-30630	adjusted	_	
147-10	30631-30641	Bonferroni	_	
147-11	30642-30652	correction	_	
147-12	30653-30662	corrected	_	
147-13	30663-30672	threshold	_	
147-14	30673-30674	p	_	
147-15	30675-30676	<	_	
147-16	30677-30682	0.007	_	
147-17	30682-30683	)	_	
147-18	30684-30692	included	_	
147-19	30693-30697	MPFC	_	
147-20	30698-30706	non-loss	_	
147-21	30707-30714	outcome	_	
147-22	30715-30723	response	_	
147-23	30724-30728	with	_	
147-24	30729-30732	BAS	_	
147-25	30733-30736	fun	_	
147-26	30737-30744	seeking	_	
147-27	30745-30753	subscale	_	
147-28	30754-30755	(	_	
147-29	30755-30756	p	_	
147-30	30757-30758	=	_	
147-31	30759-30764	0.365	_	
147-32	30764-30765	,	_	
147-33	30766-30767	r	_	
147-34	30768-30769	=	_	
147-35	30770-30775	0.047	_	
147-36	30775-30776	,	_	
147-37	30777-30778	N	_	
147-38	30779-30780	=	_	
147-39	30781-30783	30	_	
147-40	30783-30784	)	_	
147-41	30785-30788	and	_	
147-42	30789-30793	MPFC	_	
147-43	30794-30800	reward	_	
147-44	30801-30813	anticipatory	_	
147-45	30814-30822	response	_	
147-46	30823-30824	(	_	
147-47	30824-30830	GVNant	_	
147-48	30831-30836	betas	_	
147-49	30836-30837	)	_	
147-50	30838-30842	with	_	
147-51	30843-30846	BAS	_	
147-52	30847-30853	reward	_	
147-53	30854-30868	responsiveness	_	
147-54	30869-30877	subscale	_	
147-55	30878-30879	(	_	
147-56	30879-30880	r	_	
147-57	30881-30882	=	_	
147-58	30883-30888	0.397	_	
147-59	30888-30889	,	_	
147-60	30890-30891	p	_	
147-61	30892-30893	=	_	
147-62	30894-30899	0.030	_	
147-63	30899-30900	,	_	
147-64	30901-30902	N	_	
147-65	30903-30904	=	_	
147-66	30905-30907	30	_	
147-67	30907-30908	)	_	
147-68	30908-30909	.	_	

#Text=No other ROI fMRI responses were correlated with questionnaire measures across the fibromyalgia groups (Supplementary Table S1).
148-1	30910-30912	No	_	
148-2	30913-30918	other	_	
148-3	30919-30922	ROI	_	
148-4	30923-30927	fMRI	_	
148-5	30928-30937	responses	_	
148-6	30938-30942	were	_	
148-7	30943-30953	correlated	_	
148-8	30954-30958	with	_	
148-9	30959-30972	questionnaire	_	
148-10	30973-30981	measures	_	
148-11	30982-30988	across	_	
148-12	30989-30992	the	_	
148-13	30993-31005	fibromyalgia	_	
148-14	31006-31012	groups	_	
148-15	31013-31014	(	_	
148-16	31014-31027	Supplementary	_	
148-17	31028-31033	Table	_	
148-18	31033-31034	 	_	
148-19	31034-31036	S1	_	
148-20	31036-31037	)	_	
148-21	31037-31038	.	_	

#Text=Impact of opioid duration, dose, and active phase
#Text=To further inform the findings of the fMRI and questionnaire analyses, additional analyses were performed within the opioid fibromyalgia group to determine potential effects due to specific characteristics of opioid use.
149-1	31039-31045	Impact	_	
149-2	31046-31048	of	_	
149-3	31049-31055	opioid	_	
149-4	31056-31064	duration	_	
149-5	31064-31065	,	_	
149-6	31066-31070	dose	_	
149-7	31070-31071	,	_	
149-8	31072-31075	and	_	
149-9	31076-31082	active	_	
149-10	31083-31088	phase	_	
149-11	31089-31091	To	_	
149-12	31092-31099	further	_	
149-13	31100-31106	inform	_	
149-14	31107-31110	the	_	
149-15	31111-31119	findings	_	
149-16	31120-31122	of	_	
149-17	31123-31126	the	_	
149-18	31127-31131	fMRI	_	
149-19	31132-31135	and	_	
149-20	31136-31149	questionnaire	_	
149-21	31150-31158	analyses	_	
149-22	31158-31159	,	_	
149-23	31160-31170	additional	_	
149-24	31171-31179	analyses	_	
149-25	31180-31184	were	_	
149-26	31185-31194	performed	_	
149-27	31195-31201	within	_	
149-28	31202-31205	the	_	
149-29	31206-31212	opioid	_	
149-30	31213-31225	fibromyalgia	_	
149-31	31226-31231	group	_	
149-32	31232-31234	to	_	
149-33	31235-31244	determine	_	
149-34	31245-31254	potential	_	
149-35	31255-31262	effects	_	
149-36	31263-31266	due	_	
149-37	31267-31269	to	_	
149-38	31270-31278	specific	_	
149-39	31279-31294	characteristics	_	
149-40	31295-31297	of	_	
149-41	31298-31304	opioid	_	
149-42	31305-31308	use	_	
149-43	31308-31309	.	_	

#Text=Exploratory correlation analyses within the opioid fibromyalgia group identified that opioid dose (morphine equivalent) was correlated with positive affect (PANAS positive affect subscale, r = 0.483, p = 0.049, N = 17) and behavioral reward responsiveness (BAS reward responsiveness subscale, r = 0.547, p = 0.043, N = 14), however, after excluding the single fibromyalgia participant who was taking high dose opioids these relationships were no longer significant (PANAS positive affect subscale, r = 0.485, p = 0.057, N = 16; BAS reward responsiveness subscale, r = 0.169, p = 0.580, N = 13).
150-1	31310-31321	Exploratory	_	
150-2	31322-31333	correlation	_	
150-3	31334-31342	analyses	_	
150-4	31343-31349	within	_	
150-5	31350-31353	the	_	
150-6	31354-31360	opioid	_	
150-7	31361-31373	fibromyalgia	_	
150-8	31374-31379	group	_	
150-9	31380-31390	identified	_	
150-10	31391-31395	that	_	
150-11	31396-31402	opioid	_	
150-12	31403-31407	dose	_	
150-13	31408-31409	(	_	
150-14	31409-31417	morphine	_	
150-15	31418-31428	equivalent	_	
150-16	31428-31429	)	_	
150-17	31430-31433	was	_	
150-18	31434-31444	correlated	_	
150-19	31445-31449	with	_	
150-20	31450-31458	positive	_	
150-21	31459-31465	affect	_	
150-22	31466-31467	(	_	
150-23	31467-31472	PANAS	_	
150-24	31473-31481	positive	_	
150-25	31482-31488	affect	_	
150-26	31489-31497	subscale	_	
150-27	31497-31498	,	_	
150-28	31499-31500	r	_	
150-29	31501-31502	=	_	
150-30	31503-31508	0.483	_	
150-31	31508-31509	,	_	
150-32	31510-31511	p	_	
150-33	31512-31513	=	_	
150-34	31514-31519	0.049	_	
150-35	31519-31520	,	_	
150-36	31521-31522	N	_	
150-37	31523-31524	=	_	
150-38	31525-31527	17	_	
150-39	31527-31528	)	_	
150-40	31529-31532	and	_	
150-41	31533-31543	behavioral	_	
150-42	31544-31550	reward	_	
150-43	31551-31565	responsiveness	_	
150-44	31566-31567	(	_	
150-45	31567-31570	BAS	_	
150-46	31571-31577	reward	_	
150-47	31578-31592	responsiveness	_	
150-48	31593-31601	subscale	_	
150-49	31601-31602	,	_	
150-50	31603-31604	r	_	
150-51	31605-31606	=	_	
150-52	31607-31612	0.547	_	
150-53	31612-31613	,	_	
150-54	31614-31615	p	_	
150-55	31616-31617	=	_	
150-56	31618-31623	0.043	_	
150-57	31623-31624	,	_	
150-58	31625-31626	N	_	
150-59	31627-31628	=	_	
150-60	31629-31631	14	_	
150-61	31631-31632	)	_	
150-62	31632-31633	,	_	
150-63	31634-31641	however	_	
150-64	31641-31642	,	_	
150-65	31643-31648	after	_	
150-66	31649-31658	excluding	_	
150-67	31659-31662	the	_	
150-68	31663-31669	single	_	
150-69	31670-31682	fibromyalgia	_	
150-70	31683-31694	participant	_	
150-71	31695-31698	who	_	
150-72	31699-31702	was	_	
150-73	31703-31709	taking	_	
150-74	31710-31714	high	_	
150-75	31715-31719	dose	_	
150-76	31720-31727	opioids	_	
150-77	31728-31733	these	_	
150-78	31734-31747	relationships	_	
150-79	31748-31752	were	_	
150-80	31753-31755	no	_	
150-81	31756-31762	longer	_	
150-82	31763-31774	significant	_	
150-83	31775-31776	(	_	
150-84	31776-31781	PANAS	_	
150-85	31782-31790	positive	_	
150-86	31791-31797	affect	_	
150-87	31798-31806	subscale	_	
150-88	31806-31807	,	_	
150-89	31808-31809	r	_	
150-90	31810-31811	=	_	
150-91	31812-31817	0.485	_	
150-92	31817-31818	,	_	
150-93	31819-31820	p	_	
150-94	31821-31822	=	_	
150-95	31823-31828	0.057	_	
150-96	31828-31829	,	_	
150-97	31830-31831	N	_	
150-98	31832-31833	=	_	
150-99	31834-31836	16	_	
150-100	31836-31837	;	_	
150-101	31838-31841	BAS	_	
150-102	31842-31848	reward	_	
150-103	31849-31863	responsiveness	_	
150-104	31864-31872	subscale	_	
150-105	31872-31873	,	_	
150-106	31874-31875	r	_	
150-107	31876-31877	=	_	
150-108	31878-31883	0.169	_	
150-109	31883-31884	,	_	
150-110	31885-31886	p	_	
150-111	31887-31888	=	_	
150-112	31889-31894	0.580	_	
150-113	31894-31895	,	_	
150-114	31896-31897	N	_	
150-115	31898-31899	=	_	
150-116	31900-31902	13	_	
150-117	31902-31903	)	_	
150-118	31903-31904	.	_	

#Text=No other relationships were identified for opioid dose, opioid use duration, ROI fMRI response (beta values), arousal, or other questionnaire variables.
151-1	31905-31907	No	_	
151-2	31908-31913	other	_	
151-3	31914-31927	relationships	_	
151-4	31928-31932	were	_	
151-5	31933-31943	identified	_	
151-6	31944-31947	for	_	
151-7	31948-31954	opioid	_	
151-8	31955-31959	dose	_	
151-9	31959-31960	,	_	
151-10	31961-31967	opioid	_	
151-11	31968-31971	use	_	
151-12	31972-31980	duration	_	
151-13	31980-31981	,	_	
151-14	31982-31985	ROI	_	
151-15	31986-31990	fMRI	_	
151-16	31991-31999	response	_	
151-17	32000-32001	(	_	
151-18	32001-32005	beta	_	
151-19	32006-32012	values	_	
151-20	32012-32013	)	_	
151-21	32013-32014	,	_	
151-22	32015-32022	arousal	_	
151-23	32022-32023	,	_	
151-24	32024-32026	or	_	
151-25	32027-32032	other	_	
151-26	32033-32046	questionnaire	_	
151-27	32047-32056	variables	_	
151-28	32056-32057	.	_	

#Text=Approximately half of the opioid fibromyalgia participants (N = 8 out of a total N = 17) were estimated (based on collected data: time of last dose and opioid medication type) to have undergone the fMRI scan during active phase of their opioid medication.
152-1	32058-32071	Approximately	_	
152-2	32072-32076	half	_	
152-3	32077-32079	of	_	
152-4	32080-32083	the	_	
152-5	32084-32090	opioid	_	
152-6	32091-32103	fibromyalgia	_	
152-7	32104-32116	participants	_	
152-8	32117-32118	(	_	
152-9	32118-32119	N	_	
152-10	32120-32121	=	_	
152-11	32122-32123	8	_	
152-12	32124-32127	out	_	
152-13	32128-32130	of	_	
152-14	32131-32132	a	_	
152-15	32133-32138	total	_	
152-16	32139-32140	N	_	
152-17	32141-32142	=	_	
152-18	32143-32145	17	_	
152-19	32145-32146	)	_	
152-20	32147-32151	were	_	
152-21	32152-32161	estimated	_	
152-22	32162-32163	(	_	
152-23	32163-32168	based	_	
152-24	32169-32171	on	_	
152-25	32172-32181	collected	_	
152-26	32182-32186	data	_	
152-27	32186-32187	:	_	
152-28	32188-32192	time	_	
152-29	32193-32195	of	_	
152-30	32196-32200	last	_	
152-31	32201-32205	dose	_	
152-32	32206-32209	and	_	
152-33	32210-32216	opioid	_	
152-34	32217-32227	medication	_	
152-35	32228-32232	type	_	
152-36	32232-32233	)	_	
152-37	32234-32236	to	_	
152-38	32237-32241	have	_	
152-39	32242-32251	undergone	_	
152-40	32252-32255	the	_	
152-41	32256-32260	fMRI	_	
152-42	32261-32265	scan	_	
152-43	32266-32272	during	_	
152-44	32273-32279	active	_	
152-45	32280-32285	phase	_	
152-46	32286-32288	of	_	
152-47	32289-32294	their	_	
152-48	32295-32301	opioid	_	
152-49	32302-32312	medication	_	
152-50	32312-32313	.	_	

#Text=Comparison of extracted ROI fMRI beta values revealed no significant differences between the two opioid sub-groups (active versus inactive opioid phases) for NAcc reward anticipatory response (GVNant betas) [t(14) = 0.8, p = 0.433], MPFC reward anticipatory response (GVNant betas) [t(14) = −0.6, p = 0.591] and MPFC no-loss outcome response (NVLout betas) [t(14) = −0.9, p = 0.389].
153-1	32314-32324	Comparison	_	
153-2	32325-32327	of	_	
153-3	32328-32337	extracted	_	
153-4	32338-32341	ROI	_	
153-5	32342-32346	fMRI	_	
153-6	32347-32351	beta	_	
153-7	32352-32358	values	_	
153-8	32359-32367	revealed	_	
153-9	32368-32370	no	_	
153-10	32371-32382	significant	_	
153-11	32383-32394	differences	_	
153-12	32395-32402	between	_	
153-13	32403-32406	the	_	
153-14	32407-32410	two	_	
153-15	32411-32417	opioid	_	
153-16	32418-32428	sub-groups	_	
153-17	32429-32430	(	_	
153-18	32430-32436	active	_	
153-19	32437-32443	versus	_	
153-20	32444-32452	inactive	_	
153-21	32453-32459	opioid	_	
153-22	32460-32466	phases	_	
153-23	32466-32467	)	_	
153-24	32468-32471	for	_	
153-25	32472-32476	NAcc	_	
153-26	32477-32483	reward	_	
153-27	32484-32496	anticipatory	_	
153-28	32497-32505	response	_	
153-29	32506-32507	(	_	
153-30	32507-32513	GVNant	_	
153-31	32514-32519	betas	_	
153-32	32519-32520	)	_	
153-33	32521-32522	[	_	
153-34	32522-32523	t	_	
153-35	32523-32524	(	_	
153-36	32524-32526	14	_	
153-37	32526-32527	)	_	
153-38	32528-32529	=	_	
153-39	32530-32533	0.8	_	
153-40	32533-32534	,	_	
153-41	32535-32536	p	_	
153-42	32537-32538	=	_	
153-43	32539-32544	0.433	_	
153-44	32544-32545	]	_	
153-45	32545-32546	,	_	
153-46	32547-32551	MPFC	_	
153-47	32552-32558	reward	_	
153-48	32559-32571	anticipatory	_	
153-49	32572-32580	response	_	
153-50	32581-32582	(	_	
153-51	32582-32588	GVNant	_	
153-52	32589-32594	betas	_	
153-53	32594-32595	)	_	
153-54	32596-32597	[	_	
153-55	32597-32598	t	_	
153-56	32598-32599	(	_	
153-57	32599-32601	14	_	
153-58	32601-32602	)	_	
153-59	32603-32604	=	_	
153-60	32605-32606	−	_	
153-61	32606-32609	0.6	_	
153-62	32609-32610	,	_	
153-63	32611-32612	p	_	
153-64	32613-32614	=	_	
153-65	32615-32620	0.591	_	
153-66	32620-32621	]	_	
153-67	32622-32625	and	_	
153-68	32626-32630	MPFC	_	
153-69	32631-32638	no-loss	_	
153-70	32639-32646	outcome	_	
153-71	32647-32655	response	_	
153-72	32656-32657	(	_	
153-73	32657-32663	NVLout	_	
153-74	32664-32669	betas	_	
153-75	32669-32670	)	_	
153-76	32671-32672	[	_	
153-77	32672-32673	t	_	
153-78	32673-32674	(	_	
153-79	32674-32676	14	_	
153-80	32676-32677	)	_	
153-81	32678-32679	=	_	
153-82	32680-32681	−	_	
153-83	32681-32684	0.9	_	
153-84	32684-32685	,	_	
153-85	32686-32687	p	_	
153-86	32688-32689	=	_	
153-87	32690-32695	0.389	_	
153-88	32695-32696	]	_	
153-89	32696-32697	.	_	

#Text=Post-hoc whole brain ANOVA fMRI results
#Text=Post-hoc whole brain analyses were conducted to 1) confirm the ROI findings and 2) to identify additional brain regions that may be differently involved in reward processes among the groups.
154-1	32698-32706	Post-hoc	_	
154-2	32707-32712	whole	_	
154-3	32713-32718	brain	_	
154-4	32719-32724	ANOVA	_	
154-5	32725-32729	fMRI	_	
154-6	32730-32737	results	_	
154-7	32738-32746	Post-hoc	_	
154-8	32747-32752	whole	_	
154-9	32753-32758	brain	_	
154-10	32759-32767	analyses	_	
154-11	32768-32772	were	_	
154-12	32773-32782	conducted	_	
154-13	32783-32785	to	_	
154-14	32786-32787	1	_	
154-15	32787-32788	)	_	
154-16	32789-32796	confirm	_	
154-17	32797-32800	the	_	
154-18	32801-32804	ROI	_	
154-19	32805-32813	findings	_	
154-20	32814-32817	and	_	
154-21	32818-32819	2	_	
154-22	32819-32820	)	_	
154-23	32821-32823	to	_	
154-24	32824-32832	identify	_	
154-25	32833-32843	additional	_	
154-26	32844-32849	brain	_	
154-27	32850-32857	regions	_	
154-28	32858-32862	that	_	
154-29	32863-32866	may	_	
154-30	32867-32869	be	_	
154-31	32870-32881	differently	_	
154-32	32882-32890	involved	_	
154-33	32891-32893	in	_	
154-34	32894-32900	reward	_	
154-35	32901-32910	processes	_	
154-36	32911-32916	among	_	
154-37	32917-32920	the	_	
154-38	32921-32927	groups	_	
154-39	32927-32928	.	_	

#Text=Whole brain fMRI data compared across the 3 groups for reward anticipation (GVNant contrast) and non-loss outcome (NVLout contrast) generally confirmed the observed group differences from the ROI analyses (Supplementary Results and Supplementary Figs S1 and S2).
155-1	32929-32934	Whole	_	
155-2	32935-32940	brain	_	
155-3	32941-32945	fMRI	_	
155-4	32946-32950	data	_	
155-5	32951-32959	compared	_	
155-6	32960-32966	across	_	
155-7	32967-32970	the	_	
155-8	32971-32972	3	_	
155-9	32973-32979	groups	_	
155-10	32980-32983	for	_	
155-11	32984-32990	reward	_	
155-12	32991-33003	anticipation	_	
155-13	33004-33005	(	_	
155-14	33005-33011	GVNant	_	
155-15	33012-33020	contrast	_	
155-16	33020-33021	)	_	
155-17	33022-33025	and	_	
155-18	33026-33034	non-loss	_	
155-19	33035-33042	outcome	_	
155-20	33043-33044	(	_	
155-21	33044-33050	NVLout	_	
155-22	33051-33059	contrast	_	
155-23	33059-33060	)	_	
155-24	33061-33070	generally	_	
155-25	33071-33080	confirmed	_	
155-26	33081-33084	the	_	
155-27	33085-33093	observed	_	
155-28	33094-33099	group	_	
155-29	33100-33111	differences	_	
155-30	33112-33116	from	_	
155-31	33117-33120	the	_	
155-32	33121-33124	ROI	_	
155-33	33125-33133	analyses	_	
155-34	33134-33135	(	_	
155-35	33135-33148	Supplementary	_	
155-36	33149-33156	Results	_	
155-37	33157-33160	and	_	
155-38	33161-33174	Supplementary	_	
155-39	33175-33179	Figs	_	
155-40	33179-33180	 	_	
155-41	33180-33182	S1	_	
155-42	33183-33186	and	_	
155-43	33187-33189	S2	_	
155-44	33189-33190	)	_	
155-45	33190-33191	.	_	

#Text=Whole brain results for LVNant and GVNout contrasts are presented in Supplementary Figs S3 and S4.
156-1	33192-33197	Whole	_	
156-2	33198-33203	brain	_	
156-3	33204-33211	results	_	
156-4	33212-33215	for	_	
156-5	33216-33222	LVNant	_	
156-6	33223-33226	and	_	
156-7	33227-33233	GVNout	_	
156-8	33234-33243	contrasts	_	
156-9	33244-33247	are	_	
156-10	33248-33257	presented	_	
156-11	33258-33260	in	_	
156-12	33261-33274	Supplementary	_	
156-13	33275-33279	Figs	_	
156-14	33279-33280	 	_	
156-15	33280-33282	S3	_	
156-16	33283-33286	and	_	
156-17	33287-33289	S4	_	
156-18	33289-33290	.	_	

#Text=Discussion
#Text=Summary of Main Findings.
157-1	33291-33301	Discussion	_	
157-2	33302-33309	Summary	_	
157-3	33310-33312	of	_	
157-4	33313-33317	Main	_	
157-5	33318-33326	Findings	_	
157-6	33326-33327	.	_	

#Text=NAcc gain anticipation response was not significantly different from healthy controls in either non-opioid fibromyalgia (FM) and opioid fibromyalgia groups (gain versus no-gain anticipation, GVNant contrast) (top row).
158-1	33328-33332	NAcc	_	
158-2	33333-33337	gain	_	
158-3	33338-33350	anticipation	_	
158-4	33351-33359	response	_	
158-5	33360-33363	was	_	
158-6	33364-33367	not	_	
158-7	33368-33381	significantly	_	
158-8	33382-33391	different	_	
158-9	33392-33396	from	_	
158-10	33397-33404	healthy	_	
158-11	33405-33413	controls	_	
158-12	33414-33416	in	_	
158-13	33417-33423	either	_	
158-14	33424-33434	non-opioid	_	
158-15	33435-33447	fibromyalgia	_	
158-16	33448-33449	(	_	
158-17	33449-33451	FM	_	
158-18	33451-33452	)	_	
158-19	33453-33456	and	_	
158-20	33457-33463	opioid	_	
158-21	33464-33476	fibromyalgia	_	
158-22	33477-33483	groups	_	
158-23	33484-33485	(	_	
158-24	33485-33489	gain	_	
158-25	33490-33496	versus	_	
158-26	33497-33504	no-gain	_	
158-27	33505-33517	anticipation	_	
158-28	33517-33518	,	_	
158-29	33519-33525	GVNant	_	
158-30	33526-33534	contrast	_	
158-31	33534-33535	)	_	
158-32	33536-33537	(	_	
158-33	33537-33540	top	_	
158-34	33541-33544	row	_	
158-35	33544-33545	)	_	
158-36	33545-33546	.	_	

#Text=NAcc no-loss outcome response (non-punishment) was not significantly different from healthy controls in either non-opioid fibromyalgia and opioid fibromyalgia groups (no-loss versus loss outcome, NVLout contrast; second row).
159-1	33547-33551	NAcc	_	
159-2	33552-33559	no-loss	_	
159-3	33560-33567	outcome	_	
159-4	33568-33576	response	_	
159-5	33577-33578	(	_	
159-6	33578-33592	non-punishment	_	
159-7	33592-33593	)	_	
159-8	33594-33597	was	_	
159-9	33598-33601	not	_	
159-10	33602-33615	significantly	_	
159-11	33616-33625	different	_	
159-12	33626-33630	from	_	
159-13	33631-33638	healthy	_	
159-14	33639-33647	controls	_	
159-15	33648-33650	in	_	
159-16	33651-33657	either	_	
159-17	33658-33668	non-opioid	_	
159-18	33669-33681	fibromyalgia	_	
159-19	33682-33685	and	_	
159-20	33686-33692	opioid	_	
159-21	33693-33705	fibromyalgia	_	
159-22	33706-33712	groups	_	
159-23	33713-33714	(	_	
159-24	33714-33721	no-loss	_	
159-25	33722-33728	versus	_	
159-26	33729-33733	loss	_	
159-27	33734-33741	outcome	_	
159-28	33741-33742	,	_	
159-29	33743-33749	NVLout	_	
159-30	33750-33758	contrast	_	
159-31	33758-33759	;	_	
159-32	33760-33766	second	_	
159-33	33767-33770	row	_	
159-34	33770-33771	)	_	
159-35	33771-33772	.	_	

#Text=MPFC gain anticipation response was significantly decreased (blue arrow) in the non-opioid fibromyalgia group compared to healthy controls, but this decrease was not significant in the opioid fibromyalgia group (GVNant contrast; third row).
160-1	33773-33777	MPFC	_	
160-2	33778-33782	gain	_	
160-3	33783-33795	anticipation	_	
160-4	33796-33804	response	_	
160-5	33805-33808	was	_	
160-6	33809-33822	significantly	_	
160-7	33823-33832	decreased	_	
160-8	33833-33834	(	_	
160-9	33834-33838	blue	_	
160-10	33839-33844	arrow	_	
160-11	33844-33845	)	_	
160-12	33846-33848	in	_	
160-13	33849-33852	the	_	
160-14	33853-33863	non-opioid	_	
160-15	33864-33876	fibromyalgia	_	
160-16	33877-33882	group	_	
160-17	33883-33891	compared	_	
160-18	33892-33894	to	_	
160-19	33895-33902	healthy	_	
160-20	33903-33911	controls	_	
160-21	33911-33912	,	_	
160-22	33913-33916	but	_	
160-23	33917-33921	this	_	
160-24	33922-33930	decrease	_	
160-25	33931-33934	was	_	
160-26	33935-33938	not	_	
160-27	33939-33950	significant	_	
160-28	33951-33953	in	_	
160-29	33954-33957	the	_	
160-30	33958-33964	opioid	_	
160-31	33965-33977	fibromyalgia	_	
160-32	33978-33983	group	_	
160-33	33984-33985	(	_	
160-34	33985-33991	GVNant	_	
160-35	33992-34000	contrast	_	
160-36	34000-34001	;	_	
160-37	34002-34007	third	_	
160-38	34008-34011	row	_	
160-39	34011-34012	)	_	
160-40	34012-34013	.	_	

#Text=MPFC no-loss outcome response was significantly increased (red arrow) in the non-opioid fibromyalgia group compared to healthy controls, and non-significantly decreased in the opioid fibromyalgia group (NVLout contrast; fourth row).
161-1	34014-34018	MPFC	_	
161-2	34019-34026	no-loss	_	
161-3	34027-34034	outcome	_	
161-4	34035-34043	response	_	
161-5	34044-34047	was	_	
161-6	34048-34061	significantly	_	
161-7	34062-34071	increased	_	
161-8	34072-34073	(	_	
161-9	34073-34076	red	_	
161-10	34077-34082	arrow	_	
161-11	34082-34083	)	_	
161-12	34084-34086	in	_	
161-13	34087-34090	the	_	
161-14	34091-34101	non-opioid	_	
161-15	34102-34114	fibromyalgia	_	
161-16	34115-34120	group	_	
161-17	34121-34129	compared	_	
161-18	34130-34132	to	_	
161-19	34133-34140	healthy	_	
161-20	34141-34149	controls	_	
161-21	34149-34150	,	_	
161-22	34151-34154	and	_	
161-23	34155-34172	non-significantly	_	
161-24	34173-34182	decreased	_	
161-25	34183-34185	in	_	
161-26	34186-34189	the	_	
161-27	34190-34196	opioid	_	
161-28	34197-34209	fibromyalgia	_	
161-29	34210-34215	group	_	
161-30	34216-34217	(	_	
161-31	34217-34223	NVLout	_	
161-32	34224-34232	contrast	_	
161-33	34232-34233	;	_	
161-34	34234-34240	fourth	_	
161-35	34241-34244	row	_	
161-36	34244-34245	)	_	
161-37	34245-34246	.	_	

#Text=(Light blue arrows within green circles indicate non-significant direction of response relative to controls; these are shown to inform future replication studies with larger sample sizes.)
162-1	34247-34248	(	_	
162-2	34248-34253	Light	_	
162-3	34254-34258	blue	_	
162-4	34259-34265	arrows	_	
162-5	34266-34272	within	_	
162-6	34273-34278	green	_	
162-7	34279-34286	circles	_	
162-8	34287-34295	indicate	_	
162-9	34296-34311	non-significant	_	
162-10	34312-34321	direction	_	
162-11	34322-34324	of	_	
162-12	34325-34333	response	_	
162-13	34334-34342	relative	_	
162-14	34343-34345	to	_	
162-15	34346-34354	controls	_	
162-16	34354-34355	;	_	
162-17	34356-34361	these	_	
162-18	34362-34365	are	_	
162-19	34366-34371	shown	_	
162-20	34372-34374	to	_	
162-21	34375-34381	inform	_	
162-22	34382-34388	future	_	
162-23	34389-34400	replication	_	
162-24	34401-34408	studies	_	
162-25	34409-34413	with	_	
162-26	34414-34420	larger	_	
162-27	34421-34427	sample	_	
162-28	34428-34433	sizes	_	
162-29	34433-34434	.	_	
162-30	34434-34435	)	_	

#Text=Fibromyalgia, FM; nucleus accumbens, NAcc; medial prefrontal cortex, MPFC.
163-1	34436-34448	Fibromyalgia	_	
163-2	34448-34449	,	_	
163-3	34450-34452	FM	_	
163-4	34452-34453	;	_	
163-5	34454-34461	nucleus	_	
163-6	34462-34471	accumbens	_	
163-7	34471-34472	,	_	
163-8	34473-34477	NAcc	_	
163-9	34477-34478	;	_	
163-10	34479-34485	medial	_	
163-11	34486-34496	prefrontal	_	
163-12	34497-34503	cortex	_	
163-13	34503-34504	,	_	
163-14	34505-34509	MPFC	_	
163-15	34509-34510	.	_	

#Text=In this sample of individuals with fibromyalgia taking opioid medications, we observed relatively normal brain activity in response to anticipation and outcome of monetary rewards and non-loss (relative to healthy controls) using fMRI during a monetary incentive delay task.
164-1	34511-34513	In	_	
164-2	34514-34518	this	_	
164-3	34519-34525	sample	_	
164-4	34526-34528	of	_	
164-5	34529-34540	individuals	_	
164-6	34541-34545	with	_	
164-7	34546-34558	fibromyalgia	_	
164-8	34559-34565	taking	_	
164-9	34566-34572	opioid	_	
164-10	34573-34584	medications	_	
164-11	34584-34585	,	_	
164-12	34586-34588	we	_	
164-13	34589-34597	observed	_	
164-14	34598-34608	relatively	_	
164-15	34609-34615	normal	_	
164-16	34616-34621	brain	_	
164-17	34622-34630	activity	_	
164-18	34631-34633	in	_	
164-19	34634-34642	response	_	
164-20	34643-34645	to	_	
164-21	34646-34658	anticipation	_	
164-22	34659-34662	and	_	
164-23	34663-34670	outcome	_	
164-24	34671-34673	of	_	
164-25	34674-34682	monetary	_	
164-26	34683-34690	rewards	_	
164-27	34691-34694	and	_	
164-28	34695-34703	non-loss	_	
164-29	34704-34705	(	_	
164-30	34705-34713	relative	_	
164-31	34714-34716	to	_	
164-32	34717-34724	healthy	_	
164-33	34725-34733	controls	_	
164-34	34733-34734	)	_	
164-35	34735-34740	using	_	
164-36	34741-34745	fMRI	_	
164-37	34746-34752	during	_	
164-38	34753-34754	a	_	
164-39	34755-34763	monetary	_	
164-40	34764-34773	incentive	_	
164-41	34774-34779	delay	_	
164-42	34780-34784	task	_	
164-43	34784-34785	.	_	

#Text=This sharply contrasted with our previously published observations in a sample of individuals with fibromyalgia not taking opioids who demonstrated blunted brain response to anticipated rewards and enhanced response to non-loss outcomes (non-punishments) in the MPFC (see summary Fig. 4).
165-1	34786-34790	This	_	
165-2	34791-34798	sharply	_	
165-3	34799-34809	contrasted	_	
165-4	34810-34814	with	_	
165-5	34815-34818	our	_	
165-6	34819-34829	previously	_	
165-7	34830-34839	published	_	
165-8	34840-34852	observations	_	
165-9	34853-34855	in	_	
165-10	34856-34857	a	_	
165-11	34858-34864	sample	_	
165-12	34865-34867	of	_	
165-13	34868-34879	individuals	_	
165-14	34880-34884	with	_	
165-15	34885-34897	fibromyalgia	_	
165-16	34898-34901	not	_	
165-17	34902-34908	taking	_	
165-18	34909-34916	opioids	_	
165-19	34917-34920	who	_	
165-20	34921-34933	demonstrated	_	
165-21	34934-34941	blunted	_	
165-22	34942-34947	brain	_	
165-23	34948-34956	response	_	
165-24	34957-34959	to	_	
165-25	34960-34971	anticipated	_	
165-26	34972-34979	rewards	_	
165-27	34980-34983	and	_	
165-28	34984-34992	enhanced	_	
165-29	34993-35001	response	_	
165-30	35002-35004	to	_	
165-31	35005-35013	non-loss	_	
165-32	35014-35022	outcomes	_	
165-33	35023-35024	(	_	
165-34	35024-35039	non-punishments	_	
165-35	35039-35040	)	_	
165-36	35041-35043	in	_	
165-37	35044-35047	the	_	
165-38	35048-35052	MPFC	_	
165-39	35053-35054	(	_	
165-40	35054-35057	see	_	
165-41	35058-35065	summary	_	
165-42	35066-35069	Fig	_	
165-43	35069-35070	.	_	
165-44	35070-35071	 	_	
165-45	35071-35072	4	_	
165-46	35072-35073	)	_	
165-47	35073-35074	.	_	

#Text=Together, these findings indicate less altered brain response in individuals with fibromyalgia taking opioid medications during incentive processing, compared to individuals with fibromyalgia not taking opioids.
166-1	35075-35083	Together	_	
166-2	35083-35084	,	_	
166-3	35085-35090	these	_	
166-4	35091-35099	findings	_	
166-5	35100-35108	indicate	_	
166-6	35109-35113	less	_	
166-7	35114-35121	altered	_	
166-8	35122-35127	brain	_	
166-9	35128-35136	response	_	
166-10	35137-35139	in	_	
166-11	35140-35151	individuals	_	
166-12	35152-35156	with	_	
166-13	35157-35169	fibromyalgia	_	
166-14	35170-35176	taking	_	
166-15	35177-35183	opioid	_	
166-16	35184-35195	medications	_	
166-17	35196-35202	during	_	
166-18	35203-35212	incentive	_	
166-19	35213-35223	processing	_	
166-20	35223-35224	,	_	
166-21	35225-35233	compared	_	
166-22	35234-35236	to	_	
166-23	35237-35248	individuals	_	
166-24	35249-35253	with	_	
166-25	35254-35266	fibromyalgia	_	
166-26	35267-35270	not	_	
166-27	35271-35277	taking	_	
166-28	35278-35285	opioids	_	
166-29	35285-35286	.	_	

#Text=Across the non-opioid and opioid fibromyalgia groups, levels of pain, clinical symptoms, psychological measures, and behavioral measures were similar.
167-1	35287-35293	Across	_	
167-2	35294-35297	the	_	
167-3	35298-35308	non-opioid	_	
167-4	35309-35312	and	_	
167-5	35313-35319	opioid	_	
167-6	35320-35332	fibromyalgia	_	
167-7	35333-35339	groups	_	
167-8	35339-35340	,	_	
167-9	35341-35347	levels	_	
167-10	35348-35350	of	_	
167-11	35351-35355	pain	_	
167-12	35355-35356	,	_	
167-13	35357-35365	clinical	_	
167-14	35366-35374	symptoms	_	
167-15	35374-35375	,	_	
167-16	35376-35389	psychological	_	
167-17	35390-35398	measures	_	
167-18	35398-35399	,	_	
167-19	35400-35403	and	_	
167-20	35404-35414	behavioral	_	
167-21	35415-35423	measures	_	
167-22	35424-35428	were	_	
167-23	35429-35436	similar	_	
167-24	35436-35437	.	_	

#Text=The similarities between the two groups were incidental - in other words, we did not attempt to match fibromyalgia participants based on variables other than age (and sex).
168-1	35438-35441	The	_	
168-2	35442-35454	similarities	_	
168-3	35455-35462	between	_	
168-4	35463-35466	the	_	
168-5	35467-35470	two	_	
168-6	35471-35477	groups	_	
168-7	35478-35482	were	_	
168-8	35483-35493	incidental	_	
168-9	35494-35495	-	_	
168-10	35496-35498	in	_	
168-11	35499-35504	other	_	
168-12	35505-35510	words	_	
168-13	35510-35511	,	_	
168-14	35512-35514	we	_	
168-15	35515-35518	did	_	
168-16	35519-35522	not	_	
168-17	35523-35530	attempt	_	
168-18	35531-35533	to	_	
168-19	35534-35539	match	_	
168-20	35540-35552	fibromyalgia	_	
168-21	35553-35565	participants	_	
168-22	35566-35571	based	_	
168-23	35572-35574	on	_	
168-24	35575-35584	variables	_	
168-25	35585-35590	other	_	
168-26	35591-35595	than	_	
168-27	35596-35599	age	_	
168-28	35600-35601	(	_	
168-29	35601-35604	and	_	
168-30	35605-35608	sex	_	
168-31	35608-35609	)	_	
168-32	35609-35610	.	_	

#Text=Therefore, among the cohorts that we had access to and recruited for the study, despite some participants taking opioids and others not taking opioids, the psychological and symptom profiles were comparable.
169-1	35611-35620	Therefore	_	
169-2	35620-35621	,	_	
169-3	35622-35627	among	_	
169-4	35628-35631	the	_	
169-5	35632-35639	cohorts	_	
169-6	35640-35644	that	_	
169-7	35645-35647	we	_	
169-8	35648-35651	had	_	
169-9	35652-35658	access	_	
169-10	35659-35661	to	_	
169-11	35662-35665	and	_	
169-12	35666-35675	recruited	_	
169-13	35676-35679	for	_	
169-14	35680-35683	the	_	
169-15	35684-35689	study	_	
169-16	35689-35690	,	_	
169-17	35691-35698	despite	_	
169-18	35699-35703	some	_	
169-19	35704-35716	participants	_	
169-20	35717-35723	taking	_	
169-21	35724-35731	opioids	_	
169-22	35732-35735	and	_	
169-23	35736-35742	others	_	
169-24	35743-35746	not	_	
169-25	35747-35753	taking	_	
169-26	35754-35761	opioids	_	
169-27	35761-35762	,	_	
169-28	35763-35766	the	_	
169-29	35767-35780	psychological	_	
169-30	35781-35784	and	_	
169-31	35785-35792	symptom	_	
169-32	35793-35801	profiles	_	
169-33	35802-35806	were	_	
169-34	35807-35817	comparable	_	
169-35	35817-35818	.	_	

#Text=This may have implications for reasonably high functioning (i.e., they were willing, able, and motivated to participate in the research study) people with fibromyalgia in the general population taking opioids at relatively low to moderate doses–in that they may generally have similar psychological, behavioral, and clinical profiles as compared with people of a similar status not taking opioids.
170-1	35819-35823	This	_	
170-2	35824-35827	may	_	
170-3	35828-35832	have	_	
170-4	35833-35845	implications	_	
170-5	35846-35849	for	_	
170-6	35850-35860	reasonably	_	
170-7	35861-35865	high	_	
170-8	35866-35877	functioning	_	
170-9	35878-35879	(	_	
170-10	35879-35882	i.e	_	
170-11	35882-35883	.	_	
170-12	35883-35884	,	_	
170-13	35885-35889	they	_	
170-14	35890-35894	were	_	
170-15	35895-35902	willing	_	
170-16	35902-35903	,	_	
170-17	35904-35908	able	_	
170-18	35908-35909	,	_	
170-19	35910-35913	and	_	
170-20	35914-35923	motivated	_	
170-21	35924-35926	to	_	
170-22	35927-35938	participate	_	
170-23	35939-35941	in	_	
170-24	35942-35945	the	_	
170-25	35946-35954	research	_	
170-26	35955-35960	study	_	
170-27	35960-35961	)	_	
170-28	35962-35968	people	_	
170-29	35969-35973	with	_	
170-30	35974-35986	fibromyalgia	_	
170-31	35987-35989	in	_	
170-32	35990-35993	the	_	
170-33	35994-36001	general	_	
170-34	36002-36012	population	_	
170-35	36013-36019	taking	_	
170-36	36020-36027	opioids	_	
170-37	36028-36030	at	_	
170-38	36031-36041	relatively	_	
170-39	36042-36045	low	_	
170-40	36046-36048	to	_	
170-41	36049-36057	moderate	_	
170-42	36058-36066	doses–in	_	
170-43	36067-36071	that	_	
170-44	36072-36076	they	_	
170-45	36077-36080	may	_	
170-46	36081-36090	generally	_	
170-47	36091-36095	have	_	
170-48	36096-36103	similar	_	
170-49	36104-36117	psychological	_	
170-50	36117-36118	,	_	
170-51	36119-36129	behavioral	_	
170-52	36129-36130	,	_	
170-53	36131-36134	and	_	
170-54	36135-36143	clinical	_	
170-55	36144-36152	profiles	_	
170-56	36153-36155	as	_	
170-57	36156-36164	compared	_	
170-58	36165-36169	with	_	
170-59	36170-36176	people	_	
170-60	36177-36179	of	_	
170-61	36180-36181	a	_	
170-62	36182-36189	similar	_	
170-63	36190-36196	status	_	
170-64	36197-36200	not	_	
170-65	36201-36207	taking	_	
170-66	36208-36215	opioids	_	
170-67	36215-36216	.	_	

#Text=Furthermore, although greater than the control group, relatively low levels of negative affect in our fibromyalgia groups (only 5 individuals with scores >30 and none >40 on the negative affect subscale, PANAS) may be related to lower pain scores and greater medication efficacy in our study population.
171-1	36217-36228	Furthermore	_	
171-2	36228-36229	,	_	
171-3	36230-36238	although	_	
171-4	36239-36246	greater	_	
171-5	36247-36251	than	_	
171-6	36252-36255	the	_	
171-7	36256-36263	control	_	
171-8	36264-36269	group	_	
171-9	36269-36270	,	_	
171-10	36271-36281	relatively	_	
171-11	36282-36285	low	_	
171-12	36286-36292	levels	_	
171-13	36293-36295	of	_	
171-14	36296-36304	negative	_	
171-15	36305-36311	affect	_	
171-16	36312-36314	in	_	
171-17	36315-36318	our	_	
171-18	36319-36331	fibromyalgia	_	
171-19	36332-36338	groups	_	
171-20	36339-36340	(	_	
171-21	36340-36344	only	_	
171-22	36345-36346	5	_	
171-23	36347-36358	individuals	_	
171-24	36359-36363	with	_	
171-25	36364-36370	scores	_	
171-26	36371-36372	>	_	
171-27	36372-36374	30	_	
171-28	36375-36378	and	_	
171-29	36379-36383	none	_	
171-30	36384-36385	>	_	
171-31	36385-36387	40	_	
171-32	36388-36390	on	_	
171-33	36391-36394	the	_	
171-34	36395-36403	negative	_	
171-35	36404-36410	affect	_	
171-36	36411-36419	subscale	_	
171-37	36419-36420	,	_	
171-38	36421-36426	PANAS	_	
171-39	36426-36427	)	_	
171-40	36428-36431	may	_	
171-41	36432-36434	be	_	
171-42	36435-36442	related	_	
171-43	36443-36445	to	_	
171-44	36446-36451	lower	_	
171-45	36452-36456	pain	_	
171-46	36457-36463	scores	_	
171-47	36464-36467	and	_	
171-48	36468-36475	greater	_	
171-49	36476-36486	medication	_	
171-50	36487-36495	efficacy	_	
171-51	36496-36498	in	_	
171-52	36499-36502	our	_	
171-53	36503-36508	study	_	
171-54	36509-36519	population	_	
171-55	36519-36520	.	_	

#Text=Similar levels of pain intensity, pain interference, and cognition have been identified between cohorts of individuals with chronic back pain taking (>3 months duration) and not taking opioid medications, despite lower self-efficacy beliefs and attention in the opioid group.
172-1	36521-36528	Similar	_	
172-2	36529-36535	levels	_	
172-3	36536-36538	of	_	
172-4	36539-36543	pain	_	
172-5	36544-36553	intensity	_	
172-6	36553-36554	,	_	
172-7	36555-36559	pain	_	
172-8	36560-36572	interference	_	
172-9	36572-36573	,	_	
172-10	36574-36577	and	_	
172-11	36578-36587	cognition	_	
172-12	36588-36592	have	_	
172-13	36593-36597	been	_	
172-14	36598-36608	identified	_	
172-15	36609-36616	between	_	
172-16	36617-36624	cohorts	_	
172-17	36625-36627	of	_	
172-18	36628-36639	individuals	_	
172-19	36640-36644	with	_	
172-20	36645-36652	chronic	_	
172-21	36653-36657	back	_	
172-22	36658-36662	pain	_	
172-23	36663-36669	taking	_	
172-24	36670-36671	(	_	
172-25	36671-36672	>	_	
172-26	36672-36673	3	_	
172-27	36674-36680	months	_	
172-28	36681-36689	duration	_	
172-29	36689-36690	)	_	
172-30	36691-36694	and	_	
172-31	36695-36698	not	_	
172-32	36699-36705	taking	_	
172-33	36706-36712	opioid	_	
172-34	36713-36724	medications	_	
172-35	36724-36725	,	_	
172-36	36726-36733	despite	_	
172-37	36734-36739	lower	_	
172-38	36740-36753	self-efficacy	_	
172-39	36754-36761	beliefs	_	
172-40	36762-36765	and	_	
172-41	36766-36775	attention	_	
172-42	36776-36778	in	_	
172-43	36779-36782	the	_	
172-44	36783-36789	opioid	_	
172-45	36790-36795	group	_	
172-46	36795-36796	.	_	

#Text=Currently, the number of neuroimaging studies comparing individuals with chronic pain who are taking versus not taking opioid medications are very limited.
173-1	36797-36806	Currently	_	
173-2	36806-36807	,	_	
173-3	36808-36811	the	_	
173-4	36812-36818	number	_	
173-5	36819-36821	of	_	
173-6	36822-36834	neuroimaging	_	
173-7	36835-36842	studies	_	
173-8	36843-36852	comparing	_	
173-9	36853-36864	individuals	_	
173-10	36865-36869	with	_	
173-11	36870-36877	chronic	_	
173-12	36878-36882	pain	_	
173-13	36883-36886	who	_	
173-14	36887-36890	are	_	
173-15	36891-36897	taking	_	
173-16	36898-36904	versus	_	
173-17	36905-36908	not	_	
173-18	36909-36915	taking	_	
173-19	36916-36922	opioid	_	
173-20	36923-36934	medications	_	
173-21	36935-36938	are	_	
173-22	36939-36943	very	_	
173-23	36944-36951	limited	_	
173-24	36951-36952	.	_	

#Text=Further research is needed to provide increased understanding of the impact of opioid use on pain and psychological factors in chronic pain.
174-1	36953-36960	Further	_	
174-2	36961-36969	research	_	
174-3	36970-36972	is	_	
174-4	36973-36979	needed	_	
174-5	36980-36982	to	_	
174-6	36983-36990	provide	_	
174-7	36991-37000	increased	_	
174-8	37001-37014	understanding	_	
174-9	37015-37017	of	_	
174-10	37018-37021	the	_	
174-11	37022-37028	impact	_	
174-12	37029-37031	of	_	
174-13	37032-37038	opioid	_	
174-14	37039-37042	use	_	
174-15	37043-37045	on	_	
174-16	37046-37050	pain	_	
174-17	37051-37054	and	_	
174-18	37055-37068	psychological	_	
174-19	37069-37076	factors	_	
174-20	37077-37079	in	_	
174-21	37080-37087	chronic	_	
174-22	37088-37092	pain	_	
174-23	37092-37093	.	_	

#Text=Despite the similar behavioral, psychological, and clinical profiles in the two fibromyalgia groups, we observed notable differences in the MPFC volume of interest response, specifically during gain anticipation and in response to non-loss outcomes.
175-1	37094-37101	Despite	_	
175-2	37102-37105	the	_	
175-3	37106-37113	similar	_	
175-4	37114-37124	behavioral	_	
175-5	37124-37125	,	_	
175-6	37126-37139	psychological	_	
175-7	37139-37140	,	_	
175-8	37141-37144	and	_	
175-9	37145-37153	clinical	_	
175-10	37154-37162	profiles	_	
175-11	37163-37165	in	_	
175-12	37166-37169	the	_	
175-13	37170-37173	two	_	
175-14	37174-37186	fibromyalgia	_	
175-15	37187-37193	groups	_	
175-16	37193-37194	,	_	
175-17	37195-37197	we	_	
175-18	37198-37206	observed	_	
175-19	37207-37214	notable	_	
175-20	37215-37226	differences	_	
175-21	37227-37229	in	_	
175-22	37230-37233	the	_	
175-23	37234-37238	MPFC	_	
175-24	37239-37245	volume	_	
175-25	37246-37248	of	_	
175-26	37249-37257	interest	_	
175-27	37258-37266	response	_	
175-28	37266-37267	,	_	
175-29	37268-37280	specifically	_	
175-30	37281-37287	during	_	
175-31	37288-37292	gain	_	
175-32	37293-37305	anticipation	_	
175-33	37306-37309	and	_	
175-34	37310-37312	in	_	
175-35	37313-37321	response	_	
175-36	37322-37324	to	_	
175-37	37325-37333	non-loss	_	
175-38	37334-37342	outcomes	_	
175-39	37342-37343	.	_	

#Text=This indicates that functional neuroimaging of task-based reward processes may provide novel insights to the effects of opioids on brain reward systems (and behavior) in chronic pain that would otherwise not be identified from non-imaging sources such as behavioral testing or questionnaires.
176-1	37344-37348	This	_	
176-2	37349-37358	indicates	_	
176-3	37359-37363	that	_	
176-4	37364-37374	functional	_	
176-5	37375-37387	neuroimaging	_	
176-6	37388-37390	of	_	
176-7	37391-37401	task-based	_	
176-8	37402-37408	reward	_	
176-9	37409-37418	processes	_	
176-10	37419-37422	may	_	
176-11	37423-37430	provide	_	
176-12	37431-37436	novel	_	
176-13	37437-37445	insights	_	
176-14	37446-37448	to	_	
176-15	37449-37452	the	_	
176-16	37453-37460	effects	_	
176-17	37461-37463	of	_	
176-18	37464-37471	opioids	_	
176-19	37472-37474	on	_	
176-20	37475-37480	brain	_	
176-21	37481-37487	reward	_	
176-22	37488-37495	systems	_	
176-23	37496-37497	(	_	
176-24	37497-37500	and	_	
176-25	37501-37509	behavior	_	
176-26	37509-37510	)	_	
176-27	37511-37513	in	_	
176-28	37514-37521	chronic	_	
176-29	37522-37526	pain	_	
176-30	37527-37531	that	_	
176-31	37532-37537	would	_	
176-32	37538-37547	otherwise	_	
176-33	37548-37551	not	_	
176-34	37552-37554	be	_	
176-35	37555-37565	identified	_	
176-36	37566-37570	from	_	
176-37	37571-37582	non-imaging	_	
176-38	37583-37590	sources	_	
176-39	37591-37595	such	_	
176-40	37596-37598	as	_	
176-41	37599-37609	behavioral	_	
176-42	37610-37617	testing	_	
176-43	37618-37620	or	_	
176-44	37621-37635	questionnaires	_	
176-45	37635-37636	.	_	

#Text=We observed significant relationships between MPFC fMRI activity and behavioral drive, along with other trend relationships for additional BAS questionnaire subscale measures.
177-1	37637-37639	We	_	
177-2	37640-37648	observed	_	
177-3	37649-37660	significant	_	
177-4	37661-37674	relationships	_	
177-5	37675-37682	between	_	
177-6	37683-37687	MPFC	_	
177-7	37688-37692	fMRI	_	
177-8	37693-37701	activity	_	
177-9	37702-37705	and	_	
177-10	37706-37716	behavioral	_	
177-11	37717-37722	drive	_	
177-12	37722-37723	,	_	
177-13	37724-37729	along	_	
177-14	37730-37734	with	_	
177-15	37735-37740	other	_	
177-16	37741-37746	trend	_	
177-17	37747-37760	relationships	_	
177-18	37761-37764	for	_	
177-19	37765-37775	additional	_	
177-20	37776-37779	BAS	_	
177-21	37780-37793	questionnaire	_	
177-22	37794-37802	subscale	_	
177-23	37803-37811	measures	_	
177-24	37811-37812	.	_	

#Text=Behavioral drive (and to a lesser extent, behavioral fun seeking) was positively correlated with MPFC non-loss outcome responses indicating that greater behavioral drive (and fun seeking) in the non-opioid fibromyalgia group may have contributed to heightened response to non-loss outcomes (i.e., non-punishment).
178-1	37813-37823	Behavioral	_	
178-2	37824-37829	drive	_	
178-3	37830-37831	(	_	
178-4	37831-37834	and	_	
178-5	37835-37837	to	_	
178-6	37838-37839	a	_	
178-7	37840-37846	lesser	_	
178-8	37847-37853	extent	_	
178-9	37853-37854	,	_	
178-10	37855-37865	behavioral	_	
178-11	37866-37869	fun	_	
178-12	37870-37877	seeking	_	
178-13	37877-37878	)	_	
178-14	37879-37882	was	_	
178-15	37883-37893	positively	_	
178-16	37894-37904	correlated	_	
178-17	37905-37909	with	_	
178-18	37910-37914	MPFC	_	
178-19	37915-37923	non-loss	_	
178-20	37924-37931	outcome	_	
178-21	37932-37941	responses	_	
178-22	37942-37952	indicating	_	
178-23	37953-37957	that	_	
178-24	37958-37965	greater	_	
178-25	37966-37976	behavioral	_	
178-26	37977-37982	drive	_	
178-27	37983-37984	(	_	
178-28	37984-37987	and	_	
178-29	37988-37991	fun	_	
178-30	37992-37999	seeking	_	
178-31	37999-38000	)	_	
178-32	38001-38003	in	_	
178-33	38004-38007	the	_	
178-34	38008-38018	non-opioid	_	
178-35	38019-38031	fibromyalgia	_	
178-36	38032-38037	group	_	
178-37	38038-38041	may	_	
178-38	38042-38046	have	_	
178-39	38047-38058	contributed	_	
178-40	38059-38061	to	_	
178-41	38062-38072	heightened	_	
178-42	38073-38081	response	_	
178-43	38082-38084	to	_	
178-44	38085-38093	non-loss	_	
178-45	38094-38102	outcomes	_	
178-46	38103-38104	(	_	
178-47	38104-38107	i.e	_	
178-48	38107-38108	.	_	
178-49	38108-38109	,	_	
178-50	38110-38124	non-punishment	_	
178-51	38124-38125	)	_	
178-52	38125-38126	.	_	

#Text=Meanwhile, the opioid fibromyalgia group showed less behavioral drive related to less MPFC non-loss outcome response.
179-1	38127-38136	Meanwhile	_	
179-2	38136-38137	,	_	
179-3	38138-38141	the	_	
179-4	38142-38148	opioid	_	
179-5	38149-38161	fibromyalgia	_	
179-6	38162-38167	group	_	
179-7	38168-38174	showed	_	
179-8	38175-38179	less	_	
179-9	38180-38190	behavioral	_	
179-10	38191-38196	drive	_	
179-11	38197-38204	related	_	
179-12	38205-38207	to	_	
179-13	38208-38212	less	_	
179-14	38213-38217	MPFC	_	
179-15	38218-38226	non-loss	_	
179-16	38227-38234	outcome	_	
179-17	38235-38243	response	_	
179-18	38243-38244	.	_	

#Text=From our uncorrected and exploratory analyses, behavioral reward responsiveness was correlated (uncorrected, p < 0.05) with MPFC gain anticipation response across the fibromyalgia groups and with opioid dose (morphine equivalent, uncorrected exploratory analyses p < 0.05) within the opioid fibromyalgia group.
180-1	38245-38249	From	_	
180-2	38250-38253	our	_	
180-3	38254-38265	uncorrected	_	
180-4	38266-38269	and	_	
180-5	38270-38281	exploratory	_	
180-6	38282-38290	analyses	_	
180-7	38290-38291	,	_	
180-8	38292-38302	behavioral	_	
180-9	38303-38309	reward	_	
180-10	38310-38324	responsiveness	_	
180-11	38325-38328	was	_	
180-12	38329-38339	correlated	_	
180-13	38340-38341	(	_	
180-14	38341-38352	uncorrected	_	
180-15	38352-38353	,	_	
180-16	38354-38355	p	_	
180-17	38356-38357	<	_	
180-18	38358-38362	0.05	_	
180-19	38362-38363	)	_	
180-20	38364-38368	with	_	
180-21	38369-38373	MPFC	_	
180-22	38374-38378	gain	_	
180-23	38379-38391	anticipation	_	
180-24	38392-38400	response	_	
180-25	38401-38407	across	_	
180-26	38408-38411	the	_	
180-27	38412-38424	fibromyalgia	_	
180-28	38425-38431	groups	_	
180-29	38432-38435	and	_	
180-30	38436-38440	with	_	
180-31	38441-38447	opioid	_	
180-32	38448-38452	dose	_	
180-33	38453-38454	(	_	
180-34	38454-38462	morphine	_	
180-35	38463-38473	equivalent	_	
180-36	38473-38474	,	_	
180-37	38475-38486	uncorrected	_	
180-38	38487-38498	exploratory	_	
180-39	38499-38507	analyses	_	
180-40	38508-38509	p	_	
180-41	38510-38511	<	_	
180-42	38512-38516	0.05	_	
180-43	38516-38517	)	_	
180-44	38518-38524	within	_	
180-45	38525-38528	the	_	
180-46	38529-38535	opioid	_	
180-47	38536-38548	fibromyalgia	_	
180-48	38549-38554	group	_	
180-49	38554-38555	.	_	

#Text=Thus, sensitivity to potential rewards appeared to be related to MPFC gain anticipation response and impacted by opioid use.
181-1	38556-38560	Thus	_	
181-2	38560-38561	,	_	
181-3	38562-38573	sensitivity	_	
181-4	38574-38576	to	_	
181-5	38577-38586	potential	_	
181-6	38587-38594	rewards	_	
181-7	38595-38603	appeared	_	
181-8	38604-38606	to	_	
181-9	38607-38609	be	_	
181-10	38610-38617	related	_	
181-11	38618-38620	to	_	
181-12	38621-38625	MPFC	_	
181-13	38626-38630	gain	_	
181-14	38631-38643	anticipation	_	
181-15	38644-38652	response	_	
181-16	38653-38656	and	_	
181-17	38657-38665	impacted	_	
181-18	38666-38668	by	_	
181-19	38669-38675	opioid	_	
181-20	38676-38679	use	_	
181-21	38679-38680	.	_	

#Text=Future analyses are needed, however, to confirm these exploratory and uncorrected findings.
182-1	38681-38687	Future	_	
182-2	38688-38696	analyses	_	
182-3	38697-38700	are	_	
182-4	38701-38707	needed	_	
182-5	38707-38708	,	_	
182-6	38709-38716	however	_	
182-7	38716-38717	,	_	
182-8	38718-38720	to	_	
182-9	38721-38728	confirm	_	
182-10	38729-38734	these	_	
182-11	38735-38746	exploratory	_	
182-12	38747-38750	and	_	
182-13	38751-38762	uncorrected	_	
182-14	38763-38771	findings	_	
182-15	38771-38772	.	_	

#Text=The MPFC plays a critical role in processing of memory and emotionally salient stimuli and is widely interconnected with a network of regions related to these processes (for review).
183-1	38773-38776	The	_	
183-2	38777-38781	MPFC	_	
183-3	38782-38787	plays	_	
183-4	38788-38789	a	_	
183-5	38790-38798	critical	_	
183-6	38799-38803	role	_	
183-7	38804-38806	in	_	
183-8	38807-38817	processing	_	
183-9	38818-38820	of	_	
183-10	38821-38827	memory	_	
183-11	38828-38831	and	_	
183-12	38832-38843	emotionally	_	
183-13	38844-38851	salient	_	
183-14	38852-38859	stimuli	_	
183-15	38860-38863	and	_	
183-16	38864-38866	is	_	
183-17	38867-38873	widely	_	
183-18	38874-38888	interconnected	_	
183-19	38889-38893	with	_	
183-20	38894-38895	a	_	
183-21	38896-38903	network	_	
183-22	38904-38906	of	_	
183-23	38907-38914	regions	_	
183-24	38915-38922	related	_	
183-25	38923-38925	to	_	
183-26	38926-38931	these	_	
183-27	38932-38941	processes	_	
183-28	38942-38943	(	_	
183-29	38943-38946	for	_	
183-30	38947-38953	review	_	
183-31	38953-38954	)	_	
183-32	38954-38955	.	_	

#Text=The altered MPFC response in fibromyalgia may be due to reduced expectation of positive outcomes (during gain anticipation) and enhanced responses to non-losses due to its involvement in predicting reward probability.
184-1	38956-38959	The	_	
184-2	38960-38967	altered	_	
184-3	38968-38972	MPFC	_	
184-4	38973-38981	response	_	
184-5	38982-38984	in	_	
184-6	38985-38997	fibromyalgia	_	
184-7	38998-39001	may	_	
184-8	39002-39004	be	_	
184-9	39005-39008	due	_	
184-10	39009-39011	to	_	
184-11	39012-39019	reduced	_	
184-12	39020-39031	expectation	_	
184-13	39032-39034	of	_	
184-14	39035-39043	positive	_	
184-15	39044-39052	outcomes	_	
184-16	39053-39054	(	_	
184-17	39054-39060	during	_	
184-18	39061-39065	gain	_	
184-19	39066-39078	anticipation	_	
184-20	39078-39079	)	_	
184-21	39080-39083	and	_	
184-22	39084-39092	enhanced	_	
184-23	39093-39102	responses	_	
184-24	39103-39105	to	_	
184-25	39106-39116	non-losses	_	
184-26	39117-39120	due	_	
184-27	39121-39123	to	_	
184-28	39124-39127	its	_	
184-29	39128-39139	involvement	_	
184-30	39140-39142	in	_	
184-31	39143-39153	predicting	_	
184-32	39154-39160	reward	_	
184-33	39161-39172	probability	_	
184-34	39172-39173	.	_	

#Text=Although unexpected, the findings of relatively normal MPFC activity (relative to controls) during gain anticipation and outcomes in the opioid fibromyalgia group suggests that these individuals may have higher expectations of positive outcomes (similar to controls, but in contrast to non-opioid fibromyalgia patients).
185-1	39174-39182	Although	_	
185-2	39183-39193	unexpected	_	
185-3	39193-39194	,	_	
185-4	39195-39198	the	_	
185-5	39199-39207	findings	_	
185-6	39208-39210	of	_	
185-7	39211-39221	relatively	_	
185-8	39222-39228	normal	_	
185-9	39229-39233	MPFC	_	
185-10	39234-39242	activity	_	
185-11	39243-39244	(	_	
185-12	39244-39252	relative	_	
185-13	39253-39255	to	_	
185-14	39256-39264	controls	_	
185-15	39264-39265	)	_	
185-16	39266-39272	during	_	
185-17	39273-39277	gain	_	
185-18	39278-39290	anticipation	_	
185-19	39291-39294	and	_	
185-20	39295-39303	outcomes	_	
185-21	39304-39306	in	_	
185-22	39307-39310	the	_	
185-23	39311-39317	opioid	_	
185-24	39318-39330	fibromyalgia	_	
185-25	39331-39336	group	_	
185-26	39337-39345	suggests	_	
185-27	39346-39350	that	_	
185-28	39351-39356	these	_	
185-29	39357-39368	individuals	_	
185-30	39369-39372	may	_	
185-31	39373-39377	have	_	
185-32	39378-39384	higher	_	
185-33	39385-39397	expectations	_	
185-34	39398-39400	of	_	
185-35	39401-39409	positive	_	
185-36	39410-39418	outcomes	_	
185-37	39419-39420	(	_	
185-38	39420-39427	similar	_	
185-39	39428-39430	to	_	
185-40	39431-39439	controls	_	
185-41	39439-39440	,	_	
185-42	39441-39444	but	_	
185-43	39445-39447	in	_	
185-44	39448-39456	contrast	_	
185-45	39457-39459	to	_	
185-46	39460-39470	non-opioid	_	
185-47	39471-39483	fibromyalgia	_	
185-48	39484-39492	patients	_	
185-49	39492-39493	)	_	
185-50	39493-39494	.	_	

#Text=If so, this could be due to the effects of opioid medication on brain reward systems or pre-existing factors–future investigations are needed to determine the relative contributions of actual opioid use/drug effects versus opioid preference/individual differences.
186-1	39495-39497	If	_	
186-2	39498-39500	so	_	
186-3	39500-39501	,	_	
186-4	39502-39506	this	_	
186-5	39507-39512	could	_	
186-6	39513-39515	be	_	
186-7	39516-39519	due	_	
186-8	39520-39522	to	_	
186-9	39523-39526	the	_	
186-10	39527-39534	effects	_	
186-11	39535-39537	of	_	
186-12	39538-39544	opioid	_	
186-13	39545-39555	medication	_	
186-14	39556-39558	on	_	
186-15	39559-39564	brain	_	
186-16	39565-39571	reward	_	
186-17	39572-39579	systems	_	
186-18	39580-39582	or	_	
186-19	39583-39595	pre-existing	_	
186-20	39596-39610	factors–future	_	
186-21	39611-39625	investigations	_	
186-22	39626-39629	are	_	
186-23	39630-39636	needed	_	
186-24	39637-39639	to	_	
186-25	39640-39649	determine	_	
186-26	39650-39653	the	_	
186-27	39654-39662	relative	_	
186-28	39663-39676	contributions	_	
186-29	39677-39679	of	_	
186-30	39680-39686	actual	_	
186-31	39687-39693	opioid	_	
186-32	39694-39697	use	_	
186-33	39697-39698	/	_	
186-34	39698-39702	drug	_	
186-35	39703-39710	effects	_	
186-36	39711-39717	versus	_	
186-37	39718-39724	opioid	_	
186-38	39725-39735	preference	_	
186-39	39735-39736	/	_	
186-40	39736-39746	individual	_	
186-41	39747-39758	differences	_	
186-42	39758-39759	.	_	

#Text=Multiple factors could influence the group differences in neural responses to incentives beyond those studied presently.
187-1	39760-39768	Multiple	_	
187-2	39769-39776	factors	_	
187-3	39777-39782	could	_	
187-4	39783-39792	influence	_	
187-5	39793-39796	the	_	
187-6	39797-39802	group	_	
187-7	39803-39814	differences	_	
187-8	39815-39817	in	_	
187-9	39818-39824	neural	_	
187-10	39825-39834	responses	_	
187-11	39835-39837	to	_	
187-12	39838-39848	incentives	_	
187-13	39849-39855	beyond	_	
187-14	39856-39861	those	_	
187-15	39862-39869	studied	_	
187-16	39870-39879	presently	_	
187-17	39879-39880	.	_	

#Text=Widespread pain is the predominant symptom of fibromyalgia, and although we measured the distribution, severity, and interference of pain symptoms across the fibromyalgia groups, these were not significantly different between fibromyalgia groups or correlated with neuroimaging findings.
188-1	39881-39891	Widespread	_	
188-2	39892-39896	pain	_	
188-3	39897-39899	is	_	
188-4	39900-39903	the	_	
188-5	39904-39915	predominant	_	
188-6	39916-39923	symptom	_	
188-7	39924-39926	of	_	
188-8	39927-39939	fibromyalgia	_	
188-9	39939-39940	,	_	
188-10	39941-39944	and	_	
188-11	39945-39953	although	_	
188-12	39954-39956	we	_	
188-13	39957-39965	measured	_	
188-14	39966-39969	the	_	
188-15	39970-39982	distribution	_	
188-16	39982-39983	,	_	
188-17	39984-39992	severity	_	
188-18	39992-39993	,	_	
188-19	39994-39997	and	_	
188-20	39998-40010	interference	_	
188-21	40011-40013	of	_	
188-22	40014-40018	pain	_	
188-23	40019-40027	symptoms	_	
188-24	40028-40034	across	_	
188-25	40035-40038	the	_	
188-26	40039-40051	fibromyalgia	_	
188-27	40052-40058	groups	_	
188-28	40058-40059	,	_	
188-29	40060-40065	these	_	
188-30	40066-40070	were	_	
188-31	40071-40074	not	_	
188-32	40075-40088	significantly	_	
188-33	40089-40098	different	_	
188-34	40099-40106	between	_	
188-35	40107-40119	fibromyalgia	_	
188-36	40120-40126	groups	_	
188-37	40127-40129	or	_	
188-38	40130-40140	correlated	_	
188-39	40141-40145	with	_	
188-40	40146-40158	neuroimaging	_	
188-41	40159-40167	findings	_	
188-42	40167-40168	.	_	

#Text=Cognitive symptoms are also present in fibromyalgia, but we did not directly assess cognition, which has been noted to be further impaired by opioids in chronic pain.
189-1	40169-40178	Cognitive	_	
189-2	40179-40187	symptoms	_	
189-3	40188-40191	are	_	
189-4	40192-40196	also	_	
189-5	40197-40204	present	_	
189-6	40205-40207	in	_	
189-7	40208-40220	fibromyalgia	_	
189-8	40220-40221	,	_	
189-9	40222-40225	but	_	
189-10	40226-40228	we	_	
189-11	40229-40232	did	_	
189-12	40233-40236	not	_	
189-13	40237-40245	directly	_	
189-14	40246-40252	assess	_	
189-15	40253-40262	cognition	_	
189-16	40262-40263	,	_	
189-17	40264-40269	which	_	
189-18	40270-40273	has	_	
189-19	40274-40278	been	_	
189-20	40279-40284	noted	_	
189-21	40285-40287	to	_	
189-22	40288-40290	be	_	
189-23	40291-40298	further	_	
189-24	40299-40307	impaired	_	
189-25	40308-40310	by	_	
189-26	40311-40318	opioids	_	
189-27	40319-40321	in	_	
189-28	40322-40329	chronic	_	
189-29	40330-40334	pain	_	
189-30	40334-40335	.	_	

#Text=However, task performance (e.g., arousal, reaction time, and accuracy) was comparable between the fibromyalgia groups and controls, indicating minimal effects of cognitive impairments on the MID task.
190-1	40336-40343	However	_	
190-2	40343-40344	,	_	
190-3	40345-40349	task	_	
190-4	40350-40361	performance	_	
190-5	40362-40363	(	_	
190-6	40363-40366	e.g	_	
190-7	40366-40367	.	_	
190-8	40367-40368	,	_	
190-9	40369-40376	arousal	_	
190-10	40376-40377	,	_	
190-11	40378-40386	reaction	_	
190-12	40387-40391	time	_	
190-13	40391-40392	,	_	
190-14	40393-40396	and	_	
190-15	40397-40405	accuracy	_	
190-16	40405-40406	)	_	
190-17	40407-40410	was	_	
190-18	40411-40421	comparable	_	
190-19	40422-40429	between	_	
190-20	40430-40433	the	_	
190-21	40434-40446	fibromyalgia	_	
190-22	40447-40453	groups	_	
190-23	40454-40457	and	_	
190-24	40458-40466	controls	_	
190-25	40466-40467	,	_	
190-26	40468-40478	indicating	_	
190-27	40479-40486	minimal	_	
190-28	40487-40494	effects	_	
190-29	40495-40497	of	_	
190-30	40498-40507	cognitive	_	
190-31	40508-40519	impairments	_	
190-32	40520-40522	on	_	
190-33	40523-40526	the	_	
190-34	40527-40530	MID	_	
190-35	40531-40535	task	_	
190-36	40535-40536	.	_	

#Text=Additionally, fatigue was slightly greater in the opioid fibromyalgia group (assessed by Tukey post-hoc t-test, though not significant) and could have contributed to differences in neural responses to incentives.
191-1	40537-40549	Additionally	_	
191-2	40549-40550	,	_	
191-3	40551-40558	fatigue	_	
191-4	40559-40562	was	_	
191-5	40563-40571	slightly	_	
191-6	40572-40579	greater	_	
191-7	40580-40582	in	_	
191-8	40583-40586	the	_	
191-9	40587-40593	opioid	_	
191-10	40594-40606	fibromyalgia	_	
191-11	40607-40612	group	_	
191-12	40613-40614	(	_	
191-13	40614-40622	assessed	_	
191-14	40623-40625	by	_	
191-15	40626-40631	Tukey	_	
191-16	40632-40640	post-hoc	_	
191-17	40641-40647	t-test	_	
191-18	40647-40648	,	_	
191-19	40649-40655	though	_	
191-20	40656-40659	not	_	
191-21	40660-40671	significant	_	
191-22	40671-40672	)	_	
191-23	40673-40676	and	_	
191-24	40677-40682	could	_	
191-25	40683-40687	have	_	
191-26	40688-40699	contributed	_	
191-27	40700-40702	to	_	
191-28	40703-40714	differences	_	
191-29	40715-40717	in	_	
191-30	40718-40724	neural	_	
191-31	40725-40734	responses	_	
191-32	40735-40737	to	_	
191-33	40738-40748	incentives	_	
191-34	40748-40749	.	_	

#Text=The different neural responses between the non-opioid and opioid fibromyalgia groups could be due to several interacting factors across multiple psychological and neurophysiological domains.
192-1	40750-40753	The	_	
192-2	40754-40763	different	_	
192-3	40764-40770	neural	_	
192-4	40771-40780	responses	_	
192-5	40781-40788	between	_	
192-6	40789-40792	the	_	
192-7	40793-40803	non-opioid	_	
192-8	40804-40807	and	_	
192-9	40808-40814	opioid	_	
192-10	40815-40827	fibromyalgia	_	
192-11	40828-40834	groups	_	
192-12	40835-40840	could	_	
192-13	40841-40843	be	_	
192-14	40844-40847	due	_	
192-15	40848-40850	to	_	
192-16	40851-40858	several	_	
192-17	40859-40870	interacting	_	
192-18	40871-40878	factors	_	
192-19	40879-40885	across	_	
192-20	40886-40894	multiple	_	
192-21	40895-40908	psychological	_	
192-22	40909-40912	and	_	
192-23	40913-40931	neurophysiological	_	
192-24	40932-40939	domains	_	
192-25	40939-40940	.	_	

#Text=Expectations, shaped by both prior experiences and environment, can strongly contribute to different responses to medications and preferences for different types of medications.
193-1	40941-40953	Expectations	_	
193-2	40953-40954	,	_	
193-3	40955-40961	shaped	_	
193-4	40962-40964	by	_	
193-5	40965-40969	both	_	
193-6	40970-40975	prior	_	
193-7	40976-40987	experiences	_	
193-8	40988-40991	and	_	
193-9	40992-41003	environment	_	
193-10	41003-41004	,	_	
193-11	41005-41008	can	_	
193-12	41009-41017	strongly	_	
193-13	41018-41028	contribute	_	
193-14	41029-41031	to	_	
193-15	41032-41041	different	_	
193-16	41042-41051	responses	_	
193-17	41052-41054	to	_	
193-18	41055-41066	medications	_	
193-19	41067-41070	and	_	
193-20	41071-41082	preferences	_	
193-21	41083-41086	for	_	
193-22	41087-41096	different	_	
193-23	41097-41102	types	_	
193-24	41103-41105	of	_	
193-25	41106-41117	medications	_	
193-26	41117-41118	.	_	

#Text=A randomized controlled trial of individuals with musculoskeletal pain to take opioids or not take opioids for 12-months identified that outcomes were similar across both groups, but expectations and experiences throughout the trial shaped patient responses to medications.
194-1	41119-41120	A	_	
194-2	41121-41131	randomized	_	
194-3	41132-41142	controlled	_	
194-4	41143-41148	trial	_	
194-5	41149-41151	of	_	
194-6	41152-41163	individuals	_	
194-7	41164-41168	with	_	
194-8	41169-41184	musculoskeletal	_	
194-9	41185-41189	pain	_	
194-10	41190-41192	to	_	
194-11	41193-41197	take	_	
194-12	41198-41205	opioids	_	
194-13	41206-41208	or	_	
194-14	41209-41212	not	_	
194-15	41213-41217	take	_	
194-16	41218-41225	opioids	_	
194-17	41226-41229	for	_	
194-18	41230-41232	12	_	
194-19	41232-41233	-	_	
194-20	41233-41239	months	_	
194-21	41240-41250	identified	_	
194-22	41251-41255	that	_	
194-23	41256-41264	outcomes	_	
194-24	41265-41269	were	_	
194-25	41270-41277	similar	_	
194-26	41278-41284	across	_	
194-27	41285-41289	both	_	
194-28	41290-41296	groups	_	
194-29	41296-41297	,	_	
194-30	41298-41301	but	_	
194-31	41302-41314	expectations	_	
194-32	41315-41318	and	_	
194-33	41319-41330	experiences	_	
194-34	41331-41341	throughout	_	
194-35	41342-41345	the	_	
194-36	41346-41351	trial	_	
194-37	41352-41358	shaped	_	
194-38	41359-41366	patient	_	
194-39	41367-41376	responses	_	
194-40	41377-41379	to	_	
194-41	41380-41391	medications	_	
194-42	41391-41392	.	_	

#Text=Thus, even the differences in neural responses to incentives observed across the opioid and non-opioid fibromyalgia groups could have resulted from different psychological, behavioral, and emotional networks formed prior to opioid use.
195-1	41393-41397	Thus	_	
195-2	41397-41398	,	_	
195-3	41399-41403	even	_	
195-4	41404-41407	the	_	
195-5	41408-41419	differences	_	
195-6	41420-41422	in	_	
195-7	41423-41429	neural	_	
195-8	41430-41439	responses	_	
195-9	41440-41442	to	_	
195-10	41443-41453	incentives	_	
195-11	41454-41462	observed	_	
195-12	41463-41469	across	_	
195-13	41470-41473	the	_	
195-14	41474-41480	opioid	_	
195-15	41481-41484	and	_	
195-16	41485-41495	non-opioid	_	
195-17	41496-41508	fibromyalgia	_	
195-18	41509-41515	groups	_	
195-19	41516-41521	could	_	
195-20	41522-41526	have	_	
195-21	41527-41535	resulted	_	
195-22	41536-41540	from	_	
195-23	41541-41550	different	_	
195-24	41551-41564	psychological	_	
195-25	41564-41565	,	_	
195-26	41566-41576	behavioral	_	
195-27	41576-41577	,	_	
195-28	41578-41581	and	_	
195-29	41582-41591	emotional	_	
195-30	41592-41600	networks	_	
195-31	41601-41607	formed	_	
195-32	41608-41613	prior	_	
195-33	41614-41616	to	_	
195-34	41617-41623	opioid	_	
195-35	41624-41627	use	_	
195-36	41627-41628	.	_	

#Text=However, the exploratory correlation between opioid dose and behavioral reward responsiveness suggests that the actual use of opioids in our cohort may contribute to the different neural responses to reward.
196-1	41629-41636	However	_	
196-2	41636-41637	,	_	
196-3	41638-41641	the	_	
196-4	41642-41653	exploratory	_	
196-5	41654-41665	correlation	_	
196-6	41666-41673	between	_	
196-7	41674-41680	opioid	_	
196-8	41681-41685	dose	_	
196-9	41686-41689	and	_	
196-10	41690-41700	behavioral	_	
196-11	41701-41707	reward	_	
196-12	41708-41722	responsiveness	_	
196-13	41723-41731	suggests	_	
196-14	41732-41736	that	_	
196-15	41737-41740	the	_	
196-16	41741-41747	actual	_	
196-17	41748-41751	use	_	
196-18	41752-41754	of	_	
196-19	41755-41762	opioids	_	
196-20	41763-41765	in	_	
196-21	41766-41769	our	_	
196-22	41770-41776	cohort	_	
196-23	41777-41780	may	_	
196-24	41781-41791	contribute	_	
196-25	41792-41794	to	_	
196-26	41795-41798	the	_	
196-27	41799-41808	different	_	
196-28	41809-41815	neural	_	
196-29	41816-41825	responses	_	
196-30	41826-41828	to	_	
196-31	41829-41835	reward	_	
196-32	41835-41836	.	_	

#Text=Additional limitations include: 1) a lack of validation of opioid dose, 2) the use of more non-opioid medications in the opioid group (N.B. we have found it challenging to recruit sufficient fibromyalgia patients who were only taking opioids), 3) the possibility that the observed group differences might result from variability in fibromyalgia patients, and 4) modest sample size which limits our ability to identify associations of fMRI with behavioral data.
197-1	41837-41847	Additional	_	
197-2	41848-41859	limitations	_	
197-3	41860-41867	include	_	
197-4	41867-41868	:	_	
197-5	41869-41870	1	_	
197-6	41870-41871	)	_	
197-7	41872-41873	a	_	
197-8	41874-41878	lack	_	
197-9	41879-41881	of	_	
197-10	41882-41892	validation	_	
197-11	41893-41895	of	_	
197-12	41896-41902	opioid	_	
197-13	41903-41907	dose	_	
197-14	41907-41908	,	_	
197-15	41909-41910	2	_	
197-16	41910-41911	)	_	
197-17	41912-41915	the	_	
197-18	41916-41919	use	_	
197-19	41920-41922	of	_	
197-20	41923-41927	more	_	
197-21	41928-41938	non-opioid	_	
197-22	41939-41950	medications	_	
197-23	41951-41953	in	_	
197-24	41954-41957	the	_	
197-25	41958-41964	opioid	_	
197-26	41965-41970	group	_	
197-27	41971-41972	(	_	
197-28	41972-41975	N.B	_	
197-29	41975-41976	.	_	
197-30	41977-41979	we	_	
197-31	41980-41984	have	_	
197-32	41985-41990	found	_	
197-33	41991-41993	it	_	
197-34	41994-42005	challenging	_	
197-35	42006-42008	to	_	
197-36	42009-42016	recruit	_	
197-37	42017-42027	sufficient	_	
197-38	42028-42040	fibromyalgia	_	
197-39	42041-42049	patients	_	
197-40	42050-42053	who	_	
197-41	42054-42058	were	_	
197-42	42059-42063	only	_	
197-43	42064-42070	taking	_	
197-44	42071-42078	opioids	_	
197-45	42078-42079	)	_	
197-46	42079-42080	,	_	
197-47	42081-42082	3	_	
197-48	42082-42083	)	_	
197-49	42084-42087	the	_	
197-50	42088-42099	possibility	_	
197-51	42100-42104	that	_	
197-52	42105-42108	the	_	
197-53	42109-42117	observed	_	
197-54	42118-42123	group	_	
197-55	42124-42135	differences	_	
197-56	42136-42141	might	_	
197-57	42142-42148	result	_	
197-58	42149-42153	from	_	
197-59	42154-42165	variability	_	
197-60	42166-42168	in	_	
197-61	42169-42181	fibromyalgia	_	
197-62	42182-42190	patients	_	
197-63	42190-42191	,	_	
197-64	42192-42195	and	_	
197-65	42196-42197	4	_	
197-66	42197-42198	)	_	
197-67	42199-42205	modest	_	
197-68	42206-42212	sample	_	
197-69	42213-42217	size	_	
197-70	42218-42223	which	_	
197-71	42224-42230	limits	_	
197-72	42231-42234	our	_	
197-73	42235-42242	ability	_	
197-74	42243-42245	to	_	
197-75	42246-42254	identify	_	
197-76	42255-42267	associations	_	
197-77	42268-42270	of	_	
197-78	42271-42275	fMRI	_	
197-79	42276-42280	with	_	
197-80	42281-42291	behavioral	_	
197-81	42292-42296	data	_	
197-82	42296-42297	.	_	

#Text=Future studies investigating changes in neural responses to incentives may advance our understanding of how opioids influence human incentive processing and, in turn, the quality of life in chronic pain.
198-1	42298-42304	Future	_	
198-2	42305-42312	studies	_	
198-3	42313-42326	investigating	_	
198-4	42327-42334	changes	_	
198-5	42335-42337	in	_	
198-6	42338-42344	neural	_	
198-7	42345-42354	responses	_	
198-8	42355-42357	to	_	
198-9	42358-42368	incentives	_	
198-10	42369-42372	may	_	
198-11	42373-42380	advance	_	
198-12	42381-42384	our	_	
198-13	42385-42398	understanding	_	
198-14	42399-42401	of	_	
198-15	42402-42405	how	_	
198-16	42406-42413	opioids	_	
198-17	42414-42423	influence	_	
198-18	42424-42429	human	_	
198-19	42430-42439	incentive	_	
198-20	42440-42450	processing	_	
198-21	42451-42454	and	_	
198-22	42454-42455	,	_	
198-23	42456-42458	in	_	
198-24	42459-42463	turn	_	
198-25	42463-42464	,	_	
198-26	42465-42468	the	_	
198-27	42469-42476	quality	_	
198-28	42477-42479	of	_	
198-29	42480-42484	life	_	
198-30	42485-42487	in	_	
198-31	42488-42495	chronic	_	
198-32	42496-42500	pain	_	
198-33	42500-42501	.	_	

#Text=Together, these preliminary data suggest that neural responses to monetary incentives differ between individuals with fibromyalgia who are not taking versus taking opioid medications.
199-1	42502-42510	Together	_	
199-2	42510-42511	,	_	
199-3	42512-42517	these	_	
199-4	42518-42529	preliminary	_	
199-5	42530-42534	data	_	
199-6	42535-42542	suggest	_	
199-7	42543-42547	that	_	
199-8	42548-42554	neural	_	
199-9	42555-42564	responses	_	
199-10	42565-42567	to	_	
199-11	42568-42576	monetary	_	
199-12	42577-42587	incentives	_	
199-13	42588-42594	differ	_	
199-14	42595-42602	between	_	
199-15	42603-42614	individuals	_	
199-16	42615-42619	with	_	
199-17	42620-42632	fibromyalgia	_	
199-18	42633-42636	who	_	
199-19	42637-42640	are	_	
199-20	42641-42644	not	_	
199-21	42645-42651	taking	_	
199-22	42652-42658	versus	_	
199-23	42659-42665	taking	_	
199-24	42666-42672	opioid	_	
199-25	42673-42684	medications	_	
199-26	42684-42685	.	_	

#Text=The relatively “normalized” MPFC response to anticipated rewards and non-punishments in individuals with fibromyalgia taking opioids may relate to opioids’ ability to positively influence hedonic experience in chronic pain (i.e., or the belief of individuals with fibromyalgia that they benefit from opioid use), despite other potentially negative influences of long-term opioid use on chronic pain.
200-1	42686-42689	The	_	
200-2	42690-42700	relatively	_	
200-3	42701-42702	“	_	
200-4	42702-42712	normalized	_	
200-5	42712-42713	”	_	
200-6	42714-42718	MPFC	_	
200-7	42719-42727	response	_	
200-8	42728-42730	to	_	
200-9	42731-42742	anticipated	_	
200-10	42743-42750	rewards	_	
200-11	42751-42754	and	_	
200-12	42755-42770	non-punishments	_	
200-13	42771-42773	in	_	
200-14	42774-42785	individuals	_	
200-15	42786-42790	with	_	
200-16	42791-42803	fibromyalgia	_	
200-17	42804-42810	taking	_	
200-18	42811-42818	opioids	_	
200-19	42819-42822	may	_	
200-20	42823-42829	relate	_	
200-21	42830-42832	to	_	
200-22	42833-42840	opioids	_	
200-23	42840-42841	’	_	
200-24	42842-42849	ability	_	
200-25	42850-42852	to	_	
200-26	42853-42863	positively	_	
200-27	42864-42873	influence	_	
200-28	42874-42881	hedonic	_	
200-29	42882-42892	experience	_	
200-30	42893-42895	in	_	
200-31	42896-42903	chronic	_	
200-32	42904-42908	pain	_	
200-33	42909-42910	(	_	
200-34	42910-42913	i.e	_	
200-35	42913-42914	.	_	
200-36	42914-42915	,	_	
200-37	42916-42918	or	_	
200-38	42919-42922	the	_	
200-39	42923-42929	belief	_	
200-40	42930-42932	of	_	
200-41	42933-42944	individuals	_	
200-42	42945-42949	with	_	
200-43	42950-42962	fibromyalgia	_	
200-44	42963-42967	that	_	
200-45	42968-42972	they	_	
200-46	42973-42980	benefit	_	
200-47	42981-42985	from	_	
200-48	42986-42992	opioid	_	
200-49	42993-42996	use	_	
200-50	42996-42997	)	_	
200-51	42997-42998	,	_	
200-52	42999-43006	despite	_	
200-53	43007-43012	other	_	
200-54	43013-43024	potentially	_	
200-55	43025-43033	negative	_	
200-56	43034-43044	influences	_	
200-57	43045-43047	of	_	
200-58	43048-43057	long-term	_	
200-59	43058-43064	opioid	_	
200-60	43065-43068	use	_	
200-61	43069-43071	on	_	
200-62	43072-43079	chronic	_	
200-63	43080-43084	pain	_	
200-64	43084-43085	.	_	

#Text=Based on the current debate on the utility of opioids for long-term management of chronic pain, these findings may be controversial.
201-1	43086-43091	Based	_	
201-2	43092-43094	on	_	
201-3	43095-43098	the	_	
201-4	43099-43106	current	_	
201-5	43107-43113	debate	_	
201-6	43114-43116	on	_	
201-7	43117-43120	the	_	
201-8	43121-43128	utility	_	
201-9	43129-43131	of	_	
201-10	43132-43139	opioids	_	
201-11	43140-43143	for	_	
201-12	43144-43153	long-term	_	
201-13	43154-43164	management	_	
201-14	43165-43167	of	_	
201-15	43168-43175	chronic	_	
201-16	43176-43180	pain	_	
201-17	43180-43181	,	_	
201-18	43182-43187	these	_	
201-19	43188-43196	findings	_	
201-20	43197-43200	may	_	
201-21	43201-43203	be	_	
201-22	43204-43217	controversial	_	
201-23	43217-43218	.	_	

#Text=We therefore encourage readers not to extrapolate these findings to suggest that opioids may, or may not, be of value in the treatment of fibromyalgia.
202-1	43219-43221	We	_	
202-2	43222-43231	therefore	_	
202-3	43232-43241	encourage	_	
202-4	43242-43249	readers	_	
202-5	43250-43253	not	_	
202-6	43254-43256	to	_	
202-7	43257-43268	extrapolate	_	
202-8	43269-43274	these	_	
202-9	43275-43283	findings	_	
202-10	43284-43286	to	_	
202-11	43287-43294	suggest	_	
202-12	43295-43299	that	_	
202-13	43300-43307	opioids	_	
202-14	43308-43311	may	_	
202-15	43311-43312	,	_	
202-16	43313-43315	or	_	
202-17	43316-43319	may	_	
202-18	43320-43323	not	_	
202-19	43323-43324	,	_	
202-20	43325-43327	be	_	
202-21	43328-43330	of	_	
202-22	43331-43336	value	_	
202-23	43337-43339	in	_	
202-24	43340-43343	the	_	
202-25	43344-43353	treatment	_	
202-26	43354-43356	of	_	
202-27	43357-43369	fibromyalgia	_	
202-28	43369-43370	.	_	

#Text=Methods
#Text=Participants
#Text=Thirty-seven females with fibromyalgia and 17 healthy females participated in the study.
203-1	43371-43378	Methods	_	
203-2	43379-43391	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-3	43392-43404	Thirty-seven	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-4	43405-43412	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-5	43413-43417	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-6	43418-43430	fibromyalgia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-7	43431-43434	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-8	43435-43437	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-9	43438-43445	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-10	43446-43453	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-11	43454-43466	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-12	43467-43469	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-13	43470-43473	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-14	43474-43479	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
203-15	43479-43480	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=All fibromyalgia participants met the following inclusion criteria: American College of Rheumatology (ACR) 2011 criteria for fibromyalgia [(1) widespread pain index (WPI) score ≥ 7 + symptom severity (SS) score ≥ 5, or WPI score 3–6 + SS score ≥ 9, (2) similar level of symptoms present for at least 3 months, (3) no disorder to otherwise explain the pain], pain in 4 body quadrants, previous month average pain score of at least 2 (0–10 verbal scale), not pregnant or nursing, no MRI contraindications (e.g., claustrophobia, metal in body), and no uncontrolled depression or anxiety.
204-1	43481-43484	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-2	43485-43497	fibromyalgia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-3	43498-43510	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-4	43511-43514	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-5	43515-43518	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-6	43519-43528	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-7	43529-43538	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-8	43539-43547	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-9	43547-43548	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-10	43549-43557	American	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-11	43558-43565	College	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-12	43566-43568	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-13	43569-43581	Rheumatology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-14	43582-43583	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-15	43583-43586	ACR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-16	43586-43587	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-17	43588-43592	2011	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-18	43593-43601	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-19	43602-43605	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-20	43606-43618	fibromyalgia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-21	43619-43620	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-22	43620-43621	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-23	43621-43622	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-24	43622-43623	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-25	43624-43634	widespread	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-26	43635-43639	pain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-27	43640-43645	index	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-28	43646-43647	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-29	43647-43650	WPI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-30	43650-43651	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-31	43652-43657	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-32	43658-43659	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-33	43660-43661	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-34	43662-43663	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-35	43664-43671	symptom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-36	43672-43680	severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-37	43681-43682	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-38	43682-43684	SS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-39	43684-43685	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-40	43686-43691	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-41	43692-43693	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-42	43694-43695	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-43	43695-43696	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-44	43697-43699	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-45	43700-43703	WPI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-46	43704-43709	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-47	43710-43711	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-48	43711-43712	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-49	43712-43713	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-50	43714-43715	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-51	43716-43718	SS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-52	43719-43724	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-53	43725-43726	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-54	43727-43728	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-55	43728-43729	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-56	43730-43731	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-57	43731-43732	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-58	43732-43733	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-59	43734-43741	similar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-60	43742-43747	level	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-61	43748-43750	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-62	43751-43759	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-63	43760-43767	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-64	43768-43771	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-65	43772-43774	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-66	43775-43780	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-67	43781-43782	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-68	43783-43789	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-69	43789-43790	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-70	43791-43792	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-71	43792-43793	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-72	43793-43794	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-73	43795-43797	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-74	43798-43806	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-75	43807-43809	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-76	43810-43819	otherwise	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-77	43820-43827	explain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-78	43828-43831	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-79	43832-43836	pain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-80	43836-43837	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-81	43837-43838	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-82	43839-43843	pain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-83	43844-43846	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-84	43847-43848	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-85	43849-43853	body	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-86	43854-43863	quadrants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-87	43863-43864	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-88	43865-43873	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-89	43874-43879	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-90	43880-43887	average	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-91	43888-43892	pain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-92	43893-43898	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-93	43899-43901	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-94	43902-43904	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-95	43905-43910	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-96	43911-43912	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-97	43913-43914	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-98	43914-43915	0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-99	43915-43916	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-100	43916-43918	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-101	43919-43925	verbal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-102	43926-43931	scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-103	43931-43932	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-104	43932-43933	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-105	43934-43937	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-106	43938-43946	pregnant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-107	43947-43949	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-108	43950-43957	nursing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-109	43957-43958	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-110	43959-43961	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-111	43962-43965	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-112	43966-43983	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-113	43984-43985	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-114	43985-43988	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-115	43988-43989	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-116	43989-43990	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-117	43991-44005	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-118	44005-44006	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-119	44007-44012	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-120	44013-44015	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-121	44016-44020	body	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-122	44020-44021	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-123	44021-44022	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-124	44023-44026	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-125	44027-44029	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-126	44030-44042	uncontrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-127	44043-44053	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-128	44054-44056	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-129	44057-44064	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
204-130	44064-44065	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=All fibromyalgia participants were allowed to continue their normal use of medications during the study.
205-1	44066-44069	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-2	44070-44082	fibromyalgia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-3	44083-44095	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-4	44096-44100	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-5	44101-44108	allowed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-6	44109-44111	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-7	44112-44120	continue	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-8	44121-44126	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-9	44127-44133	normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-10	44134-44137	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-11	44138-44140	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-12	44141-44152	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-13	44153-44159	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-14	44160-44163	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-15	44164-44169	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
205-16	44169-44170	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=To be included in the non-opioid fibromyalgia group, individuals were not to be taking opioids as part of their treatment, not to have taken any opioids during the 90 days prior to study participation, and never to have taken opioids for a period greater than 30 days.
206-1	44171-44173	To	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-2	44174-44176	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-3	44177-44185	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-4	44186-44188	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-5	44189-44192	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-6	44193-44203	non-opioid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-7	44204-44216	fibromyalgia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-8	44217-44222	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-9	44222-44223	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-10	44224-44235	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-11	44236-44240	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-12	44241-44244	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-13	44245-44247	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-14	44248-44250	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-15	44251-44257	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-16	44258-44265	opioids	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-17	44266-44268	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-18	44269-44273	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-19	44274-44276	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-20	44277-44282	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-21	44283-44292	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-22	44292-44293	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-23	44294-44297	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-24	44298-44300	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-25	44301-44305	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-26	44306-44311	taken	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-27	44312-44315	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-28	44316-44323	opioids	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-29	44324-44330	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-30	44331-44334	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-31	44335-44337	90	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-32	44338-44342	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-33	44343-44348	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-34	44349-44351	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-35	44352-44357	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-36	44358-44371	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-37	44371-44372	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-38	44373-44376	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-39	44377-44382	never	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-40	44383-44385	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-41	44386-44390	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-42	44391-44396	taken	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-43	44397-44404	opioids	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-44	44405-44408	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-45	44409-44410	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-46	44411-44417	period	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-47	44418-44425	greater	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-48	44426-44430	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-49	44431-44433	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-50	44434-44438	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
206-51	44438-44439	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=To be included in the opioid fibromyalgia group, individuals were required to be have been taking opioid medications as part of their treatment for at least 3 months and at the time of study participation.
207-1	44440-44442	To	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-2	44443-44445	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-3	44446-44454	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-4	44455-44457	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-5	44458-44461	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-6	44462-44468	opioid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-7	44469-44481	fibromyalgia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-8	44482-44487	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-9	44487-44488	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-10	44489-44500	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-11	44501-44505	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-12	44506-44514	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-13	44515-44517	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-14	44518-44520	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-15	44521-44525	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-16	44526-44530	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-17	44531-44537	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-18	44538-44544	opioid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-19	44545-44556	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-20	44557-44559	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-21	44560-44564	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-22	44565-44567	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-23	44568-44573	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-24	44574-44583	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-25	44584-44587	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-26	44588-44590	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-27	44591-44596	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-28	44597-44598	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-29	44599-44605	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-30	44606-44609	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-31	44610-44612	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-32	44613-44616	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-33	44617-44621	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-34	44622-44624	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-35	44625-44630	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-36	44631-44644	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
207-37	44644-44645	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=Control participants were required to not have chronic pain, not be pregnant or nursing, have no MRI contraindications, and have no depression or anxiety.
208-1	44646-44653	Control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-2	44654-44666	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-3	44667-44671	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-4	44672-44680	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-5	44681-44683	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-6	44684-44687	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-7	44688-44692	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-8	44693-44700	chronic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-9	44701-44705	pain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-10	44705-44706	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-11	44707-44710	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-12	44711-44713	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-13	44714-44722	pregnant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-14	44723-44725	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-15	44726-44733	nursing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-16	44733-44734	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-17	44735-44739	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-18	44740-44742	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-19	44743-44746	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-20	44747-44764	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-21	44764-44765	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-22	44766-44769	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-23	44770-44774	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-24	44775-44777	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-25	44778-44788	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-26	44789-44791	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-27	44792-44799	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
208-28	44799-44800	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Study procedures
#Text=All procedures were approved by the Stanford University Institutional Review Board, were carried out in accordance with the approved protocols, and were conducted at the Stanford University Richard M.
209-1	44801-44806	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-2	44807-44817	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-3	44818-44821	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-4	44822-44832	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-5	44833-44837	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-6	44838-44846	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-7	44847-44849	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-8	44850-44853	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-9	44854-44862	Stanford	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-10	44863-44873	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-11	44874-44887	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-12	44888-44894	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-13	44895-44900	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-14	44900-44901	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-15	44902-44906	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-16	44907-44914	carried	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-17	44915-44918	out	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-18	44919-44921	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-19	44922-44932	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-20	44933-44937	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-21	44938-44941	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-22	44942-44950	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-23	44951-44960	protocols	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-24	44960-44961	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-25	44962-44965	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-26	44966-44970	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-27	44971-44980	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-28	44981-44983	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-29	44984-44987	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-30	44988-44996	Stanford	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-31	44997-45007	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-32	45008-45015	Richard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-33	45016-45017	M	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
209-34	45017-45018	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=Lucas Center for Imaging.
210-1	45019-45024	Lucas	_	
210-2	45025-45031	Center	_	
210-3	45032-45035	for	_	
210-4	45036-45043	Imaging	_	
210-5	45043-45044	.	_	

#Text=All participants signed written and informed consent acknowledging their willingness to participate in the study, understanding of all study procedures, and understanding that they were free to withdraw their study participation at any time.
211-1	45045-45048	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-2	45049-45061	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-3	45062-45068	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-4	45069-45076	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-5	45077-45080	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-6	45081-45089	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-7	45090-45097	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-8	45098-45111	acknowledging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-9	45112-45117	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-10	45118-45129	willingness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-11	45130-45132	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-12	45133-45144	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-13	45145-45147	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-14	45148-45151	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-15	45152-45157	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-16	45157-45158	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-17	45159-45172	understanding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-18	45173-45175	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-19	45176-45179	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-20	45180-45185	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-21	45186-45196	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-22	45196-45197	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-23	45198-45201	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-24	45202-45215	understanding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-25	45216-45220	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-26	45221-45225	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-27	45226-45230	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-28	45231-45235	free	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-29	45236-45238	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-30	45239-45247	withdraw	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-31	45248-45253	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-32	45254-45259	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-33	45260-45273	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-34	45274-45276	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-35	45277-45280	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-36	45281-45285	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
211-37	45285-45286	.	_	

#Text=Data from the control and non-opioid fibromyalgia groups were analyzed previously and included in another publication.
212-1	45287-45291	Data	_	
212-2	45292-45296	from	_	
212-3	45297-45300	the	_	
212-4	45301-45308	control	_	
212-5	45309-45312	and	_	
212-6	45313-45323	non-opioid	_	
212-7	45324-45336	fibromyalgia	_	
212-8	45337-45343	groups	_	
212-9	45344-45348	were	_	
212-10	45349-45357	analyzed	_	
212-11	45358-45368	previously	_	
212-12	45369-45372	and	_	
212-13	45373-45381	included	_	
212-14	45382-45384	in	_	
212-15	45385-45392	another	_	
212-16	45393-45404	publication	_	
212-17	45404-45405	.	_	

#Text=Prior to the scan session, study participants received instruction and practiced the MID task (for approximately 5 minutes) and use of arousal and valence rating scales.
213-1	45406-45411	Prior	_	
213-2	45412-45414	to	_	
213-3	45415-45418	the	_	
213-4	45419-45423	scan	_	
213-5	45424-45431	session	_	
213-6	45431-45432	,	_	
213-7	45433-45438	study	_	
213-8	45439-45451	participants	_	
213-9	45452-45460	received	_	
213-10	45461-45472	instruction	_	
213-11	45473-45476	and	_	
213-12	45477-45486	practiced	_	
213-13	45487-45490	the	_	
213-14	45491-45494	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
213-15	45495-45499	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
213-16	45500-45501	(	_	
213-17	45501-45504	for	_	
213-18	45505-45518	approximately	_	
213-19	45519-45520	5	_	
213-20	45521-45528	minutes	_	
213-21	45528-45529	)	_	
213-22	45530-45533	and	_	
213-23	45534-45537	use	_	
213-24	45538-45540	of	_	
213-25	45541-45548	arousal	_	
213-26	45549-45552	and	_	
213-27	45553-45560	valence	_	
213-28	45561-45567	rating	_	
213-29	45568-45574	scales	_	
213-30	45574-45575	.	_	

#Text=If necessary, the MID task practice was repeated until the participant understood the task and performed the task successfully.
214-1	45576-45578	If	_	
214-2	45579-45588	necessary	_	
214-3	45588-45589	,	_	
214-4	45590-45593	the	_	
214-5	45594-45597	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[13]	
214-6	45598-45602	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[13]	
214-7	45603-45611	practice	_	
214-8	45612-45615	was	_	
214-9	45616-45624	repeated	_	
214-10	45625-45630	until	_	
214-11	45631-45634	the	_	
214-12	45635-45646	participant	_	
214-13	45647-45657	understood	_	
214-14	45658-45661	the	_	
214-15	45662-45666	task	_	
214-16	45667-45670	and	_	
214-17	45671-45680	performed	_	
214-18	45681-45684	the	_	
214-19	45685-45689	task	_	
214-20	45690-45702	successfully	_	
214-21	45702-45703	.	_	

#Text=Participants underwent training on the rating scales for arousal and valence with written instructions presented on a laptop and explained to participants by trained personnel.
215-1	45704-45716	Participants	_	
215-2	45717-45726	underwent	_	
215-3	45727-45735	training	_	
215-4	45736-45738	on	_	
215-5	45739-45742	the	_	
215-6	45743-45749	rating	_	
215-7	45750-45756	scales	_	
215-8	45757-45760	for	_	
215-9	45761-45768	arousal	_	
215-10	45769-45772	and	_	
215-11	45773-45780	valence	_	
215-12	45781-45785	with	_	
215-13	45786-45793	written	_	
215-14	45794-45806	instructions	_	
215-15	45807-45816	presented	_	
215-16	45817-45819	on	_	
215-17	45820-45821	a	_	
215-18	45822-45828	laptop	_	
215-19	45829-45832	and	_	
215-20	45833-45842	explained	_	
215-21	45843-45845	to	_	
215-22	45846-45858	participants	_	
215-23	45859-45861	by	_	
215-24	45862-45869	trained	_	
215-25	45870-45879	personnel	_	
215-26	45879-45880	.	_	

#Text=Questionnaires were administered to all subjects to determine clinical and psychological measures among the two fibromyalgia groups and control group.
216-1	45881-45895	Questionnaires	_	
216-2	45896-45900	were	_	
216-3	45901-45913	administered	_	
216-4	45914-45916	to	_	
216-5	45917-45920	all	_	
216-6	45921-45929	subjects	_	
216-7	45930-45932	to	_	
216-8	45933-45942	determine	_	
216-9	45943-45951	clinical	_	
216-10	45952-45955	and	_	
216-11	45956-45969	psychological	_	
216-12	45970-45978	measures	_	
216-13	45979-45984	among	_	
216-14	45985-45988	the	_	
216-15	45989-45992	two	_	
216-16	45993-46005	fibromyalgia	_	
216-17	46006-46012	groups	_	
216-18	46013-46016	and	_	
216-19	46017-46024	control	_	
216-20	46025-46030	group	_	
216-21	46030-46031	.	_	

#Text=Questionnaires measured depression, anxiety, behavioral inhibition/approach, mood, positive and negative affect, pain distribution, pain intensity, pain interference, pain distribution, and fatigue (see Table 2 and Supplementary Methods for a list and references for questionnaires included in the analysis).
217-1	46032-46046	Questionnaires	_	
217-2	46047-46055	measured	_	
217-3	46056-46066	depression	_	
217-4	46066-46067	,	_	
217-5	46068-46075	anxiety	_	
217-6	46075-46076	,	_	
217-7	46077-46087	behavioral	_	
217-8	46088-46098	inhibition	_	
217-9	46098-46099	/	_	
217-10	46099-46107	approach	_	
217-11	46107-46108	,	_	
217-12	46109-46113	mood	_	
217-13	46113-46114	,	_	
217-14	46115-46123	positive	_	
217-15	46124-46127	and	_	
217-16	46128-46136	negative	_	
217-17	46137-46143	affect	_	
217-18	46143-46144	,	_	
217-19	46145-46149	pain	_	
217-20	46150-46162	distribution	_	
217-21	46162-46163	,	_	
217-22	46164-46168	pain	_	
217-23	46169-46178	intensity	_	
217-24	46178-46179	,	_	
217-25	46180-46184	pain	_	
217-26	46185-46197	interference	_	
217-27	46197-46198	,	_	
217-28	46199-46203	pain	_	
217-29	46204-46216	distribution	_	
217-30	46216-46217	,	_	
217-31	46218-46221	and	_	
217-32	46222-46229	fatigue	_	
217-33	46230-46231	(	_	
217-34	46231-46234	see	_	
217-35	46235-46240	Table	_	
217-36	46240-46241	 	_	
217-37	46241-46242	2	_	
217-38	46243-46246	and	_	
217-39	46247-46260	Supplementary	_	
217-40	46261-46268	Methods	_	
217-41	46269-46272	for	_	
217-42	46273-46274	a	_	
217-43	46275-46279	list	_	
217-44	46280-46283	and	_	
217-45	46284-46294	references	_	
217-46	46295-46298	for	_	
217-47	46299-46313	questionnaires	_	
217-48	46314-46322	included	_	
217-49	46323-46325	in	_	
217-50	46326-46329	the	_	
217-51	46330-46338	analysis	_	
217-52	46338-46339	)	_	
217-53	46339-46340	.	_	

#Text=Structural MRI and fMRI data were acquired from all participants using a 3T General Electric scanner using an 8-channel head coil (GE Systems, Chicago, Illinois).
218-1	46341-46351	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[14]	
218-2	46352-46355	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[14]	
218-3	46356-46359	and	_	
218-4	46360-46364	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
218-5	46365-46369	data	_	
218-6	46370-46374	were	_	
218-7	46375-46383	acquired	_	
218-8	46384-46388	from	_	
218-9	46389-46392	all	_	
218-10	46393-46405	participants	_	
218-11	46406-46411	using	_	
218-12	46412-46413	a	_	
218-13	46414-46416	3T	_	
218-14	46417-46424	General	_	
218-15	46425-46433	Electric	_	
218-16	46434-46441	scanner	_	
218-17	46442-46447	using	_	
218-18	46448-46450	an	_	
218-19	46451-46452	8	_	
218-20	46452-46453	-	_	
218-21	46453-46460	channel	_	
218-22	46461-46465	head	_	
218-23	46466-46470	coil	_	
218-24	46471-46472	(	_	
218-25	46472-46474	GE	_	
218-26	46475-46482	Systems	_	
218-27	46482-46483	,	_	
218-28	46484-46491	Chicago	_	
218-29	46491-46492	,	_	
218-30	46493-46501	Illinois	_	
218-31	46501-46502	)	_	
218-32	46502-46503	.	_	

#Text=The scan session consisted of a localizer scan, asset calibration scans, 2 MID task fMRI scans, and a T1 anatomical scan.
219-1	46504-46507	The	_	
219-2	46508-46512	scan	_	
219-3	46513-46520	session	_	
219-4	46521-46530	consisted	_	
219-5	46531-46533	of	_	
219-6	46534-46535	a	_	
219-7	46536-46545	localizer	_	
219-8	46546-46550	scan	_	
219-9	46550-46551	,	_	
219-10	46552-46557	asset	_	
219-11	46558-46569	calibration	_	
219-12	46570-46575	scans	_	
219-13	46575-46576	,	_	
219-14	46577-46578	2	_	
219-15	46579-46582	MID	_	
219-16	46583-46587	task	_	
219-17	46588-46592	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
219-18	46593-46598	scans	_	
219-19	46598-46599	,	_	
219-20	46600-46603	and	_	
219-21	46604-46605	a	_	
219-22	46606-46608	T1	_	
219-23	46609-46619	anatomical	_	
219-24	46620-46624	scan	_	
219-25	46624-46625	.	_	

#Text=The 2 MID fMRI task scans were acquired sequentially (no break in between) and with the following parameters: Gradient Echo Pulse Sequence with spiral in-out acquisition, flip angle of 76°, echo time (TE) of 30 seconds, repetition time (TR) of 2 seconds, sequential descending slice order, 32 oblique slices, slice thickness 4 mm, gap 0.5 mm, pixel size 3.43 mm.
220-1	46626-46629	The	_	
220-2	46630-46631	2	_	
220-3	46632-46635	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
220-4	46636-46640	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
220-5	46641-46645	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[15]	
220-6	46646-46651	scans	_	
220-7	46652-46656	were	_	
220-8	46657-46665	acquired	_	
220-9	46666-46678	sequentially	_	
220-10	46679-46680	(	_	
220-11	46680-46682	no	_	
220-12	46683-46688	break	_	
220-13	46689-46691	in	_	
220-14	46692-46699	between	_	
220-15	46699-46700	)	_	
220-16	46701-46704	and	_	
220-17	46705-46709	with	_	
220-18	46710-46713	the	_	
220-19	46714-46723	following	_	
220-20	46724-46734	parameters	_	
220-21	46734-46735	:	_	
220-22	46736-46744	Gradient	_	
220-23	46745-46749	Echo	_	
220-24	46750-46755	Pulse	_	
220-25	46756-46764	Sequence	_	
220-26	46765-46769	with	_	
220-27	46770-46776	spiral	_	
220-28	46777-46783	in-out	_	
220-29	46784-46795	acquisition	_	
220-30	46795-46796	,	_	
220-31	46797-46801	flip	_	
220-32	46802-46807	angle	_	
220-33	46808-46810	of	_	
220-34	46811-46813	76	_	
220-35	46813-46814	°	_	
220-36	46814-46815	,	_	
220-37	46816-46820	echo	_	
220-38	46821-46825	time	_	
220-39	46826-46827	(	_	
220-40	46827-46829	TE	_	
220-41	46829-46830	)	_	
220-42	46831-46833	of	_	
220-43	46834-46836	30	_	
220-44	46837-46844	seconds	_	
220-45	46844-46845	,	_	
220-46	46846-46856	repetition	_	
220-47	46857-46861	time	_	
220-48	46862-46863	(	_	
220-49	46863-46865	TR	_	
220-50	46865-46866	)	_	
220-51	46867-46869	of	_	
220-52	46870-46871	2	_	
220-53	46872-46879	seconds	_	
220-54	46879-46880	,	_	
220-55	46881-46891	sequential	_	
220-56	46892-46902	descending	_	
220-57	46903-46908	slice	_	
220-58	46909-46914	order	_	
220-59	46914-46915	,	_	
220-60	46916-46918	32	_	
220-61	46919-46926	oblique	_	
220-62	46927-46933	slices	_	
220-63	46933-46934	,	_	
220-64	46935-46940	slice	_	
220-65	46941-46950	thickness	_	
220-66	46951-46952	4	_	
220-67	46953-46955	mm	_	
220-68	46955-46956	,	_	
220-69	46957-46960	gap	_	
220-70	46961-46964	0.5	_	
220-71	46965-46967	mm	_	
220-72	46967-46968	,	_	
220-73	46969-46974	pixel	_	
220-74	46975-46979	size	_	
220-75	46980-46984	3.43	_	
220-76	46985-46987	mm	_	
220-77	46987-46988	.	_	

#Text=The spiral in-out scan sequence was used because it reduces orbitofrontal signal drop-out and improves acquisition of the medial prefrontal cortex and orbitofrontal cortex.
221-1	46989-46992	The	_	
221-2	46993-46999	spiral	_	
221-3	47000-47006	in-out	_	
221-4	47007-47011	scan	_	
221-5	47012-47020	sequence	_	
221-6	47021-47024	was	_	
221-7	47025-47029	used	_	
221-8	47030-47037	because	_	
221-9	47038-47040	it	_	
221-10	47041-47048	reduces	_	
221-11	47049-47062	orbitofrontal	_	
221-12	47063-47069	signal	_	
221-13	47070-47078	drop-out	_	
221-14	47079-47082	and	_	
221-15	47083-47091	improves	_	
221-16	47092-47103	acquisition	_	
221-17	47104-47106	of	_	
221-18	47107-47110	the	_	
221-19	47111-47117	medial	_	
221-20	47118-47128	prefrontal	_	
221-21	47129-47135	cortex	_	
221-22	47136-47139	and	_	
221-23	47140-47153	orbitofrontal	_	
221-24	47154-47160	cortex	_	
221-25	47160-47161	.	_	

#Text=The MID 1 fMRI scan included 266 volumes and the MID 2 fMRI scan included 302 volumes, excluding 12 s lead-in and 8 s lead-out.
222-1	47162-47165	The	_	
222-2	47166-47169	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[16]	
222-3	47170-47171	1	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[16]	
222-4	47172-47176	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[16]	
222-5	47177-47181	scan	_	
222-6	47182-47190	included	_	
222-7	47191-47194	266	_	
222-8	47195-47202	volumes	_	
222-9	47203-47206	and	_	
222-10	47207-47210	the	_	
222-11	47211-47214	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
222-12	47215-47216	2	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
222-13	47217-47221	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
222-14	47222-47226	scan	_	
222-15	47227-47235	included	_	
222-16	47236-47239	302	_	
222-17	47240-47247	volumes	_	
222-18	47247-47248	,	_	
222-19	47249-47258	excluding	_	
222-20	47259-47261	12	_	
222-21	47262-47263	s	_	
222-22	47264-47271	lead-in	_	
222-23	47272-47275	and	_	
222-24	47276-47277	8	_	
222-25	47278-47279	s	_	
222-26	47280-47288	lead-out	_	
222-27	47288-47289	.	_	

#Text=The T1 anatomical scan was acquired using 3D FSPGR (fast spoiled gradient-echo) IRprep BRAVO for registration of functional images and included whole brain, brainstem and cerebellum coverage; slice thickness 1 mm; frequency field of view (FOV) 22 mm, anterior/posterior frequency direction, 2 number of excitations (NEX), 11° flip angle, 6.8 TR, 2.6 TE, 256 frequency, 256 phase, 50.00 bandwidth.
223-1	47290-47293	The	_	
223-2	47294-47296	T1	_	
223-3	47297-47307	anatomical	_	
223-4	47308-47312	scan	_	
223-5	47313-47316	was	_	
223-6	47317-47325	acquired	_	
223-7	47326-47331	using	_	
223-8	47332-47334	3D	_	
223-9	47335-47340	FSPGR	_	
223-10	47341-47342	(	_	
223-11	47342-47346	fast	_	
223-12	47347-47354	spoiled	_	
223-13	47355-47368	gradient-echo	_	
223-14	47368-47369	)	_	
223-15	47370-47376	IRprep	_	
223-16	47377-47382	BRAVO	_	
223-17	47383-47386	for	_	
223-18	47387-47399	registration	_	
223-19	47400-47402	of	_	
223-20	47403-47413	functional	_	
223-21	47414-47420	images	_	
223-22	47421-47424	and	_	
223-23	47425-47433	included	_	
223-24	47434-47439	whole	_	
223-25	47440-47445	brain	_	
223-26	47445-47446	,	_	
223-27	47447-47456	brainstem	_	
223-28	47457-47460	and	_	
223-29	47461-47471	cerebellum	_	
223-30	47472-47480	coverage	_	
223-31	47480-47481	;	_	
223-32	47482-47487	slice	_	
223-33	47488-47497	thickness	_	
223-34	47498-47499	1	_	
223-35	47500-47502	mm	_	
223-36	47502-47503	;	_	
223-37	47504-47513	frequency	_	
223-38	47514-47519	field	_	
223-39	47520-47522	of	_	
223-40	47523-47527	view	_	
223-41	47528-47529	(	_	
223-42	47529-47532	FOV	_	
223-43	47532-47533	)	_	
223-44	47534-47536	22	_	
223-45	47537-47539	mm	_	
223-46	47539-47540	,	_	
223-47	47541-47549	anterior	_	
223-48	47549-47550	/	_	
223-49	47550-47559	posterior	_	
223-50	47560-47569	frequency	_	
223-51	47570-47579	direction	_	
223-52	47579-47580	,	_	
223-53	47581-47582	2	_	
223-54	47583-47589	number	_	
223-55	47590-47592	of	_	
223-56	47593-47604	excitations	_	
223-57	47605-47606	(	_	
223-58	47606-47609	NEX	_	
223-59	47609-47610	)	_	
223-60	47610-47611	,	_	
223-61	47612-47614	11	_	
223-62	47614-47615	°	_	
223-63	47616-47620	flip	_	
223-64	47621-47626	angle	_	
223-65	47626-47627	,	_	
223-66	47628-47631	6.8	_	
223-67	47632-47634	TR	_	
223-68	47634-47635	,	_	
223-69	47636-47639	2.6	_	
223-70	47640-47642	TE	_	
223-71	47642-47643	,	_	
223-72	47644-47647	256	_	
223-73	47648-47657	frequency	_	
223-74	47657-47658	,	_	
223-75	47659-47662	256	_	
223-76	47663-47668	phase	_	
223-77	47668-47669	,	_	
223-78	47670-47675	50.00	_	
223-79	47676-47685	bandwidth	_	
223-80	47685-47686	.	_	

#Text=Monetary Incentive Delay (MID) fMRI Task
#Text=We ran the MID task in MATLAB (MATLAB R2012b, MathWorks, Natick, MA), using Psychophysics Toolbox for presentation of visual stimuli (Psychtoolbox-3) via a screen placed above the participant in the scanner.
224-1	47687-47695	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
224-2	47696-47705	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
224-3	47706-47711	Delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
224-4	47712-47713	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
224-5	47713-47716	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
224-6	47716-47717	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
224-7	47718-47722	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
224-8	47723-47727	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
224-9	47728-47730	We	_	
224-10	47731-47734	ran	_	
224-11	47735-47738	the	_	
224-12	47739-47742	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
224-13	47743-47747	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
224-14	47748-47750	in	_	
224-15	47751-47757	MATLAB	_	
224-16	47758-47759	(	_	
224-17	47759-47765	MATLAB	_	
224-18	47766-47772	R2012b	_	
224-19	47772-47773	,	_	
224-20	47774-47783	MathWorks	_	
224-21	47783-47784	,	_	
224-22	47785-47791	Natick	_	
224-23	47791-47792	,	_	
224-24	47793-47795	MA	_	
224-25	47795-47796	)	_	
224-26	47796-47797	,	_	
224-27	47798-47803	using	_	
224-28	47804-47817	Psychophysics	_	
224-29	47818-47825	Toolbox	_	
224-30	47826-47829	for	_	
224-31	47830-47842	presentation	_	
224-32	47843-47845	of	_	
224-33	47846-47852	visual	_	
224-34	47853-47860	stimuli	_	
224-35	47861-47862	(	_	
224-36	47862-47874	Psychtoolbox	_	
224-37	47874-47875	-	_	
224-38	47875-47876	3	_	
224-39	47876-47877	)	_	
224-40	47878-47881	via	_	
224-41	47882-47883	a	_	
224-42	47884-47890	screen	_	
224-43	47891-47897	placed	_	
224-44	47898-47903	above	_	
224-45	47904-47907	the	_	
224-46	47908-47919	participant	_	
224-47	47920-47922	in	_	
224-48	47923-47926	the	_	
224-49	47927-47934	scanner	_	
224-50	47934-47935	.	_	

#Text=Participant responses to the task were collected using a custom designed button box.
225-1	47936-47947	Participant	_	
225-2	47948-47957	responses	_	
225-3	47958-47960	to	_	
225-4	47961-47964	the	_	
225-5	47965-47969	task	_	
225-6	47970-47974	were	_	
225-7	47975-47984	collected	_	
225-8	47985-47990	using	_	
225-9	47991-47992	a	_	
225-10	47993-47999	custom	_	
225-11	48000-48008	designed	_	
225-12	48009-48015	button	_	
225-13	48016-48019	box	_	
225-14	48019-48020	.	_	

#Text=A total of 90 trials were administered during the two MID task scans as performed previously.
226-1	48021-48022	A	_	
226-2	48023-48028	total	_	
226-3	48029-48031	of	_	
226-4	48032-48034	90	_	
226-5	48035-48041	trials	_	
226-6	48042-48046	were	_	
226-7	48047-48059	administered	_	
226-8	48060-48066	during	_	
226-9	48067-48070	the	_	
226-10	48071-48074	two	_	
226-11	48075-48078	MID	_	
226-12	48079-48083	task	_	
226-13	48084-48089	scans	_	
226-14	48090-48092	as	_	
226-15	48093-48102	performed	_	
226-16	48103-48113	previously	_	
226-17	48113-48114	.	_	

#Text=Cues indicated the amount of money to be potentially gained (+$5.00, +$1.00, +$0.00) or lost (−$5.00, −$1.00, −$0.00) during each trial.
227-1	48115-48119	Cues	_	
227-2	48120-48129	indicated	_	
227-3	48130-48133	the	_	
227-4	48134-48140	amount	_	
227-5	48141-48143	of	_	
227-6	48144-48149	money	_	
227-7	48150-48152	to	_	
227-8	48153-48155	be	_	
227-9	48156-48167	potentially	_	
227-10	48168-48174	gained	_	
227-11	48175-48176	(	_	
227-12	48176-48177	+	_	
227-13	48177-48182	$5.00	_	
227-14	48182-48183	,	_	
227-15	48184-48185	+	_	
227-16	48185-48190	$1.00	_	
227-17	48190-48191	,	_	
227-18	48192-48193	+	_	
227-19	48193-48198	$0.00	_	
227-20	48198-48199	)	_	
227-21	48200-48202	or	_	
227-22	48203-48207	lost	_	
227-23	48208-48209	(	_	
227-24	48209-48210	−	_	
227-25	48210-48215	$5.00	_	
227-26	48215-48216	,	_	
227-27	48217-48218	−	_	
227-28	48218-48223	$1.00	_	
227-29	48223-48224	,	_	
227-30	48225-48226	−	_	
227-31	48226-48231	$0.00	_	
227-32	48231-48232	)	_	
227-33	48233-48239	during	_	
227-34	48240-48244	each	_	
227-35	48245-48250	trial	_	
227-36	48250-48251	.	_	

#Text=After a 2 s delay (fixation cross) a target (triangle) was presented.
228-1	48252-48257	After	_	
228-2	48258-48259	a	_	
228-3	48260-48261	2	_	
228-4	48262-48263	s	_	
228-5	48264-48269	delay	_	
228-6	48270-48271	(	_	
228-7	48271-48279	fixation	_	
228-8	48280-48285	cross	_	
228-9	48285-48286	)	_	
228-10	48287-48288	a	_	
228-11	48289-48295	target	_	
228-12	48296-48297	(	_	
228-13	48297-48305	triangle	_	
228-14	48305-48306	)	_	
228-15	48307-48310	was	_	
228-16	48311-48320	presented	_	
228-17	48320-48321	.	_	

#Text=Participants needed to initiate a response (button press) to either win (positive cues) or avoid losing (negative cues) the amount shown.
229-1	48322-48334	Participants	_	
229-2	48335-48341	needed	_	
229-3	48342-48344	to	_	
229-4	48345-48353	initiate	_	
229-5	48354-48355	a	_	
229-6	48356-48364	response	_	
229-7	48365-48366	(	_	
229-8	48366-48372	button	_	
229-9	48373-48378	press	_	
229-10	48378-48379	)	_	
229-11	48380-48382	to	_	
229-12	48383-48389	either	_	
229-13	48390-48393	win	_	
229-14	48394-48395	(	_	
229-15	48395-48403	positive	_	
229-16	48404-48408	cues	_	
229-17	48408-48409	)	_	
229-18	48410-48412	or	_	
229-19	48413-48418	avoid	_	
229-20	48419-48425	losing	_	
229-21	48426-48427	(	_	
229-22	48427-48435	negative	_	
229-23	48436-48440	cues	_	
229-24	48440-48441	)	_	
229-25	48442-48445	the	_	
229-26	48446-48452	amount	_	
229-27	48453-48458	shown	_	
229-28	48458-48459	.	_	

#Text=Successful responses (i.e., occurring prior to target duration offset) generated a “hit” and unsuccessful responses generated a “miss”.
230-1	48460-48470	Successful	_	
230-2	48471-48480	responses	_	
230-3	48481-48482	(	_	
230-4	48482-48485	i.e	_	
230-5	48485-48486	.	_	
230-6	48486-48487	,	_	
230-7	48488-48497	occurring	_	
230-8	48498-48503	prior	_	
230-9	48504-48506	to	_	
230-10	48507-48513	target	_	
230-11	48514-48522	duration	_	
230-12	48523-48529	offset	_	
230-13	48529-48530	)	_	
230-14	48531-48540	generated	_	
230-15	48541-48542	a	_	
230-16	48543-48544	“	_	
230-17	48544-48547	hit	_	
230-18	48547-48548	”	_	
230-19	48549-48552	and	_	
230-20	48553-48565	unsuccessful	_	
230-21	48566-48575	responses	_	
230-22	48576-48585	generated	_	
230-23	48586-48587	a	_	
230-24	48588-48589	“	_	
230-25	48589-48593	miss	_	
230-26	48593-48594	”	_	
230-27	48594-48595	.	_	

#Text=Outcomes for each trial were presented as the amount gained (e.g., +$5.00), not gained (+$0.00), not lost (−$0.00), or lost (e.g., −$5.00).
231-1	48596-48604	Outcomes	_	
231-2	48605-48608	for	_	
231-3	48609-48613	each	_	
231-4	48614-48619	trial	_	
231-5	48620-48624	were	_	
231-6	48625-48634	presented	_	
231-7	48635-48637	as	_	
231-8	48638-48641	the	_	
231-9	48642-48648	amount	_	
231-10	48649-48655	gained	_	
231-11	48656-48657	(	_	
231-12	48657-48660	e.g	_	
231-13	48660-48661	.	_	
231-14	48661-48662	,	_	
231-15	48663-48664	+	_	
231-16	48664-48669	$5.00	_	
231-17	48669-48670	)	_	
231-18	48670-48671	,	_	
231-19	48672-48675	not	_	
231-20	48676-48682	gained	_	
231-21	48683-48684	(	_	
231-22	48684-48685	+	_	
231-23	48685-48690	$0.00	_	
231-24	48690-48691	)	_	
231-25	48691-48692	,	_	
231-26	48693-48696	not	_	
231-27	48697-48701	lost	_	
231-28	48702-48703	(	_	
231-29	48703-48704	−	_	
231-30	48704-48709	$0.00	_	
231-31	48709-48710	)	_	
231-32	48710-48711	,	_	
231-33	48712-48714	or	_	
231-34	48715-48719	lost	_	
231-35	48720-48721	(	_	
231-36	48721-48724	e.g	_	
231-37	48724-48725	.	_	
231-38	48725-48726	,	_	
231-39	48727-48728	−	_	
231-40	48728-48733	$5.00	_	
231-41	48733-48734	)	_	
231-42	48734-48735	.	_	

#Text=Target durations varied: initial target durations were set at the beginning of the scan (typically 250 ms) and programmatically adjusted throughout the task to target “hit” rate of approximately 66% across trials.
232-1	48736-48742	Target	_	
232-2	48743-48752	durations	_	
232-3	48753-48759	varied	_	
232-4	48759-48760	:	_	
232-5	48761-48768	initial	_	
232-6	48769-48775	target	_	
232-7	48776-48785	durations	_	
232-8	48786-48790	were	_	
232-9	48791-48794	set	_	
232-10	48795-48797	at	_	
232-11	48798-48801	the	_	
232-12	48802-48811	beginning	_	
232-13	48812-48814	of	_	
232-14	48815-48818	the	_	
232-15	48819-48823	scan	_	
232-16	48824-48825	(	_	
232-17	48825-48834	typically	_	
232-18	48835-48838	250	_	
232-19	48839-48841	ms	_	
232-20	48841-48842	)	_	
232-21	48843-48846	and	_	
232-22	48847-48863	programmatically	_	
232-23	48864-48872	adjusted	_	
232-24	48873-48883	throughout	_	
232-25	48884-48887	the	_	
232-26	48888-48892	task	_	
232-27	48893-48895	to	_	
232-28	48896-48902	target	_	
232-29	48903-48904	“	_	
232-30	48904-48907	hit	_	
232-31	48907-48908	”	_	
232-32	48909-48913	rate	_	
232-33	48914-48916	of	_	
232-34	48917-48930	approximately	_	
232-35	48931-48934	66%	_	
232-36	48935-48941	across	_	
232-37	48942-48948	trials	_	
232-38	48948-48949	.	_	

#Text=Arousal (low-medium-high) and valence (negative-neutral-positive) ratings were collected after the MID task fMRI scans using 7-point Likert scales.
233-1	48950-48957	Arousal	_	
233-2	48958-48959	(	_	
233-3	48959-48974	low-medium-high	_	
233-4	48974-48975	)	_	
233-5	48976-48979	and	_	
233-6	48980-48987	valence	_	
233-7	48988-48989	(	_	
233-8	48989-49014	negative-neutral-positive	_	
233-9	49014-49015	)	_	
233-10	49016-49023	ratings	_	
233-11	49024-49028	were	_	
233-12	49029-49038	collected	_	
233-13	49039-49044	after	_	
233-14	49045-49048	the	_	
233-15	49049-49052	MID	_	
233-16	49053-49057	task	_	
233-17	49058-49062	fMRI	_	
233-18	49063-49068	scans	_	
233-19	49069-49074	using	_	
233-20	49075-49076	7	_	
233-21	49076-49077	-	_	
233-22	49077-49082	point	_	
233-23	49083-49089	Likert	_	
233-24	49090-49096	scales	_	
233-25	49096-49097	.	_	

#Text=Participants were sent Amazon electronic gift cards for the combined total of gains and losses during the task after completion of the scan.
#Text=fMRI Data preprocessing
#Text=Neuroimaging data were preprocessed using AFNI software (Analysis of Functional Neuroimages) [precompiled binary macosx_10.7_Intel_64: Jun 10 2016 (Version AFNI_16.1.21)] using custom scripts, and as performed previously.
234-1	49098-49110	Participants	_	
234-2	49111-49115	were	_	
234-3	49116-49120	sent	_	
234-4	49121-49127	Amazon	_	
234-5	49128-49138	electronic	_	
234-6	49139-49143	gift	_	
234-7	49144-49149	cards	_	
234-8	49150-49153	for	_	
234-9	49154-49157	the	_	
234-10	49158-49166	combined	_	
234-11	49167-49172	total	_	
234-12	49173-49175	of	_	
234-13	49176-49181	gains	_	
234-14	49182-49185	and	_	
234-15	49186-49192	losses	_	
234-16	49193-49199	during	_	
234-17	49200-49203	the	_	
234-18	49204-49208	task	_	
234-19	49209-49214	after	_	
234-20	49215-49225	completion	_	
234-21	49226-49228	of	_	
234-22	49229-49232	the	_	
234-23	49233-49237	scan	_	
234-24	49237-49238	.	_	
234-25	49239-49243	fMRI	_	
234-26	49244-49248	Data	_	
234-27	49249-49262	preprocessing	_	
234-28	49263-49275	Neuroimaging	_	
234-29	49276-49280	data	_	
234-30	49281-49285	were	_	
234-31	49286-49298	preprocessed	_	
234-32	49299-49304	using	_	
234-33	49305-49309	AFNI	_	
234-34	49310-49318	software	_	
234-35	49319-49320	(	_	
234-36	49320-49328	Analysis	_	
234-37	49329-49331	of	_	
234-38	49332-49342	Functional	_	
234-39	49343-49354	Neuroimages	_	
234-40	49354-49355	)	_	
234-41	49356-49357	[	_	
234-42	49357-49368	precompiled	_	
234-43	49369-49375	binary	_	
234-44	49376-49382	macosx	_	
234-45	49382-49383	_	_	
234-46	49383-49387	10.7	_	
234-47	49387-49388	_	_	
234-48	49388-49393	Intel	_	
234-49	49393-49394	_	_	
234-50	49394-49396	64	_	
234-51	49396-49397	:	_	
234-52	49398-49401	Jun	_	
234-53	49402-49404	10	_	
234-54	49405-49409	2016	_	
234-55	49410-49411	(	_	
234-56	49411-49418	Version	_	
234-57	49419-49423	AFNI	_	
234-58	49423-49424	_	_	
234-59	49424-49431	16.1.21	_	
234-60	49431-49432	)	_	
234-61	49432-49433	]	_	
234-62	49434-49439	using	_	
234-63	49440-49446	custom	_	
234-64	49447-49454	scripts	_	
234-65	49454-49455	,	_	
234-66	49456-49459	and	_	
234-67	49460-49462	as	_	
234-68	49463-49472	performed	_	
234-69	49473-49483	previously	_	
234-70	49483-49484	.	_	

#Text=First, 6 read-in and 9 read-out volumes were excluded from the scan data, the 2 MID fMRI scans were then concatenated into one series of images.
235-1	49485-49490	First	_	
235-2	49490-49491	,	_	
235-3	49492-49493	6	_	
235-4	49494-49501	read-in	_	
235-5	49502-49505	and	_	
235-6	49506-49507	9	_	
235-7	49508-49516	read-out	_	
235-8	49517-49524	volumes	_	
235-9	49525-49529	were	_	
235-10	49530-49538	excluded	_	
235-11	49539-49543	from	_	
235-12	49544-49547	the	_	
235-13	49548-49552	scan	_	
235-14	49553-49557	data	_	
235-15	49557-49558	,	_	
235-16	49559-49562	the	_	
235-17	49563-49564	2	_	
235-18	49565-49568	MID	_	
235-19	49569-49573	fMRI	_	
235-20	49574-49579	scans	_	
235-21	49580-49584	were	_	
235-22	49585-49589	then	_	
235-23	49590-49602	concatenated	_	
235-24	49603-49607	into	_	
235-25	49608-49611	one	_	
235-26	49612-49618	series	_	
235-27	49619-49621	of	_	
235-28	49622-49628	images	_	
235-29	49628-49629	.	_	

#Text=Next, the functional images were slice time corrected, transformed from oblique to axial slice orientation, and aligned with the structural images.
236-1	49630-49634	Next	_	
236-2	49634-49635	,	_	
236-3	49636-49639	the	_	
236-4	49640-49650	functional	_	
236-5	49651-49657	images	_	
236-6	49658-49662	were	_	
236-7	49663-49668	slice	_	
236-8	49669-49673	time	_	
236-9	49674-49683	corrected	_	
236-10	49683-49684	,	_	
236-11	49685-49696	transformed	_	
236-12	49697-49701	from	_	
236-13	49702-49709	oblique	_	
236-14	49710-49712	to	_	
236-15	49713-49718	axial	_	
236-16	49719-49724	slice	_	
236-17	49725-49736	orientation	_	
236-18	49736-49737	,	_	
236-19	49738-49741	and	_	
236-20	49742-49749	aligned	_	
236-21	49750-49754	with	_	
236-22	49755-49758	the	_	
236-23	49759-49769	structural	_	
236-24	49770-49776	images	_	
236-25	49776-49777	.	_	

#Text=Motion correction was performed with 6 degrees of movement [translation (x, y, z), rotation (roll, pitch, yaw)].
237-1	49778-49784	Motion	_	
237-2	49785-49795	correction	_	
237-3	49796-49799	was	_	
237-4	49800-49809	performed	_	
237-5	49810-49814	with	_	
237-6	49815-49816	6	_	
237-7	49817-49824	degrees	_	
237-8	49825-49827	of	_	
237-9	49828-49836	movement	_	
237-10	49837-49838	[	_	
237-11	49838-49849	translation	_	
237-12	49850-49851	(	_	
237-13	49851-49852	x	_	
237-14	49852-49853	,	_	
237-15	49854-49855	y	_	
237-16	49855-49856	,	_	
237-17	49857-49858	z	_	
237-18	49858-49859	)	_	
237-19	49859-49860	,	_	
237-20	49861-49869	rotation	_	
237-21	49870-49871	(	_	
237-22	49871-49875	roll	_	
237-23	49875-49876	,	_	
237-24	49877-49882	pitch	_	
237-25	49882-49883	,	_	
237-26	49884-49887	yaw	_	
237-27	49887-49888	)	_	
237-28	49888-49889	]	_	
237-29	49889-49890	.	_	

#Text=The functional images were spatially smoothed using a 4 mm (full-width half-maximum, FWHM) Gaussian kernel.
238-1	49891-49894	The	_	
238-2	49895-49905	functional	_	
238-3	49906-49912	images	_	
238-4	49913-49917	were	_	
238-5	49918-49927	spatially	_	
238-6	49928-49936	smoothed	_	
238-7	49937-49942	using	_	
238-8	49943-49944	a	_	
238-9	49945-49946	4	_	
238-10	49947-49949	mm	_	
238-11	49950-49951	(	_	
238-12	49951-49961	full-width	_	
238-13	49962-49974	half-maximum	_	
238-14	49974-49975	,	_	
238-15	49976-49980	FWHM	_	
238-16	49980-49981	)	_	
238-17	49982-49990	Gaussian	_	
238-18	49991-49997	kernel	_	
238-19	49997-49998	.	_	

#Text=Intensity normalization was applied by calculating the percent signal change per voxel and division by the average.
239-1	49999-50008	Intensity	_	
239-2	50009-50022	normalization	_	
239-3	50023-50026	was	_	
239-4	50027-50034	applied	_	
239-5	50035-50037	by	_	
239-6	50038-50049	calculating	_	
239-7	50050-50053	the	_	
239-8	50054-50061	percent	_	
239-9	50062-50068	signal	_	
239-10	50069-50075	change	_	
239-11	50076-50079	per	_	
239-12	50080-50085	voxel	_	
239-13	50086-50089	and	_	
239-14	50090-50098	division	_	
239-15	50099-50101	by	_	
239-16	50102-50105	the	_	
239-17	50106-50113	average	_	
239-18	50113-50114	.	_	

#Text=We applied a 0.011 Hz high-pass filter to the functional data.
240-1	50115-50117	We	_	
240-2	50118-50125	applied	_	
240-3	50126-50127	a	_	
240-4	50128-50133	0.011	_	
240-5	50134-50136	Hz	_	
240-6	50137-50146	high-pass	_	
240-7	50147-50153	filter	_	
240-8	50154-50156	to	_	
240-9	50157-50160	the	_	
240-10	50161-50171	functional	_	
240-11	50172-50176	data	_	
240-12	50176-50177	.	_	

#Text=Structural images were warped to Talairach space and functional images were warped to the Talairach warped structural images.
241-1	50178-50188	Structural	_	
241-2	50189-50195	images	_	
241-3	50196-50200	were	_	
241-4	50201-50207	warped	_	
241-5	50208-50210	to	_	
241-6	50211-50220	Talairach	_	
241-7	50221-50226	space	_	
241-8	50227-50230	and	_	
241-9	50231-50241	functional	_	
241-10	50242-50248	images	_	
241-11	50249-50253	were	_	
241-12	50254-50260	warped	_	
241-13	50261-50263	to	_	
241-14	50264-50267	the	_	
241-15	50268-50277	Talairach	_	
241-16	50278-50284	warped	_	
241-17	50285-50295	structural	_	
241-18	50296-50302	images	_	
241-19	50302-50303	.	_	

#Text=A white matter (WM) and a cerebrospinal fluid (CSF) mask were created for each subject’s functional image based on signal intensity in seed loci in WM and CSF regions, respectively.
#Text=fMRI Task contrasts
#Text=As used previously four separate orthogonal regressors contrasted responses to gain and loss during anticipation and outcome: gain versus no-gain anticipation (GVNant), loss versus no-loss anticipation (LVNant), gain versus no-gain outcome (GVNout), and no-loss versus loss outcome (NVLout).
242-1	50304-50305	A	_	
242-2	50306-50311	white	_	
242-3	50312-50318	matter	_	
242-4	50319-50320	(	_	
242-5	50320-50322	WM	_	
242-6	50322-50323	)	_	
242-7	50324-50327	and	_	
242-8	50328-50329	a	_	
242-9	50330-50343	cerebrospinal	_	
242-10	50344-50349	fluid	_	
242-11	50350-50351	(	_	
242-12	50351-50354	CSF	_	
242-13	50354-50355	)	_	
242-14	50356-50360	mask	_	
242-15	50361-50365	were	_	
242-16	50366-50373	created	_	
242-17	50374-50377	for	_	
242-18	50378-50382	each	_	
242-19	50383-50390	subject	_	
242-20	50390-50391	’	_	
242-21	50391-50392	s	_	
242-22	50393-50403	functional	_	
242-23	50404-50409	image	_	
242-24	50410-50415	based	_	
242-25	50416-50418	on	_	
242-26	50419-50425	signal	_	
242-27	50426-50435	intensity	_	
242-28	50436-50438	in	_	
242-29	50439-50443	seed	_	
242-30	50444-50448	loci	_	
242-31	50449-50451	in	_	
242-32	50452-50454	WM	_	
242-33	50455-50458	and	_	
242-34	50459-50462	CSF	_	
242-35	50463-50470	regions	_	
242-36	50470-50471	,	_	
242-37	50472-50484	respectively	_	
242-38	50484-50485	.	_	
242-39	50486-50490	fMRI	_	
242-40	50491-50495	Task	_	
242-41	50496-50505	contrasts	_	
242-42	50506-50508	As	_	
242-43	50509-50513	used	_	
242-44	50514-50524	previously	_	
242-45	50525-50529	four	_	
242-46	50530-50538	separate	_	
242-47	50539-50549	orthogonal	_	
242-48	50550-50560	regressors	_	
242-49	50561-50571	contrasted	_	
242-50	50572-50581	responses	_	
242-51	50582-50584	to	_	
242-52	50585-50589	gain	_	
242-53	50590-50593	and	_	
242-54	50594-50598	loss	_	
242-55	50599-50605	during	_	
242-56	50606-50618	anticipation	_	
242-57	50619-50622	and	_	
242-58	50623-50630	outcome	_	
242-59	50630-50631	:	_	
242-60	50632-50636	gain	_	
242-61	50637-50643	versus	_	
242-62	50644-50651	no-gain	_	
242-63	50652-50664	anticipation	_	
242-64	50665-50666	(	_	
242-65	50666-50672	GVNant	_	
242-66	50672-50673	)	_	
242-67	50673-50674	,	_	
242-68	50675-50679	loss	_	
242-69	50680-50686	versus	_	
242-70	50687-50694	no-loss	_	
242-71	50695-50707	anticipation	_	
242-72	50708-50709	(	_	
242-73	50709-50715	LVNant	_	
242-74	50715-50716	)	_	
242-75	50716-50717	,	_	
242-76	50718-50722	gain	_	
242-77	50723-50729	versus	_	
242-78	50730-50737	no-gain	_	
242-79	50738-50745	outcome	_	
242-80	50746-50747	(	_	
242-81	50747-50753	GVNout	_	
242-82	50753-50754	)	_	
242-83	50754-50755	,	_	
242-84	50756-50759	and	_	
242-85	50760-50767	no-loss	_	
242-86	50768-50774	versus	_	
242-87	50775-50779	loss	_	
242-88	50780-50787	outcome	_	
242-89	50788-50789	(	_	
242-90	50789-50795	NVLout	_	
242-91	50795-50796	)	_	
242-92	50796-50797	.	_	

#Text=Contrasts compared gain and loss conditions to neutral (i.e., +/−$0) conditions, rather than to a no-stimulus baseline condition, in order to (1) focus on differences in reward/value processes in the brain and (2) to exclude general performance-related brain activity from the evaluated signal.
243-1	50798-50807	Contrasts	_	
243-2	50808-50816	compared	_	
243-3	50817-50821	gain	_	
243-4	50822-50825	and	_	
243-5	50826-50830	loss	_	
243-6	50831-50841	conditions	_	
243-7	50842-50844	to	_	
243-8	50845-50852	neutral	_	
243-9	50853-50854	(	_	
243-10	50854-50857	i.e	_	
243-11	50857-50858	.	_	
243-12	50858-50859	,	_	
243-13	50860-50861	+	_	
243-14	50861-50862	/	_	
243-15	50862-50863	−	_	
243-16	50863-50865	$0	_	
243-17	50865-50866	)	_	
243-18	50867-50877	conditions	_	
243-19	50877-50878	,	_	
243-20	50879-50885	rather	_	
243-21	50886-50890	than	_	
243-22	50891-50893	to	_	
243-23	50894-50895	a	_	
243-24	50896-50907	no-stimulus	_	
243-25	50908-50916	baseline	_	
243-26	50917-50926	condition	_	
243-27	50926-50927	,	_	
243-28	50928-50930	in	_	
243-29	50931-50936	order	_	
243-30	50937-50939	to	_	
243-31	50940-50941	(	_	
243-32	50941-50942	1	_	
243-33	50942-50943	)	_	
243-34	50944-50949	focus	_	
243-35	50950-50952	on	_	
243-36	50953-50964	differences	_	
243-37	50965-50967	in	_	
243-38	50968-50974	reward	_	
243-39	50974-50975	/	_	
243-40	50975-50980	value	_	
243-41	50981-50990	processes	_	
243-42	50991-50993	in	_	
243-43	50994-50997	the	_	
243-44	50998-51003	brain	_	
243-45	51004-51007	and	_	
243-46	51008-51009	(	_	
243-47	51009-51010	2	_	
243-48	51010-51011	)	_	
243-49	51012-51014	to	_	
243-50	51015-51022	exclude	_	
243-51	51023-51030	general	_	
243-52	51031-51050	performance-related	_	
243-53	51051-51056	brain	_	
243-54	51057-51065	activity	_	
243-55	51066-51070	from	_	
243-56	51071-51074	the	_	
243-57	51075-51084	evaluated	_	
243-58	51085-51091	signal	_	
243-59	51091-51092	.	_	

#Text=Specifically, the contrasts included:
#Text=GVNant: anticipation during potential gain (+$5 cue) trials versus anticipation during potential no-gain (+/−$0 cue) trials; LVNant: anticipation during potential loss (−$5 cue) trials versus anticipation during potential no-loss (+/−$0 cue) trials; GVNout: hit (+$5 outcome) versus miss (+$0 outcome) during the outcome period for potential gain (+$5 cue) trials; NVLout: hit (−$0 outcome) versus miss (−$5 outcome) during the outcome period for potential loss (−$5 cue) trials.
244-1	51093-51105	Specifically	_	
244-2	51105-51106	,	_	
244-3	51107-51110	the	_	
244-4	51111-51120	contrasts	_	
244-5	51121-51129	included	_	
244-6	51129-51130	:	_	
244-7	51131-51137	GVNant	_	
244-8	51137-51138	:	_	
244-9	51139-51151	anticipation	_	
244-10	51152-51158	during	_	
244-11	51159-51168	potential	_	
244-12	51169-51173	gain	_	
244-13	51174-51175	(	_	
244-14	51175-51176	+	_	
244-15	51176-51178	$5	_	
244-16	51179-51182	cue	_	
244-17	51182-51183	)	_	
244-18	51184-51190	trials	_	
244-19	51191-51197	versus	_	
244-20	51198-51210	anticipation	_	
244-21	51211-51217	during	_	
244-22	51218-51227	potential	_	
244-23	51228-51235	no-gain	_	
244-24	51236-51237	(	_	
244-25	51237-51238	+	_	
244-26	51238-51239	/	_	
244-27	51239-51240	−	_	
244-28	51240-51242	$0	_	
244-29	51243-51246	cue	_	
244-30	51246-51247	)	_	
244-31	51248-51254	trials	_	
244-32	51254-51255	;	_	
244-33	51256-51262	LVNant	_	
244-34	51262-51263	:	_	
244-35	51264-51276	anticipation	_	
244-36	51277-51283	during	_	
244-37	51284-51293	potential	_	
244-38	51294-51298	loss	_	
244-39	51299-51300	(	_	
244-40	51300-51301	−	_	
244-41	51301-51303	$5	_	
244-42	51304-51307	cue	_	
244-43	51307-51308	)	_	
244-44	51309-51315	trials	_	
244-45	51316-51322	versus	_	
244-46	51323-51335	anticipation	_	
244-47	51336-51342	during	_	
244-48	51343-51352	potential	_	
244-49	51353-51360	no-loss	_	
244-50	51361-51362	(	_	
244-51	51362-51363	+	_	
244-52	51363-51364	/	_	
244-53	51364-51365	−	_	
244-54	51365-51367	$0	_	
244-55	51368-51371	cue	_	
244-56	51371-51372	)	_	
244-57	51373-51379	trials	_	
244-58	51379-51380	;	_	
244-59	51381-51387	GVNout	_	
244-60	51387-51388	:	_	
244-61	51389-51392	hit	_	
244-62	51393-51394	(	_	
244-63	51394-51395	+	_	
244-64	51395-51397	$5	_	
244-65	51398-51405	outcome	_	
244-66	51405-51406	)	_	
244-67	51407-51413	versus	_	
244-68	51414-51418	miss	_	
244-69	51419-51420	(	_	
244-70	51420-51421	+	_	
244-71	51421-51423	$0	_	
244-72	51424-51431	outcome	_	
244-73	51431-51432	)	_	
244-74	51433-51439	during	_	
244-75	51440-51443	the	_	
244-76	51444-51451	outcome	_	
244-77	51452-51458	period	_	
244-78	51459-51462	for	_	
244-79	51463-51472	potential	_	
244-80	51473-51477	gain	_	
244-81	51478-51479	(	_	
244-82	51479-51480	+	_	
244-83	51480-51482	$5	_	
244-84	51483-51486	cue	_	
244-85	51486-51487	)	_	
244-86	51488-51494	trials	_	
244-87	51494-51495	;	_	
244-88	51496-51502	NVLout	_	
244-89	51502-51503	:	_	
244-90	51504-51507	hit	_	
244-91	51508-51509	(	_	
244-92	51509-51510	−	_	
244-93	51510-51512	$0	_	
244-94	51513-51520	outcome	_	
244-95	51520-51521	)	_	
244-96	51522-51528	versus	_	
244-97	51529-51533	miss	_	
244-98	51534-51535	(	_	
244-99	51535-51536	−	_	
244-100	51536-51538	$5	_	
244-101	51539-51546	outcome	_	
244-102	51546-51547	)	_	
244-103	51548-51554	during	_	
244-104	51555-51558	the	_	
244-105	51559-51566	outcome	_	
244-106	51567-51573	period	_	
244-107	51574-51577	for	_	
244-108	51578-51587	potential	_	
244-109	51588-51592	loss	_	
244-110	51593-51594	(	_	
244-111	51594-51595	−	_	
244-112	51595-51597	$5	_	
244-113	51598-51601	cue	_	
244-114	51601-51602	)	_	
244-115	51603-51609	trials	_	
244-116	51609-51610	.	_	

#Text=The regressors of interest were convolved with a single gamma function approximating the hemodynamic response, with approximately a 6 second delay.
245-1	51611-51614	The	_	
245-2	51615-51625	regressors	_	
245-3	51626-51628	of	_	
245-4	51629-51637	interest	_	
245-5	51638-51642	were	_	
245-6	51643-51652	convolved	_	
245-7	51653-51657	with	_	
245-8	51658-51659	a	_	
245-9	51660-51666	single	_	
245-10	51667-51672	gamma	_	
245-11	51673-51681	function	_	
245-12	51682-51695	approximating	_	
245-13	51696-51699	the	_	
245-14	51700-51711	hemodynamic	_	
245-15	51712-51720	response	_	
245-16	51720-51721	,	_	
245-17	51722-51726	with	_	
245-18	51727-51740	approximately	_	
245-19	51741-51742	a	_	
245-20	51743-51744	6	_	
245-21	51745-51751	second	_	
245-22	51752-51757	delay	_	
245-23	51757-51758	.	_	

#Text=We applied conservative motion censoring to the regressors so that any volume showing motion greater than 0.5 mm (and preceding volume) were excluded.
246-1	51759-51761	We	_	
246-2	51762-51769	applied	_	
246-3	51770-51782	conservative	_	
246-4	51783-51789	motion	_	
246-5	51790-51799	censoring	_	
246-6	51800-51802	to	_	
246-7	51803-51806	the	_	
246-8	51807-51817	regressors	_	
246-9	51818-51820	so	_	
246-10	51821-51825	that	_	
246-11	51826-51829	any	_	
246-12	51830-51836	volume	_	
246-13	51837-51844	showing	_	
246-14	51845-51851	motion	_	
246-15	51852-51859	greater	_	
246-16	51860-51864	than	_	
246-17	51865-51868	0.5	_	
246-18	51869-51871	mm	_	
246-19	51872-51873	(	_	
246-20	51873-51876	and	_	
246-21	51877-51886	preceding	_	
246-22	51887-51893	volume	_	
246-23	51893-51894	)	_	
246-24	51895-51899	were	_	
246-25	51900-51908	excluded	_	
246-26	51908-51909	.	_	

#Text=Resulting activation maps “activity” for each participant represented blood oxygenation level dependent (BOLD) signal (a correlate of blood oxygenation levels which are a correlate of neural activity in fMRI) response corresponding to the regressor for each contrast separately.
247-1	51910-51919	Resulting	_	
247-2	51920-51930	activation	_	
247-3	51931-51935	maps	_	
247-4	51936-51937	“	_	
247-5	51937-51945	activity	_	
247-6	51945-51946	”	_	
247-7	51947-51950	for	_	
247-8	51951-51955	each	_	
247-9	51956-51967	participant	_	
247-10	51968-51979	represented	_	
247-11	51980-51985	blood	_	
247-12	51986-51997	oxygenation	_	
247-13	51998-52003	level	_	
247-14	52004-52013	dependent	_	
247-15	52014-52015	(	_	
247-16	52015-52019	BOLD	_	
247-17	52019-52020	)	_	
247-18	52021-52027	signal	_	
247-19	52028-52029	(	_	
247-20	52029-52030	a	_	
247-21	52031-52040	correlate	_	
247-22	52041-52043	of	_	
247-23	52044-52049	blood	_	
247-24	52050-52061	oxygenation	_	
247-25	52062-52068	levels	_	
247-26	52069-52074	which	_	
247-27	52075-52078	are	_	
247-28	52079-52080	a	_	
247-29	52081-52090	correlate	_	
247-30	52091-52093	of	_	
247-31	52094-52100	neural	_	
247-32	52101-52109	activity	_	
247-33	52110-52112	in	_	
247-34	52113-52117	fMRI	_	
247-35	52117-52118	)	_	
247-36	52119-52127	response	_	
247-37	52128-52141	corresponding	_	
247-38	52142-52144	to	_	
247-39	52145-52148	the	_	
247-40	52149-52158	regressor	_	
247-41	52159-52162	for	_	
247-42	52163-52167	each	_	
247-43	52168-52176	contrast	_	
247-44	52177-52187	separately	_	
247-45	52187-52188	.	_	

#Text=These individual activation maps were tested for group differences within a priori ROIs and post-hoc whole brain group comparisons.
248-1	52189-52194	These	_	
248-2	52195-52205	individual	_	
248-3	52206-52216	activation	_	
248-4	52217-52221	maps	_	
248-5	52222-52226	were	_	
248-6	52227-52233	tested	_	
248-7	52234-52237	for	_	
248-8	52238-52243	group	_	
248-9	52244-52255	differences	_	
248-10	52256-52262	within	_	
248-11	52263-52264	a	_	
248-12	52265-52271	priori	_	
248-13	52272-52276	ROIs	_	
248-14	52277-52280	and	_	
248-15	52281-52289	post-hoc	_	
248-16	52290-52295	whole	_	
248-17	52296-52301	brain	_	
248-18	52302-52307	group	_	
248-19	52308-52319	comparisons	_	
248-20	52319-52320	.	_	

#Text=To maximize our chances of identifying significant group effects and consistent with previously published methods, trials with +$1 cues were excluded from the fMRI contrasts because the strength of BOLD signal response for these trials was determined to be much lower than trials with +$5 cues (Supplementary Fig. 
249-1	52321-52323	To	_	
249-2	52324-52332	maximize	_	
249-3	52333-52336	our	_	
249-4	52337-52344	chances	_	
249-5	52345-52347	of	_	
249-6	52348-52359	identifying	_	
249-7	52360-52371	significant	_	
249-8	52372-52377	group	_	
249-9	52378-52385	effects	_	
249-10	52386-52389	and	_	
249-11	52390-52400	consistent	_	
249-12	52401-52405	with	_	
249-13	52406-52416	previously	_	
249-14	52417-52426	published	_	
249-15	52427-52434	methods	_	
249-16	52434-52435	,	_	
249-17	52436-52442	trials	_	
249-18	52443-52447	with	_	
249-19	52448-52449	+	_	
249-20	52449-52451	$1	_	
249-21	52452-52456	cues	_	
249-22	52457-52461	were	_	
249-23	52462-52470	excluded	_	
249-24	52471-52475	from	_	
249-25	52476-52479	the	_	
249-26	52480-52484	fMRI	_	
249-27	52485-52494	contrasts	_	
249-28	52495-52502	because	_	
249-29	52503-52506	the	_	
249-30	52507-52515	strength	_	
249-31	52516-52518	of	_	
249-32	52519-52523	BOLD	_	
249-33	52524-52530	signal	_	
249-34	52531-52539	response	_	
249-35	52540-52543	for	_	
249-36	52544-52549	these	_	
249-37	52550-52556	trials	_	
249-38	52557-52560	was	_	
249-39	52561-52571	determined	_	
249-40	52572-52574	to	_	
249-41	52575-52577	be	_	
249-42	52578-52582	much	_	
249-43	52583-52588	lower	_	
249-44	52589-52593	than	_	
249-45	52594-52600	trials	_	
249-46	52601-52605	with	_	
249-47	52606-52607	+	_	
249-48	52607-52609	$5	_	
249-49	52610-52614	cues	_	
249-50	52615-52616	(	_	
249-51	52616-52629	Supplementary	_	
249-52	52630-52633	Fig	_	
249-53	52633-52634	.	_	
249-54	52634-52635	 	_	

#Text=S5).
250-1	52635-52637	S5	_	
250-2	52637-52638	)	_	
250-3	52638-52639	.	_	

#Text=Region of Interest fMRI analyses
#Text=Region of interest (ROI) analyses focused on the NAcc and MPFC.
251-1	52640-52646	Region	_	
251-2	52647-52649	of	_	
251-3	52650-52658	Interest	_	
251-4	52659-52663	fMRI	_	
251-5	52664-52672	analyses	_	
251-6	52673-52679	Region	_	
251-7	52680-52682	of	_	
251-8	52683-52691	interest	_	
251-9	52692-52693	(	_	
251-10	52693-52696	ROI	_	
251-11	52696-52697	)	_	
251-12	52698-52706	analyses	_	
251-13	52707-52714	focused	_	
251-14	52715-52717	on	_	
251-15	52718-52721	the	_	
251-16	52722-52726	NAcc	_	
251-17	52727-52730	and	_	
251-18	52731-52735	MPFC	_	
251-19	52735-52736	.	_	

#Text=We predicted that, in comparison to both control and non-opioid fibromyalgia, the opioid fibromyalgia group would show: 1) decreased NAcc activity during gain anticipation (GVNant) and no-loss outcome (NVLout), 2) decreased MPFC activity during gain anticipation (GVNant), and 3) increased MPFC activity during no-loss outcome (NVLout).
252-1	52737-52739	We	_	
252-2	52740-52749	predicted	_	
252-3	52750-52754	that	_	
252-4	52754-52755	,	_	
252-5	52756-52758	in	_	
252-6	52759-52769	comparison	_	
252-7	52770-52772	to	_	
252-8	52773-52777	both	_	
252-9	52778-52785	control	_	
252-10	52786-52789	and	_	
252-11	52790-52800	non-opioid	_	
252-12	52801-52813	fibromyalgia	_	
252-13	52813-52814	,	_	
252-14	52815-52818	the	_	
252-15	52819-52825	opioid	_	
252-16	52826-52838	fibromyalgia	_	
252-17	52839-52844	group	_	
252-18	52845-52850	would	_	
252-19	52851-52855	show	_	
252-20	52855-52856	:	_	
252-21	52857-52858	1	_	
252-22	52858-52859	)	_	
252-23	52860-52869	decreased	_	
252-24	52870-52874	NAcc	_	
252-25	52875-52883	activity	_	
252-26	52884-52890	during	_	
252-27	52891-52895	gain	_	
252-28	52896-52908	anticipation	_	
252-29	52909-52910	(	_	
252-30	52910-52916	GVNant	_	
252-31	52916-52917	)	_	
252-32	52918-52921	and	_	
252-33	52922-52929	no-loss	_	
252-34	52930-52937	outcome	_	
252-35	52938-52939	(	_	
252-36	52939-52945	NVLout	_	
252-37	52945-52946	)	_	
252-38	52946-52947	,	_	
252-39	52948-52949	2	_	
252-40	52949-52950	)	_	
252-41	52951-52960	decreased	_	
252-42	52961-52965	MPFC	_	
252-43	52966-52974	activity	_	
252-44	52975-52981	during	_	
252-45	52982-52986	gain	_	
252-46	52987-52999	anticipation	_	
252-47	53000-53001	(	_	
252-48	53001-53007	GVNant	_	
252-49	53007-53008	)	_	
252-50	53008-53009	,	_	
252-51	53010-53013	and	_	
252-52	53014-53015	3	_	
252-53	53015-53016	)	_	
252-54	53017-53026	increased	_	
252-55	53027-53031	MPFC	_	
252-56	53032-53040	activity	_	
252-57	53041-53047	during	_	
252-58	53048-53055	no-loss	_	
252-59	53056-53063	outcome	_	
252-60	53064-53065	(	_	
252-61	53065-53071	NVLout	_	
252-62	53071-53072	)	_	
252-63	53072-53073	.	_	

#Text=We created the bilateral NAcc ROI by combining the left and right accumbens regions from the Desai Atlas (AFNI) and resampling to functional image resolution (52 voxels; voxel size = 2.9 mm × 2.9 mm × 2.9 mm).
253-1	53074-53076	We	_	
253-2	53077-53084	created	_	
253-3	53085-53088	the	_	
253-4	53089-53098	bilateral	_	
253-5	53099-53103	NAcc	_	
253-6	53104-53107	ROI	_	
253-7	53108-53110	by	_	
253-8	53111-53120	combining	_	
253-9	53121-53124	the	_	
253-10	53125-53129	left	_	
253-11	53130-53133	and	_	
253-12	53134-53139	right	_	
253-13	53140-53149	accumbens	_	
253-14	53150-53157	regions	_	
253-15	53158-53162	from	_	
253-16	53163-53166	the	_	
253-17	53167-53172	Desai	_	
253-18	53173-53178	Atlas	_	
253-19	53179-53180	(	_	
253-20	53180-53184	AFNI	_	
253-21	53184-53185	)	_	
253-22	53186-53189	and	_	
253-23	53190-53200	resampling	_	
253-24	53201-53203	to	_	
253-25	53204-53214	functional	_	
253-26	53215-53220	image	_	
253-27	53221-53231	resolution	_	
253-28	53232-53233	(	_	
253-29	53233-53235	52	_	
253-30	53236-53242	voxels	_	
253-31	53242-53243	;	_	
253-32	53244-53249	voxel	_	
253-33	53250-53254	size	_	
253-34	53255-53256	=	_	
253-35	53257-53260	2.9	_	
253-36	53261-53263	mm	_	
253-37	53264-53265	×	_	
253-38	53266-53269	2.9	_	
253-39	53270-53272	mm	_	
253-40	53273-53274	×	_	
253-41	53275-53278	2.9	_	
253-42	53279-53281	mm	_	
253-43	53281-53282	)	_	
253-44	53282-53283	.	_	

#Text=We created the bilateral MPFC ROI by drawing two conjoined 4 mm radius spheres (+/−4, 50, −3) within Brodmann Area 10 corresponding the frontal pole and resampling to functional image resolution (42 voxels).
254-1	53284-53286	We	_	
254-2	53287-53294	created	_	
254-3	53295-53298	the	_	
254-4	53299-53308	bilateral	_	
254-5	53309-53313	MPFC	_	
254-6	53314-53317	ROI	_	
254-7	53318-53320	by	_	
254-8	53321-53328	drawing	_	
254-9	53329-53332	two	_	
254-10	53333-53342	conjoined	_	
254-11	53343-53344	4	_	
254-12	53345-53347	mm	_	
254-13	53348-53354	radius	_	
254-14	53355-53362	spheres	_	
254-15	53363-53364	(	_	
254-16	53364-53365	+	_	
254-17	53365-53366	/	_	
254-18	53366-53367	−	_	
254-19	53367-53368	4	_	
254-20	53368-53369	,	_	
254-21	53370-53372	50	_	
254-22	53372-53373	,	_	
254-23	53374-53375	−	_	
254-24	53375-53376	3	_	
254-25	53376-53377	)	_	
254-26	53378-53384	within	_	
254-27	53385-53393	Brodmann	_	
254-28	53394-53398	Area	_	
254-29	53399-53401	10	_	
254-30	53402-53415	corresponding	_	
254-31	53416-53419	the	_	
254-32	53420-53427	frontal	_	
254-33	53428-53432	pole	_	
254-34	53433-53436	and	_	
254-35	53437-53447	resampling	_	
254-36	53448-53450	to	_	
254-37	53451-53461	functional	_	
254-38	53462-53467	image	_	
254-39	53468-53478	resolution	_	
254-40	53479-53480	(	_	
254-41	53480-53482	42	_	
254-42	53483-53489	voxels	_	
254-43	53489-53490	)	_	
254-44	53490-53491	.	_	

#Text=Additional information regarding the precise selection of the MPFC ROI can be found in the Supplementary Methods.
255-1	53492-53502	Additional	_	
255-2	53503-53514	information	_	
255-3	53515-53524	regarding	_	
255-4	53525-53528	the	_	
255-5	53529-53536	precise	_	
255-6	53537-53546	selection	_	
255-7	53547-53549	of	_	
255-8	53550-53553	the	_	
255-9	53554-53558	MPFC	_	
255-10	53559-53562	ROI	_	
255-11	53563-53566	can	_	
255-12	53567-53569	be	_	
255-13	53570-53575	found	_	
255-14	53576-53578	in	_	
255-15	53579-53582	the	_	
255-16	53583-53596	Supplementary	_	
255-17	53597-53604	Methods	_	
255-18	53604-53605	.	_	

#Text=We extracted fMRI values from these ROIs and performed group statistical comparisons using analysis of variance (ANOVA) and post-hoc t-tests in SPSS (IBM SPSS Statistics for Macintosh, Version 22.0.
256-1	53606-53608	We	_	
256-2	53609-53618	extracted	_	
256-3	53619-53623	fMRI	_	
256-4	53624-53630	values	_	
256-5	53631-53635	from	_	
256-6	53636-53641	these	_	
256-7	53642-53646	ROIs	_	
256-8	53647-53650	and	_	
256-9	53651-53660	performed	_	
256-10	53661-53666	group	_	
256-11	53667-53678	statistical	_	
256-12	53679-53690	comparisons	_	
256-13	53691-53696	using	_	
256-14	53697-53705	analysis	_	
256-15	53706-53708	of	_	
256-16	53709-53717	variance	_	
256-17	53718-53719	(	_	
256-18	53719-53724	ANOVA	_	
256-19	53724-53725	)	_	
256-20	53726-53729	and	_	
256-21	53730-53738	post-hoc	_	
256-22	53739-53746	t-tests	_	
256-23	53747-53749	in	_	
256-24	53750-53754	SPSS	_	
256-25	53755-53756	(	_	
256-26	53756-53759	IBM	_	
256-27	53760-53764	SPSS	_	
256-28	53765-53775	Statistics	_	
256-29	53776-53779	for	_	
256-30	53780-53789	Macintosh	_	
256-31	53789-53790	,	_	
256-32	53791-53798	Version	_	
256-33	53799-53803	22.0	_	
256-34	53803-53804	.	_	

#Text=Armonk, NY).
257-1	53805-53811	Armonk	_	
257-2	53811-53812	,	_	
257-3	53813-53815	NY	_	
257-4	53815-53816	)	_	
257-5	53816-53817	.	_	

#Text=Additional correlation analyses were performed between the ROI data and behavioral and clinical measures using SPSS.
258-1	53818-53828	Additional	_	
258-2	53829-53840	correlation	_	
258-3	53841-53849	analyses	_	
258-4	53850-53854	were	_	
258-5	53855-53864	performed	_	
258-6	53865-53872	between	_	
258-7	53873-53876	the	_	
258-8	53877-53880	ROI	_	
258-9	53881-53885	data	_	
258-10	53886-53889	and	_	
258-11	53890-53900	behavioral	_	
258-12	53901-53904	and	_	
258-13	53905-53913	clinical	_	
258-14	53914-53922	measures	_	
258-15	53923-53928	using	_	
258-16	53929-53933	SPSS	_	
258-17	53933-53934	.	_	

#Text=Clinical and psychological data analysis
#Text=Questionnaire data were quantified for each questionnaire separately and then assessed for group differences using ANOVA (SPSS).
259-1	53935-53943	Clinical	_	
259-2	53944-53947	and	_	
259-3	53948-53961	psychological	_	
259-4	53962-53966	data	_	
259-5	53967-53975	analysis	_	
259-6	53976-53989	Questionnaire	_	
259-7	53990-53994	data	_	
259-8	53995-53999	were	_	
259-9	54000-54010	quantified	_	
259-10	54011-54014	for	_	
259-11	54015-54019	each	_	
259-12	54020-54033	questionnaire	_	
259-13	54034-54044	separately	_	
259-14	54045-54048	and	_	
259-15	54049-54053	then	_	
259-16	54054-54062	assessed	_	
259-17	54063-54066	for	_	
259-18	54067-54072	group	_	
259-19	54073-54084	differences	_	
259-20	54085-54090	using	_	
259-21	54091-54096	ANOVA	_	
259-22	54097-54098	(	_	
259-23	54098-54102	SPSS	_	
259-24	54102-54103	)	_	
259-25	54103-54104	.	_	

#Text=Post-hoc between group t-tests were then used to determine differences between individual groups (Tukey, SPSS).
260-1	54105-54113	Post-hoc	_	
260-2	54114-54121	between	_	
260-3	54122-54127	group	_	
260-4	54128-54135	t-tests	_	
260-5	54136-54140	were	_	
260-6	54141-54145	then	_	
260-7	54146-54150	used	_	
260-8	54151-54153	to	_	
260-9	54154-54163	determine	_	
260-10	54164-54175	differences	_	
260-11	54176-54183	between	_	
260-12	54184-54194	individual	_	
260-13	54195-54201	groups	_	
260-14	54202-54203	(	_	
260-15	54203-54208	Tukey	_	
260-16	54208-54209	,	_	
260-17	54210-54214	SPSS	_	
260-18	54214-54215	)	_	
260-19	54215-54216	.	_	

#Text=(See Table 2 and Supplementary Methods for list and descriptions of questionnaires).
261-1	54217-54218	(	_	
261-2	54218-54221	See	_	
261-3	54222-54227	Table	_	
261-4	54227-54228	 	_	
261-5	54228-54229	2	_	
261-6	54230-54233	and	_	
261-7	54234-54247	Supplementary	_	
261-8	54248-54255	Methods	_	
261-9	54256-54259	for	_	
261-10	54260-54264	list	_	
261-11	54265-54268	and	_	
261-12	54269-54281	descriptions	_	
261-13	54282-54284	of	_	
261-14	54285-54299	questionnaires	_	
261-15	54299-54300	)	_	
261-16	54300-54301	.	_	

#Text=Behavioral analysis
#Text=We assessed performance and behavioral responses to the MID task by analyzing accuracy (percent hit rate), reaction times, and post-task ratings of arousal and valence to monetary cues.
262-1	54302-54312	Behavioral	_	
262-2	54313-54321	analysis	_	
262-3	54322-54324	We	_	
262-4	54325-54333	assessed	_	
262-5	54334-54345	performance	_	
262-6	54346-54349	and	_	
262-7	54350-54360	behavioral	_	
262-8	54361-54370	responses	_	
262-9	54371-54373	to	_	
262-10	54374-54377	the	_	
262-11	54378-54381	MID	_	
262-12	54382-54386	task	_	
262-13	54387-54389	by	_	
262-14	54390-54399	analyzing	_	
262-15	54400-54408	accuracy	_	
262-16	54409-54410	(	_	
262-17	54410-54417	percent	_	
262-18	54418-54421	hit	_	
262-19	54422-54426	rate	_	
262-20	54426-54427	)	_	
262-21	54427-54428	,	_	
262-22	54429-54437	reaction	_	
262-23	54438-54443	times	_	
262-24	54443-54444	,	_	
262-25	54445-54448	and	_	
262-26	54449-54458	post-task	_	
262-27	54459-54466	ratings	_	
262-28	54467-54469	of	_	
262-29	54470-54477	arousal	_	
262-30	54478-54481	and	_	
262-31	54482-54489	valence	_	
262-32	54490-54492	to	_	
262-33	54493-54501	monetary	_	
262-34	54502-54506	cues	_	
262-35	54506-54507	.	_	

#Text=Additionally, measures of positive arousal and negative arousal were calculated from mean-deviated ratings of arousal and valence within subjects as done previously.
263-1	54508-54520	Additionally	_	
263-2	54520-54521	,	_	
263-3	54522-54530	measures	_	
263-4	54531-54533	of	_	
263-5	54534-54542	positive	_	
263-6	54543-54550	arousal	_	
263-7	54551-54554	and	_	
263-8	54555-54563	negative	_	
263-9	54564-54571	arousal	_	
263-10	54572-54576	were	_	
263-11	54577-54587	calculated	_	
263-12	54588-54592	from	_	
263-13	54593-54606	mean-deviated	_	
263-14	54607-54614	ratings	_	
263-15	54615-54617	of	_	
263-16	54618-54625	arousal	_	
263-17	54626-54629	and	_	
263-18	54630-54637	valence	_	
263-19	54638-54644	within	_	
263-20	54645-54653	subjects	_	
263-21	54654-54656	as	_	
263-22	54657-54661	done	_	
263-23	54662-54672	previously	_	
263-24	54672-54673	.	_	

#Text=Each of these measures were assessed separately for differences across the 3 groups using a two-way ANOVA with factors of trial (here, “trial” simply refers to trials with different cues: +$0, +$1, +$5, −$0, −$1, −$5), group (HC, FMN, FMO), and trial by group interaction).
264-1	54674-54678	Each	_	
264-2	54679-54681	of	_	
264-3	54682-54687	these	_	
264-4	54688-54696	measures	_	
264-5	54697-54701	were	_	
264-6	54702-54710	assessed	_	
264-7	54711-54721	separately	_	
264-8	54722-54725	for	_	
264-9	54726-54737	differences	_	
264-10	54738-54744	across	_	
264-11	54745-54748	the	_	
264-12	54749-54750	3	_	
264-13	54751-54757	groups	_	
264-14	54758-54763	using	_	
264-15	54764-54765	a	_	
264-16	54766-54773	two-way	_	
264-17	54774-54779	ANOVA	_	
264-18	54780-54784	with	_	
264-19	54785-54792	factors	_	
264-20	54793-54795	of	_	
264-21	54796-54801	trial	_	
264-22	54802-54803	(	_	
264-23	54803-54807	here	_	
264-24	54807-54808	,	_	
264-25	54809-54810	“	_	
264-26	54810-54815	trial	_	
264-27	54815-54816	”	_	
264-28	54817-54823	simply	_	
264-29	54824-54830	refers	_	
264-30	54831-54833	to	_	
264-31	54834-54840	trials	_	
264-32	54841-54845	with	_	
264-33	54846-54855	different	_	
264-34	54856-54860	cues	_	
264-35	54860-54861	:	_	
264-36	54862-54863	+	_	
264-37	54863-54865	$0	_	
264-38	54865-54866	,	_	
264-39	54867-54868	+	_	
264-40	54868-54870	$1	_	
264-41	54870-54871	,	_	
264-42	54872-54873	+	_	
264-43	54873-54875	$5	_	
264-44	54875-54876	,	_	
264-45	54877-54878	−	_	
264-46	54878-54880	$0	_	
264-47	54880-54881	,	_	
264-48	54882-54883	−	_	
264-49	54883-54885	$1	_	
264-50	54885-54886	,	_	
264-51	54887-54888	−	_	
264-52	54888-54890	$5	_	
264-53	54890-54891	)	_	
264-54	54891-54892	,	_	
264-55	54893-54898	group	_	
264-56	54899-54900	(	_	
264-57	54900-54902	HC	_	
264-58	54902-54903	,	_	
264-59	54904-54907	FMN	_	
264-60	54907-54908	,	_	
264-61	54909-54912	FMO	_	
264-62	54912-54913	)	_	
264-63	54913-54914	,	_	
264-64	54915-54918	and	_	
264-65	54919-54924	trial	_	
264-66	54925-54927	by	_	
264-67	54928-54933	group	_	
264-68	54934-54945	interaction	_	
264-69	54945-54946	)	_	
264-70	54946-54947	.	_	

#Text=Post-hoc one-way ANOVA tests were also used to determine group effects for each trial/cue separately (MATLAB, R2017a).
265-1	54948-54956	Post-hoc	_	
265-2	54957-54964	one-way	_	
265-3	54965-54970	ANOVA	_	
265-4	54971-54976	tests	_	
265-5	54977-54981	were	_	
265-6	54982-54986	also	_	
265-7	54987-54991	used	_	
265-8	54992-54994	to	_	
265-9	54995-55004	determine	_	
265-10	55005-55010	group	_	
265-11	55011-55018	effects	_	
265-12	55019-55022	for	_	
265-13	55023-55027	each	_	
265-14	55028-55033	trial	_	
265-15	55033-55034	/	_	
265-16	55034-55037	cue	_	
265-17	55038-55048	separately	_	
265-18	55049-55050	(	_	
265-19	55050-55056	MATLAB	_	
265-20	55056-55057	,	_	
265-21	55058-55064	R2017a	_	
265-22	55064-55065	)	_	
265-23	55065-55066	.	_	

#Text=MID Task fMRI analysis
#Text=Averaged beta values (parameter estimates) were extracted for each ROI from each participant for each contrast combination using custom scripts (MATLAB, AFNI).
266-1	55067-55070	MID	_	
266-2	55071-55075	Task	_	
266-3	55076-55080	fMRI	_	
266-4	55081-55089	analysis	_	
266-5	55090-55098	Averaged	_	
266-6	55099-55103	beta	_	
266-7	55104-55110	values	_	
266-8	55111-55112	(	_	
266-9	55112-55121	parameter	_	
266-10	55122-55131	estimates	_	
266-11	55131-55132	)	_	
266-12	55133-55137	were	_	
266-13	55138-55147	extracted	_	
266-14	55148-55151	for	_	
266-15	55152-55156	each	_	
266-16	55157-55160	ROI	_	
266-17	55161-55165	from	_	
266-18	55166-55170	each	_	
266-19	55171-55182	participant	_	
266-20	55183-55186	for	_	
266-21	55187-55191	each	_	
266-22	55192-55200	contrast	_	
266-23	55201-55212	combination	_	
266-24	55213-55218	using	_	
266-25	55219-55225	custom	_	
266-26	55226-55233	scripts	_	
266-27	55234-55235	(	_	
266-28	55235-55241	MATLAB	_	
266-29	55241-55242	,	_	
266-30	55243-55247	AFNI	_	
266-31	55247-55248	)	_	
266-32	55248-55249	.	_	

#Text=The extracted beta values were compared among groups using ANOVA (SPSS).
267-1	55250-55253	The	_	
267-2	55254-55263	extracted	_	
267-3	55264-55268	beta	_	
267-4	55269-55275	values	_	
267-5	55276-55280	were	_	
267-6	55281-55289	compared	_	
267-7	55290-55295	among	_	
267-8	55296-55302	groups	_	
267-9	55303-55308	using	_	
267-10	55309-55314	ANOVA	_	
267-11	55315-55316	(	_	
267-12	55316-55320	SPSS	_	
267-13	55320-55321	)	_	
267-14	55321-55322	.	_	

#Text=We set the significance threshold to p < 0.0125 (initial p < 0.05 threshold Bonferroni corrected for 4 predetermined ROI x contrast comparisons: NAcc GVNant, NAcc NVLout, MPFC GVNant, MPFC NVLout).
268-1	55323-55325	We	_	
268-2	55326-55329	set	_	
268-3	55330-55333	the	_	
268-4	55334-55346	significance	_	
268-5	55347-55356	threshold	_	
268-6	55357-55359	to	_	
268-7	55360-55361	p	_	
268-8	55362-55363	<	_	
268-9	55364-55370	0.0125	_	
268-10	55371-55372	(	_	
268-11	55372-55379	initial	_	
268-12	55380-55381	p	_	
268-13	55382-55383	<	_	
268-14	55384-55388	0.05	_	
268-15	55389-55398	threshold	_	
268-16	55399-55409	Bonferroni	_	
268-17	55410-55419	corrected	_	
268-18	55420-55423	for	_	
268-19	55424-55425	4	_	
268-20	55426-55439	predetermined	_	
268-21	55440-55443	ROI	_	
268-22	55444-55445	x	_	
268-23	55446-55454	contrast	_	
268-24	55455-55466	comparisons	_	
268-25	55466-55467	:	_	
268-26	55468-55472	NAcc	_	
268-27	55473-55479	GVNant	_	
268-28	55479-55480	,	_	
268-29	55481-55485	NAcc	_	
268-30	55486-55492	NVLout	_	
268-31	55492-55493	,	_	
268-32	55494-55498	MPFC	_	
268-33	55499-55505	GVNant	_	
268-34	55505-55506	,	_	
268-35	55507-55511	MPFC	_	
268-36	55512-55518	NVLout	_	
268-37	55518-55519	)	_	
268-38	55519-55520	.	_	

#Text=Additionally, raw time course data were plotted by extracting each participant’s fMRI data, sorting by trial type, and removing volumes with signal exceeding >4 standard deviations from mean activity.
#Text=fMRI Correlation analysis
#Text=Correlations between fMRI beta values (NAcc GVNant, NAcc NVLout, MPFC GVNant, and MPFC NVLout) and questionnaire variables were tested across the two fibromyalgia groups (2-tailed, bivariate, Pearson correlation, SPSS) (see Supplementary Methods for list of included questionnaires).
269-1	55521-55533	Additionally	_	
269-2	55533-55534	,	_	
269-3	55535-55538	raw	_	
269-4	55539-55543	time	_	
269-5	55544-55550	course	_	
269-6	55551-55555	data	_	
269-7	55556-55560	were	_	
269-8	55561-55568	plotted	_	
269-9	55569-55571	by	_	
269-10	55572-55582	extracting	_	
269-11	55583-55587	each	_	
269-12	55588-55599	participant	_	
269-13	55599-55600	’	_	
269-14	55600-55601	s	_	
269-15	55602-55606	fMRI	_	
269-16	55607-55611	data	_	
269-17	55611-55612	,	_	
269-18	55613-55620	sorting	_	
269-19	55621-55623	by	_	
269-20	55624-55629	trial	_	
269-21	55630-55634	type	_	
269-22	55634-55635	,	_	
269-23	55636-55639	and	_	
269-24	55640-55648	removing	_	
269-25	55649-55656	volumes	_	
269-26	55657-55661	with	_	
269-27	55662-55668	signal	_	
269-28	55669-55678	exceeding	_	
269-29	55679-55680	>	_	
269-30	55680-55681	4	_	
269-31	55682-55690	standard	_	
269-32	55691-55701	deviations	_	
269-33	55702-55706	from	_	
269-34	55707-55711	mean	_	
269-35	55712-55720	activity	_	
269-36	55720-55721	.	_	
269-37	55722-55726	fMRI	_	
269-38	55727-55738	Correlation	_	
269-39	55739-55747	analysis	_	
269-40	55748-55760	Correlations	_	
269-41	55761-55768	between	_	
269-42	55769-55773	fMRI	_	
269-43	55774-55778	beta	_	
269-44	55779-55785	values	_	
269-45	55786-55787	(	_	
269-46	55787-55791	NAcc	_	
269-47	55792-55798	GVNant	_	
269-48	55798-55799	,	_	
269-49	55800-55804	NAcc	_	
269-50	55805-55811	NVLout	_	
269-51	55811-55812	,	_	
269-52	55813-55817	MPFC	_	
269-53	55818-55824	GVNant	_	
269-54	55824-55825	,	_	
269-55	55826-55829	and	_	
269-56	55830-55834	MPFC	_	
269-57	55835-55841	NVLout	_	
269-58	55841-55842	)	_	
269-59	55843-55846	and	_	
269-60	55847-55860	questionnaire	_	
269-61	55861-55870	variables	_	
269-62	55871-55875	were	_	
269-63	55876-55882	tested	_	
269-64	55883-55889	across	_	
269-65	55890-55893	the	_	
269-66	55894-55897	two	_	
269-67	55898-55910	fibromyalgia	_	
269-68	55911-55917	groups	_	
269-69	55918-55919	(	_	
269-70	55919-55920	2	_	
269-71	55920-55921	-	_	
269-72	55921-55927	tailed	_	
269-73	55927-55928	,	_	
269-74	55929-55938	bivariate	_	
269-75	55938-55939	,	_	
269-76	55940-55947	Pearson	_	
269-77	55948-55959	correlation	_	
269-78	55959-55960	,	_	
269-79	55961-55965	SPSS	_	
269-80	55965-55966	)	_	
269-81	55967-55968	(	_	
269-82	55968-55971	see	_	
269-83	55972-55985	Supplementary	_	
269-84	55986-55993	Methods	_	
269-85	55994-55997	for	_	
269-86	55998-56002	list	_	
269-87	56003-56005	of	_	
269-88	56006-56014	included	_	
269-89	56015-56029	questionnaires	_	
269-90	56029-56030	)	_	
269-91	56030-56031	.	_	

#Text=Correlations between ROI fMRI beta values and questionnaire variables were corrected for multiple comparisons based on the inclusion of 7 independent (not correlated) measures (Supplementary Methods).
270-1	56032-56044	Correlations	_	
270-2	56045-56052	between	_	
270-3	56053-56056	ROI	_	
270-4	56057-56061	fMRI	_	
270-5	56062-56066	beta	_	
270-6	56067-56073	values	_	
270-7	56074-56077	and	_	
270-8	56078-56091	questionnaire	_	
270-9	56092-56101	variables	_	
270-10	56102-56106	were	_	
270-11	56107-56116	corrected	_	
270-12	56117-56120	for	_	
270-13	56121-56129	multiple	_	
270-14	56130-56141	comparisons	_	
270-15	56142-56147	based	_	
270-16	56148-56150	on	_	
270-17	56151-56154	the	_	
270-18	56155-56164	inclusion	_	
270-19	56165-56167	of	_	
270-20	56168-56169	7	_	
270-21	56170-56181	independent	_	
270-22	56182-56183	(	_	
270-23	56183-56186	not	_	
270-24	56187-56197	correlated	_	
270-25	56197-56198	)	_	
270-26	56199-56207	measures	_	
270-27	56208-56209	(	_	
270-28	56209-56222	Supplementary	_	
270-29	56223-56230	Methods	_	
270-30	56230-56231	)	_	
270-31	56231-56232	.	_	

#Text=Additional analyses were conducted to rule out potential influences of motion on the results and to confirm ROI findings with whole brain analyses (Supplementary Methods).
271-1	56233-56243	Additional	_	
271-2	56244-56252	analyses	_	
271-3	56253-56257	were	_	
271-4	56258-56267	conducted	_	
271-5	56268-56270	to	_	
271-6	56271-56275	rule	_	
271-7	56276-56279	out	_	
271-8	56280-56289	potential	_	
271-9	56290-56300	influences	_	
271-10	56301-56303	of	_	
271-11	56304-56310	motion	_	
271-12	56311-56313	on	_	
271-13	56314-56317	the	_	
271-14	56318-56325	results	_	
271-15	56326-56329	and	_	
271-16	56330-56332	to	_	
271-17	56333-56340	confirm	_	
271-18	56341-56344	ROI	_	
271-19	56345-56353	findings	_	
271-20	56354-56358	with	_	
271-21	56359-56364	whole	_	
271-22	56365-56370	brain	_	
271-23	56371-56379	analyses	_	
271-24	56380-56381	(	_	
271-25	56381-56394	Supplementary	_	
271-26	56395-56402	Methods	_	
271-27	56402-56403	)	_	
271-28	56403-56404	.	_	

#Text=Supplementary information
#Text=Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
272-1	56405-56418	Supplementary	_	
272-2	56419-56430	information	_	
272-3	56431-56440	Publisher	_	
272-4	56440-56441	’	_	
272-5	56441-56442	s	_	
272-6	56443-56447	note	_	
272-7	56447-56448	:	_	
272-8	56449-56457	Springer	_	
272-9	56458-56464	Nature	_	
272-10	56465-56472	remains	_	
272-11	56473-56480	neutral	_	
272-12	56481-56485	with	_	
272-13	56486-56492	regard	_	
272-14	56493-56495	to	_	
272-15	56496-56510	jurisdictional	_	
272-16	56511-56517	claims	_	
272-17	56518-56520	in	_	
272-18	56521-56530	published	_	
272-19	56531-56535	maps	_	
272-20	56536-56539	and	_	
272-21	56540-56553	institutional	_	
272-22	56554-56566	affiliations	_	
272-23	56566-56567	.	_	

#Text=Supplementary information
#Text=Supplementary information accompanies this paper at 10.1038/s41598-019-45961-y.
273-1	56568-56581	Supplementary	_	
273-2	56582-56593	information	_	
273-3	56594-56607	Supplementary	_	
273-4	56608-56619	information	_	
273-5	56620-56631	accompanies	_	
273-6	56632-56636	this	_	
273-7	56637-56642	paper	_	
273-8	56643-56645	at	_	
273-9	56646-56653	10.1038	_	
273-10	56653-56654	/	_	
273-11	56654-56660	s41598	_	
273-12	56660-56661	-	_	
273-13	56661-56664	019	_	
273-14	56664-56665	-	_	
273-15	56665-56670	45961	_	
273-16	56670-56671	-	_	
273-17	56671-56672	y	_	
273-18	56672-56673	.	_	

#Text=Author Contributions
#Text=Designed the study, collected the data, analyzed the data, wrote the manuscript, and edited and revised the manuscript (K.T.M.).
274-1	56674-56680	Author	_	
274-2	56681-56694	Contributions	_	
274-3	56695-56703	Designed	_	
274-4	56704-56707	the	_	
274-5	56708-56713	study	_	
274-6	56713-56714	,	_	
274-7	56715-56724	collected	_	
274-8	56725-56728	the	_	
274-9	56729-56733	data	_	
274-10	56733-56734	,	_	
274-11	56735-56743	analyzed	_	
274-12	56744-56747	the	_	
274-13	56748-56752	data	_	
274-14	56752-56753	,	_	
274-15	56754-56759	wrote	_	
274-16	56760-56763	the	_	
274-17	56764-56774	manuscript	_	
274-18	56774-56775	,	_	
274-19	56776-56779	and	_	
274-20	56780-56786	edited	_	
274-21	56787-56790	and	_	
274-22	56791-56798	revised	_	
274-23	56799-56802	the	_	
274-24	56803-56813	manuscript	_	
274-25	56814-56815	(	_	
274-26	56815-56820	K.T.M	_	
274-27	56820-56821	.	_	
274-28	56821-56822	)	_	
274-29	56822-56823	.	_	

#Text=Assisted with study design, data analysis, and manuscript editing (K.H.M., N.B., B.K., S.C.M.).
275-1	56824-56832	Assisted	_	
275-2	56833-56837	with	_	
275-3	56838-56843	study	_	
275-4	56844-56850	design	_	
275-5	56850-56851	,	_	
275-6	56852-56856	data	_	
275-7	56857-56865	analysis	_	
275-8	56865-56866	,	_	
275-9	56867-56870	and	_	
275-10	56871-56881	manuscript	_	
275-11	56882-56889	editing	_	
275-12	56890-56891	(	_	
275-13	56891-56896	K.H.M	_	
275-14	56896-56897	.	_	
275-15	56897-56898	,	_	
275-16	56899-56902	N.B	_	
275-17	56902-56903	.	_	
275-18	56903-56904	,	_	
275-19	56905-56908	B.K	_	
275-20	56908-56909	.	_	
275-21	56909-56910	,	_	
275-22	56911-56916	S.C.M	_	
275-23	56916-56917	.	_	
275-24	56917-56918	)	_	
275-25	56918-56919	.	_	

#Text=All authors read and approved the manuscript (K.T.M., K.H.M., N.B., B.K., S.C.M.).
276-1	56920-56923	All	_	
276-2	56924-56931	authors	_	
276-3	56932-56936	read	_	
276-4	56937-56940	and	_	
276-5	56941-56949	approved	_	
276-6	56950-56953	the	_	
276-7	56954-56964	manuscript	_	
276-8	56965-56966	(	_	
276-9	56966-56971	K.T.M	_	
276-10	56971-56972	.	_	
276-11	56972-56973	,	_	
276-12	56974-56979	K.H.M	_	
276-13	56979-56980	.	_	
276-14	56980-56981	,	_	
276-15	56982-56985	N.B	_	
276-16	56985-56986	.	_	
276-17	56986-56987	,	_	
276-18	56988-56991	B.K	_	
276-19	56991-56992	.	_	
276-20	56992-56993	,	_	
276-21	56994-56999	S.C.M	_	
276-22	56999-57000	.	_	
276-23	57000-57001	)	_	
276-24	57001-57002	.	_	

#Text=Data Availability
#Text=The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
277-1	57003-57007	Data	_	
277-2	57008-57020	Availability	_	
277-3	57021-57024	The	_	
277-4	57025-57033	datasets	_	
277-5	57034-57043	generated	_	
277-6	57044-57050	during	_	
277-7	57051-57054	and	_	
277-8	57054-57055	/	_	
277-9	57055-57057	or	_	
277-10	57058-57066	analyzed	_	
277-11	57067-57073	during	_	
277-12	57074-57077	the	_	
277-13	57078-57085	current	_	
277-14	57086-57091	study	_	
277-15	57092-57095	are	_	
277-16	57096-57105	available	_	
277-17	57106-57110	from	_	
277-18	57111-57114	the	_	
277-19	57115-57128	corresponding	_	
277-20	57129-57135	author	_	
277-21	57136-57138	on	_	
277-22	57139-57149	reasonable	_	
277-23	57150-57157	request	_	
277-24	57157-57158	.	_	

#Text=Competing Interests
#Text=The authors declare no competing interests.
278-1	57159-57168	Competing	_	
278-2	57169-57178	Interests	_	
278-3	57179-57182	The	_	
278-4	57183-57190	authors	_	
278-5	57191-57198	declare	_	
278-6	57199-57201	no	_	
278-7	57202-57211	competing	_	
278-8	57212-57221	interests	_	
278-9	57221-57222	.	_	

#Text=References
#Text=Understanding How Opioids Contribute to Reward and Analgesia
#Text=Long-term evaluation of opioid treatment in fibromyalgia
#Text=Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial
#Text=Opioid use, misuse, and abuse in patients labeled as fibromyalgia
#Text=Efficacy of tramadol in treatment of pain in fibromyalgia
#Text=Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study
#Text=Patient-Centered Prescription Opioid Tapering in Community Outpatients With Chronic Pain
#Text=Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies
#Text=Understanding opioid reward
#Text=Common Brain Mechanisms of Chronic Pain and Addiction
#Text=The reward circuit: linking primate anatomy and human imaging
#Text=Drug reinforcement studied by the use of place conditioning in rat
#Text=Pavlovian conditioning of opioid and nonopioid pain inhibitory mechanisms in humans
#Text=Alterations in brain structure and functional connectivity in prescription opioid-dependent patients
#Text=One Month of Oral Morphine Decreases Gray Matter Volume in the Right Amygdala of Individuals with Low Back Pain: Confirmation of Previously Reported Magnetic Resonance Imaging Results
#Text=Prescription opioid analgesics rapidly change the human brain
#Text=The Tampa Scale for Kinesiophobia: further examination of psychometric properties in patients with chronic low back pain and fibromyalgia
#Text=Chronic pain.
279-1	57223-57233	References	_	
279-2	57234-57247	Understanding	_	
279-3	57248-57251	How	_	
279-4	57252-57259	Opioids	_	
279-5	57260-57270	Contribute	_	
279-6	57271-57273	to	_	
279-7	57274-57280	Reward	_	
279-8	57281-57284	and	_	
279-9	57285-57294	Analgesia	_	
279-10	57295-57304	Long-term	_	
279-11	57305-57315	evaluation	_	
279-12	57316-57318	of	_	
279-13	57319-57325	opioid	_	
279-14	57326-57335	treatment	_	
279-15	57336-57338	in	_	
279-16	57339-57351	fibromyalgia	_	
279-17	57352-57358	Effect	_	
279-18	57359-57361	of	_	
279-19	57362-57368	Opioid	_	
279-20	57369-57371	vs	_	
279-21	57372-57381	Nonopioid	_	
279-22	57382-57393	Medications	_	
279-23	57394-57396	on	_	
279-24	57397-57409	Pain-Related	_	
279-25	57410-57418	Function	_	
279-26	57419-57421	in	_	
279-27	57422-57430	Patients	_	
279-28	57431-57435	With	_	
279-29	57436-57443	Chronic	_	
279-30	57444-57448	Back	_	
279-31	57449-57453	Pain	_	
279-32	57454-57456	or	_	
279-33	57457-57460	Hip	_	
279-34	57461-57463	or	_	
279-35	57464-57468	Knee	_	
279-36	57469-57483	Osteoarthritis	_	
279-37	57484-57488	Pain	_	
279-38	57488-57489	:	_	
279-39	57490-57493	The	_	
279-40	57494-57499	SPACE	_	
279-41	57500-57510	Randomized	_	
279-42	57511-57519	Clinical	_	
279-43	57520-57525	Trial	_	
279-44	57526-57532	Opioid	_	
279-45	57533-57536	use	_	
279-46	57536-57537	,	_	
279-47	57538-57544	misuse	_	
279-48	57544-57545	,	_	
279-49	57546-57549	and	_	
279-50	57550-57555	abuse	_	
279-51	57556-57558	in	_	
279-52	57559-57567	patients	_	
279-53	57568-57575	labeled	_	
279-54	57576-57578	as	_	
279-55	57579-57591	fibromyalgia	_	
279-56	57592-57600	Efficacy	_	
279-57	57601-57603	of	_	
279-58	57604-57612	tramadol	_	
279-59	57613-57615	in	_	
279-60	57616-57625	treatment	_	
279-61	57626-57628	of	_	
279-62	57629-57633	pain	_	
279-63	57634-57636	in	_	
279-64	57637-57649	fibromyalgia	_	
279-65	57650-57658	Tramadol	_	
279-66	57659-57662	and	_	
279-67	57663-57676	acetaminophen	_	
279-68	57677-57688	combination	_	
279-69	57689-57696	tablets	_	
279-70	57697-57699	in	_	
279-71	57700-57703	the	_	
279-72	57704-57713	treatment	_	
279-73	57714-57716	of	_	
279-74	57717-57729	fibromyalgia	_	
279-75	57730-57734	pain	_	
279-76	57734-57735	:	_	
279-77	57736-57737	a	_	
279-78	57738-57750	double-blind	_	
279-79	57750-57751	,	_	
279-80	57752-57762	randomized	_	
279-81	57762-57763	,	_	
279-82	57764-57782	placebo-controlled	_	
279-83	57783-57788	study	_	
279-84	57789-57805	Patient-Centered	_	
279-85	57806-57818	Prescription	_	
279-86	57819-57825	Opioid	_	
279-87	57826-57834	Tapering	_	
279-88	57835-57837	in	_	
279-89	57838-57847	Community	_	
279-90	57848-57859	Outpatients	_	
279-91	57860-57864	With	_	
279-92	57865-57872	Chronic	_	
279-93	57873-57877	Pain	_	
279-94	57878-57884	Opioid	_	
279-95	57885-57890	Abuse	_	
279-96	57891-57893	in	_	
279-97	57894-57901	Chronic	_	
279-98	57902-57906	Pain	_	
279-99	57907-57908	—	_	
279-100	57909-57923	Misconceptions	_	
279-101	57924-57927	and	_	
279-102	57928-57938	Mitigation	_	
279-103	57939-57949	Strategies	_	
279-104	57950-57963	Understanding	_	
279-105	57964-57970	opioid	_	
279-106	57971-57977	reward	_	
279-107	57978-57984	Common	_	
279-108	57985-57990	Brain	_	
279-109	57991-58001	Mechanisms	_	
279-110	58002-58004	of	_	
279-111	58005-58012	Chronic	_	
279-112	58013-58017	Pain	_	
279-113	58018-58021	and	_	
279-114	58022-58031	Addiction	_	
279-115	58032-58035	The	_	
279-116	58036-58042	reward	_	
279-117	58043-58050	circuit	_	
279-118	58050-58051	:	_	
279-119	58052-58059	linking	_	
279-120	58060-58067	primate	_	
279-121	58068-58075	anatomy	_	
279-122	58076-58079	and	_	
279-123	58080-58085	human	_	
279-124	58086-58093	imaging	_	
279-125	58094-58098	Drug	_	
279-126	58099-58112	reinforcement	_	
279-127	58113-58120	studied	_	
279-128	58121-58123	by	_	
279-129	58124-58127	the	_	
279-130	58128-58131	use	_	
279-131	58132-58134	of	_	
279-132	58135-58140	place	_	
279-133	58141-58153	conditioning	_	
279-134	58154-58156	in	_	
279-135	58157-58160	rat	_	
279-136	58161-58170	Pavlovian	_	
279-137	58171-58183	conditioning	_	
279-138	58184-58186	of	_	
279-139	58187-58193	opioid	_	
279-140	58194-58197	and	_	
279-141	58198-58207	nonopioid	_	
279-142	58208-58212	pain	_	
279-143	58213-58223	inhibitory	_	
279-144	58224-58234	mechanisms	_	
279-145	58235-58237	in	_	
279-146	58238-58244	humans	_	
279-147	58245-58256	Alterations	_	
279-148	58257-58259	in	_	
279-149	58260-58265	brain	_	
279-150	58266-58275	structure	_	
279-151	58276-58279	and	_	
279-152	58280-58290	functional	_	
279-153	58291-58303	connectivity	_	
279-154	58304-58306	in	_	
279-155	58307-58319	prescription	_	
279-156	58320-58336	opioid-dependent	_	
279-157	58337-58345	patients	_	
279-158	58346-58349	One	_	
279-159	58350-58355	Month	_	
279-160	58356-58358	of	_	
279-161	58359-58363	Oral	_	
279-162	58364-58372	Morphine	_	
279-163	58373-58382	Decreases	_	
279-164	58383-58387	Gray	_	
279-165	58388-58394	Matter	_	
279-166	58395-58401	Volume	_	
279-167	58402-58404	in	_	
279-168	58405-58408	the	_	
279-169	58409-58414	Right	_	
279-170	58415-58423	Amygdala	_	
279-171	58424-58426	of	_	
279-172	58427-58438	Individuals	_	
279-173	58439-58443	with	_	
279-174	58444-58447	Low	_	
279-175	58448-58452	Back	_	
279-176	58453-58457	Pain	_	
279-177	58457-58458	:	_	
279-178	58459-58471	Confirmation	_	
279-179	58472-58474	of	_	
279-180	58475-58485	Previously	_	
279-181	58486-58494	Reported	_	
279-182	58495-58503	Magnetic	_	
279-183	58504-58513	Resonance	_	
279-184	58514-58521	Imaging	_	
279-185	58522-58529	Results	_	
279-186	58530-58542	Prescription	_	
279-187	58543-58549	opioid	_	
279-188	58550-58560	analgesics	_	
279-189	58561-58568	rapidly	_	
279-190	58569-58575	change	_	
279-191	58576-58579	the	_	
279-192	58580-58585	human	_	
279-193	58586-58591	brain	_	
279-194	58592-58595	The	_	
279-195	58596-58601	Tampa	_	
279-196	58602-58607	Scale	_	
279-197	58608-58611	for	_	
279-198	58612-58625	Kinesiophobia	_	
279-199	58625-58626	:	_	
279-200	58627-58634	further	_	
279-201	58635-58646	examination	_	
279-202	58647-58649	of	_	
279-203	58650-58662	psychometric	_	
279-204	58663-58673	properties	_	
279-205	58674-58676	in	_	
279-206	58677-58685	patients	_	
279-207	58686-58690	with	_	
279-208	58691-58698	chronic	_	
279-209	58699-58702	low	_	
279-210	58703-58707	back	_	
279-211	58708-58712	pain	_	
279-212	58713-58716	and	_	
279-213	58717-58729	fibromyalgia	_	
279-214	58730-58737	Chronic	_	
279-215	58738-58742	pain	_	
279-216	58742-58743	.	_	

#Text=Decreased motivation during chronic pain requires long-term depression in the nucleus accumbens
#Text=Predicting value of pain and analgesia: nucleus accumbens response to noxious stimuli changes in the presence of chronic pain
#Text=Alterations in endogenous opioid functional measures in chronic back pain
#Text=Decreased central mu-opioid receptor availability in fibromyalgia
#Text=Fibromyalgia patients show an abnormal dopamine response to pain
#Text=Altered prefrontal correlates of monetary anticipation and outcome in chronic pain
#Text=Distributed neural representation of expected value
#Text=Anticipatory affect: neural correlates and consequences for choice
#Text=Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
#Text=Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A)
#Text=The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity
#Text=Relationship of negative affect and outcome of an opioid therapy trial among low back pain patients
#Text=Effects of long-term opioid analgesics on cognitive performance and plasma cytokine concentrations in patients with chronic low back pain: a cross-sectional pilot study
#Text=The role of medial prefrontal cortex in memory and decision making
#Text=A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI
#Text=Evidence of specific cognitive deficits in patients with chronic low back pain under long-term substitution treatment of opioids
#Text=“I Was a Little Surprised”: Qualitative Insights From Patients Enrolled in a 12-Month Trial Comparing Opioids With Nonopioid Medications for Chronic Musculoskeletal Pain
#Text=Spiral-in/out BOLD fMRI for increased SNR and reduced susceptibility artifacts
#Text=The Psychophysics Toolbox
#Text=Neural responses to monetary incentives in major depression
#Text=Spatial smoothing systematically biases the localization of reward-related brain activity
#Text=An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest
#Text=Neural valuation of environmental resources
280-1	58744-58753	Decreased	_	
280-2	58754-58764	motivation	_	
280-3	58765-58771	during	_	
280-4	58772-58779	chronic	_	
280-5	58780-58784	pain	_	
280-6	58785-58793	requires	_	
280-7	58794-58803	long-term	_	
280-8	58804-58814	depression	_	
280-9	58815-58817	in	_	
280-10	58818-58821	the	_	
280-11	58822-58829	nucleus	_	
280-12	58830-58839	accumbens	_	
280-13	58840-58850	Predicting	_	
280-14	58851-58856	value	_	
280-15	58857-58859	of	_	
280-16	58860-58864	pain	_	
280-17	58865-58868	and	_	
280-18	58869-58878	analgesia	_	
280-19	58878-58879	:	_	
280-20	58880-58887	nucleus	_	
280-21	58888-58897	accumbens	_	
280-22	58898-58906	response	_	
280-23	58907-58909	to	_	
280-24	58910-58917	noxious	_	
280-25	58918-58925	stimuli	_	
280-26	58926-58933	changes	_	
280-27	58934-58936	in	_	
280-28	58937-58940	the	_	
280-29	58941-58949	presence	_	
280-30	58950-58952	of	_	
280-31	58953-58960	chronic	_	
280-32	58961-58965	pain	_	
280-33	58966-58977	Alterations	_	
280-34	58978-58980	in	_	
280-35	58981-58991	endogenous	_	
280-36	58992-58998	opioid	_	
280-37	58999-59009	functional	_	
280-38	59010-59018	measures	_	
280-39	59019-59021	in	_	
280-40	59022-59029	chronic	_	
280-41	59030-59034	back	_	
280-42	59035-59039	pain	_	
280-43	59040-59049	Decreased	_	
280-44	59050-59057	central	_	
280-45	59058-59067	mu-opioid	_	
280-46	59068-59076	receptor	_	
280-47	59077-59089	availability	_	
280-48	59090-59092	in	_	
280-49	59093-59105	fibromyalgia	_	
280-50	59106-59118	Fibromyalgia	_	
280-51	59119-59127	patients	_	
280-52	59128-59132	show	_	
280-53	59133-59135	an	_	
280-54	59136-59144	abnormal	_	
280-55	59145-59153	dopamine	_	
280-56	59154-59162	response	_	
280-57	59163-59165	to	_	
280-58	59166-59170	pain	_	
280-59	59171-59178	Altered	_	
280-60	59179-59189	prefrontal	_	
280-61	59190-59200	correlates	_	
280-62	59201-59203	of	_	
280-63	59204-59212	monetary	_	
280-64	59213-59225	anticipation	_	
280-65	59226-59229	and	_	
280-66	59230-59237	outcome	_	
280-67	59238-59240	in	_	
280-68	59241-59248	chronic	_	
280-69	59249-59253	pain	_	
280-70	59254-59265	Distributed	_	
280-71	59266-59272	neural	_	
280-72	59273-59287	representation	_	
280-73	59288-59290	of	_	
280-74	59291-59299	expected	_	
280-75	59300-59305	value	_	
280-76	59306-59318	Anticipatory	_	
280-77	59319-59325	affect	_	
280-78	59325-59326	:	_	
280-79	59327-59333	neural	_	
280-80	59334-59344	correlates	_	
280-81	59345-59348	and	_	
280-82	59349-59361	consequences	_	
280-83	59362-59365	for	_	
280-84	59366-59372	choice	_	
280-85	59373-59385	Psychometric	_	
280-86	59386-59396	properties	_	
280-87	59397-59399	of	_	
280-88	59400-59403	the	_	
280-89	59404-59408	Beck	_	
280-90	59409-59419	Depression	_	
280-91	59420-59429	Inventory	_	
280-92	59429-59430	:	_	
280-93	59431-59442	Twenty-five	_	
280-94	59443-59448	years	_	
280-95	59449-59451	of	_	
280-96	59452-59462	evaluation	_	
280-97	59463-59471	Measures	_	
280-98	59472-59474	of	_	
280-99	59475-59482	anxiety	_	
280-100	59482-59483	:	_	
280-101	59484-59495	State-Trait	_	
280-102	59496-59503	Anxiety	_	
280-103	59504-59513	Inventory	_	
280-104	59514-59515	(	_	
280-105	59515-59519	STAI	_	
280-106	59519-59520	)	_	
280-107	59520-59521	,	_	
280-108	59522-59526	Beck	_	
280-109	59527-59534	Anxiety	_	
280-110	59535-59544	Inventory	_	
280-111	59545-59546	(	_	
280-112	59546-59549	BAI	_	
280-113	59549-59550	)	_	
280-114	59550-59551	,	_	
280-115	59552-59555	and	_	
280-116	59556-59564	Hospital	_	
280-117	59565-59572	Anxiety	_	
280-118	59573-59576	and	_	
280-119	59577-59587	Depression	_	
280-120	59588-59601	Scale-Anxiety	_	
280-121	59602-59603	(	_	
280-122	59603-59609	HADS-A	_	
280-123	59609-59610	)	_	
280-124	59611-59614	The	_	
280-125	59615-59623	American	_	
280-126	59624-59631	College	_	
280-127	59632-59634	of	_	
280-128	59635-59647	Rheumatology	_	
280-129	59648-59659	preliminary	_	
280-130	59660-59670	diagnostic	_	
280-131	59671-59679	criteria	_	
280-132	59680-59683	for	_	
280-133	59684-59696	fibromyalgia	_	
280-134	59697-59700	and	_	
280-135	59701-59712	measurement	_	
280-136	59713-59715	of	_	
280-137	59716-59723	symptom	_	
280-138	59724-59732	severity	_	
280-139	59733-59745	Relationship	_	
280-140	59746-59748	of	_	
280-141	59749-59757	negative	_	
280-142	59758-59764	affect	_	
280-143	59765-59768	and	_	
280-144	59769-59776	outcome	_	
280-145	59777-59779	of	_	
280-146	59780-59782	an	_	
280-147	59783-59789	opioid	_	
280-148	59790-59797	therapy	_	
280-149	59798-59803	trial	_	
280-150	59804-59809	among	_	
280-151	59810-59813	low	_	
280-152	59814-59818	back	_	
280-153	59819-59823	pain	_	
280-154	59824-59832	patients	_	
280-155	59833-59840	Effects	_	
280-156	59841-59843	of	_	
280-157	59844-59853	long-term	_	
280-158	59854-59860	opioid	_	
280-159	59861-59871	analgesics	_	
280-160	59872-59874	on	_	
280-161	59875-59884	cognitive	_	
280-162	59885-59896	performance	_	
280-163	59897-59900	and	_	
280-164	59901-59907	plasma	_	
280-165	59908-59916	cytokine	_	
280-166	59917-59931	concentrations	_	
280-167	59932-59934	in	_	
280-168	59935-59943	patients	_	
280-169	59944-59948	with	_	
280-170	59949-59956	chronic	_	
280-171	59957-59960	low	_	
280-172	59961-59965	back	_	
280-173	59966-59970	pain	_	
280-174	59970-59971	:	_	
280-175	59972-59973	a	_	
280-176	59974-59989	cross-sectional	_	
280-177	59990-59995	pilot	_	
280-178	59996-60001	study	_	
280-179	60002-60005	The	_	
280-180	60006-60010	role	_	
280-181	60011-60013	of	_	
280-182	60014-60020	medial	_	
280-183	60021-60031	prefrontal	_	
280-184	60032-60038	cortex	_	
280-185	60039-60041	in	_	
280-186	60042-60048	memory	_	
280-187	60049-60052	and	_	
280-188	60053-60061	decision	_	
280-189	60062-60068	making	_	
280-190	60069-60070	A	_	
280-191	60071-60077	region	_	
280-192	60078-60080	of	_	
280-193	60081-60087	mesial	_	
280-194	60088-60098	prefrontal	_	
280-195	60099-60105	cortex	_	
280-196	60106-60112	tracks	_	
280-197	60113-60123	monetarily	_	
280-198	60124-60133	rewarding	_	
280-199	60134-60142	outcomes	_	
280-200	60142-60143	:	_	
280-201	60144-60160	characterization	_	
280-202	60161-60165	with	_	
280-203	60166-60171	rapid	_	
280-204	60172-60185	event-related	_	
280-205	60186-60190	fMRI	_	
280-206	60191-60199	Evidence	_	
280-207	60200-60202	of	_	
280-208	60203-60211	specific	_	
280-209	60212-60221	cognitive	_	
280-210	60222-60230	deficits	_	
280-211	60231-60233	in	_	
280-212	60234-60242	patients	_	
280-213	60243-60247	with	_	
280-214	60248-60255	chronic	_	
280-215	60256-60259	low	_	
280-216	60260-60264	back	_	
280-217	60265-60269	pain	_	
280-218	60270-60275	under	_	
280-219	60276-60285	long-term	_	
280-220	60286-60298	substitution	_	
280-221	60299-60308	treatment	_	
280-222	60309-60311	of	_	
280-223	60312-60319	opioids	_	
280-224	60320-60321	“	_	
280-225	60321-60322	I	_	
280-226	60323-60326	Was	_	
280-227	60327-60328	a	_	
280-228	60329-60335	Little	_	
280-229	60336-60345	Surprised	_	
280-230	60345-60346	”	_	
280-231	60346-60347	:	_	
280-232	60348-60359	Qualitative	_	
280-233	60360-60368	Insights	_	
280-234	60369-60373	From	_	
280-235	60374-60382	Patients	_	
280-236	60383-60391	Enrolled	_	
280-237	60392-60394	in	_	
280-238	60395-60396	a	_	
280-239	60397-60399	12	_	
280-240	60399-60400	-	_	
280-241	60400-60405	Month	_	
280-242	60406-60411	Trial	_	
280-243	60412-60421	Comparing	_	
280-244	60422-60429	Opioids	_	
280-245	60430-60434	With	_	
280-246	60435-60444	Nonopioid	_	
280-247	60445-60456	Medications	_	
280-248	60457-60460	for	_	
280-249	60461-60468	Chronic	_	
280-250	60469-60484	Musculoskeletal	_	
280-251	60485-60489	Pain	_	
280-252	60490-60499	Spiral-in	_	
280-253	60499-60500	/	_	
280-254	60500-60503	out	_	
280-255	60504-60508	BOLD	_	
280-256	60509-60513	fMRI	_	
280-257	60514-60517	for	_	
280-258	60518-60527	increased	_	
280-259	60528-60531	SNR	_	
280-260	60532-60535	and	_	
280-261	60536-60543	reduced	_	
280-262	60544-60558	susceptibility	_	
280-263	60559-60568	artifacts	_	
280-264	60569-60572	The	_	
280-265	60573-60586	Psychophysics	_	
280-266	60587-60594	Toolbox	_	
280-267	60595-60601	Neural	_	
280-268	60602-60611	responses	_	
280-269	60612-60614	to	_	
280-270	60615-60623	monetary	_	
280-271	60624-60634	incentives	_	
280-272	60635-60637	in	_	
280-273	60638-60643	major	_	
280-274	60644-60654	depression	_	
280-275	60655-60662	Spatial	_	
280-276	60663-60672	smoothing	_	
280-277	60673-60687	systematically	_	
280-278	60688-60694	biases	_	
280-279	60695-60698	the	_	
280-280	60699-60711	localization	_	
280-281	60712-60714	of	_	
280-282	60715-60729	reward-related	_	
280-283	60730-60735	brain	_	
280-284	60736-60744	activity	_	
280-285	60745-60747	An	_	
280-286	60748-60757	automated	_	
280-287	60758-60766	labeling	_	
280-288	60767-60773	system	_	
280-289	60774-60777	for	_	
280-290	60778-60789	subdividing	_	
280-291	60790-60793	the	_	
280-292	60794-60799	human	_	
280-293	60800-60808	cerebral	_	
280-294	60809-60815	cortex	_	
280-295	60816-60818	on	_	
280-296	60819-60822	MRI	_	
280-297	60823-60828	scans	_	
280-298	60829-60833	into	_	
280-299	60834-60839	gyral	_	
280-300	60840-60845	based	_	
280-301	60846-60853	regions	_	
280-302	60854-60856	of	_	
280-303	60857-60865	interest	_	
280-304	60866-60872	Neural	_	
280-305	60873-60882	valuation	_	
280-306	60883-60885	of	_	
280-307	60886-60899	environmental	_	
280-308	60900-60909	resources	_	
